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ABSTRACT 
This thesis describes and analyses a case study of contested innovation in 
medical technology using actor network theory (ANT). As well as ANT 
other areas of sociology are drawn upon, such as the public 
understanding of science, and the sociologies of the body and 
consumption. The multiple approaches are used in order to develop ANT 
in novel directions. The particular medical innovation is the introduction 
and use of human insulin. Human insulin was first prescribed to diabetics 
in 1981, and was initially welcomed as a technological innovation that 
would reduce diabetic complications that are associated with animal 
insulin. However, as human insulin began to be used, the superiority of 
human insulin began to be questioned by some diabetics, doctors and care 
groups. One particular concern was the change in warning signs of 
approaching hypoglycaemia that were reported by some diabetics. 
Importantly, there was no agreement within the medical and scientific 
communities as to whether human insulin did cause negative effects. 
Data came from different types of documented evidence, including: 
scientific studies, medical reports, articles published by care groups and 
letters fi-om diabetics. Aspects of ANT, and certain elaborations of ANT 
(e. g. the `network body ), were used to explore this data. Thus, the thesis 
analyses some of the means by which human insulin was initially 
constructed as being superior to existing animal insulins, and how, later, 
actors began to marshal resources in order to redefine the meaning of 
human insulin. The thesis also describes how diabetics, aided by care 
groups, were able to have an influence on the insulin species they were to 
use by stressing the value of their experiential knowledge. Not only this, 
actors wanting to claim facticity' within the human insulin debate had to 
collectivize texts firom both `lay' and `scientific' sources. 
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1. Introduction 
1. INTRODUCTION 
This research concerns the development, introduction and use of human insulin. 
Insulin is used by diabetics that are unable to produce enough insulin naturally, known 
as Type I diabetes or Insulin Dependent Diabetes Mellitus (IDDM). Conventionally, 
Type I diabetics' injected themselves with insulin taken from the pancreases of dead 
animals - either from pigs or cows. Without insulin, diabetics will die, and as a 
consequence, the World Health Organisation has identified insulin as a `life saving 
drug' (1991). 
The amino acid sequence of animal insulin differs from that of natural pancreatic 
human insulin (see Figure 2-3). Although diabetics have lived a relatively `normal' 
life using animal insulin, there were some concerns that the differences between 
animal and human insulin could cause diabetic complications, such as retinopathy and 
neuropathy. There were also concerns that the supply of animal insulin would not be 
able to meet the future demand for insulin. As a result of these considerations, during 
the late 1970s a number of research groups became interested in producing human 
insulin in commercial quantities. 
The progress of the research groups was presented in the media as a `race', and later 
as a `battle' between two pharmaceutical companies - Eli Lilly and Novo Industri. 
The race was won by Novo Industri, who converted porcine insulin to human insulin 
in 1980, with Eli Lilly, who used genetic engineering to produce human insulin, not 
far behind. 
The energetic marketing of human insulin, by both Eli Lilly and Novo Industri, led to 
the dramatic increase in its use. In 1986 only about 6% of insulin sold in Britain was 
human insulin, however by 1989, about 80% of insulin dependent diabetics used 
human insulin. It was not just the marketing of human insulin that. led to this increase. 
Due to media interest in human insulin some diabetics requested to be transferred to 
the new, technologically advanced human insulin. Some doctors were also under the 
misconception that animal insulins were all being withdrawn and so transferred their 
patients to human insulin. 
In future, the word `diabetics' refers to those with Type I diabetes. 
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Initially the production of human insulin was welcomed, since it was believed that it 
would reduce diabetic complications that were associated with animal insulin. 
However, as human insulin began to be used, the superiority of human insulin began 
to be questioned by some diabetics, doctors and care groups. One particular concern 
was the change in warning signs of approaching hypoglycaemia that were reported by 
some diabetics. 
As a result of an awareness, by the medical and scientific community, that some 
diabetics were experiencing problems on human insulin a number of studies were 
carried out which attempted to assess the possible adverse effects of human insulin. 
These studies were inconclusive, with some studies showing that human insulin did 
have a negative effect, and others showing that it did not. This disagreement led to 
much debate within the scientific and medical community. 
As a result of reports from diabetics, and the inconclusive findings of the scientific 
community, diabetic care groups became involved in the human insulin debate. The 
British Diabetic Association (BDA) received many letters from diabetics who were 
experiencing problems on human insulin. Letters from diabetics did not just describe 
their problems due to using human insulin, but also, the responses of their doctors 
when they reported their problems. In a significant number of cases doctors would 
not transfer diabetics back to animal insulin, even though their letters suggested that 
they were experiencing problems on human insulin. As a result of the concerns of 
diabetics, the BDA investigated the claim that human insulin caused adverse effects; 
they formed a number of groups and funded scientific research. 
One interesting feature of the human insulin debate is that as a result of dissatisfaction 
with the way in which the BDA conducted itself, another care group was formed. In 
1995 the Insulin Dependent Diabetic Trust (IDDT) was formed. Members of the trust 
were concerned that the BDA was not adequately representing those diabetics who 
were experiencing problems on human insulin. In particular, they argued that the 
BDA were not informing diabetics of the problems experienced by diabetics. 
At the present time the human insulin debate is still unresolved. However, there is 
now a general consensus that those diabetics who are experiencing problems on 
10 
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human insulin should be returned to animal insulin. Further, pressure has been 
exerted on pharmaceutical companies, by both care groups and the medical 
community, to ensure the continued availability of animal insulins. 
1.1 THEMES OF THE STUDY 
These then are the bare bones of the story I will tell. But, the story I tell is structured 
by a number of sociological concerns. The backbone of this study is formed using 
actor network theory (ANT). In particular, I am interested in the ways in which the 
initial identity of human insulin was constructed as superior to existing animal 
insulins. This was done by a number of entities who brought together a number of 
disparate actors, both human and nonhuman. Then, when some actors began to 
suggest that human insulin caused negative effects for some diabetics, the initially 
`superior' identity of human insulin began to be questioned. Key actors, such as 
scientists and care groups, began to form associations with other actors in order to 
claim `facticity' within the human insulin debate. It was not just the identity of human 
insulin that was being redefined. Actors, in particular care groups, also began to 
question what was to count as expertise within the human insulin debate. 
So, my theoretical perspective comes from the sociology of scientific knowledge 
(SSK), in particular from science studies, however, this is not to say that this work has 
not been affected by other areas of sociology. This work has been influenced by such 
areas of sociology as the sociology of the body and the public understanding of 
science, and to a lesser extent, the sociology of consumption. By using these other 
theoretical areas, I hope to develop and enhance actor network theory. 
Since this study concerns itself with a medical controversy, something also has to be 
said about the place of this study within medical sociology. For example, the 
sociology of health and illness has been interested in the doctor-patient relationship 
and this is something that I will deal with throughout this thesis. I am also interested 
in the meaning and definition of `lay' beliefs, which has been a concern of medical 
sociology for some time. 
However, as Arksey (1998) points out, it has only been in the last decade that some 
medical sociologists have challenged the notion that medical knowledge has 
1.1 Themes of the study 
`superiority' over `lay' knowledge (Abraham, 1994). The idea that scientific and 
expert knowledge is superior to lay knowledge is of key interest to this study, 
therefore. this work will be of interest to those who write within this new area of 
medical sociology. 
This work is also relevant to researchers who have an interest in the experience of 
chronic illness. The sociology of chronic illness has moved away from describing the 
burden of chronic illness (Bury, 1991), to looking at the steps people take to manage, 
mitigate, or adapt to chronic illness (Bury, 1991). Work within this field has looked at 
the onset of chronic illness as a `biographical disruption' (Bury, 1982) and this is 
something that I will draw upon. However, rather than looking at the onset of illness, 
in this case diabetes, I am interested in the negotiations that diabetics go through when 
their existing knowledge of their illness no longer seems relevant. 
Another area of sociology that I am interested in is the sociology of the body. I take 
an actor network approach to the body in which the body is seen as a network; that is, 
the body should be seen as consisting of various heterogeneous relations. ANT has 
not dealt with the body in much depth and this is something that I wish to correct. 
Even recent work that has looked at patients and used ANT theory, such as Arksey's 
study (1998) of RSI, did not develop the notion of the body within ANT. 
In my view of the body, the body should be seen as a network consisting of different 
actors, both human and nonhuman. It is the composition of this network body that 
affects the actions of an actor. For example, human insulin was inserted into the 
diabetic network body, and as a result, in some cases, diabetics contacted care groups 
regarding the change in their warning signs of hypoglycaemia. One important feature 
of the network body is that there is some flexibility as to which actors/entities become 
part of the network body. This is illustrated by the observation that not all diabetics 
use the same species of insulin, or are influenced by the same actors. For example, 
some diabetics were influenced by the Insulin Dependent Diabetic Trust and others by 
the British Diabetic Association. 
One of the aims of this thesis therefore, is to consider the ways in which actors 
become part of the network body. For example: How did Eli Lilly and Novo Industri, 
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two of the major insulin manufacturers, enable human insulin to become part of the 
network body? Conversely, I am also interested in the influence that other actors, 
such as care groups, have in removing actors/entities from an individual's network 
body. A preliminary explanation is that in order for entities/actors to be added or 
removed from the network body, actors need to marshal a wide variety of other actors 
and resources. 
Anothe, - int'1\ st cif this thesis is the public understanding of science, or more 
precisely, the division between `expert' and `lay' knowledge. I address the types of 
knowledge possessed by diabetics, care groups, the medical profession and scientists. 
A particular concern is how actors attempted to establish the relevance of the 
knowledge that they possessed to the human insulin debate. Further, I am also 
interested in the value that various actors placed on the knowledge held by others, and 
how this knowledge became incorporated or collectivized into texts which could assist 
in the process of establishing facticity. 
Scientific knowledge should not be seen as being superior to other knowledge. Lay 
knowledge is usually of a different order to scientific knowledge since it is likely to be 
based, at least in part, on the experiences of individuals. A particular interest of this 
thesis is looking at the ways in which actors, who do not possess scientific knowledge, 
attempt to claim facticity for their own particular type of knowledge. This is 
especially the case when scientific evidence is inconclusive. In such cases, care 
groups, and those actors that they represent, are likely to claim the superiority of 
anecdotal evidence. Therefore, the public can be `experts' too. However, their 
expertise may not only come from experiencing illness, but also through contact with 
versions of `scientific' and `medical' evidence, in the form of newspaper articles and 
reports in care group literature. 
Another concern of this thesis is looking at the way in which bodily experiences 
become expressed. In particular, I am interested in the ways in which non-experts, at 
least from the point of view of the medical profession, are able to collectivise their 
own experiences. Here I am interested in the way in which a diabetic's experience of 
their body moves from a personal and `private' experience to one that becomes 
`public'. One way in which this occurs is through the publication of letters which 
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describe a diabetic's experiences. Care groups may collectivize experiences which are 
used to `stand against' competing and contradictory scientific evidence. Further, 
diabetics themselves may use collectivized texts to persuade other actors, doctors for 
example, of the facticity of their experiences. 
The way in which actors identify with particular texts is also important. In this study 
some scientists were claiming that human insulin did not cause negative effects, while 
others were claiming that it did. Due to the lack of closure within the scientific 
community, different groups identified with different `products' of science. Those 
that were claiming that human insulin did not cause side effects, such as the 
pharmaceutical companies, identified with scientific work that showed that human 
insulin was `safe and efficient'. On the other hand, care groups, and in particular the 
Insulin Dependent Diabetes Trust, identified with scientific work that claimed that 
human insulin did cause side effects. Therefore, one theoretical area that I am 
concerned with is looking at what sources actors go to when they desire more 
`information' on a particular issue. 
Finally, although not central, I look at some themes within the sociology of 
consumption. I explore the ways in which the use of human insulin enabled diabetics 
to express a particular identity: one that was based on the use of insulin that had the 
same amino acid sequence as that used by `healthy' individuals. In a similar vein, the 
ability of diabetics to change their insulin species expressed elements of control over 
diabetic treatment. 
The framework that I adopt therefore draws upon a number of theoretical areas of 
sociology. The choice of ANT as the central facet of the work is due to my belief that 
ANT is able to bring out the heterogeneous nature of actors. It is also able to show the 
processes involved in network (re)building, in particular, how actors attempt to break 
apart existing networks and then rebuild them according to their own pattern. 
However, in ANT, the body has mostly been neglected, so I wished to correct this 
omission by developing an ANT approach to the body. 
Within my framework it was also important to include some discussion of expertise. 
In particular, I wanted to bring out the conflicts and trials that exist when actors, 
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possessing different types of knowledge, attempt to claim facticity over particular 
issues. The issue of expertise is particularly pertinent when there is a lack of closure 
within the scientific community. 
It is my hope that by using a number of areas of sociology, within an ANT framework, 
I have been able to not only enhance ANT, but also suggest how other areas of 
sociology can benefit from using an ANT approach. 
I have indicated above how this thesis is relevant to a number of theoretical areas. 
This thesis also has some practical implications. As I will show in later chapters, 
patient communities can have an influence on the way in which science is conducted, 
moreover, they can also influence the information and options available to patients. 
Through contact with care groups patients/sufferers may then become empowered, 
and as a result of this empowering, may be able to affect medical policy. 
Medical communities can also learn from this study. It is important to realise that the 
experience of patients, in this case diabetics, should be taken as a credible source of 
knowledge. Rather than `lay' knowledge being seen, by doctors, as a challenge to 
their authority, and therefore something that has to be dismissed, `lay' knowledge 
should be incorporated into a doctor's knowledge. This is especially the case when 
there is not a consensus within the scientific and medical community as to whether a 
particular drugs produces negative side effects. 
From a personal point of view, I became interested in the problems associated with 
human insulin through my father. He has been a diabetic for over 30 years, and in the 
mid 1980s he was transferred to human insulin. He did experience some problems, 
and like many diabetics in this study, there was uncertainty as to whether the problems 
were due to human insulin or to some other `natural' cause, like the long duration of 
his diabetes. When it came time for me to put together a proposal for a Ph. D., it 
occurred to me that the subject of human insulin would be not only be of interest to 
diabetics, but also to others, not only in academic fields such as sociology, but 
practitioners and policy makers. 
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1.2 OVERVIEW OF THE THESIS 
The thesis is organised in the following way. Chapter 2 describes the theoretical 
background of the study. I begin by placing actor network theory (ANT) within other 
social scientific, in particular within science studies. I then go on to present an 
overview of ANT. My aim is to define and explain some of the central concepts of 
ANT. In particular, I describe the key moments of translation: problematization, 
interessement, enrolment and mobilization. Once I have outlined some of the key 
concepts, I will illustrate them with a number of studies carried out from an ANT 
perspective. I then go on to critically assess the importance of ANT. One of the 
important concepts that I will bring out in this thesis is what has been called a 
`program of action', so this will be dealt with in this chapter. This thesis does not 
only concern itself with ANT. It is necessary therefore to describe other areas of 
sociology that will be used in this thesis, these are the sociologies of the body and 
consumption, and the public understanding of science. 
Chapter 3 places the development of human insulin within a historical context. In 
particular, I am interested in outlining the way key actors, in particular pharmaceutical 
companies, were interested in the progress of the research teams. I will also pay 
attention to the ways in which key actors first stressed the need for, and then the 
superiority of, human insulin. I will then go on to theorise the development of human 
insulin. This chapter is important because it sets the scene for future chapters, in 
particular, it outlines the meanings of human insulin. In future chapters I will describe 
how various actors, such as phaninaceutical companies and scientists, drew on these 
meanings to support their own claims. 
Chapter 4 begins to describe some of the negative effects experienced by some 
diabetics on human insulin. I begin the chapter by outlining the meaning of 
hypoglycaemia, in particular, how it can be seen as a biographical disruption. I then 
go on to describe the meaning of hypoglycaemia unawareness, which was one of the 
most common complaints of those diabetics experiencing problems on human insulin. 
I also describe some of the initial reactions of a number of key actors, help groups, 
scientific and medical community, to reports that diabetics were experiencing negative 
effects on human insulin. 
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Chapters 5 and 6 deal with similar issues, but from two different perspectives. 
Chapter 5 looks at the role of the scientific community and pharmaceutical companies 
in the human insulin debate. I begin by providing an overview of the human insulin 
debate. 1 then go on to describe the scientific studies that were carried out that hoped 
to show whether human insulin did or did not cause adverse effects. I not only 
describe some of the key studies that were carried out, but I also describe some of the 
key discussions within the scientific community, particularly over the `ideal study'. I 
then go on to describe some of the reactions of the pharmaceutical companies to the 
possible problems experienced by some diabetics on human insulin. 
Chapter 6 goes on to describe the role of diabetics and care groups in the human 
insulin debate. I begin by describing the role of mediating others, the family and the 
media, in making diabetics aware of the problems experienced by diabetics on human 
insulin. I then go on to describe the solutions and resolutions presented by doctors 
that were accepted or rejected by diabetics. In Chapter 6I will also describe one 
important feature of the human insulin debate: the issue of choice of insulin species. I 
will conclude this chapter by outlining some of the key differences between the two 
major care groups in this study, the British Diabetic Association and the Insulin 
Dependent Diabetic Trust. 
Chapter 7, the concluding chapter, aims to theorise the human insulin controversy 
more comprehensively. I begin by describing the conditions under which diabetics 
produced texts to care groups, and how these texts were then collectivized and 
circulated to other actors by care groups. However, I also stress that it is not just care 
groups who collectivize texts, we also have to be aware of the collectivization carried 
out by other actors, such as the medical profession. One of the important features in 
the collectivization of texts is that actors draw texts from a wide variety of sources. In 
theorising these processes, I draw and expand the notion of the core set. I then go on 
to conceptualise three key issues in the human insulin debate: the way in which the 
solutions were presented to diabetics; how agreement between a number of actors was 
maintained; and, the actions of care groups towards key members in the human insulin 
debate. Finally, I assess the implications of the thesis; look at any changes that could 
be made to the thesis; and, point to possible future research. 
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2. THEORETICAL PERSPECTIVES 
2.1 INTRODUCTION 
The aim of this chapter is to explore the theoretical perspective that I adopt in this 
study. My interest is in looking at the process by which actors, whether human or 
nonhuman, are able to unite actors to form durable networks. In forming durable 
networks, actors not only need to define themselves as central actors, but also to 
challenge, undermine and shatter competing networks. I use ANT to do this, as it is 
very good at describing the work of network builders since it looks at the strategies 
used by actors to form credible networks. 
However, before I look at actor network theory (ANT) it is important to have some 
awareness of where ANT is situated within sociology. Pickering argues that the early 
1970s saw the emergence of a new "approach about thinking about science" (1992: 1) 
known as the sociology of scientific knowledge (SSK). This new approach began by 
arguing that scientific activity was social to its core and should be studied like any 
other social activity. It was argued that "SSK was determinedly empirical and 
naturalistic" (Pickering, 1992: 1). In this early period of SSK, Pickering argues that 
the conceptual and geographical map of SSK remained simple and readily surveyed. 
He argues that there were two main schools. Those in Edinburgh laid out the macro- 
social approach (Bloor, 1976; Barnes and Shapin, 1979), while those in Bath 
pioneered a more micro-social approach (summarised in Collins, 1985). However, by 
the late 1970s the map had begun to change. 
In the late 1970s new approaches that had a lot in common with SSK began to 
surface. Pickering (1992) outlines a number of these developments: ethnographic 
study (Latour and Woolgar, 1979); work carried out from an ethnomethodology 
perspective (Lynch et al., 1983; Lynch, 1985; Livingston, 1986); some philosophers 
of science developed a "new empirically informed approach within their discipline" 
(Hacking, 1983; Cartwright, 1983); and a discourse analysis program (Gilbert and 
Mulkay, 1984). Later Latour went in a different direction to Woolgar, and developed 
his actor network approach with Michel Callon and John Law (Latour, 1987; Latour, 
1988). These new studies should be placed under the umbrella of `science studies'. 
Work within science studies has been carried out in a number of locations and 
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contexts. Some work has studied the laboratory bench, some has looked at 
controversies (within both scientific communities and the public sphere), and other 
studies have looked at fringe science. However, although the context of the research 
may change, what is of interest to the researcher is the process by which certain 
knowledge claims are successful and others unsuccessful. An overriding theme in 
these studies is that there is nothing special about the generation of scientific 
knowledge. Scientific knowledge is, instead, simply one form of cultural activity, 
which can, like any other form of knowledge production be studied. 
ANT fits very well with this perspective, since it argues that all actors are potential 
network builders. It is not just scientists who enrol `lay' actors, lay actors also enrol 
scientists. The important point is that actors need to enrol human and nonhuman 
actors if they are to form durable networks. By using the new vocabulary of ANT, 
which uses the same teens to describe the actions of all actors, we do not lapse into 
treating human and nonhuman actors differently. An awareness of this concept is 
very important in this thesis because one of the important entities is human insulin -a 
nonhuman. 
However, those using ANT to describe medical controversies have not, by and large, 
developed the way in which the body should be fommnulated. My theoretical 
perspective attempts to correct this by including some analysis of the body from an 
ANT perspective. As such, the body, as with any network, is heterogeneous, in that it 
incorporates both human and nonhuman actors. Usually the actors that make up 
healthy bodies are hidden, but in times of illness, new actors may be included into the 
body. Not only this, but the relationship that the body has with existing actors, such 
as relatives, may also be re-negotiated. 
In times of illness new knowledge may be incorporated into the network body, and as 
a result, it will be necessary for me to refer to the types of knowledge that actors 
possess. Patients' primary source of knowledge about their illness is likely to be 
taken from their experiences, and this is likely to be different from the knowledge 
possessed by doctors. Patients who are dissatisfied with the way they are treated by 
`experts' may seek out other sources of expertise; one such source is care groups. 
Care groups are likely to collectivize evidence from multiple sources, both `lay' and 
`expert', which is then used to challenge the authority of the medical profession. In 
19 
2. Theoretical perspectives 
order to do this, care groups need to bring together disparate actors in order to form a 
durable network. 
Of course, there are alternatives to ANT. One of the reasons for using ANT in this 
study is its ability to describe the heterogeneity of the networks that permeate our 
lives. Crucial to this heterogeneity is that networks are made up of both human and 
nonhuman actors. Not only does ANT argue that the analyst should describe the 
actions of humans and nonhumans, it also provides a vocabulary by which this can be 
done. The vocabulary is able to describe the way in which actors problematize 
existing networks, and at the same time, define themselves as being able to provide 
solutions. 
In this chapter I will firstly describe some of the central themes behind ANT. 
Secondly, I will describe some of the studies that have been carried out under an ANT 
framework and point to some modifications. Thirdly, I will deal with some 
methodological and theoretical criticisms that have been levelled at ANT. Fourthly, I 
will explore a concept particularly pertinent to the present research that has been used 
within ANT, that of `program of action'. The fifth section looks at how ideas behind 
the sociologies of the body and consumption, and the public understanding of science 
(particularly the division between `expert' and `lay knowledge') can enrich ANT. 
Then, in the final section, I will point to a number of theoretical areas that I will 
develop in later chapters. 
2.2 AN OVERVIEW OF ACTOR NETWORK THEORY 
The journal Lingua Franca claims, on the back cover of Latour's `Aramis or the Love 
of Technology', that "Latour [a proponent of ANT] is one of the most rigorous 
thinkers in the loose combination of disciplines known as `science studies"' (1996 
[ 1993]). Perl, ips what sets ANT apart from other `science studies' is that it states that 
there should be no divide between human and nonhuman entities. Therefore, when 
we talk about society we need to adopt a different approach than has previously been 
adopted, since other approaches have `ignored' nonhuman entities, or spoke of them 
in secondary terms. But, before I continue, we must engage with the principles 
behind actor network theory. 
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2.2.1 Methodological Principles 
At the centre of ANT are three methodological principles or tenets that we must "obey 
faithfully" (Callon, 1986a: 200). The agnosticism principle states that the observer 
should be impartial to the scientific and technological arguments of those involved in 
controversies, and further, the observer should refrain from censoring any entity when 
they speak about themselves or their social environment. This idea is summed up by 
Callon: 
"No point of view is privileged and no interpretation is censored. The observer 
does not fix the identity of the implicated actors if this identity is still being 
negotiated. " 
(Callon, 1986a: 200) 
The second principle is of generalized or radical symmetry. This states that the 
researcher should use the same vocabulary for entities, whether they are human or 
nonhuman. We should also not change the repertoire when we move from the 
technical to the social. This goes further than Bloor (1976) and the `Strong 
Programme', where the principle of symmetry only referred to claims of truth or 
falsity of viewpoints and arguments in a specific controversy. 
Finally, the principle of free association, reinstates what the two other principles have 
only hinted at. It argues that we should abandon all a priori distinctions between 
natural (or technical) and social events, we should "reject the hypothesis of a definite 
boundary which separates the two. " (Callon, 1986a: 200-1). Added to this, we should 
not pre-define or impose a pre-established grid of analysis on the categories used, the 
entities that are mobilised or the relationship between various `actors'. Indeed, 
describing the changing interrelations between actors, whether human or nonhuman, 
is one of the issues at hand. 
By using these tenets the actions of scientists (or any other actor, such as a public 
official or a pressure group campaigner) are treated not simply as carrying out 
something called `science' (public policy or collective action). Instead, we should 
view such actors as attempting to extend their influence and power beyond the 
networks in which they are situated. For example, scientists attempt to extend their 
influences beyond the laboratory, into other social worlds, as well as conducting work 
that can he labelled `scientific'. Indeed `scientific' work is expanded to encompass a 
whole range of different activities. As such, in order to extend their influence, 
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scientists (or any actor) need to carry out `heterogeneous engineering' (Law, 1987). 
This refers not only to the linking of differing social worlds, but also to the 
association of human and nonhuman entities to form patterned networks. This brings 
me to what in ANT is termed the moments of translation. Indeed Callon has called 
his work the sociology of translation (1986a). 
However, before I turn to translation, something needs to be said about the vocabulary 
that is used in ANT. The second principle above argues for a new vocabulary that 
breaks away from the distinction between nature and society. ANT theorists wish to 
blur the distinction between "the really social and human-centred terms and the really 
natural and object-centred repertoires. " (Callon and Latour, 1992: 347). In an attempt 
to do this a new vocabulary is proposed. 
Actant is the term that Latour, and others, use for both human and nonhuman entities, 
and forms part of the vocabulary of the actor network or the non-modern constitution 
(1993). An actant is defined as any "entity able to associate texts, humans, 
nonhurnans and money. " (Callon, 1991: 140). By using the term octant instead of 
actor it is hoped that the boundary between the human and nonhuman will be blurred. 
An `aim' of an actant is to carry out heterogeneous engineering in order to form 
heterogeneous networks. 
Traditional Term Actor Network Term 
actor actant 
social relations actor network 
interaction translation 
discovery negotiation 
proof immutable mobiles 
data inscriptions 
social roles delegation 
Figure 2-1: A vocabulary for a new ontological status for society and things 
The use of new terms maps out a new ontological status for society and things. Some 
of the terms, in this new vocabulary, are listed in Figure 2-1. I will define, and return 
to these terms, throughout this, and subsequent chapters. 
2.2.2 Moments of Translation 
Heterogeneous engineering involves carrying out practices that aim to entice other 
actors into a particular network, and is carried out through what has been termed 
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moments of translation. Before I describe these r oments, we first need to be aware 
of what we mean by translation. Translation can broadly be defined as the process 
whereby "the identity of actors, the possibility of interaction and the margins of 
manoeuvre are negotiated and delimited. " (Callon, 1986a: 203). The process of 
translation can be divided into a number of factors, it involves the translator, 
something that is translated, and a medium in which the translation is inscribed or 
mediated. To get a better understanding of translation I will now look at the moments 
of translation. 
2.2.2.1 Problematization, Interessemnent, Enrolment and Mobilization 
The aim of the moments of translation is to create a network of heterogeneous actors, 
and involves four moments or phases of translation. Although these moments are 
presented sequentially, it is important to be aware that they are not necessarily 
discrete moments and in a particularly study there may be some overlap between the 
moments (Arksey, 1998). 
The first moment is that of problematization. It involves actors' preliminary attempts 
to determine a set of actors and define "their identities in such a way as to establish 
themselves as an obligatory passage point" (Callon, 1986a: 204). The process of 
problematization therefore involves two movements. Firstly, a particular problem is 
identified by an actor and how it relates to other actors. Secondly, the defining actor 
attempts to become indispensable to the targeted entities by defining themselves as 
the means by which the defined problem can be solved, and thus become the 
obligatory passage point. Singleton and Michael argue that obligatory passage points 
(OPPs) act as "unavoidable conduits - narrative bottlenecks - through which they 
[entities] must pass in order to articulate both their identity and their raison d'etre. " 
(1993: 229-230). 
The second moment of translation is interessement. Problematization hypothetically 
sets up the identities and wants of other entities, interessement however, involves the 
"group of actions by which an entity attempts to impose and stabilize the identity of 
the other actors it defined through problematization. " (Callon, 1986a: 208-209). 
Interessernent entails "one entity attracting another by coming between that entity and 
a third" (Callon et al., 1986: xvii) as shown in Figure 2-2. 
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DE 
B 
A 
A uses various forces. anything from brute force to persuasion by the 
use of texts and other inscriptions. to interest B. by breaking existing 
ties that B has with C, D, E etc. (if they exist). 
Figure 2-2: To show the elementary form of interessement 
The means by which existing ties are broken and others re-established are unlimited. 
As Law writes, interessement may: 
"... operate through the medium of interests, but also via naked force, apparent 
inevitability, love, duty, bribery, physical fact, superior command of 
information, spirituality or lack of imagination. " 
(Law, 1986: 71-72) 
Particular examples of interessement devices include conferences, scientific papers 
and promotional material, although the precise devices will depend on the networks 
involved. 
The third moment of translation is enrolment. Although enrolment is not an actual 
technique, it describes the success of interessement and the various multilateral 
negotiations that it involved. With successful enrolment comes the acceptance of 
identities and problems by those involved, the discontinuation of ties with other 
competing entities, and the defining actor becomes accepted as an obligatory passage 
point. It is however important to be aware that just because an entity has been 
enrolled, does not mean that it always will be. 
24 
2.2 An overview of actor network theory 
The possible transient nature of enrolment leads us to a particular definition of power. 
Power should not be seen as something that can be possessed or stored, rather power 
is the "consequence of the energy given to the token by everyone in the chain who 
does something with it, as in the case of rugby players and a rugby ball. " (Latour, 
1981: 267). Therefore, when an entity becomes part of a network it is giving its 
power to that network. The multilateral nature of power involves both the 
`66capturing' of the other and the other's `yielding'. " (Singleton and Michael, 1993: 
229). Further, it is only when an entity begins to lose its power that it realises that it 
was `made of the wills of others. 
The fourth and final moment of translation is mobilization. This final moment can be 
seen as a consolidation of the previous moments, and the success of mobilization will 
affect the robustness of the network. Mobilization can be seen as the methods by 
which a small number of entities are able to silence and speak for others, or as Callon 
argues, "To speak for others is to first silence those in whose name we speak. " 
(1986a: 216). For example, when scientists present their work at conferences they are 
acting as a representative of all the enrolled entities behind their work. However, for 
the entities to remain mobilized the enrolling entity will have to continually carry out 
translations to enable them to represent (silence) the enrolled entities. The aim of an 
enrolling entity is to construct a durable network, that is, a network that will not easily 
disintegrate. Indeed, the ability to form durable networks is dependent on the 
capacity of certain actors to interrelate both society and nature into a coherent 
network (Callon, 1986a). 
One way in which actors become silenced is through the production of inscriptions. 
When scientists present their work at meetings, their work will be represented in the 
form of inscriptions. When presenting their work at a conference it is unlikely that 
the original scientists will repeat their experiment at the conference or seminar. 
Instead, scientists are more likely to present a number of graphs, figures, data sets and 
other textual representations, which simplify/obscure the translations. In order to 
produce 
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these inscriptions, it has been necessary for the scientists to carry out a number of 
translations to make the visible invisible 
In the laboratory the scientist may pass any number of entities through any number of 
machines, they may carry out any number of calculations and attend any number of 
team meetings. Where once all sorts of uncertainties and negotiations were visible in 
the laboratory they now become invisible; the complexities become silenced to form a 
single (black-boxed) entity. As Callon writes, "Out of laboratories come quarks, 
enzymes, and proteins, all new actants that did not exist before being brought into 
play by statements, tables, machines, or embodied skills. " (1995: 54). Therefore, 
when we look at the amino acid sequence of a number of Insulins (Figure 2-3) we are 
not aware of the specific chemical reactions and techniques used to separate the 
peptides and identify the amino acids, instead we are presented with a textual 
inscription of the end product. Other inscriptions are more explanatory, for example, 
Figure 2-4 (taken from Chien (1996)) shows some of the translations necessary to 
produce a form of human insulin, and Figure 2-5 (adapted from Office of Technology 
Assessment (1982)) shows some of the translations necessary in the development 
process for genetically engineered pharmaceuticals. 
The site where heterogeneous elements are brought together or translated Latour calls 
a `centre of calculation'. The laboratory is one such site. Through the laboratory 
complicated translations are performed to produce seemingly uncomplicated units or 
black boxes. The various entities within the network, that comprises these entities, 
are black boxed or hidden. Part of the sociology of translation is looking at the 
"process in which sets of relations between projects, interests, goals, and naturally 
occurring entities - objects which might otherwise be separate from one another - are 
proposed and brought into being. " (Callon and Law, 1989: 58-59). These relations 
form part of the network that constitutes what comes to be `known', or the product of 
science, such as scientific theories. In such cases `heterogeneous engineering' can be 
seen as successful, although whether this heterogeneous network will always be stable 
is never certain. Indeed, the production of `knowledge' is always under negotiation. 
Inscriptions not only act as a form of simplification, but also as a means of acting at a 
distance. Enrolment can be more problematic when the enroler and the enrolee are 
27 
2. Theoretical perspectives 
SS 
A-chain COOH 
s 
B-chain 
NHS 
Porcine Insulin 
Trr psis (porcine.. -24 kD) 
Insulin ýý s"' Alai" 
C 
OO Scr Ti) psin 
O 
Insulin 
DCO 
Scr Tn-psin 
Ai 
H, O H2N Thr --COOR 
Thrconme ester 
Hydrolysis V Ad. soin. Aminolvsis V Organic solvent 
O Tr'psin removed by 
Insulin C OH y gel filtration at low PH 
des_ (Ala"")_- insulin Q 
Insulin Lis"' TD -C OR 
Insulin ester 
(optimized yield: 97%) 
1 Cleavage & separation 
(ion exchange chromatography) 
SS 
A-chain COOH 
(21 amino acids) 
NH, Lý s'> Thr'o 
Hunan Insulin B-chain 
(30 amino acids) 
Figure 2-4: Procedure involved in the conversion of porcine insulin to human 
insulin by Novo Industri Nordisk (taken from Chien (1996)) 
28 
2.2 An overview of actor network theory 
Chemicals 
ffi-`ý 
) 
2. Tissues 
Micro organisms such as E. coli 10,0 
4. Control 
*sinals 
Genc 5. Gen 
i;. Recombinat 
DNA 
[ 3. Laboratory 
II 
scale fernleiltation 
At*** 
  
14. Process 
development 
scale tip 
15. Large-scale 
fermentation 
7. Cutting 6. Plasmid 
4 
9. Insertion 
10. P1aasmid 
multiplication 
40 ((: Oo 0 
11. Expression 
--ý -º )e, (7e 
18. Animal 
16. Purification 17. Packaging testing 
P-4 1 
22. Health care 
applications 
12. Cell 
division 
21. Submit NDA 20. Clinical testing 19. Submit NDA 
Ile dev'elopmeni process begins by obtaining DNA either through organic synthesis ( 1) or derived fron biological sources 
such as tissues (2). The DN. A obtained from one or both sources is tailored to Ann the basic 'gene' (3) which contains the 
genetic information to 'code' for a desired product. such as human interl'eron or human insulin. Control signals (I containing 
plasmids (6) are isolated from micro-organisms such as F. coli: an open (7) and spliced back (8) together with genes and 
control signals to turnt 'recombinant 1)N. A molecules 'These molecules are then introduced into a host cell (9). 
Each plasmmid is copied man times in a cell (1 U). Fach cell then translates the information contained in these plasinids into 
the desired product. a process railed 'cypression' (11) Cells divide (12) and pass on to their offspring the same genetic 
intoi-niation contained in the parent cell. 
Fermentation of large populations of genetically engineered micro-organisms is first done in shaker flasks (13), and then in 
small fermenters (14) to determine growth conditions and eventually in larger b nnentation tanks (15). Cellular extract 
obtained from the fermentation process is then separated. purified (16), and packaged (17) for health care applications. 
Health care products an first tested in animal studies (18) to demonstrate a product's pharmacological activity and safety, in 
the 1 sited Staten an investigational neu drug application (19) is submitted to begin human clinical trials to establish safety 
and efficacy. Follow ing clinical testing (20). a new drug application (NI). A) (2 1) is filed with the Food and Drug 
Administration (FD. A). When the Nl). A has been review cd and approved by the FD. ý the product may be marketed in the 
i'sited States (22) 
Figure 2-5: The development process for genetically engineered pharmaceuticals 
(adapted from Office of Technology Assessment (1982)) 
29 
2. Theoretical perspectives 
separated by distance. One solution to this `problem' of distance is to produce textual 
inscriptions that are "mobile but also immutable, presentable, readable and 
combinable with each other. " (Latour, 1986: 7). Since inscriptions can also be 
immutable mobiles they can be moved, compared and combined without losing the 
meaning generated from the centre of calculation. In other words, the inscription is 
durable. The result is a text which because it combines a large amount of information 
into a simple representation, is a powerfully persuasive text (Latour, 1987). However, 
as Law and Michael (Law, 1994; Michael, 1996a) have pointed out, this immutability 
is relational, that is, its potency is dependent on the authority of the generating 
network. 
2.2.3 Intermediaries 
I described above the role of textual inscriptions and how they can be seen as 
representing a number of (hidden) translations. An inscription is one example of an 
intermediary which describes anything that passes between various actants (Law and 
Callon, 1992: 25). Further, this passing or circulation describes a particular setting2 or 
event (Akrich and Latour, 1992: 259). By studying the circulation of these 
intermediaries we are able to study the relationship between various networks. Each 
intermediary should be seen as a particular `point of view', and when these points of 
view are circulated researchers become aware of a particular version of `truth'. As 
Star writes: 
"... every viewpoint is a part of some picture, but not the whole picture. The 
implications are that only in the articulation of viewpoints can we understand 
anything about truth, that is a fundamentally interactional, social phenomenon. " 
(Star, 1991b: 278) 
Callon (1991) argues that there are four main types of intermediary, as shown in 
Figure 2-6 with examples. It is crucial to realise that intermediaries are likely to be 
networks (or their representatives), even though they may be represented as a single 
(or singularized) artefact. For example, a scientific paper is comprised of a collection 
and representation of many entities, actants and intermediaries. As with inscriptions, 
the effect of intermediaries is dependent on the (continued) authority of the generating 
network. 
2 Assemblies of humans and nonhumans, where the competences and performances are distributed. It is 
these assemblies that is the object of analysis (Akrich and Latour, 1992: 259). 
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Intermediary Type Examples 
Texts Reports, books, articles, floppy discs etc. 
(literary inscriptions) Scientific articles, Balance and IDDT magazines. 
Technical artefacts Scientific instruments, machines, robots and consumer 
goods. 
Human insulin, syringes, and blood glucose monitoring 
equipment. 
Human beings The skills, knowledge and the know-how that they 
incorporate. 
The skills a diabetic possesses in order to maintain a healthy 
body. 
Money In all its forms. 
Figure 2-6: Types of intermediaries 
In the definition of an actant above, I pointed to the circulation and generation of 
intermediaries, in the form of texts, humans, nonhumans and money. There is an 
important distinction between intermediaries and actants. Intermediaries can become 
actants when they are able to generate other intermediaries. For example, when 
human insulin is passed between the doctor and patient it is an intermediary. 
However, if the patient then experiences problems on human insulin, and speaks to 
their doctor, clinic or other diabetics about their problems, then human insulin 
becomes an actant. Another example is the insulin pen. An insulin pen is an insulin 
injection device, about the size of a pen, which includes a needle and holds a vial of 
insulin. Using the pen set insulin doses can be administered, by the diabetic, in a 
convenient way. When passed between the patient and doctor it is an intermediary. 
However, if, because of its convenient method of insulin administration, it enables the 
diabetic to do things they were unable to do using a traditional syringe, it becomes an 
actant. 
However, as Callon points out, "the division between actors and intermediaries is a 
purely technical matter" (1991: 141) and is dependent on the focus that the researcher 
chooses to take. We may look at a scientific paper and study how it affects other 
actors, in which case it is an actant. On the other hand, we could look at scientists in 
general and how papers are constructed, published and circulated, in which case the 
paper passes between various groups. Michael makes the interesting point, taken 
from Law (1994), that deciding whether an entity is an intermediary or an actant is 
"essentially a question of who/what can `persuade' us that they comprise such a locus 
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of agency" (Michael, 1996a: 55). 3 
I have now given an outline of the main base of actor network theory. In the next 
section I would like to describe some of the studies that have been carried out under 
the auspices of ANT. I have two aims: to illustrate the concepts of ANT in detail, and 
to outline some additions and modifications to ANT. 
?.?. 4 New and Old Studies 
One of the most often cited papers on actor network theory is Michel Callon's (1986a) 
study of the fishermen of St Brieuc Bay in France. He describes how three scientists 
wished to develop a conservation strategy for the scallop (the Pecten Maximus 
species) population of the bay. At the time of the study the stocks were becoming 
depleted due to over-fishing. In order to develop the conservation strategy it was 
necessary for the scientists to interest a number of key groups: local fishermen (not to 
over-fish); the scallops (to reproduce more frequently); and the scientific community 
(to agree with, and support, the methods proposed by the three scientists). 
What followed was a process of problematization where the identities of the three 
principle actors were defined. The fishermen where defined as needing to `assure a 
long-term profit'; the scallops as wanting to `perpetuate themselves'; and scientific 
colleagues as wanting to `increase knowledge about Pecten Maximus'. Importantly, it 
was the scientists who set themselves up as the pathway, the obligatory passage point, 
by which these aims could be achieved. In the second moment of translation, 
interessement, the scientists had to separate the various actors from their existing ties 
using a number of different interessernent devices. With the use of towlines scallops 
were (physically) disassociated from those actors that threatened them. For the 
fishermen, the interessement devices included texts and conversations, which 
attempted to persuade the fishermen not to over fish. The researchers also produced 
graphs, charts and data to persuade the scientific community that the techniques that 
they were employing would work. 
Taken a step further, we can argue that entities are literally persuading us of their power and 
importance. Indeed, why do any of us investigate certain areas and not others? Why do we identify 
with particular theories and methodologies and not others'? In each case we are persuaded of their 
importance. We are persuaded to investigate certain areas of society because of our belief that this 
area has had an influence on other areas of society. We use particular theories and methodologies 
because they persuade us that they are able to produce something credible. 
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For the first year or two the scallops did reproduce more frequently, the fishermen did 
not over-fish, and the scientific community did not openly question the research team. 
In other words, the various actors had been enrolled. Further, the research team can 
be said to represent the `wants' of the various actors involved. However, on one 
Christmas Eve the fisherman over fished. Added to this, other scientists began 
expressing doubts over the researchers' theorising about `sustainable development' 
(Arksey, 1998: 202) and the scallops stopped reproducing. 
This example illustrates the nature of power. For the research group, their power was 
made up of the wills of the fishermen, scallops, and the scientific community. Yet 
when the enrolled groups no longer followed their defined `wants' they removed their 
will from the scientists, at which point the scientists could no longer claim to be 
`acting on their behalf. ' Although Callon portrays this as a betrayal, we have to 
recognise that it may well have been that the fishermen always had some unexpressed 
doubts over the scientists techniques. Perhaps this is illustrated by their lack of 
involvement in the work of the scientists, Callon writes: 
"They [the fishermen] watch like amused spectators and wait for the final 
verdict. They are prepared simply to accept the conclusions drawn by the 
specialists. Their consent is obtained (in advance) without any discussion. " 
(Callon, 1986a: 213) 
We need to be aware that there may be other influences that affect the collapse of a 
network. Wynne (1992) has pointed to the power struggles that go on within wider 
culture, by which I mean the discourses that permeate across networks, such as the 
`need to provide for your family'. Importantly, "it is possible to focus upon these big 
cultural factors as they are realised in the identities of actors" (Michael, 1996a: 157). 
The key point here is that we should be aware of the cultural backdrop or grounds to 
such micro-processes (although this is something that ANT researchers might dispute) 
(Michael, 1996a: 157). 
Pressures originating from the cultural backdrop may not show themselves within a 
particular network until some specific point, when they may be perceived, by the 
analyst, as a betrayal of that network. It may be no coincidence that the fishermen 
decided to over fish on Christmas Eve, when it can be argued that there were extra 
economic pressures, from wider culture, to provide for their families. Therefore, the 
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movement from acquiescence to betrayal may not reflect a binary opposition. Work 
by Singleton and Michael (1993) has shed light on this feature, and this is where my 
attention now turns. 
From reading earlier actor network accounts the reader can be forgiven for seeing 
networks as being "nested one within the other. " (Lee and Brown, 1994: 784). 
However, other work has shown that networks are not necessarily clean and clear, but 
rather, the appearance of this (temporary) crispness is the result of the "singular flow 
of the narrative of a particular study. " (Singleton and Michael, 1993: 232). As a result 
sonne authors have suggested that networks should be seen in terms of ambivalence 
and marginality. 
Singleton and Michael (1993) carried out an analysis of general practitioners' (GPs') 
discourses around the UK Cervical Screening Programme (CSP). The study describes 
how GPs were enrolled into the screening program with particular identities, such as 
ambassadors of medical science and skilful providers of the cervical smear test. 
However, other elements that did not enter into the CSP actor network entered into 
the GPs' network. For example, the CSP network represents an unproblematic circuit 
of associations: women-GPs-laboratory-GPs-women. In this network women present 
themselves unproblematically to doctors. Thus, within this network there was not a 
place for unco-operative women, that is, those who consistently do not attend their 
screening test. 
Another point is that GPs `complexify' and problematize themselves in order to 
ensure that they are seen as important actors within the CSP. For example, at times 
GPs stressed their autonomous role in interpreting smear test results that came back 
from the laboratory. Yet, at other times, when they wished to stress the efficiency of 
the CSP program, they represented the laboratory as the `source of true knowledge 
about cervical smears. ' 
Singleton and Michael view GPs as `internal network builders' who construct their 
own GP Cervical Screening Programme within the governmental programme. This 
new network does not totally disregard the definitions of the governmental screening 
program, nor does it totally accept all its definitions, as Singleton and Michael write: 
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"To overstress uncertainty and multiplicity would be to endanger the 
governmental CSP and undermine the GP role; yet, to follow unflinchingly the 
government's model of the GP role would be to render that role unworkable... " 
(Singleton and Michael, 1993: 259) 
Importantly, this ambivalence may help us to understand that betrayal and defeat are 
no longer dramatic events. Instead, betrayal should be seen as the result of a 
"congealment of a disparate array of ambivalences into a focused pattern of 
resistances" (Singleton and Michael, -1993: 259). In previous actor network studies 
these ambivalences would usually be `out of focus', only to appear later as a betrayal 
that seems to come `out of the blue'. 
It is also important to realise that some actors may be marginal but not silent. For 
GPs marginality was internal to the relevant network, however another form of 
marginality stresses exclusion of a network from the target network analysed by the 
theorist (Star, 1991 a). Michael and Birke (1994) use the example of pro-animal 
experimentation scientists who refer to various `others', such as the cosmetic industry 
and pet owners, to represent themselves in a more positive light. The exclusion is 
something that is actually constructed, as Star writes, "Every enrolment entails both a 
failure to enrol and a destruction of the world of the non-enrolled" (1991 a). 
From the point of view of objects themselves, it is interesting to look at a novel paper 
by Bruno Latour, which looked at the sociology of a door closer (1988; 1992). In the 
paper Latour describes how a, "`purely' technical artifact [the door closer] is a highly 
moral, highly social actor that deserves careful consideration" (1988: 298). He 
describes how a door, a nonhuman, carries out a number of tasks that could be carried 
out by a human, for example, doors allow people through them and also prevent 
people (noise, rats and dust) to go through them. If the door was not there, every time 
a human wanted to go through a wall, s/he would have to dismantle the wall and then 
rebuild it to prevent others from passing through it. As a general descriptive rule 
Latour tells us that: 
"... every time you want to know what a nonhuman does, simply imagine what 
other humans or other nonhumans would have to do if the character was not 
present. " 
(Latour, 1992: 229) 
There is however another problem with doors, they can be left open. One solution 
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would be to employ a doorman or groom to open and close the door. Such a solution 
may lead to other problems, for example, the groom would need to be trained and 
disciplined, s/he may fall ill, and it would be costly. However, it is possible to fix a 
door closer (a nonhuman groom) to the door to do the opening and closing. Through 
looking at the door closer Latour has shown that simple, mundane artefacts should 
have a place within social theory. 
Latour's study of the door closer is relevant to my work because it illustrates how it is 
possible to study a `mundane' artefact. Further, it also illustrates how various 
translations occur to alter the characteristics of an artefact, to redefine its meaning. 
For example, a door closer may allow people to pass through the door, but may also 
prevent those unable to open the door to pass through the `gap in the wall'. In such 
cases then, the door is a barrier to the disabled or those carrying packages: as Langdon 
Winner may say, `artifacts have politics' (1985). However, with the use of weight 
detectors and electronic motors, anyone may be able to pass through the `gap in the 
wall'. 
However Bijker asks, `Whose politics do artifacts have? ' (1995). It is choices made 
in the design of artefacts that instil politics into artefacts. These choices affect the 
way that `others' can engage with this artefact. One of the aims of the researcher is to 
study who gives what politics to an artefact and to unravel the negotiations that were 
necessary for an artefact to have particular features. It is also important to study how 
these features may sometimes change. I will show later in this thesis how the 
meaning of human insulin changed due to various translations. 
As a final example of work carried out under the auspices of ANT, I would like to 
look at the case of the metered dose inhaler (Prout, 1996). The metered dose inhaler 
(MDI) is used in the treatment and management of asthma by supplying the patient 
with therapeutic substances when needed. The MDI has advantages in that: it can 
deliver a dose direct to the lungs and so is absorbed quickly; patients report relief of 
symptoms with few side effects; the device is easy to use; and patients appreciate the 
controlled dose (Prout, 1996: 205). Importantly however, studies have shown that the 
substances in the MDI can be dangerous. The drugs contained within MDIs have an 
effect on the heart and a large dose can cause arrythmia and a risk of death. 
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In order for the MDI to be seen as successful it needs to balance two contradictions: 
on the one hand it needs to deliver measured therapeutic doses at the appropriate time; 
on the other hand, access to these substances has to be restricted since they are 
potentially dangerous. Prout argues that the MDI `stands in for' (what Latour calls 
delegation (1992)) biomedical control by encoding the ability to meter a dose within 
the MDI. Importantly, it is necessary for the MDI to give autonomy to the patient, but 
also restrict access to the therapeutic chemicals in the MDI to a biornedically pre- 
determined quantity. Prout also points out that the device works to reduce criticism of 
biomedicine, by providing a device that helps asthma sufferers who were previously 
unhappy with existing therapeutic devices (1996: 207). 
Prout also describes how the user needs to be configured to use the inhaler. It was 
found that many users were not getting the full benefit from the MDI because they 
were using it incorrectly. A number of attempts were made to enable patients to use 
the MDI better, for example, instructions were given to patients, some physicians 
began to teach patients to use the MDI, and variations on the original MDI were 
produced. These activities can be seen as attempts by the enrolling network to 
maintain enrolment. Without such activities the MDI would not help asthmatics, and 
so the medical profession would lose some of its authority. 
What the study also illustrates is how a "whole series of natural, technical and human 
elements are brought together and packaged into a particular device" (Prout, 1996: 
213). The package includes: the inhaler with its therapeutic substances; the clinicians 
and other medical professionals; and the user and his/her competencies. 
In this section 1 have described some of the main principles behind ANT. As should 
be clear, one of the important features is that we should not divide the human and the 
non-human. Instead, society is made up of heterogeneous networks which are the 
result of various acts of translation by actants. The aim of the analyst is to describe 
under what circumstances these heterogeneous networks are formed, and how the 
needs and wants of the actants involved are translated and defined. I would now like 
to look at some of the methodological and theoretical considerations within ANT. 
2.3 METHODOLOGICAL AND THEORETICAL CONCERNS 
Within ANT one particular methodological concern is the identification of actants. 
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ANT has mostly concentrated on `powerful' actants, and as a result, there has been a 
tendency to neglect the oppressed and underrepresented in society. Although, as Law 
points out, when studying `powerful' actors we are not so much celebrating but 
deconstructing them. When studying actors we are interested in the alliances of 
heterogeneous materials that enabled an actor to become a powerful actor (1991). 
One reason for the concentration on powerful actants, by researchers, could be that 
some actors are able to silence the less powerful, or as Callon claims, "successful 
translation quickly makes us forget its [an actant's] history. " (1986b: 28). This, of 
course, does not completely answer the question, since we do not have an account of 
how the oppressed in society manage - how they might mobilize, as it were, counter- 
networks. 
Indeed Law (1991) suggests that it is dangerous to concentrate on the heroes, and asks 
the question: How is ANT to give a voice to marginal actors? Star (1991 a) points out 
that these marginal actors are never completely lost, and may lurk in the background 
informing enrolled actors, indeed, "We are all marginal in some regard, as members 
of more than one community of practice" (Star, 1991 a: 52). 
As Arksey (1998) has pointed out, the vast majority of actor network stories have 
concentrated on the `heroines' of the story. This may be because many studies have 
been concerned to explain the power of scientists (Arksey, 1998: 202). Arksey's 
book looking at the network-building accomplishments of the relatively powerless, 
sufferers of RSI, attempts to counter this imbalance. 
Another concern is that in dealing with human and nonhuman actors we could be 
swamped by the number of available actors; as Rachel wrote, "I was paralysed by the 
choice of actants to follow - humiliated by their agility - confounded by their 
constantly changing forms. " (1994: 810). Therefore, for practical reasons, it is 
necessary for a researcher to justify why particular actants have been included, as no 
particular study can include all those actants that may be involved in a particular 
story. Within ANT there is also no final analysis, as Lee and Stenner, referring to 
Strathern (1996), have pointed out: 
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"... there is no final word, no line to draw under an analysis to bring it to a close, 
no necessary completion of accounts. Thus there is no necessary end to the 
elements that may contribute to a network, no general criteria by which ANT 
may bring an end to the list of what belongs and what is responsible. " 
(Lee and Stenner, 1999: 93) 
Indeed we are only telling a `story', that is, just as scientific accounts of science are 
`stories', so is the work of academic theorists. The work has to be a story because 
another researcher, studying the same episode, may produce a different account. 
Latour and Woolgar call this the `problem of fallibility', in which "all forms of 
description, report, observation and so on can always be undermined" (1979: 282). 
This includes my own. 
If there is no `final' interpretation, then why should we accept that of the analyst? As 
Collins and Yearley argue, if a researcher wants to speak on behalf of an entity: 
"He [sic] must show a firn grip on the nature of the scallops [entity]... In fact, 
we readers would prefer him to be more of a scallop [entity] expert than the 
others [other experts] if he is to speak authoritatively on the subject. " 
(Collins and Yearley, 1991: 316) 
However, I would argue that it is a knowledge of the heterogeneous networks that is 
important, of which the scallops, or any object or human, is only one part. As an 
actor network theorist I must show knowledge of all the `implicated actors'. 
Some have argued that, "The language changes, but the story remains the same. " 
(Collins and Yearley, 1991: 315). Thus, Collins and Yearley argue that actor network 
theory simply re-describes what could be said in another way. They claim that an 
actor network account can look like the account of a conventional historian of science 
(Collins and Yearley, 1991: 315n. 14). From this view it does not add anything new to 
science studies. 
Yet, it is necessary for actor network theory to change the language for the very 
reason that the original language, of the social sciences, does not do justice to the 
heterogeneity and relationality of the world. As noted above, it is argued that by 
using the same language for both the human and nonhuman we are able to criss-cross 
the human/nonhuman divide, and "so hope to overcome the difficulty of siding with 
one, and only one of the camps" (Callon and Latour, 1992: 354). 
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Further, it is argued that everyone in society deals with heterogeneous networks, that 
is, we are all heterogeneous engineers who "seek to associate entities that range from 
people, through skills, to artefacts and natural phenomena. " (Law, 1987: 129). In a 
sense ANT sets itself above other theorists. Although we all deal with heterogeneous 
networks, it is those who believe in generalised symmetry who have the theoretical 
means to give non-humans their `rightful' voice in society. It is those who use ANT 
who are able to fully accept the nonhuman - they are able to follow the `rules' of 
liberal democracy. For Latour and others, liberal democracy does not just include the 
human, but also the nonhuman. As a result, to follow the rules of liberal democracy 
means giving an equal voice to the missing masses - the nonhumans. This brings me 
to the politics of ANT. 
As already mentioned, ANT does not claim a separation between the human and the 
nonhuman. Latour has argued that if we believe in liberal democracy, if we believe in 
equality, then there is no reason why we should discriminate between the human and 
nonhuman. As Latour writes: 
"You discriminate between the human and the inhuman. I do not hold this bias 
(at least not this one) and see only actants-some human, some nonhuman, some 
skilled, some unskilled-that exchange their properties. " 
(Latour, 1992: 236) 
Although Lee and Brown (1994) argue that there are many vocabularies to choose 
from, it is one of liberal democracy that has been the most popular amongst actor 
network theorists. We are however caught in a kind of logical trap: 
Do you believe in liberal democracy? 
Should it be applied to all parts of society? 
Then you must believe in actor network theory. 
We are, in theory, caught within the trap on all levels. Who could, in principle, deny 
the concept of equality and liberal democracy (the first statement), once we accept 
this then we cannot deny the second, since it means we deny the idea of liberal 
democracy (the first). We are then led to agree with the final statement. If we do not 
accept that liberal democracy should be applied to all parts of society, then we are 
denying a version of liberal democracy itself. Of course, this is dependent on the 
definition of `society'. For Latour and others, society consists of not just humans, but 
nonhumans as well. In their version of liberal democracy all actants, human and 
40 
2.3 Methodological and theoretical concerns 
nonhuman, have a place, a voice, in society. 
As a result of these steps there is a "foreclosure on all alternative descriptions of the 
world through the assertion of total democracy and complete ontological monadism. " 
(Lee and Brown, 1994: 781). Indeed Latour has claimed "We will never do any 
better. " (1988: 231). 1 would prefer to be more cautious, and follow Joan Fujimura 
(although not talking particularly about ANT), when she argues that, "There is no 
finally stable ground on which any of us... base our stories" (1991: 237). However, 
Callon and Latour do not claim to be totally contented with their theory, as they write: 
"We believe.. . that although it is experimental, uncertain, and incomplete, it 
should be carried all the way, with the help of the many clever and excellent 
scholars inspired by the various science studies schools... " 
(Callon and Latour, 1992: 367) 
Indeed, a number of theorists, from a number of disciplines, have carried out work 
within an ANT framework, for example: human geography (Murdoch, 1997); 
management (Busch and Juska, 1997; Soderbaum, 1993); and health (Arksey, 1998; 
Prout, 1996; Singleton and Michael, 1993). Murdoch points out that one reason for 
this is that, "human geographers and sociologists have begun to focus on the prospects 
for theories without dualisms. " (1997; p. 731). 
An obvious question that arises within ANT is: Where is the account from the 
nonhumans? Or as Collins and Yearley have asked: `Just how radical is the 
symmetry? ' Collins and Yearley argue that from a truly radical point of view we 
would need to hear an account from the scallops or from the electric vehicle. Does 
the fact that we have no account of human insulin written by e-coli affect radical 
symmetry? Collins and Yearley argue, "Fortunately we do not need an answer to 
these questions before we continue our analysis. " (1991: 313n. 13). However, one 
answer is that when scientists talk about their work they talk about nonhumans, since 
it is central to their work. As Callon and Latour write, "Scientists never exist simply 
as people talking among people about people" (1992: 353). 
It has also been pointed out that: 
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"... the notion of symmetry elides a critical examination of how and why some 
entities are assigned to one end of the continuum, whereas others are assigned to 
the opposite end. " 
(Casper, 1994: 845) 
That is, we have already decided that DNA fingerprinting, scallops, human insulin 
and countless other entities, are nonhuman at the outset without examining their 
constitution. Latour argues that this separation occurs in society through the process 
of purification (1993). The process of purification creates two "entirely distinct 
ontological zones" (Latour, 1993: 10), which compose part of the modern 
constitution. However, as Latour points out, "The constitution explained everything, 
but only by leaving out what was in the middle. " (1993: 47). This `middle' comprises 
hybrids, quasi-objects and quasi-subjects (Latour, 1993) or what Haraway (1991) calls 
`cyborgs' and `tricksters', which form part of our everyday life. One of the aims of 
actor network theory is to open up the purification process by `following the actors'. 
By following the actors we are able to elaborate just how human and nonhuman 
entities attained their respective status. It may then be possible, contra Casper, to 
describe how and why entities have been purified into two extremes. 
We should also be aware that the purification of society into a nature and society pole 
means that we are not generally aware of the hybrid nature of entities. Humans exist 
within networks made up of both the human and nonhuman, just as nonhuman objects 
are. As Latour writes: 
"We are never faced with objects or social relations, we are faced with chains 
which are associations of humans (H) and nonhumans (NH). No-one has ever 
seen a social relation by itself .. nor a technical relation... Instead we are always faced with chains which look like this H-NH-H-HN-H-HN... " 
(Latour, 1991 a: 110) 
Indeed, one of the aims of the actor network theorist is to `bring out' the nature of 
these hybrids or networks; to describe how they are constructed; how identities are 
defined; what is needed to maintain these networks; and under what conditions such 
networks break down. In sum the aim is to make the invisible visible. By doing so 
we are able to demonstrate the way hybridity is composed of both the social and the 
natural, and the human and the nonhuman. The argument is not that we are creating 
something that doesn't exist, rather, we are showing how parts of society become 
invisible or visible. As Susan Leigh Star writes, of what Anselm Strauss has taught 
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us, "Visibles are not automatically organized into pregiven abstractions. Someone 
does the ordering, someone living in the visible world" (1991 b: 265). 
2.4 PROGRAM OF ACTION 
Now that I have presented an overview of ANT, I would like to describe one 
particular facet of this approach that I will be using throughout my research. I will 
adopt and expand the work of Akrich and Latour and their symmetrical vocabulary 
for describing human and nonhuman assemblies (1992). 1 am particularly interested 
in this work because although it has been broadly used in a number of studies (Latour, 
1992; Akrich, 1992; Latour et al., 1992), it has not been fully developed. From my 
reading, the symmetrical vocabulary for describing human and nonhuman assemblies 
has not been used extensively. Although work has drawn on this vocabulary, it has 
not been used to describe the changing nature of human and nonhuman assemblies. 
In particular, I am interested in using this vocabulary to describe the resistances and 
negotiations that occurred around a particular artefact, namely human insulin. 
I described above how an enrolling actor defines a particular set of identities, 
problems and solutions through the moments of translation. In particular, the 
enrolling entity defines itself as the point of passage through which defined objectives 
can be achieved. With successful enrolment the defining entity can be seen as the 
spokesperson for the network; for example, when a union representative is 
campaigning for increased wages, he/she is acting on behalf of those workers who are 
members of the union. However, enrolling entities are likely to speak `in different 
ways' to different potential `enrolees'. When a pharmaceutical company wishes to 
interest the medical profession it may talk in terms of the health of individuals and 
patient care. However, when the same company's board meets one of the aims 
discussed is likely to be increasing profit. 
Networks therefore, usually have more than one aim. In the St. Brieuc Bay case 
study, the aims ranged from increased reproduction for the scallops to long-term 
profits for the fishermen. Although these aims existed simultaneously within the 
network, they were not all defined as applicable to all entities within that network, i. e. 
the scallops were not defined as being worried about long term profits. These 
simultaneous aims can exist side by side, unless there is some great disparity between 
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the aims. 
These aims we call a program of action. 4 The program of action can range from 
something as simple as a hotelier wanting guests to return their keys (Latour, 1992), 
to the aims of multi-national corporations. Importantly, the defining of a program of 
action is dependent on the point of view taken by the analyst, for example, a hotelier 
may wish guests to lock the door after them, while guests may wish easy access for 
their friends. 
The fact that the programs of action of different entities are not the same, suggests the 
notion of an antiprograrn. An antiprogram is any program of action that is in conflict 
with another program of action, taken from the point of view of the analyst (Akrich 
and Latour, 1992), or the holder of a given program. It is important to stress that an 
antiprogram is not judged against some `objective' scale of the `way it should be'. 
Instead, the antiprogram is judged against a particular definition of the social world 
that has been proposed by the potentially enrolling network. It is this network that 
defines `the way it should be'. Akrich and Latour point out that "what is a program 
and what is an antiprogram is relative to the chosen observer. " (1992: 261). 
Latour often uses the example of the Berliner keys, where the hotelier wishes that 
guests close and lock the main door behind them. This is the program of action from 
the perspective of the hotelier. From this perspective guests may wish to have easy 
access through the door (for friends, for example) and in some cases may leave the 
door open, this is the antiprogram. However, from the point of view of guests, the 
program could be that they wish to have easy access through the door, and the need to 
open and lock the door is an annoying antiprogram. 
Of crucial importance when looking at programs and antiprograms is the function of 
intermediaries. I described above how one of the features of translation is the 
necessity of a medium in which translations are inscribed. These mediums are what 
we call intermediaries and can come in many forms - texts, technical artefacts, human 
beings and money. When we look at a program of action we can describe the 
intermediaries that are put in place in order to ensure compliance with a particular 
4 Latour has also used the word `programme' (Latour et al., 1992) to describe the same approach. In 
my thesis I have adopted his most frequently used word, that of program. 
5 For the complete story see Latour (1991 b) and also Latour (1992) and Latour et al. (1992). 
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program of action. By studying the flow of intermediaries we are able to map the 
division between programs and antiprograms, what Latour and others call the `front 
line' (Latour et al., 1992). As a researcher we are not only interested in the movement 
of the front line, but also in what intermediaries are circulated, by whom, their 
content, and the intended audience. When there is no front line, there is no perceived 
controversy in a given situation. 
Program 
, 
Antiprogram 
Janitor Verbal I Most tenants defect notice 
Janitor Verbal Printed Few tenants comply notice signs 
Janitor Verbal Printed New lock Most tenants comply notice signs and key 
Front Line 
The janitor successively adds oral notices, written notices and finally a 
ne«- lock and key to modify the attitude of his/her guests. Finally, most 
tenants comply and lock the door after them. 
Figure 2-7: Programs, antiprograms and the front line 
If we look at Figure 2-7 we can see that the janitor wishes guests to lock the door after 
them, yet most guests do not follow this program of action. At successive stages the 
janitor uses different intermediaries to compel guests to follow his or her own 
program of action. In the first stages, the network can be seen as having little 
durability. Although the janitor has defined that guests should close the door, they 
have not done so; in other words they have not been enrolled. However, through a 
string of intermediaries the front line is reduced, that is, more tenants comply to the 
janitors wishes. The intermediaries that are used "to cope with the contradictory 
demands of many antiprograms" (Akrich and Latour, 1992: 262) are called re- 
inscriptions. Re-inscription is, in principle, the same thing as inscription. However, 
whereas inscription occurred at the outset, by the engineer, inventor, manufacturer, or 
designer, re-inscription occurs when two differing programs of action meet (by very 
definition, a program and a related antiprogram). Since re-inscription occurs when 
there are conflicting programs, it should be seen as a feedback mechanism, which is 
the response to a particular antiprogram. Re-inscription should also be seen as a 
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complication, since it involves the introduction of more intermediaries and so the total 
number of assembled human and nonhumans will increase. The complication not 
only occurs because of the increased size of the setting, but also because these new 
entities have to be maintained (kept within) the setting. 
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The doctor wishes that his/her diabetic patient follows a particular program of 
monitoring in order to maintain the patient's health. She/he does this by using 
frequent appointments to assess the patients control. informs family members of the 
risks. and suggests the use of home monitoring equipment. 
Figure 2-8: Ensuring a diabetic follows a particular diabetic routine 
A similar complication may occur with newly diagnosed diabetics. Various 
intermediaries may be used to ensure that patients follow a particular diet, or maintain 
a steady blood glucose level (Figure 2-8). In cases where care groups are 
campaigning against a particular drug they may attempt to re-inscribe the description 
of the drug from `without side effects' to `with side effects'. In the case of 
prescription drugs we can say that there is a medical/institutional program of action 
for that drug. However, in some cases care groups attempt to re-define this 
medical/institutional program of action to one that is more in line with their own 
program of action. Success may occur when the pharmaceutical company is forced to 
withdraw the drug, forced to print warnings of possible side-effects on the product's 
packaging, or doctors become more strict about prescribing the drug. 
One question that we need to ask is: When is an inscription a re-inscription? A re- 
inscription can be seen as something that is added to an artefact that has been `black 
boxed', that is, when it has left one network to go to another. As I described above, 
inscription is carried out by engineers, scientists, inventors, manufacturers, or 
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designers. When scientists, or whoever, inscribe a vision of the world into an artefact 
they produce what has been called a `script' or `scenario' (Akrich, 1992). Just like a 
film script, artefacts define a structure or framework of action for the actors involved, 
and a space in which they are supposed to act (Akrich, 1992). This `script' is the 
result of inscription. Inscribers hope to persuade human and nonhuman actors to act 
out this `script'. However when, from the point of view of the original inscriber, the 
script is not followed, then some kind of re-inscription is necessary. 
Akrich and Latour have argued that "the choices made for the re-inscription defines 
the drama, the suspense, the emplotment of a setting" (1992: 262). In other words, re- 
inscription is the dynamic transformation of a silent artefact into a polemical process 
(Latour, 1992: 258n. 25). Researcher study the process by which black boxed 
inscriptions or silent artefacts come to be re-inscribed. However, we also have to be 
aware that where once a particular movement was seen as a re-inscription, it can, in 
time, be seen as an inscription. Take for example the mixing of different strength 
insulins. Originally this was carried out by the diabetic at the time of injection, and so 
was a re-inscription. However, it is now more common for diabetics to use premixed 
insulin, which is an inscription for the diabetic. 
Therefore (re-)inscription is a continual and dynamic process. As each re-inscription 
is carried out on an artefact, it may change the meaning of that artefact. For example, 
when medical drugs are being produced for consumption they need to go through a 
number of networks (e. g. regulatory bodies, clinical testing, marketing and the media) 
at each of these stages the meaning of the artefact may change. One of the aims of a 
network is to be able to control or predict the re-inscriptions that may occur around an 
artefact. For example, a pharmaceutical company does not want to employ resources 
on developing a new drug only to have its application for a licence refused. 
It is also important to understand what is actually inscribed in artefacts by those who 
designed them. Obviously inscribers need to be very aware of those who will 
eventually use an artefact so that the chance of re-inscription is kept to a minimum. 
Akrich and Latour (1992: 261) define two dimensions to these inscriptions - 
prescription and proscription. Prescription refers to what an artefact allows from the 
human and nonhuman actants that it anticipates, while proscriptions refers to what an 
artefact disallows. In order to illustrate this, I will use self administered insulin as an 
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example. 
Insulin decreases the amount of glucose in the blood, by promoting its uptake by cells. 
Therefore, through the administration of insulin, a diabetic is able to control the levels 
of glucose circulating in the blood stream (prescription). As a result, insulin allows 
diabetics to live a relatively `normal' life. However, the administration of insulin 
does not allow a diabetic to take large amounts of insulin that can be stored in the 
body for days. Neither does it allow a diabetic to ignore their diet or take spontaneous 
exercise without careful consideration. 
When we wish to describe the prescription and proscriptions of an object there are a 
number of places in which they can be found. In those artefacts that are black boxed 
they can be found in user's manuals and contracts, or we can study disputes or look at 
what happens when artefacts go wrong (Akrich, 1992: 210). For example, insulin 
packaging contains a leaflet about the insulin, describing such considerations as side 
effects, storage of the insulin, interactions with other medicines, and how to correctly 
take the insulin. From reading such a leaflet we could construct a list of prescriptions 
and proscriptions of a that artefact. 
Another important feature of an artefact is its pre-inscriptions. Pre-inscriptions can be 
described as: 
"... all the work that has to be done upstream of the scene and all the things 
assimilated by an actor (human or nonhuman) before coming to the scene as a 
user... " 
(Latour, 1992: 257n. 16) 
In our insulin example, a doctor or nurse may have explained to the diabetic 
something about diabetes, insulin and how to inject themselves. This will especially 
be the case for newly diagnosed diabetics. Therefore, when a diabetic uses their 
insulin, they will already know how to use their syringe, where best to inject 
themselves, and how they may need to change their daily routine. With such pre- 
inscriptions, a diabetic already has a degree of knowledge and various competences in 
place to be able to use the insulin. 
Now in cases where pre-inscriptions, prescriptions and proscriptions do not match the 
user of an artefact, it is likely that an antiprogram may develop. A diabetic who does 
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not understand what they have been told by their doctor may experience problems 
with the management of their diabetes, no matter how good the insulin is. To 
illustrate this point I rework a case study in the field of the `public understanding of 
science'. 
Brian Wynne has looked at the affect of the Chernobyl disaster on farmers in Cumbria 
(1992). This study can be reworked to explore the meeting of expectations of users 
(pre-inscriptions), allowances (prescriptions) and disallowances (proscriptions). 
Wynne found that not only did farmers develop an antiprogram around the disaster 
but also on a wider level. Wynne describes how the Ministry of Agriculture, Fisheries 
and Food (MAFF) went about carrying out scientific tests on the contaminated 
farmland. However, the farmers' knowledge and expertise was not drawn upon in 
carrying out the scientific tests. In this case, the pre-inscriptions of the farmers, in the 
form of their knowledge and expertise, was downgraded by the scientists and not 
thought to be of any importance. 
The farmers however, believed that their existing knowledge was credible, and so 
reacted against the negative perception of their pre-inscriptions by the MAFF 
scientists. The farmers developed a program of action which was reacting against 
some of the scientists' values. These values included: the methods and assumptions 
made by the scientists in the search for truth; the downgrading of their own 
knowledge; the claim by the scientists that there were no negative effects from 
Chernobyl, and especially Sellafield; and, the claim of the `natural' authority of 
science. 
It also appears that Chernobyl was a trigger to other unexpressed antiprograms. As 
Wynne writes: 
"The way in which fanners' scepticism was expressed suggests that Chernobyl 
acted to release a large historical backlog of more disbelief, mistrust, and 
alienation from the authorities, which related to Sellafield, and which had been 
quietly simmering over the years.. . This would also explain the apparently 
abrupt change in their position from acceptance to hostility... " 
(Wynne, 1992: 295) 
One reason why this antiprogram may have been unexpressed was because the 
farmers were members of many networks, as Wynne writes, "farmers identified with 
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family, friends and neighbours who were part of the Sellafield industrial workforce" 
(1992: 299). The work by Wynne also illustrates the nature of a feeling of 
powerlessness, and that fanners had unexpressed antiprograms outside of their 
community. He quotes two fanners: 
"You can't argue with them because you just don't know... " 
"We can't argue with them, but you can think your own ideas. I still think it 
[the radioactive caesium] was here before" 
(Wynne, 1992: 299) 
What is important here is that actors have to play, at least initially, the roles that have 
been proposed to them. A diabetic is expected to play the role defined by the medical 
profession. Diabetics need to take care of their health, watch their insulin dose, and 
diet. Upon using a new artefact (e. g. human insulin) a diabetic may become aware of 
problems with the management of their diabetes. Some problems may only require a 
small amount of re-inscription, such as a slight change in insulin dose, which can 
usually be carried out by the diabetic. However, other re-inscriptions may be more 
complex, such as a belief that an insulin has serious side effects. The ability to carry 
out these re-inscriptions will be dependent upon: the degree or amount of re- 
inscription required; the network within which the artefact is located; and, the existing 
knowledge, motivation and potential allies of the user. 
In some cases, I may wish to carry out some simple re-inscription such as sticking a 
note on my office door asking people to close it after them. In this case re-inscription 
can be accomplished simply - that is, drawing on few resources. In other cases, actors 
may group together to campaign for the re-inscription of a medical drug from `safe' to 
`dangerous'. To enrol the networks necessary for such a change, it would be 
necessary not only to involve campaign groups, but also have contact with the 
medical profession, regulatory bodies and pharmaceutical companies. Re-inscription 
therefore is an important and complicated act, since it may involve drawing upon a 
number of actors and resources. Further, these actors or networks may already have a 
particular relation to the artefact of concern. For example, the medical profession 
may initially view the drug as safe and efficient. Such links may need to be broken 
before re-inscription can occur. 
Another concern is that just because there is no perceived front line does not mean 
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that there is no antiprogram. Just as trust has been shown to be contingent (Wynne, 
1996) so, I would argue, are antiprograms. There are many reasons why researchers 
and enrolers may not be aware of a particular antiprogram. One reason could be our 
differing identities and power relations within networks. For example, there is much 
advice to diabetics on how to avoid long-term complications. Studies have shown 
however, that diabetics feel that this advice is impractical, and many have their own 
`secret' antiprogram, that is, they do not follow the program given to them by their 
doctor. The Diabetes Control and Complications Trial (DCCT) found that intensive 
insulin treatment (known as tight control) more than doubles the risk of severe 
hypoglycaernia (Gale, 1989: 1264), but reduces the chance of long-term 
complications. However, studies have shown that many diabetics prefer to have high 
blood sugar level, so as to reduce the risk of a hypoglycaemic reaction (Cox et al., 
1992; Green et al., 1990). Therefore, as work from the public understanding of 
science has shown, the acceptance and application of knowledge is dependent on the 
practicality of this knowledge within particular contexts. 
Importantly, this antiprogram, towards tight control, may not show itself in the 
doctor-patient relationship, though when diabetics are talking amongst themselves 
they may articulate such an antiprogram. In many cases this antiprogram, against the 
program of what is medically defined as `being in control' (Rajaram, 1997: 286), may 
only become evident to doctors when many years later complications begin to show 
themselves. As Wynne points out, "lack of overt public dissent or opposition towards 
expert systems is taken too easily for public trust" (1996: 50). 
However, in other cases we need to be aware of the perception of powerlessness. 
Although an individual may be able to envisage some antiprogram, they may not 
search out further relevant knowledge, because they feel that it will not accomplish 
anything. As pointed out by Irwin et al, "`information' does not exist in a social 
vacuum, but is weighed in terms of previous experience and cultural evaluations" 
(Irwin et al., 1996: 55). Indeed Michael (1996a; 1996b) has illustrated how, through 
discourse, various constructions of ignorance can be found, in which a lack of 
knowledge should not be seen simply in terms of a `deficit model' of knowledge. 
What seems to be important are the identities that individuals have of themselves and 
other bodies, and the positioning of themselves and other bodies within a particular 
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network. 
It should also not be taken for granted that just because an individual is presented with 
a possible trigger to gain information that they will actually do so. Michael has 
shown how a Radon measuring device, "was not an irresistible stimulus to find out 
more about radiation", indeed "it spurred the volunteer actually not to find out" more 
about Radon (1996b: 119). One reason for this could be that the device came to 
signify the more or less passive role of the volunteer (Michael, 1996b: 119). This is 
one of Michael's discourses of ignorance, which is based around a division of labour. 
In such cases individuals have roles (concerned citizen or Radon scientist, patient or 
doctor) which define what knowledge they should possess; `specialist knowledge' is 
deferred to others, whose role it is to know, or monopolise, this `specialist 
knowledge'. There was no need for volunteers to search out knowledge about Radon 
because there were specialists whose job it was to protect them from Radon, if it was 
a problem. 
Therefore, in any discussion of programs of action we have to be aware that there are 
wider influences on the actors involved than simply the immediate humans and 
nonhumans. Indeed, I explained above how one criticism of actor network theory is 
that they have neglected the `wider culture', or what we may call, more diffuse 
networks. 
2.5 ENRICHING ANT WITH OTHER AREAS OF SOCIOLOGY 
In this section I would like to look at three theoretical areas that I will be drawing 
upon in order to enrich my work within actor network theory. These areas are: the 
sociology of the body, the sociology of consumption, and the public understanding of 
science, in particular, discussions concerning `expert' and `lay' knowledge. 
2.5.1 The Body as a Network 
In this section I would like to develop a concept of the body that draws upon ANT. 
As stated in the introduction, a concept of the body has mostly been neglected by 
actor network theorists. One of the aims of this thesis is to develop a notion of the 
body within actor network theory. However, before I describe how I will treat the 
body, it is worthwhile considering some of the most recent work carried out by 
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researchers who have attempted to describe the body within an actor network 
framework (for example, see papers in Berg and Mot, 1998; for one of the earliest 
papers that referred to the body see Mot and Law, 1994). 
Cussins (1998) claims that when patients enter fertility clinics bodies become un- 
black-boxed. She argues that clinics allow access to bodily processes and body parts. 
Importantly, it is through the use of artefacts, such as a speculum, that body parts, 
such as a patient's uterus, are "enabled to display properties in their own right" 
(Cussins, 1998: 181). It is through heterogeneous engineering (linking) that parts of 
the body become visible. 
Willems (1998) has looked at the way in which drugs define the body. He has argued 
that types of treatment within medical practice (in his case, drugs and inhalers), make 
similarities (salbutalnol forges a connection between the occasional hayfever patient 
and the adolescent sportsman with slight asthma) and differences (asthmas and lungs), 
rather than simply mirroring existing similarities and differences. His important point 
is that as artefacts are accommodated within the body, they do not simply allow the 
body to resume functions that are restricted by disease. Drugs also define disease and 
reorganise the body by creating new identities for it (Willems, 1998: 118). 
Mol (1998) has studied atherosclerosis, a disease of blood vessels. Mol has studied 
what is involved in linking the object `atherosclerosis' of the laboratory with that of 
radiological imaging or the outpatient clinic. She argues that the process of linking 
needs a lot of work. For example, in order to reveal an association between a 
patient's complaint and clinical diagnosis of atherosclerosis, practical work has to be 
carried out. It is through practical work, whether in the form of pressure measurement 
or angiography, that links are made. Each time practical work is carried out to reveal 
links it is necessary for actors to engage with many different materials, such as forms, 
knives, hands, gloves etc. Importantly, the links are not present inside the body, but 
rather, lie within the practices that are carried out by various actors. 
There is other recent literature. Looking at muscular dystrophy, Callon and 
Rabeharisoa (1998) have described the way in which, through tests and trials, a 
`collective patient' is created. The important point is that the body is extended 
beyond the flesh through technologies to other persons and organisations. It is 
53 
2. Theoretical perspectives 
through studying trials and tests within medicine that the body can only be 
understood. Moser and Law (1999) describe the case of Liv, who is physically 
disabled. Their concern is in the ways in which people move between specificities - 
specific networks of heterogeneous materials. For Moser and Law dis/ability is about 
specific passages between equally specific arrays of heterogeneous materials. Or to 
put it another way, incomplete or missing specificities lead to dis/ability. As a result, 
the body is to some extent defined by the specificities that an individual encounters. 
Moser and Law illustrate this when they point out that Liv, who wants to be active, is 
dis/abled in a way that is different from someone who is happy to sit in a chair at 
home all day (1999: 216n4). 
Moving back to a more general discussion of the body, Law (1992) has argued that 
human beings should be viewed in the same way as other actor networks; just like 
other networks they are patterned networks of heterogeneous materials. It may 
therefore be more correct to think about the `body as a network', to bring out the 
complex nature of the body. In normal conditions networks are hidden, the network is 
durable. A sociology of the body theorist would say that the body is absent (Leder, 
1990) since we are not aware of its processes. As Kelly and Field (1997) have 
argued, the body "goes relatively unnoticed until such times as illness or other things 
impinge on it" (1997: 363). 
In illness, the `body networks' become visible: 
"Through pain, disability and death, our normal modes of bodily dis-appearance 
tend to become profoundly disrupted. The body, in other words, becomes a 
central aspect of experience, albeit in an alien form: it dys-appears (i. e. 
`appears' in a dys-functional state). " 
(Williams, 1998: 61) 
As a consequence of this `biographical disruption' (Bury, 1982) it is necessary for the 
`body' to interact more openly with other networks, for example doctors, pharmacists, 
care groups, other patients, drugs and new technologies. Of course, the `healthy' 
body is always engaged in many networks but, as mentioned above, these are usually 
invisible. Chronic illness will therefore affect the boundaries of the self, and a large 
part of chronic illness education is concerned with helping the patient to regain a 
sense of self. Those with chronic illness also need to re-interact with other networks 
and contexts, such as family, friends and technologies. Bury uses the term `strategy' 
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to refer to the "actions taken [by those with chronic illness] to mobilise resources and 
maximise outcomes" (1991: 461-462). Through these interactions an individual may 
come to a `negotiated settlement' with their body and illness. 
When an individual once again becomes `settled', the body returns to a kind of 
equilibrium. When an individual initially experiences, and is diagnosed with, chronic 
illness it may be necessary for them to adapt to new circumstances. As mentioned 
above, it is necessary for them to re-interact with other networks and contexts. In a 
sense, the once invisible becomes visible. A newly diagnosed diabetic needs to pay 
attention to what they eat and cannot take long walks without preparing themselves. 
However, over time, an individual accepts various features of their chronic illness, 
and the visible becomes, to a lesser extent at least, invisible. 
In illness therefore, there is a movement from `being a body', where the body poses 
no trouble to us, to `having a body', where there is a disjunction between the body and 
our sense of it. In such cases the body is felt to belong to someone else, such as the 
medical profession. However, in time the body again becomes something we have 
mastery over, as Turner writes, the body is seen as a: 
"... collection of practices over which we might have a certain mastery or 
sovereignty... techniques for presenting and maintaining and reproducing bodies 
in time and space. " 
(Turner, 1992: 40-1) 
Turner calls this a state of `doing a body'. What is interesting here is that when the 
body is seen in terms of `having a body', the representation of the body is carried out, 
to a large extent, by the medical profession. That is, in the form of diagnosis and 
control. Importantly, the representation of the lived body is taken on by those who 
have not (usually) lived that ill body, i. e. a doctor. However, when some mastery of 
the body is regained the representation of the ill body is taken on by the ill body itself. 
The patient is then seen in terms of `doing a body', where mastery moves from the 
medical profession to the patient. Where care groups are involved, the representation 
of the body, by the ill body itself, is even more evident. It will be even more evident 
because we are more likely to become aware of the narratives that the `ill' bodies 
themselves produce. What is important here is that representation of the body 
becomes collectivised. A network is formed of those bodies that wish to form a group 
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of `ill' people, and this network becomes represented (or performed as Law (1994) 
would put it) through letters, meetings and newsletters. This will be elaborated in 
Chapter 6. 
Another dimension of a body is the simplified network body, or representative body. 
This body is the body that is used in clinical trials. Such a body is seen to be a 
representative of all those bodies within a particular population. When experiments 
are carried out on such bodies, and results published, it is expected that the results can 
be generalised to all similar bodies. Results from the simplified body produce an 
exemplar body. It is on this exemplar body that a program of action of what other 
bodies will do on a particular drug is based. 
However, when a number of individuals experience and express symptoms that are 
different to that of the exemplar body, we can say that they are forming an 
antiprogram. In such cases, negotiations will take place in order to accommodate for 
this unrepresented body. As we will see, these negotiations can include the 
marginalisation of the non-exemplary body by the medical profession. One example 
of this marginalisation is in the non-diagnosis of RS I, where some doctors dismissed 
the possibility of a biological basis for RSI, telling their patients to `pull themselves 
together' or `it's all in the mind' (Arksey, 1998: 127). In other cases, the boundaries 
of the exemplar body may be expanded, to accommodate for the symptoms 
experienced by some patients. 
In this study, I would also like to develop something that can be called a network 
body. It seems obvious that as individuals we are not separated from the world 
outside of our body. As Haraway argues, "Why should our bodies end at our skin, or 
include at best other things encapsulated by the skin? " (1991: 178). Indeed, the image 
and experience that we have of our own bodies is influenced by other entities. Rose 
describes the body as an assemblage consisting of an interconnection of "... parts, 
forces, movements, affects of other humans, animals, objects, spaces, and places" and 
that "It is within these assemblages that subject effects are produced, effects of our 
being-assembled-together" (1996: 171). The concept of the network body attempts to 
draw out the dimensions through which we are constituted by these other entities, by 
the network, of which our bodies are a part. As Falk has argued, the body is never 
found in its `natural' state (1995: 95) since the `techniques of the body' are present 
56 
2.5 Enriching ANT with other areas of sociology 
from the start of social life (Mauss, 1973 [19351). Technologies are always acting on 
our bodies. 
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Figure 2-9: A simplified version of a network body 
There are a number of dimensions of the network body that need to be addressed. 
Firstly, the influences on the body are both human and nonhuman, and as a result, the 
network body consists of both human and nonhuman entities (Figure 2-9). Although 
in `normal' circumstances we are unaware of these entities - they are invisible - in 
times of illness elements of the network body become visible. Not only this, but in 
times of illness new entities, new relationships, will be brought into the network body. 
For example, when an individual is diagnosed with a particular illness they may need 
to take greater care over their diet, they may have more frequent contact with their 
doctor or may have to use specialised artefacts, such as crutches or monitoring 
equipment. When these entities are initially incorporated into the network body they 
are visible, however, over time, as an individual becomes accustomed to the new 
entities and they become part of `everyday life', they become invisible. 
Secondly, entities within the network body do not exist without reference to the other 
entities in the network body. For example, a doctor may suggest that monitoring 
equipment would be useful for the patient. Further, changes made to particular parts 
of the network body may have an influence on the nature of other entities. For 
example, initially a newly diagnosed diabetic may need to make frequent visits to 
their diabetic clinic. However, as the diabetic becomes accustomed with blood 
monitoring equipment, and is able to take care of their own diet, the dependence on 
the clinic will be reduced. 
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A third, and related point, is that the network body is dynamic in its nature, it is 
constantly changing - the body is an `unfinished body (network)'. Over time it is 
likely that the `ill' network body will come to a `negotiated settlement'. However, 
there will always be new entities (new medication, new doctors or new relationships) 
that come to be incorporated into this network, which may, once again, disrupt the 
network. 
It must also be stressed that technologies and the human cannot be separated from 
each other, as Prout has argued for the metered dose inhaler, "technologies and people 
mutually constitute each other" (1996: 200). 
As stated earlier, this thesis aims to correct one of the failures of actor network theory, 
namley to adequately deal with the body (although see Callon and Rabeharisoa 
(1998), Cussins (1998), Mol (1998), Willems (1998); and Moser and Law (1999) for 
some attempt to correct this failing). When talking about the network body it is also 
important to be aware of another body of work, that which deals with hybrids 
(Haraway, 1991; Latour, 1993; Martin, 1994). 6 When I talk about the network body I 
am resisting the tempatation to purify, that is, I treat humans and nonhumans the 
same. Added to this, the network body is the result of translation, in that it mixes 
nature and culture (Latour, 1993). Further, all individuals are irreducible to a unity 
(Moser and Law, 1999). Moser and Law (1999), speaking of Haraway's cyborgs 
(1991), argue that a cyborg is made of composite parts that cannot be reduce to one 
another. Importantly, because the parts are "internally related to one another" (Moser 
and Law, 1999: p. 215) they are different from the way they would be individually. 
Take for example human insulin, inserted into one network body it may `cause' no 
problems, yet within another `problems' may exist. Changes in the effect of human 
insulin have more to do with other entities within the network body, and the relation 
these entities have with human insulin and each other, than with human insulin in 
itslef. 
In the present context I want to talk in terms of programs and antiprograms with 
regard to the body. When a body becomes ill, one can say there is an antiprogram to 
Of course, there are differences in the way in which authors treat the subject of hybrids (Latour, 1993) 
and cyborgs (Haraway, 1991). One major difference is that Latour argues that hybrids have always 
been around, but in modernity we have paid scant attention to them. On the other hand, Haraway 
argues that cyborgs are relatively recent. My preference is to agree with Latour. 
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what the individual feels that their body should be doing, what it `normally' does - 
that is, their usual program. However, through time the individual may `come to 
terms with' their own antiprograrn, so that it becomes transformed into something that 
can be coped with within the illness. The means by which this could be accomplished 
are varied. For example, patients may use other artefacts to help them or enrol 
support from family and friends. When the antiprogram is reduced the individual may 
feel that they are no longer alienated from their own body. 
Further, referring back to what I have already said, it is important to realise that the 
body as an object has particular allowances (what can be called prescriptions), and 
through illness these allowances (prescriptions) may change: allowances are likely to 
be re-negotiated, and new boundaries of what the body will allow may be set. Take 
for example, the use of blood glucose monitoring equipment by diabetics: such 
equipment is used by diabetics to check their blood glucose levels and so know when 
it is necessary to digest glucose. Such equipment may allow the diabetic to live a 
`normal' life. 
One particular area of interest is what happens when an individual comes to terms 
with their illness, but then experiences some disruption to their understanding. Newly 
diagnosed diabetics are often counselled to be able to deal with their new condition, in 
effect, they are given a new set of prescriptions by which they are able to 
(re)understand their own body. These techniques then become part of the network 
body, and form a set of pre-inscriptions. When a new medication is prescribed the 
drug may fit neatly into the network body with its use being based on pre-inscriptions 
(such as moving from injecting one type of insulin to another). In other cases, new 
inscriptions have to be laid down in order for the medication to be used effectively 
(such as moving from tablets which stimulate the production of insulin to having to 
inject insulin). An area of interest is what happens when it is expected that a new 
medication will fit within the existing network body, but from the sufferer's point of 
view, does not. In this study, human insulin was expected to act in a similar way to 
animal insulin, yet a number of diabetics experienced noticeable changes in their 
symptoms on human insulin compared with animal insulin. This will be explored in 
detail, in future chapters. 
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'. 
-5.2 Consumption 
Another interest is how work on the sociology of consumption can be applied in this 
study. `Consumption' is now regarded as signifying much more than simply 
consuming things; we also consume the signs of goods. The rapid take up of human 
insulin by the medical profession (and to some extent patients) may have had 
something to do with human insulin being portrayed as the `modern' insulin. Further, 
consumption is not simply a matter of selecting a particular object or sign. Instead, 
the selection of artefacts reflects not only on the identity of the individual, but also 
back onto culture and the object itself. As Michael writes: 
"... on the one hand, consumption is a means by which the sociality of the lay 
local [non-expert knowledge within local cultural conditions] is practised; on 
the other, the lay local shapes the meanings of the activity and `objects' 
(technologies, knowledges, images, etc. ) of consumption. " 
(Michael, 1998: 317) 
It is important to understand that we consume many `things', and together, these may 
effect the meaning of an activity or `object'. For example, diabetics may consume 
human insulin and also consume information from the Insulin Dependent Diabetes 
Trust (IDDT) and British Diabetic Association (BDA). Together this consumption 
may redefine the original meaning of human insulin, from one `without side effects', 
to one `with side effects'. 
Much has been written in the sociology of consumption on the way meanings are 
attached to objects. Baudrillard has argued that we now live in a state of hyper-reality 
in which any object, in principle, could take on any meaning, in other words, or all 
that we have are signs. The consumption of food is an interesting case, since it can be 
argued that we biologically `need' food, just as we need insulin. Bourdieu (1984 
[ 1979]) has argued that eating is less about survival and more about expressing social 
meanings. On the other hand, Warde (1997: 199) points out that the use value of 
objects is often underestimated. Yet there are meanings attached to food, indeed: 
"Looking at the edible/inedible classifications of a certain food culture reveals 
the fact that not nearly everything that is (objectively) edible and available is 
really eaten (for example, insects rich in protein). " 
(Falk, 1994: 69) 
The division between edible/inedible may be adapted to be used within this study. 
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Edmund Leach (Leach, 1964) defines three categories for a edible/inedible 
distinction: 
1) Edible substances that are recognised as food within the normal diet. 
2) Edible substances that are recognised as possible food, but are prohibited or 
else allowed to be eaten only under special conditions. 
3) Edible substances that are not recognised as food at all. 
In many cultures the process by which an objectively edible food can be transformed 
from 2 to 1 involves an element of ritual. Falk (1994: 13) talks about a cultural order 
in which there is an alimentary code (food taboos, ritual rules) that defines what can 
be eaten, by whom, how and when. When the boundaries grow weaker then it is 
likely that `taste' moves from a community taste to an individual one, although still 
being "related and conditioned by cultural representations" (Falk, 1994: 13). 
It may be possible to argue that in modern society the `ritual' of the consumption of 
medical drugs involves the process by which a drug is deemed to be edible. This 
process involves clinical trials of the drug to test its efficiency and advantages to the 
patient. By `advantages', I mean the process by which one drug becomes deemed as 
`better' than previous drugs or treatment. This may be seen in a similar context to the 
changes that occur from time to time over discussions of nutrition (for example, the 
recent discussions over Vitamin B-6 (see Collier, 1998)). 
When a drug is defined as `edible' it then becomes available at consumption sites (the 
pharmacy) through what we might call a particular `consumption path'. A 
consumption path is the means by which a particular artefact is obtained, for example, 
in order to get a medical drug, I need to go to a doctor, get a prescription and then 
take it to the pharmacy. These sites and paths can be rather inflexible, being 
maintained through the circulation of standardised intermediaries. For example, you 
now need a prescription to get insulin. In order to get a prescription I need to present 
myself to my doctor, go through a number of tests, and be medically defined as 
diabetic. However, before August 1998, it was possible to obtain insulin over the 
counter, although the pharmacist had to be convinced that it would be used correctly. 
After August 1998, insulin became a prescription only medicine (POM). This change 
was partly due to the use of insulin in suicide attempts, and by body builders instead 
of steroids. However, the consumption path can be subverted, such as when actors 
attempt to obtain POMs on the black market. In such cases, it is interesting to study 
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how and why the path changes. 
When those who use a drug attempt to redefine the drug as `inedible', because they 
are experiencing negative effects, then they have to work against its ritualisation as an 
edible (without side effects) drug. In effect, they have to undo an object's meaning, 
and redefine it in their own tenors (re-inscription). This will be examined in detail 
with reference to human insulin. 
Another point of interest is how various artefacts become translated into one; that is, 
rather than consuming two linked but separate artefacts, only one artefact is 
consumed. For example, insulin pens use cartridges of insulin which fit into a pen, 
the insulin no longer needs to be measured at each injection and the insulin can stay in 
the pen until it runs out. In the case of the insulin pen, the insulin, the injection 
system (pen or syringe), and the process of measuring the correct dosage become 
closely linked. Once joined together it becomes `hermetically sealed' or what Lee 
(Lee, 1993) might call a compound commodity. In such cases, the network body 
becomes reorganised with new (translated) artefacts being introduced. Such an 
introduction may also change the identity of the patient, they may feel more able to 
travel or eat out since the injection system is self contained and easily portable. 
Artefacts therefore shape the capacities of the body (Michael, 1996a). In the case of 
the door closer described above, some actors - the very little or the very old - were 
discriminated against. In the insulin pen example, the consumption of the artefact 
enables the body. Limits are removed from the enrolled diabetic through the use of 
the pen. Such positive changes in the network body will afford new allowances to the 
patient. It is therefore through the consumption artefacts that an actor's identity is 
reconstructed. 
One way in which an actors identity may change is through an awareness of 
`normality'. It can be argued that consumption of the insulin pen network makes a 
diabetic more `normal', since they are able to present themselves to others as 
`normal'. However, we have to be careful what we mean by `normal' - normality is 
always under negotiation. When an actor becomes ill they are no longer `normal'. 
Yet over time, when they come to a negotiated settlement with their body, normality 
is redefined; normality is having regular insulin injections, having an awareness of 
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hypoglycaemia, etc. 
This definition of `normality' is the result of being part of a broad diabetes network. 
However, diabetics are also aware of wider culture, where there are other definitions 
of `normality'. It is one of these `other' definitions of normality that can be expressed 
through the consumption of the insulin pen. The meaning of normality is therefore 
not static, since it is dependent on an actor being within a particular heterogeneous 
network. Normality is therefore both context and temporally dependent. 
2.5.3 Lay and Expert Knovt'ledges 
Another theoretical area that I intend to address is that concerned with the relation 
between `expert' and `lay' knowledge, in particular, the (inter)discipline of PUS. In 
order to provide the reader with some reference points, I will briefly suggest some 
problems with the expert-lay division. 
From the outset we are presented with a problem of definition. What do we mean by 
`lay' or `expert' knowledge? The term `lay' is often used to refer to the `public'. 
However, the term `public' is itself problematic. Davison et al. (1997) have argued 
that the term `public' has been used as a residual category to refer to a non-expert or 
lay audience. Davison et al. call for a richer notion of `publicness' which recognises 
the diversity of publics and the importance of `interested publics'. By `interested 
publics' we mean members of groups who are not `experts' in a particular field, but 
have an interest because of their membership to a specific group (Schibeci et al., 
1997: 171). 
Michael et al. (1997) point out that many studies neglect the mediating professionals, 
that is those groups that straddle the social worlds of science and laity, for example 
science journalists and science teachers (in their case biotechnology teachers). I 
would argue that diabetics can be seen as mediating professionals and as an interested 
public. They are mediating professionals because diabetic education is embedded 
within the management of diabetes. That is, diabetics are actively encouraged to 
understand their diabetes. As Williams and Patrick point out, diabetes is a 
complicated disease which demands close co-operation between the patient and the 
diabetes care team (1992b: 375). As a result, there is a reduction in the competence 
gap, specifically relating to diabetes, between the diabetic and the doctor. 
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The concept of a competence gap illustrates the nature of differing power relations 
between `experts' and `publics'. One reason for this is the different knowledge that is 
drawn upon by different networks. Doctors and their knowledge have been defined as 
legitimate. Legitimacy has been defined as a "political-legal process whereby a set of 
practices is accepted as authoritative and becomes dominant through the political 
process of justification" (Willis, 1994: 55). Doctors' political-legal legitimacy has a 
basis within both scientific and clinical legitimacy (Willis, 1994: 65). Importantly, 
doctors are privy to a special body of knowledge that has been defined as 
authoritative, and itself, legitimate. This special body of knowledge has been in part 
produced by the combination of inscriptions at centres of calculation. These centres, 
the laboratory or institution, produce texts which are authoritative since they 
themselves refer to other texts and use methods, such as statistical analysis and the 
experimental method, that are deemed as able to produce `truth'. 
There is however another origin of the authority of doctors. On a macro level doctors 
are legitimised through the state, that is, doctors are given the `right' to practice 
medicine. However, on a micro level, doctors become clinically legitimised through 
contact with patients (Cooper, 1997). Patients legitimise doctors through accepting 
any diagnosis that they are given - the `double-bind' situation. Bloor and Horobin 
(1975) refer to the `double bind' situation when patients are expected to use their own 
judgement and experience to both seek medical advice and describe their experiences, 
yet they defer final judgement to the doctor for treatment. In this case, the authority 
of doctors comes from the wills of patients, or more specifically, through their lack of 
questioning. 
However, in some situations patients do not blithely accept the authority of a doctor. 
In such cases there may be a questioning of the legitimacy of individual doctors, but 
not a challenge to the medical profession as a whole. Aronowitiz would argue that 
such encounters do not lead to radical epistemological critiques of biomedicine 
(1992). 
Where publics question the knowledge of particular doctors and a particular diagnosis 
they may form an `epistemological challenge' (Williams and Popay, 1994: 123) based 
on their experiential knowledge. It is likely that this challenge will be influenced by 
information from other sources, such as the media and care groups. In such cases the 
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value of the knowledge possessed by the doctor may be questioned, as Macintyre and 
Oldman argue: 
"Those who suffer from chronic illness, particularly ones that doctors can do 
little about, develop a special knowledge of their condition. This knowledge is 
of a rather different order from that held by doctors, and from the point of view 
of the patient, it is subtly superior. " 
(Macintyre and Oldman, 1977: 55) 
In terms of ANT, where an actor (a patient) no longer identifies with another actor (a 
doctor) who is defined as being central, then there is a problem in the network: the 
network is no longer durable. The patient may no longer be enrolled within the 
network. It is likely that the patient will no longer identify the doctor as an expert, at 
least in this particular case. 
Actors may then attempt to form their own network that may in some way compete 
with that of the medical profession. This may not be easy to accomplish. For those 
who wish to challenge the medical view, it is necessary for them to enrol various 
actors, such as some members of the medical profession, into their newly forming 
network. What these actors attempt to do is form their own network with their own 
expertise, since they are no longer able to identify with the doctors version of 
expertise. This expertise is likely to be different from that of the medical profession, 
but may have involved a reworking of medical science to render it functional for the 
actors' day-to-day reality (Arksey, 1998). 
It is important to look at what types of knowledge constitutes expertise, and further, to 
look at the value of knowledge as distributed within, and by, a network. Doctors are 
likely to place more value on expert knowledge, while diabetics may place more value 
on their own experiences (although how, or even whether this is expressed, is 
something for investigation). It is also important to realise that similar networks may 
give value to different types of knowledge. For example, the Insulin Dependent 
Diabetes Trust (IDDT) appear place more value on experiential knowledge than the 
British Diabetic Association (BDA), and as a result, different actors, depending on 
their own program of action, became allied to different care groups. 
Although some have argued that it is interesting to "study the patient's illness 
experience and illness world as a social reality apart from the conception and 
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definition of illness as formulated by biomedicine. " (Hyden, 1997: 52). It is 
nevertheless important to study the meeting point of `lay' and `expert' knowledge. 
Any change in the use of human insulin by a diabetic is likely to come about as a 
result of negotiations between the possessors of `lay' and `expert' knowledge the 
patient and the doctor respectively. Due to the uncertainty of scientific studies and of 
the lack of any proved side effects of human insulin, the patient's experiences, within 
the doctor-patient relationship, forms a crucial part of this thesis. 
The doctor-patient relationship should also not be seen as being isolated from other 
networks. As I will show throughout this thesis, diabetics drew on information from a 
number of different sources, such as newspaper reports and care groups. In some 
cases these other networks affected the actions of diabetics, and in turn, affected how 
some diabetics interacted with doctors. I follow Williams and Popay when they argue 
that "lay knowledge may incorporate expert knowledge but it is interpreted in terms 
of the experience of everyday life" (1994: 120, with reference to Davison et al., 
1991). Therefore, when a diabetic experiences problems on human insulin, they are 
more likely to identify with selected `expert' knowledge. 
2.6 SOME FINAL THOUGHTS 
In the previous sections I have introduced a number of concepts and issues that I will 
be addressing in later chapters. However, there are several issues that I have only 
hinted at. In this final section I would like to point to a number of areas that I will 
develop later in the thesis. 
One particular area is the nature of information. I have already argued that care 
groups attempt to translate the feelings of individuals into a more coherent and 
collective argument. There are a number of questions that stem from this. For 
example, how do larger sympathetic networks (such as care groups) treat the claims of 
individuals, and how are these larger networks mobilised? How does a personal 
antiprogram become a collectivised and possibly more effective one? 
It is also important to be aware of the way in which information, in particular texts, 
become collectivized by actors. As actors, such as care groups and scientists, produce 
texts they are likely to include texts from other actors. For example, throughout the 
human insulin debate, many articles were published in the scientific press which 
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discussed and summarised the important issues in the debate. These articles included 
issues that were discussed in other texts, importantly however, these texts were not 
just those produced by scientific actors, but also `lay' actors. I call this process of 
inclusion, collectivization. The important point is that actors have a degree of 
flexibility as to which texts they collectivize. For example, the IDDT tended to select 
and collectivize scientific texts which `reified' the negative experiences of diabetics 
on human insulin. On the other hand, the BDA tended to collectivize texts which 
showed that evidence against human insulin was inconclusive. I will return to the 
issue of collectivization in Chapter 7. 
There is also the important question of how individuals become motivated to search 
out knowledge around a particular artefact. In the study by Lambert and Rose on a 
genetic metabolic disorder, Familial Hypercholesterolaemia, they point out that: 
"... the members of the [Familial Hypercholesterolaemia] Association were seen 
as likely, through personal necessity, to be particularly motivated to 
`understand' the relevant science... " 
(Lambert and Rose, 1996: 69-70) 
In this study a similar motivation is in evidence. When diabetics experienced 
`unusual' effects of human insulin, some searched out further knowledge about 
human insulin. This leads us to such questions as: What sources do individuals look 
to for information? In what ways do individuals express their feelings? How do 
various groups respond to individuals concerns? What effect does the network body 
have on the search for information? I have already hinted at some of the areas of the 
public understanding of science that are relevant to this study, for example, discourses 
of ignorance and trust. In future chapters I will draw further on this important body of 
work. 
In cases where the `official' meaning of an artefact is questioned, various mechanisms 
are used to regain control of what is inscribed within that artefact, and to resist 
counter-inscriptions. One method by which this occurs is `inoculation' (see Michael, 
1997 for an inoculation against ridicule). Inoculation comes into play when the 
function or usefulness of an artefact is `questioned'; for example, when controversy 
occurs around a particular drug, the manufacturers will stress that it is safe because it 
has passed through a battery of scientific tests. Inoculation therefore should be seen 
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as a defensive characteristic 
As actors for-mn an emerging counter-network to the official meaning of a drug, 
questions may be raised about the quality and representativeness of the clinical studies 
carried out. Further, actors may attempt to enrol other networks, including the 
scientific community, to form a `credible' challenge to the official meaning of the 
drug. Although care groups are likely to place more emphasis on anecdotal evidence 
than the scientific community, they are likely to also draw upon work from that 
community. 
This leads us to consider the division between what can be broadly called `lay' and 
`expert' knowledges', and whether there are particular processes by which these 
boundaries are maintained. There is also the associated question of how certain lay 
groups attempt to gain access to the knowledge within these different domains, while 
also providing their own anecdotal evidence through letters, articles and informal 
surveys. Indeed, pivotal here, is an examination of how certain groups are able to 
claim superiority for their knowledge. The scientific community may claim that 
clinical studies produce superior knowledge, while care groups may claim that such 
knowledge does not take account of the use of medical drugs in everyday life. 
Moreover, complicating this simple division, the scientific community (Gieryn, 1995) 
and care groups are not homogeneous. In the present study, the IDDT was set up to 
represent diabetics on human insulin because they felt that the British Diabetic 
Association was not adequately representing diabetics. 
A final thread in this work is how, through the process of gaining support for a 
particular program, the inscriptions around a particular artefact changes. The basis for 
any re-inscription is the decision by some actors to go against a particular 
antiprogram. For example, a diabetic may no longer view human insulin as a 
`modern' insulin, and choose to return to animal insulin. Perhaps this is 
psychological re-inscription, since the diabetic no longer believes that human insulin 
is a superior insulin. 
My particular interest is in the process by which individual antiprograms become 
`collectivised'. A collectivised antiprogram is likely to have a greater influence on an 
institutional program than an individual antiprogram because it will involve a greater 
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number of allies. In this case study, care groups attempted to re-inscribe the medical 
program for human insulin. This re-inscription can be seen as a challenge to the 
authority of the defining (inscribing) network, and as such, may be met with strong 
resistance. 
Those groups who oppose the program of action will therefore have to build 
associations or networks. The power of a particular network will be dependent on the 
strengths of the links that it has with other networks. Networks `aim' to produce 
`knowledge' that is viewed as credible. The `aim' is for statements produced by a 
network to become immutable mobiles. When this occurs, the producing network 
becomes powerful and can be seen as an `obligatory passage point' to the 
understanding of a particular phenomenon. For example, if the statement - `human 
insulin produces an increased chance of hypoglycaemia unawareness' - becomes 
indispensable to those talking about human insulin, then this becomes `knowledge'. 
Producing such knowledge may only be achieved by associating with other networks, 
in this case study this was done through the uniting of care groups, patients, members 
of the medical profession, and some members of the scientific community. 
However, it is not only a matter of producing such knowledge. For a network to be 
powerful it has to be `plugged into' other appropriate networks. As Haraway writes 
of Latour: 
"The laboratory for Latour is the railroad industry of epistemology, where facts 
can only be made to run on the tracks laid down from the laboratory out. Those 
who control the railroads control the surrounding territory. " 
(Haraway, 1991: 248n. 2) 
Therefore, in order to produce `facts' work has to be produced in the laboratory, and 
this case study is no different. However, because of the uncertain nature of these 
results, patients and care groups attempted to stress the credibility and value of their 
experiential knowledge. 
2.7 CONCLUDING REMARKS 
I have argued that we should not `purify' ANT: that is, one of my aims is to enrich 
ANT by bringing in other theoretical areas of sociology and cultural studies, namely 
the sociology of consumption and the body, and also the public understanding of 
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science. With reference to the many vocabularies for talking about society, Callon 
has argued that it is up to the "sociologist to choose the one that seems the best 
adapted to his [sic] task and then to convince his [sic] colleagues that he [sic] made 
the right choice. " (I 986a: 200). 1 will adopt a number of vocabularies in an attempt to 
produce an interesting and coherent story. By drawing upon other perspectives I hope 
to produce a credible story, which, remains `true' to the key tenets of ANT. 
Inevitably it is up to me, the researcher, to be able to stand by my work, with my 
particular set of theories. As Joan Fujimura remarks: 
"When I write ... I must take responsibility and 
hold myself accountable for the 
final perspective. The point is to be made explicit to myself and my audiences 
just where I stand, my operating perspective, and the ground on which my 
concepts are constructed. " 
(Fujimura, 1991: 237) 
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3. THE DEVELOPMENT OF HUMAN INSULIN 
3.1 INTRODUCTION 
This chapter has an important place within the thesis as it will outline some of the 
prescriptions (in ANT termns) of human insulin, that is, what human insulin would 
allow from its users. Those in the medical community and pharmaceutical companies 
would later draw upon some of these prescriptions in the use of human insulin. This 
chapter will therefore set the scene for future chapters. In actor network terms this 
chapter will define the `script' for the use of human insulin. Then in future chapters, I 
will describe how this initial script was called into question. 
In deriving this script, particular reference will be made to the following areas: the 
status of genetic engineering before and after the development of human insulin; 
reasons given for the need to develop human insulin; corporate involvement with the 
development of human insulin; and, economic influences on the development of 
human insulin. It is noteworthy that because interest in human insulin crossed a 
number of areas, such as the development of human insulin and the first use of genetic 
engineering, there was constant reporting and discussion of the developments of 
human insulin in the media. Indeed, the scientific development of human insulin was 
reported as a `race' and later as a `war' or `battle'. 
Since the sequencing of human insulin in 1960 (Nicol and Smith, 1960) attempts have 
been made to produce human insulin (see Figure 2-3). The successful sequencing of 
human insulin enabled researchers to identify some of the similarities and the 
dissimilarities between various types of insulin. Attempts were then made to 
substitute the differing amino acid(s) of animal insulins to form human insulin 
(Bodanszky and Fried, 1966; Obermeier and Geiger, 1976). However, the methods 
produced only small amounts of impure human insulin. In order for this impure 
human insulin to be consumed by diabetics it would have to go under extensive 
purification which would be expensive, and would then only yield small amounts of 
insulin. To enable the mass production of human insulin it would be necessary to 
produce larger and purer amounts of human insulin. 7 
The use of genetic engineering presented the possibility that human insulin could be 
7 See Markussen (1977) for a description of tried methods. 
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produced on a commercial scale. This possibility was of interest to a number of 
groups, such as scientists, the media, pharmaceutical companies, diabetics and 
diabetic care groups. There were a number of reasons why the development of human 
insulin was of interest to these groups: 
1) Prestige - In the development of hurnan insulin many novel techniques were 
being used, namely those involving genetic engineering. 
2) Application - The techniques being used would be applicable to many other 
areas, particularly for scarce drugs. 
3) Scientific advancement - It was believed, by some, that it would be better for 
diabetics to use human insulin rather than existing animal insulins. 
4) Shortages - There were predictions that there would be a shortage of current 
animal insulins. 
5) Economic - By developing new insulins various insulin producers could 
capture the market of other insulin producers. It was also believed that the 
development of human insulin would mean cheaper insulin. 
Between 1977 and 1981 there were three broad techniques that were under 
development to eventually produce human insulin. One technique, called enzymatic 
conversion (Figure 2-4), and was being developed by Novo Industri, aimed to replace 
the amino acid alanine, present in porcine insulin, with threonine, so as produce 
human insulin. A second, aimed to use genetic engineering to produce the whole 
human proinsulin gene in bacteria (cDNA approach), and was being developed by 
scientists at Harvard University and University of California at San Francisco (UCSF) 
(see Figure 3-2). A third, also used genetic engineering, but synthetically produced 
separate A and B chains of human insulin which were then to be combined. This 
approach was being developed by a new company called Genentech (see Figure 3-1). 
This third approach was simpler than the second, since it did not attempt to produce 
the whole human insulin hormone in one process. 
My concentration will be on the last two approaches which used genetic engineering, 
although reference will be made to the approach of Novo Industri. There are a 
number of reasons for this. Firstly, one of the reasons for the development of human 
insulin was to reduce the predicted shortage of animal insulins, something that would 
not be achieved by the conversion of animal insulin. 8 Secondly, on a practical level, 
there is little written about the development of Novo Industri's insulin, except where 
8 Novo Nordisk would later develop their own genetically engineered human insulin, and stop 
production of their conversion insulin. 
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it is compared with the other approaches. Reasons for this include: the method of 
converting porcine insulin to human insulin was not seen as novel as those methods 
which used genetic engineering; the work on converting porcine insulins was being 
carried out `in-house' so was not `public' knowledge; and, it was not seen by the 
media as being part of the human insulin `race'. 
In this chapter I will draw on two main sources. One is a book by Stephen Hall, 
`Invisible Frontiers - The Race to Synthesize a Human Gene' (1987), which describes 
the human insulin `race'. This book has attempted to reconstruct the commercial 
development of human insulin. The other source are news reports from the popular 
and scientific media. 
Since human insulin was to be the first human protein to be produced by genetic 
technology, I will first describe the meaning of genetic engineering, so that I can set 
the scene for the development of human insulin. I will then go on to describe one of 
the key points in the development of human insulin -a symposium organised around 
human insulin. The next section will describe the progress of the research groups, and 
how their respective progress was inter-related. I will then look at the process by 
which human insulin was commercially developed and awarded its product licence. 
Then, in the final section I will tie in the development of human insulin with some 
theoretical considerations. 
3.2 GENETIC ENGINEERING AND CONTROVERSY 
The techniques that were used for the development and production of human insulin 
employ genetic engineering. Therefore, before I begin, I would like to say something 
about genetic engineering, and particularly, describe some of the concerns that 
surrounded it. 
Genetic engineering, or recombinant DNA technology, is the process by which the 
genetic make-up of a living organism is changed by artificial means so that it will 
produce foreign proteins. 9 A number of features led to the development of genetic 
engineering: 
Genetic engineering is part of biotechnology. See Bud (1991) for an extensive review of the meaning 
of biotechnology. 
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"The possibility of genetic engineering derives from three major advances in 
DNA technology... these are, 1, the discovery of means for the cleavage of DNA 
at highly specific sites; 2, the development of simple and generally applicable 
methods for the joining of DNA molecules; and 3, the discovery of effective 
techniques for the introduction of DNA into previously refractory organisms. " 
(Sinsheirner, 1975: 52) 
When human insulin was first being developed genetic engineering was a novel 
technique. Due to the unfamiliarity of the techniques being used, there were a number 
of concerns over the safety of genetic engineering, from such groups as regulatory 
bodies, public groups and some scientists. It seems sensible therefore, to place human 
insulin within this historical period. 
Concerns over genetic engineering were initially voiced after Herbert Boyer and 
Stanley Cohen reported their work on gene splicing in 1973. Both Berg and Cohen 
co-signed a letter, known as the `Berg Letter' (1974), which was published in the 
journal Science, amongst others. The letter expressed concerns that similar work, 
being carried out by other scientists, would produce "infectious DNA elements whose 
biological properties cannot be completely predicted in advance. " (Berg et al., 1974: 
1). The letter called upon scientific colleagues around the world to adopt a partial and 
voluntary moratorium on certain types of recombinant DNA work. '° 
As a result of the letter, a voluntary moratorium on genetic engineering experiments 
was adopted. However, according to McKelvey, the moratorium was internal to 
science, because the debate was within scientific journals and: 
"... the regulatory guidelines which most debaters had in mind would be 
designed, watched over, and evaluated by scientists... " 
(McKelvey, 1996: 94) 
In 1975 a conference was organised, known as the Asilomar Conference, which 
attempted to codify the guidelines outlined by the Berg letter. From the Asilomar 
Conference came a set of general guidelines that were recommended by an 
international group of geneticists (Philipson, 1977) 
So in looking at the develop of human insulin by genetic engineering, we have to 
consider the controversy that existed over genetic engineering in the middle to late 
10 See Krimsky (1982) for a fuller account of the controversy in the USA. 
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1970s. In order to produce human insulin, using genetic engineering, it would be 
necessary for those involved to allay the concerns over genetic engineering. One way 
in which this was done was by stressing the reasons why there was a need to produce 
human insulin. Those wishing to develop human insulin also had to stress that it was 
only by using genetic engineering that the production of human insulin could be 
achieved. A key point at which the necessity of producing human insulin using 
genetic engineering was explicated was at a symposium held in 1976. The 
symposium was jointly organised by Eli Lilly and another 7 pharmaceutical 
companies. Although there were 8 pharmaceutical companies involved in the 
symposium, it was Eli Lilly who was by far the most prominent company. 
3.3 ELI LILLY SYMPOSIUM 
As stressed in Chapter 1, Eli Lilly are one of the main players in the insulin market. 
Eli Lilly often helped organise scientific meetings to enable researchers to discuss 
their work. The symposium held in May 1976, in Indianapolis, and sponsored by the 
National Academy of Science had a bias towards discussing the possible production 
of human insulin. Eli Lilly themselves were interested in developing a human insulin 
by genetic engineering. They had already established an in-house group of scientists 
to look into the possibilities of genetic engineering. The symposium held in May 
1976 aimed to further this interest. Eli Lilly were also interested in uniting both 
commercial interests and academia, something that they had been doing since 1922 
(Hall, 1987: 5). 
At the symposium there was a strong emphasis on the benefits of genetic engineering. 
Irving S. Johnson of Eli Lilly pointed out that there was not a shortage of insulin at 
the present time, but their could be a shortage in the future. He argued that 
theoretically pig and cow pancreases would produce enough insulin to supply 
diabetics. However, he argued that there was an unpredictable supply of pancreases 
for a number of reasons: drought conditions caused less cattle to be raised; changes in 
dietary and feeding routines meant that there was a lower amount of insulin in the 
pancreases of slaughtered animals; some pancreases were `snapped' up as food 
delicacies; and, other pancreases were too contaminated to be salvaged (Hall, 1987: 
129). 
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The image presented by Johnson was one where supply was taken out of the control 
of the pharmaceutical companies and given to nature, or practices were out of the 
control of the pharmaceutical companies, such as farming techniques and cultural 
eating habits. What Eli Lilly wanted was to be able to control the amount of insulin 
that they could supply. 
Ruth Hubbard was at the symposium as an opponent of the proposed research. She 
questioned what was meant by a potential benefit. She suggested that human insulin 
was a quick fix and would not solve the problems of diabetics. She also argued that if 
pharmaceutical companies were looking to reduce the cost of diabetes, they should 
concentrate on needles and syringes, which cost more than insulin per day (Spallone, 
1992: 59). If the groups assembled at the symposium were to be successful, they 
would need to silence these dissenting voices (actors). 
The symposium was important because it brought various research groups together. 
Further, it set the scene for a possible race, between Harvard University and 
University of California at San Francisco (UCSF). This race would be won by the 
first to develop and refine complicated DNA technology that could produce the whole 
human insulin structure. However, on another level, there was a battle for the first to 
produce a commercially viable human insulin, no matter what technique was used. 
Into this race would come Genentech. After the symposium it was believed that on a 
practical level "it seemed feasible to get bacteria to make insulin - human insulin... " 
(Hall, 1987: 6). It is to the outlining of this race that my attention now turns. 
3.4 RESEARCH GROUPS AND THEIR PROGRESS 
I would now like to describe the progress of the three research groups. Space does 
not permit a full in-depth look at the step-by-step scientific developments. " Instead, I 
will be concerned with how the research groups stressed the importance of developing 
a human insulin. 
I will also refer to the interest of Eli Lilly in the work of the various research groups. 
Eli Lilly were interested in the work of the research groups because they wanted to 
commercially produce a human insulin. Specifically, they wanted this human insulin 
11 The book by Stephen Hall provides an extensive account of the scientific developments (1987). 
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to be produced by genetic engineering, and not by the conversion of animal insulin (as 
was the aim of Novo Industri). Eli Lilly also wanted to break into a number of insulin 
markets, so the control of human insulin technology was very important. By having 
control of the human insulin production techniques that were being developed by the 
research groups, Eli Lilly would be able to prevent others from developing the 
technology. By comparison, Novo Industri were only mildly interested in the 
research groups, since, as I have already mentioned, they were developing their own 
form of human insulin. 
Two basic DNA approaches were to be tried by three different research groups to 
produce the insulin gene. Harvard University and UCSF were attempting to produce 
the human insulin gene by the full DNA approach (Figure 3-2), while Genentech 
would take the synthetic option (Figure 3-1 ). Human insulin consists of two chains, 
known as A and B chains. The DNA approach would attempt to produce both these 
chains in one process, while the synthetic approach would produce the two chains 
separately and then join them together. Both groups would have a `test' project: 
Harvard University and UCSF would initially work on rat genes; while Genentech 
would work on somatostatin. 
In the following section I will look at the development of human insulin by the three 
research groups. Some of the issues that I will look at are: the relevance of the human 
insulin work to society and how this was related to worries over the use of genetic 
engineering; the involvement of insulin manufacturers; and, how the various groups 
funded their work. 
When looking at the actions of various actors in this study, it is important to be aware 
of the place of insulin within a number of networks. The use of insulin has long been 
established as the primary treatment method for Type I diabetes. 
Before the advent of human insulin, diabetics injected insulin which had an animal 
origin. Importantly, animal insulin does not have the same amino acid sequence as 
that used by healthy individuals. It was suggested that this difference caused 
complications in diabetes, such retinopathy (damage to the retina) and nephropathy 
(damage to the kidneys). Further, it was also suggested that the worldwide demand 
for insulin would outstrip the supply of animal insulin. I suggest that by linking the 
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problems over existing animal insulin treatments and the necessity for insulin per se, 
research groups were able to negate some of the controversy over genetic engineering, 
such as that of Ruth Hubbard. Added to this, there was already an existing market for 
insulin and there were already insulin manufacturers ready to fund the development 
and production of `new' and more `efficient' insulins. 
3.4.1 The Progress of the Research Groups 
Due to the concerns over genetic engineering one of the questions that I wish to deal 
with here is: Why did the groups choose human insulin as the first project in which 
genetic engineering and commercial production would be incorporated? As I will 
show, one reason for this was the placing of insulin within society, namely that it was 
a well known drug. By using a well known drug the research groups were easily able 
to put a case forward for the development of that drug by genetic engineering. 
In 1976, noted biophysicist Walter Gilbert and his research group were working on 
globin. Globin did not have the same medical impact as other genes so the 
researchers were considering other genes. They believed that it was important to have 
an `interesting' gene so that funds and expertise could more easily be attracted to the 
project. Gilbert argued that: 
"Somewhere very early on we switched to the idea of insulin, with the argument 
that it was a smaller protein, and actually a more useful one, to make in 
bacteria... " 
(Hall, 1987: 19) 
Herb Boyer and Robert Swanson, who would form Genentech, were also interested in 
producing insulin. They wanted to establish a new pharmaceutical company with 
research, manufacturing, and marketing all under one roof. They knew that the 
selection of the initial product was very important. Swanson claimed that they: 
"... looked for a product that could have a relatively short time through the 
regulatory hurdles. That was a key factor. " 
(Hall, 1987: 24) 
They, like Walter Gilbert, also wanted a drug that already had public recognition, and 
human insulin appeared as one possible candidate. In April 1976 Boyer and Swanson 
formed their pharmaceutical company - Genentech. They received $100,000 capital 
form Kleiner and Perkins, a venture capital firm. When Genentech was formed Boyer 
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was a professor of biochemistry and biophysics at UCSF. Prior to forming 
Genentech, Robert Swanson was a partner with Kleiner & Perkins. 
Genentech issued their first contract to Arthur Riggs, the City of Hope Hospital, and 
his team for $300,000.12 The project was to produce somatostatin, a hormone which 
effects the secretion of growth hormones, insulin and glycogen. It was perceived by 
them as a good model system and stepping stone to human insulin. Somatostatin was 
used as a model system for a number of reasons: it was a relatively small hormone; its 
chemistry was well known; and sensitive tests were available to test whether it was 
active in a cell (Business Week, 1977). As Arthur Riggs argued: 
"Insulin was definitely part of the contract. The plan was just to demonstrate 
feasibility, and obtain patents, with somatostatin, then immediately go for 
insulin. " 
(Hall, 1987: 84) 
One of the problems that the research groups encountered was over the ability to carry 
out the genetic engineering work. In order to be able to do this the research groups 
had to put a case forward for their research. The moratorium on DNA technology was 
lifted by the National Institutes of Health (NIH) on the 23'-d of June 1976. It then 
became possible to carry out of genetic engineering work (Norman, 1976; Wade, 
1975). Most planned experiments were then allowed to go ahead, but under strict 
safety controls. 
However, Cambridge City Council in Massachusetts, where Walter Gilbert and his 
Harvard group would be carrying out their work, still had concerns. At a meeting 
held in July 1976, Gilbert put forward reasons why the work should be allowed to 
take place. He argued that: 
12 The team also submitted a grant proposal to the National Institutes of Health (NIH) to produce 
somatostatin. However, the NIH claimed that the work was simply an intellectual exercise, and 
that 
they didn't think that it could be done in three years. 
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"One of the experiments we're interested in is putting the gene for human 
insulin into a bacterium. The purpose of that experiment is to make human 
insulin, a specific hormone, available. You probably know that insulin is used 
to treat diabetics. You may or may not know that the source of that insulin is 
from pigs or from cows, and that molecule is not identical to the one that is in 
all our bodies. [He added that these commercially available insulins were not 
perfect]... We are making something which is, beyond price. It is not that we are 
making cheaper medication. We are making something we cannot get by other 
means... 
(Hall, 1987: 53) 
We see here that the idea of linking the science to wider social issues is very 
important. However, The Coalition for Responsible Genetic Research pointed out: 
"In spite of the pervasive effects of the atomic bomb and the increasing 
domination of so many aspects of life by technology, the assumption [that 
progress in science is progress for society] has been preserved by biologists 
who, to receive immediate public approval, have had to cite only the general 
relevance of their work to medicine. " 
(Coalition for Responsible Genetic Research, 1977) 
It is notable that one of the reasons why the research groups chose human insulin as a 
research project was also seen, by some, as a criticism. As I have already stressed, 
there was an important reason why human insulin was being developed using DNA 
technology. By surrounding the DNA technology with a prospective use-value for 
diabetics and society, it becomes more than of `internal' interest to science. However 
some, such as The Coalition for Responsible Genetic Research, saw the attachment of 
genetic engineering technology to the prospective use-value of the resulting gene as 
being a way to carry out the research. From this point of view, the production of 
human insulin came secondary to developing genetic engineering. 
Despite some of these concerns, the Harvard group was given the go-ahead to carry 
out genetic engineering work (Culliton, 1976: 25). Gilbert and his group were then 
able to carry out their work; as with the UCSF group, they would base their work on 
producing rat insulin. 
Genentech were not restricted by the National Institutes of Health (NIH) restrictions. 
They were using synthetic DNA, and the NIH guidelines said nothing about synthetic 
DNA. Boyer stated the mounting regulation against recombinant DNA work as one 
of the reasons for using the synthetic option (Hall, 1987). Boyer could 
in effect 
exploit a loophole in the guidelines, in terms of physical access to laboratories, 
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regulation and, public concern. 
Perhaps because the UCSF group were able to carry out DNA research as soon as the 
NIH lifted the ban on DNA research, they were the first to clone the gene for the rat 
insulin hormone. They put together a paper for the journal Science and applied for a 
patent. In May 1977 the paper on cloning rat insulin genes was given to the editors of 
Science magazine (Hall, 1987: 140). 
On May 23rd 1977 the UCSF team held a press conference to announce the cloning of 
the rat insulin gene, and "because insulin continued to be a magic word, the response 
was almost overwhelming. " (Hall, 1987: 142). The work received considerable 
attention in the press and within the scientific community. One reason for the 
attention was that the researchers had achieved, "much earlier than expected, the first 
step towards the goal of isolating the human insulin gene and using it for the 
manufacture of insulin protein" (Wade, 1977: 1342). Importantly, scientists could see 
the potential benefits of recombinant DNA technology. Great expectations were also 
being `whipped up' in the public sphere for the possibilities of genetic engineering. 
For example: 
"Possible benefits began to sound like certain benefits. The possibility of 
cheaper therapeutics became the certainty of cheaper therapeutics. " 
(Hall, 1987: 145) 
At the UCSF press conference the research was described, as was some future 
research - the rat insulin would be expressed in bacteria within six months - but more 
importantly, human insulin was only a year or two down the line. The paper was 
published in Science on June 17th 1977 (Ullrich et al., 1977). At this point "everyone 
in the scientific community could appreciate the resourcefulness of the San Francisco 
team. " (Hall, 1987: 145). 
It was also pointed out that the paper in Science did get published quickly and 
suffered from an unusually significant number of typographical errors. According to 
some, this suggested that there were significant political overtones to the editorial 
handling of the work. One reason could have been that the experiment was seen as a 
stepping stone to public acceptance of recombinant DNA technology by the public 
(Hall, 1987: 142). 
81 
3. The development of human insulin 
A few months later, the Genentech group had cloned and expressed somatostatin. 
With these results, Genentech burst out ahead of the biotechnology pack. Genentech 
moved ahead of UCSF because UCSF had only cloned a gene (rat insulin) and not 
expressed it. As Hall writes: 
"Somatostatin in a sense was a scientific show-and-tell; human insulin was a 
money-maker. Doing human insulin, and doing it first, might well establish 
Genentech's pre-eminence in the emerging field of biotechnology... " 
(Hall, 1987: 165) 
A paper was written and accepted by the journal Science and appeared on the 19th 
December 1977 (Itakura et al., 1977). A press conference followed a month later, in 
which the results were reiterated. Subsequent press reports claimed that recombinant 
DNA technology would now be able to deliver on its promises. Further, it became 
more obvious, as the media reported the developments, that somatostatin was the 
gateway to human insulin. ' 3 The somatostatin work was seen as a model system into 
which human insulin could be placed. According to Arthur Riggs, "essentially the 
same recombinant DNA techniques were used in the somatostatin and the present 
insulin work... " (Gunby, 1978: 1698). 
The somatostatin results added to the rat insulin work, by UCSF, in re-framing 
genetic engineering. It was argued that the public were able to see the possible social 
benefits of genetic engineering. Rather than being for science in itself, genetic 
engineering could be seen as having wider implications. Pfund and Hofstadter (1981) 
have looked at articles in the American media about industry involvement in 
recombinant DNA technology. They looked into seven major newspapers, ten 
magazines and six science/medical periodicals between 1976 and 1979. They found 
that before the mid-to-late 1977 reports concentrated on the controversy surrounding 
genetic engineering, however, towards the end of 1977 the benefits of genetic 
engineering were stressed instead. 
With the developments in DNA technology it was becoming obvious that genetic 
engineering could be big business. For example, following on from the Genentech 
press conference, Genentech easily raised $1 million dollars to move onto the 
13 Indeed, it was questionable whether somatostatin would ever be commercially produced (Hall, 1987: 
175). 
82 
3.4 Research groups and their progress 
production of human insulin. With this funding Genentech would not only go for 
human insulin, but also other important genes, such as growth hormone, the 
Interferons and interleukins. 
Not everyone, however, was interested in these new developments. In early 1978 
Genentech had approached Novo Industri about the possibilities of a R&D contract 
for genetic engineering (McKelvey, 1996: 128-129). Novo Industri were not 
interested in such a contract for a number of reasons: 
1) Genetic engineering was a new technique and very uncertain, Novo Industri 
believed that the technology wouldn't work. 
2) Novo Industri questioned the long term viability of genetic engineering 
techniques. 
3) At the time Genentech were a new and unknown company. 
4) Novo Industri were developing their own technique to convert porcine 
insulin into human insulin, that drew upon their existing competencies with 
enzymes. 
There was also corporate interest in the work being carried out by the other two 
groups. Towards the end of 1977, Gilbert was being approached by a number of 
venture capitalists. T. A. Associates wanted to bring together a `dream team' of 
scientists to form a pharmaceutical company. Although Gilbert was initially uneasy 
about uniting academia and business, after a number of meetings he became more 
interested. Gilbert was a well known and respected figure within the scientific 
community, and as a result, it appears that he was the main representative of the 
scientists that were gathering on this `dream team. ' Due to his standing in the 
scientific community other scientists saw the formation of the company in a positive 
light. It was also Gilbert who was helping to direct the possible research projects of 
the company in discussion with T. A. Associates. Gilbert admitted that his motivation 
was in: 
"... wanting to do something socially useful, wanting to create an industrial 
structure, wanting to make something grow, wanting to make money. Although 
the desire to make money is not that high, generally, in scientists... " 
(Hall, 1987: 195) 
On May 6t" Biogen was officially formed. Their primary targets were alpha interferon 
and the hepatitis B vaccine, as they promised to be large and lucrative markets. 
Gilbert also knew that another aim was to duplicate their work on rat insulin, but for 
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human insulin. Eli Lilly also attempted to gain a license to have access to the 
techniques developed by the Harvard University team, with the aim to develop them 
for use in commercial production. However they failed, with the license going to 
Biogen (McKelvey, 1996: 132). 
Eli Lilly had also been in discussion with the UCSF research group. During the 
summer of 1978, the final touches to the agreement were made to develop not only 
human insulin, but also human growth hormone. The contract was estimated at $1.3 
million dollars lasting for five years, during which time the UCSF would carry out 
research and retain ownership of the resulting material and techniques. In return, Eli 
Lilly would get first refusal as to whether they wanted to license the results 
(McKelvey, 1996: 131). They would also build a new laboratory in Strasbourg for the 
work. At the same time Eli Lilly were also having discussions with Genentech. It 
appears that Eli Lilly were covering all possibilities. 
Looking at the two main pharmaceutical companies, both Novo Industri and Eli Lilly 
seem to have seen human insulin as the direction in which future developments of 
insulin should be headed. However, the paths by which this was to be achieved were 
different. Initially, Novo Industri were interested in their in-house work on 
converting porcine insulin to human insulin. On the other hand, Eli Lilly were 
interested in the new genetic engineering approaches. 
One of the necessities of the work being carried out by both UCSF and the Harvard 
group was not just that insulin was being expressed but also that it could be secreted. 
When the UCSF research group reported their work in 1977 they had cloned rat 
insulin, but they had not secreted it. It would be necessary to secrete insulin in order 
to harness the process for industrial application. In August 1978 the Harvard group 
published a paper which described the secretion of rat pre-proinsulin (Villa-Komaroff 
et al., 1978). The paper was published in the Proceedings of the National Academy of 
Science (PNAS), which is the publication of choice when you have a `hot result' 
(Hall, 1987: 223). Although there was no actual mention of human insulin in the 
paper, there was an awareness that the work was a "step toward using bacteria to 
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produce human insulin. " (Gunby, 1978: 1698). The paper caused media excitement, 
more for the fact of the possibilities than the work in itself. It was now 
believed that 
the promised human insulin was just around the corner (Hall, 1987: 235). 
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With the secretion of rat insulin the group could now use a similar technique for the 
production of human insulin. With the backing of Biogen, Gilbert attempted to 
produce human insulin with the same team that synthesised rat insulin. 
However, by the end of August 1978 the Genentech team had successfully produced 
human insulin (Figure 3-1. Taken from Chien (1996)). There is an interesting 
comparison between somatostatin and human insulin. Compared with somatostatin, 
human insulin was not as scientifically interesting to the scientific community (since 
the production of human insulin was basically a repetition of the techniques used for 
somatostatin). However, to the general public, human insulin was more exciting than 
somatostatin. Human insulin was more embedded within the concerns of the public. 
For example, most people know that diabetics need insulin. This led Spyros 
Andreopoulos, of the Stanford University Medical Center, to claim that: 
"... while perhaps not as glamorous as human insulin, one could have written the 
same story about any number of cloning experiments at the time. " 
(Andreopoulos, 1980: 744) 
On hearing the news from Genentech, Earl B. Herr, Jr., president of Eli Lilly 
Research Laboratories, claimed that: 
"Our agreement with Genentech was made to assure diabetic patients of the 
continued availability of insulin without total dependence on animal glands. " 
(Quoted in Gunby, 1978: 1697) 
Negotiations with Eli Lilly had been going on since early 1978, but with the 
demonstration that human insulin could be produced in the laboratory, the links with 
Genentech were fixed in August that year. Eli Lilly now had links with two research 
groups - UCSF and Genentech. Swanson, the founder of Genentech, planned to link 
Genentech to Eli Lilly because, Genentech knew very little "... about processing, 
fermentation, scale-up testing, shepherding a drug through clinical trials, winning 
Food and Drug Administration (FDA) approval, marketing, and sales. " (Hall, 1987: 
268). With the knowledge that Genentech could gather from the scale up of human 
insulin. they hoped to be able to follow other projects right through to commercial 
production. 
A press conference was held on the 6th of September (Genentech, 1978) which came 
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before the scientific papers were published (Crea et al., 1978; Goeddel et al., 1979). 14 
The press conference attracted many television and media journalists. Just as with the 
development of insulin by Banting and Best in 1922, human insulin became world 
news. Bliss writes of the Banting and Best discovery: 
"... everything connected with this discovery, the development of insulin, and its 
application to human beings, was read with the greatest interest... He [Banting] 
was in demand everywhere as a speaker... and the press was constantly seeking 
to interview hisn. " 
(Bliss, 1983: 80) 
The effect of the publicity and press conference was also to show that the recombinant 
DNA work was relevant to society. In the press release, for the press conference on 
human insulin, Swanson argued that: 
"The development of human insulin demonstrates the viability of using 
recombinant DNA technology to produce products with practical application. " 
(Genentech, 1978) 
This again illustrates what Pfund and Hofstadter (1981) argued, that the view of 
recombinant DNA technology moved, between 1976 to 1979, from controversy, over 
its safety to the public, to one of medical benefits to the public. 
At the press conference, the experiments were outlined and the name Genentech 
became a `household name. ' Further, there was an outlining of the long range 
commercial development of human insulin (Gunby, 1978: 1697). Genentech also 
raised $10 million dollars, from Lubrizol Corp., to pursue other projects, such as 
interferon. 
Andreopoulos (1980) has pointed out that critical questions that would have put the 
work into perspective were not asked at the press conference. The substance had not 
actually been tested on animals, one reason for this was that the experiments were not 
producing enough insulin to make this possible. This was a criticism not just of 
human insulin, but also of other innovative discoveries, such as the synthesis of 
human growth hormone and clones of interferon-producing bacteria (Andreopoulos, 
14 A member of the research group presented their work at a seminar before the press conference, so 
that the work would be in the scientific domain. One reason for this was that there was a rumour that 
a major paper was going to be given by the Harvard group. In fact, Gilbert knew of no such meeting 
and had nothing to report anywhere, but hoped to by to produce human insulin in September 
(Medical World News, 1978: 10). 
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1980: 744). However, the majority of the media took it as a fact that insulin could be 
scaled up to commercial production, and could be used for the treatment of diabetes 
Eli Lilly were however aware of the hypothetical nature of the commercial production 
of insulin. They were aware that just because human insulin had been produced in the 
laboratory, did not mean that it could be scaled up and commercially produced. 
Although they agreed to fund research and development of human insulin, with the 
aim to scale it up, there was no commitment that human insulin would be produced 
commercially. Eli Lilly wanted to see whether the scale up of human insulin could be 
done (Hall, 1987: 276). Indeed, Eli Lilly had actually negotiated a tough deal with 
Genentech requiring them to meet a number of benchmarks. 
Before I go on to look at the scale up of human insulin, I would like to say something 
about the other two research teams. 
3.4.2 A Final Note on the Other Two Groups 
Although I have already explained who `won' the race, that is not the end of the 
human insulin story. After the agreement between Eli Lilly and UCSF was signed, 
UCSF successfully isolated and cloned the human proinsulin gene. This was around 
the time that Genentech had produced human insulin. This was not as disturbing as it 
seems since the UCSF research group were interested in isolating the human gene, 
that is, seeing the array in its entirety. Genentech's synthetic approach did not reveal 
such information, it simply produced human insulin. 
Meanwhile, one of the members of the UCSF group moved to Genentech to continue 
to develop the pre-proinsulin work. By the end of 1979, with the help of the new 
member of the group, Genentech had successfully cloned the preproinsulin in E. coli 
(Frank et al., 1981). See Figure 3-2 (taken from Chien (1996)). 
Eli Lilly now had two possible methods to produce human insulin. They opted to first 
go for commercialisation of the original procedure, the linking of the separate insulin 
chains, although privately they preferred the proinsulin bacterial method (Hall, 1987: 
294). 
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Figure 3-2: Procedure involved in the production of bio-engineered human 
insulin using the proinsulin method (taken from Chien (1996)) 
As is now clear, it was Genentech who `won the race' for human insulin. However, 
in late 1979 the UCSF group found the human insulin gene, not an abbreviated 
version, but the full genetic structure (Bell et al., 1980). The identification of the gene 
gave an excellent up-to-date understanding of genes. It is interesting that Genentech's 
bacteria were producing human insulin over a year before the actual insulin gene was 
isolated from the human chromosome. 
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The Harvard group, with the backing of Biogen, attempted to produce human insulin. 
However, again, they were having problems with access to the necessary laboratory. 
Since the human insulin experiments were using human genetic material they had to 
be carried out in a more tightly controlled laboratory than was necessary for the rat 
insulin work. Access to such a laboratory could not be found in America, so Gilbert 
applied to use the British Anny's Microbiological Research Establishment in Porton 
Down. In order to carry out the work there they had had to pack up all the equipment 
that they would need for the human insulin experiments. While carrying out some of 
the experiments for human insulin they had inadvertently cross contaminated the 
human insulin work with their previous rat insulin work, a type of contamination 
known as transtubation. Gilbert described the trip to England as a "total disaster" 
(Hall, 1987: 265). 
So the development of human insulin led to a number of outcomes: it became possible 
to produce human insulin by genetic engineering in the laboratory; techniques used in 
the laboratory could be applied to other settings; and, more was known about the 
human insulin gene. In the following section I will look at some of the issues that 
were important in the commercial production of human insulin. 
3.5 COMMERCIAL PRODUCTION 
I would now like to look at the scale up and clinical testing of human insulin, what 
Jasanoff calls regulatory science (1990). With the movement from laboratory 
production to the commercial scale up of human insulin, commentators were able to 
see how the technology could realistically solve the predicted supply problem of 
insulin. The British Veterinary Journal argued that: 
"The benefits to be derived from this work are multiple which adds to their 
importance. It is predicted that during the next 20 years the demand for insulin 
will outstrip the production capacity of the conventional technique of isolation 
from animal sources. This restriction is now being removed with the advantage 
of producing human insulin of high purity for the treatment of diabetes in man. " 
(British Veterinary Journal, 1980: 518) 
It was also predicted that the technology would go significantly beyond the 
production of human insulin. For example, it was argued that a number of uses of the 
technology were on the immediate horizon: it could be used to produce hormones, 
interferon, vaccines, antibodies, enzymes and for prenatal diagnosis (Riggs and 
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Itakura, 1979: 537-8). 
When Genentech was able to show that human insulin could be produced 
commercially, Genentech and Eli Lilly parted company. In the process of developing 
human insulin Genentech had established themselves as the first biotech company, 
and the one that had used gene-splicing to produce human insulin for the treatment of 
diabetes. The separation between the two companies was however, an amicable one. 
As McKelvey points out: 
"Lilly were not willing to share the insulin market or jointly develop insulin 
production with Genentech. Nor was Genentech overly eager to try to enter a 
market that was so completely dominated by a few firms. " 
(McKelvey, 1996: 140) 
By the middle of 1980 Eli Lilly had tested the insulin for purity and bacterial 
contamination. Human insulin was then ready to enter other clinical tests. Eli Lilly 
had also cleared the construction of large scale fermenters through the Recombinant 
DNA Advisory Commission. The fermenters would be necessary for commercial 
production of human insulin. Three months later, Eli Lilly announced plans for their 
construction, one in Indianapolis and the other in Speke, England, at an estimated cost 
of between $70 - $80 million dollars. The plant at Speke was expected to produce 
human insulin for clinical trials towards the end of 1980 (Wright, 1980). This led 
some to comment that: 
"Eli Lilly's investment in its insulin manufacturing facility devoted to 
biosynthesized human insulin should.. . prove a good 
investment - for the 
shareholders and mankind. " 
(Nossal, 1980: 286) 
Later, in 1980, Eli Lilly received permission to start large scale production of 
synthetic insulin and proinsulin, and also human growth hormone, somatostatin and 
theymosunalpha-1. By this time DNA technology was becoming big business, as a 
leading molecular biologist said, "There are millions of dollars floating around. If 
you claim something fancy you can raise a lot of money. " (Quoted in Wade, 1980: 
492). 
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Pharmacology Toxicology studies in animals (efficacy, metabolic and toxicological 
assessments). 
IN D Investigate New Drug. 
Phase I Trials to test the safety and dosage in 20-50 healthy subjects. 
Phase II Trials to test its efficacy against the targeted illness, 20-100 subjects. 
Phase III Trials to test the effectiveness against existing treatments for the 
same illness, 500-5000 subjects. 
NDA New Drug Application. 
Phase IV Continuation of Phase III or post-marketing pharmacovigilance 
survey. 
Figure 3-3: Overview of clinical testing for pharmaceuticals 
Before human insulin could become commercially available it had to go for clinical 
trials (see Figure 3-3). These clinical trials would delimit what human insulin could 
do, in effect, `checking' its theoretical claims. Chance et al. (1981) outline a 
`complex battery' of biochemical and animal systems (12 in all) through which 
human insulin was tested and compared with both pancreatic human insulin and 
standard pork insulin. Their conclusion was: 
"All results obtained on BHI indicate that it is chemically, physically, and 
biologically equivalent to pancreatic-derived insulins. " 
(Chance et a1., 1981: 149) 
Once passed through chemical and animal testing, controlled trials on healthy subjects 
could be carried out. However, there were still some voices of caution. For example: 
"... it is still in the experimental stage and much work needs to be done before 
anyone can dare hope that it will be the day-to-day insulin available for human 
use. " 
(Iveson-Iveson, 1980: 37) 
In the middle of 1980 Dr. Harry Keen, of the Unit for Metabolic Medicine at Guy's 
Hospital in London, performed the initial clinical tests, on healthy volunteers, using 
human insulin from Eli Lilly (separate chains) (Wright, 1980: 4). It was believed that 
if "successful in healthy people, clinical trials on diabetic patients could start by the 
end of September. " (New Scientist, 1980: 351). 
As each new development was reported, constant reference was made to the benefits 
of human insulin over conventional insulins, to take but one example: 
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"Unfortunately, there is a world shortage of animal insulin. Another problem 
the new synthetic insulin might solve is that animal insulin sets off an immune 
response in the body and a large proportion of the hormone is destroyed in the 
blood without ever benefiting the patient. However the hormone churned out 
by Eli Lilly's bacteria is practically identical to that produced by humans. " 
(New Scientist, 1980: 351) 
As already shown, it was believed that the best insulin was that which most closely 
resembled that produced by the body. Indeed, this was one of the reasons why pork 
insulin had superseded beef insulin. Compared to human insulin, beef insulin differs 
by three amino acids, while pork insulin differs by only one (see Figure 2-3). As 
Galloway argued: 
"... the best insulin is that which is the purest and has a chemical structure most 
like human insulin - has resulted in a marked shift of insulin usage from beef 
containing insulins to monospecies pork. It has been an important impetus to 
the research and development that has led to the production of human insulin 
using recombinant technology. " 
(Galloway, 1980: 615) 
The results from the study by Keen (1980) were published in August 1980. The 
results showed that there seemed to be no demonstrable difference between purified 
porcine and genetically synthesised human insulin: 
"We have, therefore succeeded in demonstrating, in a small number of 
intensively studied healthy volunteers, the safety and efficacy of a human 
preparation produced in E. coli by recombinant DNA technology. This is but 
the first step in a longer process of investigation of its actions, validation of 
clinical efficacy in diabetics, and continuing vigilant surveillance for 
unexpected adverse effects. " 
(Keen et al., 1980: 401) 
Keen also claimed that genetically engineered human insulin may be more 
bioefficient than animal insulin, because it would be absorbed by the body more 
quickly. It was also claimed that human insulin may suppress the production of toxic 
substances in the kidneys (Yanchinski, 1982). 
Similarly, a study carried out by Novo Industri, on diabetics using their converted 
insulin, found that human insulin's effect on the body was identical to very pure pig 
or beef insulin (Yanchinski, 1982). It is important to realise that these early studies 
did not show that human insulin was necessarily more efficient than existing 
conventional insulins, rather, they were equivalent. However, Novo Industri were 
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still pleased with their results. The prediction that human insulin would solve some of 
the complications of diabetes could not be shown, because this would require 
prolonged use of the new insulin. Indeed, there was some concern that no long term 
studies were planned (Yanchinski, 1980: 720). However, this did not prevent the 
hope that engineered human insulin would reduce the risk of diabetic complications, 
because it had the same amino acid sequence as `natural' pancreatic human insulin. 
One of the biggest costs of diabetes are the associated complications (both direct and 
indirect) which may develop over time (Datamonitor, 1997), so any attempt to reduce 
these complications would be warmly welcomed by both diabetics and the medical 
profession. 
There was also some disagreement over the interpretation of some of the experimental 
results. Teuscher and Diem questioned the results of skin tests, which aimed to test 
for adverse reactions: 
"We were surprised that Keen et al. found positive skin tests with their human 
insulin in some of the healthy volunteers. Although described as minor and 
trivial, erythema and swelling were still present 5h after intracutaneous 
injection... " 
(Teuscher and Diem, 1980: 1186) 
There were also some wider concerns over the predicted benefit of human insulin. 
Yanchinski argued that animal insulins "have worked well until now" (Yanchinski, 
1982: 697) and this was backed up by Keen's study, which concluded that: 
"... there seems to be little demonstrable difference between the purified porcine 
and the genetically synthesised human insulin. " 
(Keen et al., 1980: 400-1) 
Human insulin may not therefore solve some of the complications of diabetes. For 
example, Dr Kurt Alberti, who was instrumental in Novo Industri's clinical trials at 
the Royal Victoria Infirmary Hospital, Newcastle Upon Tyne and Nottingham 
General Hospital, claimed that most diabetic complications resulted from wide 
variations in blood glucose levels due to injecting insulin. High levels of glucose 
have been shown to damage the body's structural proteins, and subsequently, cause 
retinopathy (damage to eyes) and nephropathy (damage to the kidneys) (Yanchinski, 
1982). 
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One solution to these complications, according to Alberti, would be the use of insulin 
pumps. Insulin pumps provide a continuous controlled insulin infusion. This 
continuous infusion of insulin would prevent variations in blood glucose, which "may 
be responsible for many of the most serious complications of diabetes, such as 
blindness, vascular disease, and kidney failure. " (Sun, 1980: 1227). 
External pumps were already used by several hundred diabetics, however, the aim 
was to develop internal pumps, similar to pace makers. There were a number of 
concerns in relation to insulin pumps and insulin: conventional Insulins tended to clog 
the tubing of the pump; conventional insulin can `go off; the size of the pumps; the 
ability of the pumps to detect changes in glucose levels and adjust insulin supply 
accordingly; internal pumps would need more concentrated insulin to reduce the time 
between refills; and, there needs to be a fail-safe way to control dose, since an excess 
of insulin can result in death. The insulin suppliers were keeping abreast of the 
development of insulin pumps, and some were developing their own devices. 
There is an important link here between pumps and insulin. It was reported that the 
question of insulin type would move from the control of the manufactures of insulin 
to the manufactures of insulin pumps, since the pump manufacturers would be able to 
specify the insulin formulations that they required for the insulin pumps. Therefore, 
companies that manufactured both insulin and insulin pumps would have a strong 
advantage. John Galloway, a scientist at Eli Lilly, argued that insulin pump makers 
would demand "the best insulin, and the best insulin will be human insulin, barring 
any surprises. " (Quoted in Sun, 1980: 1227). 
It is also important to look at the insulins that human insulin was intended to replace. 
Some medical professionals questioned the advantages, claimed by using Novo 
Industri, of their purified insulins. Novo Industri claimed that their purified insulins 
would prevent allergic reactions, which occur in 5 percent of diabetics who take 
conventional insulin. Reactions include skin rashes and lipoatrophy, where the fat 
cells around the injection site deteriorate and form `dents' in the skin surface. There 
were also suggestions that purer insulins reduced antibody build up, which can block 
insulin action in patients. 
However, some in the medical profession argued that purified porcine insulin only 
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benefited a small percentage of diabetics. Those who would benefit were those who 
experience allergic reactions to conventional insulins. Josse Roth, chief of the 
National Institute of Arthritis, Metabolism, and Digestive Diseases, argued that Novo 
Industri and Nordisk had made a big deal about the purified insulins, but that patients 
would not benefit from these Insulins (Sun, 1980: 1226). A. M. Albiseer, director of 
biomedical research at Toronto's Hospital of Sick Children, put it another way, he 
argued that using purified insulins is like "using high octane gas in all vehicles. " 
(Quoted in Sun, 1980: 1226). 
Eli Lilly agreed that purified porcine insulins were unnecessary, although for different 
reasons. They argued that so much insulin was lost in the purification processes, that 
there would be a shortage of insulin if everyone used purified insulins. Novo Industri 
however, claimed that it only lost an additional 10% of insulin in its purification 
process. Even though Eli Lilly claimed there would be a shortage of animal insulins, 
they too were developing a purified porcine insulin of their own. Further, as James 
Smart of Nordisk claimed, the emphasis on a shortage was self serving: "It's very 
intelligent marketing until Lilly gets their recombinant DNA insulin. " (Quoted in Sun, 
1980: 1226). 
So was there a shortage? The Food and Drug Administration (FDA) said that 
evidence of a shortage was hard to come by. A study by the FDA and the National 
Diabetes Advisory Board in 1978 found that there would be adequate supplies of 
insulin for the next 20 years. As already pointed out, the supposed supply problem 
may be due to distribution and availability of animal glands, rather than the number of 
animals that are slaughtered each year (Teuscher and Diem, 1980: 1186). Further: 
"... with use of all available pancreas, supply could easily exceed current 
demand. Distribution is more of a problem than supply, and efforts must be 
made to improve this for the benefit of developing countries where patients with 
diabetes still die because of `non-availability of insulin. "' 
(Teeascher and Diem, 1980: 1186) 
It appears that there was little evidence of predicted shortages, as John Gueriguian of 
the FDA pointed out, "We haven't seen a shred of data about a shortage. We get the 
same letters [predicting shortages] ad nauseam but no data. " (Quoted in Sun, 1980: 
1226). 
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Just as purity was an issue with conventional insulin, it was also an issue with human 
insulin. Scientific claims of purity range form 5-50%, while for pharmaceutical 
companies, drugs have to be almost 100% pure (Hall, 1987). The most common 
impurities in recombinant drugs are proteins. Protein impurities can cause allergic 
reactions, or alter the therapeutic effects of the drug. Such impurities are not as 
important in scientific experiments. Insulin had to be so pure because the body would 
react against any impurities. In the pharmaceutical industry, purity is finally decided 
when the patient doesn't show any allergic reactions or side-effects. 15 Paul Burnett 
from Eli Lilly claimed that, "Our product [human insulin] is equal or better than the 
best porcine insulin in purity. " (Quoted in Yanchinski, 1980: 760). Claims of purity 
was even more of an issue in the case of human insulin, because the issue of purity 
was one of the causes of competition between the insulin manufactures. For example: 
"The reason for this expensive effort, according to Paul Burnett, who is in 
charge of Lilly's molecular biology unit, is that animal Insulins can cause severe 
allergies with prolonged use. However, in reality, both companies are using 
their new products to poach on each other's commercial territories. " 
(Yanchinski, 1980: 760) 
The situation between the companies was defined in strong terms, with headlines such 
as `Genetic engineers battle over insulin' (Yanchinski, 1980) and `Insulin Wars: New 
Advances May Throw Market into Turbulence. ' (Sun, 1980). The `battle' was over 
dominance of the insulin supply market: 
"A battle royal is taking place between two drug manufactures to decide which 
will be the first to sell synthetic human insulin and so dominate a market in the 
United States and Europe worth billions of dollars. " 
(Yanchinski, 1980: 760) 
Eli Lilly were unable to access other insulin markets because the Federal Trade 
Commission (FTC) were concerned with their monopoly of the insulin market in 
America. Eli Lilly did not want to fight against the FTC and agreed with the FTC to 
"license out its existing know-how in insulin manufacture to domestic and foreign 
companies. " (Sun, 1980: 1227). However, Eli Lilly managed to retain their insulin 
15 A fascinating account is given by McKelvey of the initial trials of human growth hormone, where 
subjects in phase one of clinical trials showed allergic reactions to the hormone, even though 
analytical tests showed the protein to be pure. The result therefore was that the invisible, the 
impurities, became visible though the subjects. Later, the invisible would be shown by the 
development of more sensitive analytical tools, such as silver staining SDS gels or High Pressure 
Liquid Chromatography (HPLC) (McKelvey, 1996: 205-217). 
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knowledge in respect of future developments in that they only had to share their 
knowledge with American companies. Since Novo Industri and Nordisk are not 
American, they did not have access to the recombinant DNA technology, so this new 
knowledge was a way of by-passing the FTC ruling. 
There was great competition between Novo Industri and Eli Lilly to be the first to 
market human insulin. There are many barriers that prevent entry into an insulin 
market that is already dominated by another company. One barrier is the ability to 
differentiate insulin products (Datamonitor, 1997). Novo Industri had done it with 
their purified animal insulins, and gained some success. Now both companies were 
attempting to do it with human insulin - human insulin represented a degree of 
product differentiation. 
The company to market human insulin first would be the company able to negotiate 
various regulations. In 1981, it was argued in SCRIP (A journal of world 
pharmaceutical news) that "Novo's lead could be as much as 12 months over Lilly. " 
(1981 a: 15). One reason for this suggestion was that it was believed that Novo 
Industri were enjoying a relatively trouble-free development programme (SCRIP, 
1981 a: 15), and progress through regulations. As Scott King argued: 
"Novo Industri has chosen the more expedient route of having protocols 
designed to achieve approval in the minimal time, [where as Eli Lilly] has 
devised time-consuming protocols that are evidently designed to prove human 
insulin's superiority. " 
(Scott King, a US broker, quoted in SCRIP, 1981b: 5) 
Even with some kind of scientific proof of the efficiency of human insulin, there were 
still concerns over the investment of resources in human insulin, rather than other 
areas of diabetes. For example: 
"We can be justly proud of human ingenuity, which has opened another way to 
synthesise human insulin. However, for patients, it would be far more 
important for research to reveal how to reduce vascular and neurological 
complications of diabetes. " 
(Teuscher and Diem, 1980: 1186) 
However, as time passed, more and more data was collected and regulations passed. 
Henry Miller, of the FDA, claimed that Eli Lilly's insulin was on the `fast track' for 
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approval. 16 Since the effects of natural human insulin were well known, and the new 
human insulin was the same substance, the FDA thought it was vital to pass the new 
drug (Yanchinski, 1980: 760). It could also be compared with other insulins, that is, 
"all the questions that have been asked concerning purified pork insulin will be 
applied to biosynthetic human insulin. " (Galloway, 1980: 621). Harry Keen, who 
carried out the initial clinical trials, argued that the Committee on the Safety of 
Medicines (CSM), Britain's drug regulatory body, was committed to passing the new 
drug as quickly as possible (New Scientist, 1980: 351). 
This paralleled the original case for conventional insulin, as Bliss wrote: 
"The clinical application of discovery often takes a long time, but in this case a 
bare twenty weeks had passed between the first injection of insulin to a diabetic 
dog to a diabetic human. The time was very short and many problems were 
clamouring for attention: the immediate saving of lives, the production of 
insulin, research and more. " 
(Bliss, 1983: 76) 
Permission was granted in early 1982 for limited sales of Novo Industri's human 
insulin in Malta, France and Austria (Yanchinski, 1982: 697). Novo Industri also 
received approval for the sale of Novolin in England and Germany. Novo Industri 
also formed a partnership with the US pharmaceutical firm E. R. Squibb and Sons, 
who were contracted to market Novolin in the United States. The link between 
Squibb and Novo Industri was not new, Novo Industri was already "selling 
exclusively finished, packaged insulin to Squibb. " (SCRIP, 1981 b: 5). In 1981 it was 
thought that, as a result of the link between the two companies, Squibb had around 
15%-17% of the US insulin market. Novo Industri were also experiencing increased 
sales in the European market. Before the introduction of human insulin, it was 
claimed that Novo Industri had a "projected nominal growth rate of insulin sales of 
22%-26%, excluding the impact of `human insulin. "' (Scott King, a US broker, 
quoted in SCRIP, 1981b: 5). 
By 1982, Eli Lilly were sending out advance publicity material for human insulin 
even though human insulin had not yet been licensed (Yoxen, 1983). By May 1982 
Eli Lilly had filed a New Drug Application (NDA) with the Food and Drug 
Administration. On the 29th October 1982 the FDA passed human insulin, the insulin 
16 In the 1980s the average R&D process took 12 years (Office of Technological Assessment, 1993). 
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was called Humulin and was estimated to cost twice as much as animal insulins 
(Shapley, 1982). By 1983 human insulin was in pharmacies. A month before it had 
been approved in Britain, Swanson claimed that the approval, "is a tribute to the 
collaboration of two great scientific teams - those at Eli Lilly and Genentech. " 
(Genentech, 1982). 
In 1981 Novo Industri agreed with Biogen to develop a genetically engineered human 
insulin by using yeast expression. It was hoped that it would be cheaper than the 
chemically altered insulin. It was reported in the media, that the work was 
progressing rapidly and it could be approved within 2-4 years (SCRIP, 198lb: 5). 
However, Biogen failed to get the technology to work in practice, even though they 
had the relevant technology. It was Zyrno Corporation (later ZymoGenetics) who 
would eventually express human insulin in yeast for Novo Industri. 
It is notable that the media did not report as much on Novolin as they did Humulin. 
One reason why Novo Industri were able to produce a human insulin quicker than Eli 
Lilly was because they were not using such complicated techniques, indeed, they were 
based on work carried out in the 1970s. The techniques were not as new and 
controversial as the genetic engineering methods and so the insulin passed the process 
of regulation quicker. Until October 1985, human insulin was the only genetically 
engineered product approved for sale, the second product appeared in 1985, a growth 
hormone produced by Genentech. 
In the preceding sections I have outlined a number of factors that made the 
development of human insulin interesting. I have shown how the development of 
human insulin, by genetic engineering, entered into the debate over the first use of 
genetic engineering, and how research groups chose human insulin because of its 
existing `social value'. I have also shown how problems were suggested with existing 
insulins, and that some of these problems could be solved by the development of 
human insulin. 
3.6 APPLYING SOME THEORY 
In this section I would like to relate what I have discussed above to my theoretical 
chapter (Chapter 2). I have two particular aims. One is to show how the process of 
translation can be applied to the development of human insulin. The second, is to 
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illustrate how some of the ideas behind the prescription (in actor network terms) of 
artefacts can be related to human insulin. Rather than separate these two concerns, I 
will deal with them together. One reason why this will be fruitful is because human 
insulin, as a drug in itself, and insulin more generally, already had a particular set of 
prescriptions, or allowances, at the time of the commercial development of human 
insulin. Therefore, various networks used the existing prescription of insulin to carry 
out translation, that is, to define the roles of other entities or networks. 
Before continuing with this section, it is worth pointing out that in order to produce 
this chapter I have had to construct a narrative for a complex set of events. 
Unavoidably, I have stressed the role of some actors, at the expense of others. For 
example, I have not described the complex strategies used by the various research 
teams in their experiments. It is also important to be aware that there are problems in 
assigning ANT terminology to the case study. For example, it is not always easy to 
follow the changing links and shifts between the actors involved. This reiterates the 
point that this narrative is only one out of many possible narratives. 
The structure of the remainder of this chapter will be as follows. I will first refer to 
the importance of some of the features of insulin within the insulin network. I will 
structure this section around the moments of translation that were outlined in Chapter 
2. I will describe the way in which various groups attempted to problematize the 
existing insulin network, and importantly, provided their own solutions to these 
problematizations. I will then indicate how human insulin became a black box, with a 
particular set of prescriptions. This `black boxing' required the enrolment and 
silencing of a number of actors. Throughout the discussion of these moments of 
translation, reference will be made to other elements that were discussed in Chapter 2, 
such as the body as a network. However, before I do this, let's recap on some of the 
key actors involved in the development and production of human insulin. 
Throughout this chapter I have shown how various actors have dropped in and out of 
the story. Initially there were concerns over the use of genetic engineering, for 
example, over the possibility of escaping organisms such as E. coli. However, these 
concerns disappeared from the story, although it is likely they were still present in 
some parts of the network. On the other hand, Eli Lilly were initially on the sidelines. 
They observed what was happening within the research groups, and maintained links 
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with them. Over time they became more dominant actors in the development of 
human insulin, eventually taking over from Genentech in the commercial production 
of human insulin. It is also notable that Novo Industri were always on the sidelines, 
content with developing their own human insulin. Other actors were always present 
in some form or another, such as the medical profession and diabetics. 
Therefore, when talking about the roles that various actors and networks played, and 
would later play, we have to be aware that the roles and aims are not always the same. 
When other actors become more dominant, others begin to disappear from the story - 
such as Genentech, who `left the scene' when Eli Lilly took over the commercial 
production of human insulin. But as I argued, the split between these two actors was 
amicable. There was a temporary alliance between Eli Lilly and Genentech that 
existed around the production of human insulin. It was therefore a `temporal or 
temporary artefactual relation'. That is, the reason for the relation between the two 
networks was the production of the artefact human insulin. When the artefact was 
produced, there was no longer any reason for the two networks to interact, and so the 
relationship disappeared. 
There were other similar relations that disappeared once an objective, based around an 
artefact, had been achieved. For example, for Eli Lilly to gain a licence to market 
human insulin they had to have contact with various regulatory authorities, such as the 
MCA and the FDA. On a more general level, the relations between Eli Lilly and 
regulatory bodies are continual, but they revolve around different artefacts. 
3.6.1 The Importance of Insulin 
One of the most important references made by various groups in this chapter, was to 
the existing prescription of insulin as a generic substance. As noted in Chapter 2, 
prescription refers to the attributes that are inscribed into artefacts, and what an 
artefact allows from human and nonhumans. In the case of insulin, it allows healthy 
individuals to convert glycogen into glucose. In the days before animal insulin, the 
life expectancy of a juvenile diabetic was less than a year after diagnosis (Bliss, 
1983). With animal insulin, the life expectancy of a Type 1 diabetic was multiplied 
twenty five fold. However, animal insulin did not solve all the problems of diabetes - 
the injection of insulin did not allow a diabetic to lead the same life as an individual 
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whose pancreas was working properly. Or as Bliss writes: 
"Artificially supplied insulin could not perfectly compensate for the missing 
pancreatic function. " 
(Bliss, 1983: 245) 
Those who developed engineered human insulin used the existing prescriptions of 
animal insulins and `natural' pancreatic human insulin to interest networks to become 
involved in the development and production of human insulin. To put it simply, the 
prescription of animal insulin was drawn upon because it showed that the 
administration of `non-natural' insulin worked to keep diabetics alive. The 
prescription of `natural' pancreatic human insulin was drawn upon because this is 
what healthy individuals use, so in theory, it would be better than animal insulin. 
This illustrates the `complicity' entailed in network building, in so far as some of the 
features of the use of animal insulin were drawn upon, such as the ability of the body 
to absorb injected (animal) insulin. On the other hand, certain features of the use of 
animal insulin were problematized, such as the differing amino acid sequence. In the 
development of human insulin therefore, what could be described as an animal insulin 
network (consisting of animal insulin and the entities which allowed its use) was 
being broken apart. Certain elements were being acquired or used, and others 
problematized. This illustrates that just because a network was durable, does not 
mean it always will be. As Callon has argued, the consensus and alliances that a 
network relies on can be contested at any time, and the processes of translation need 
to be continually successful to maintain a durable network (1986). 
Family and 
Doctors f--- friends k 
Syringes 
A 
Knowledge 
of diabetes 
Animal The 
insulin diabetic 
Popular 
Other 
__f BDA media diabetics (Balance) 
Figure 3-4: A simplified version of a diabetic network body 
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One of the important features of animal insulin is that it already had a place within the 
diabetic network body, as did some of the features of its use, such as syringes (Figure 
3-4). Animal insulin had been shown to work well in a large number of cases, and 
fonned a durable part of the diabetic network body. Since animal insulin had been 
shown to work well, it had become part of the institutional consumption path. That is, 
when a patient is diagnosed as having Type I diabetes they are prescribed insulin. 
Those who developed human insulin intended it to replace animal insulin in this 
institutional consumption path. Access to this consumption path would enable 
pharmaceutical companies to have a ready made market for their insulin, indeed this 
was one of the reasons stated by the research teams for the development of human 
insulin. In order for animal insulins to be replaced by human insulin, existing animal 
insulins would need to be problematized. 
3.6.2 Moments of Translation 
Those who wanted to enrol groups to adopt human insulin, whether in the 
development, production, regulation or prescription stages, both had to play on 
insulin's existing role as a life saving drug, and also to problematize existing insulin 
treatment. Through problematization questions were raised about animal insulin, but 
importantly, not about other areas of insulin administration that went with animal 
insulin. For example, if pharmaceutical companies were to problematize current 
insulin injection methods, it could be argued that the development of human insulin 
would not solve the problems of diabetes. Indeed, one of the arguments of Ruth 
Hubbard (Spallone, 1992) and the Coalition for Responsible Genetic Research (1977) 
was that it was the management of diabetes that should be problematized, and not the 
species of insulin used by diabetics. 
Others have argued that we should be treating the cause of diabetes. There is 
persuasive evidence, from studies of developing countries, that one possible cause or 
trigger of diabetes is the high level of sugar and low fibre content of the Western diet. 
Therefore, a case can be gnade for alerting individuals to these possible causes of 
diabetes, just as it is for heart disease, in order to reduce the incidence of diabetes and 
the increasing need for insulin. This was not the strategy adopted by the 
pharmaceutical companies, instead, the pharmaceutical companies gave a particular 
image of the world, as Edward Yoxen argues: 
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"... there is a clear need to try and reduce the demand for insulin, which the 
advertising rhetoric of cheaper, better insulins obscures by suggesting there is 
no alternative - disease is fixed, it is always with us so we can only cure it. " 
(Yoxen, 1983: 118) 
Instead of problematizing these areas of insulin treatment, pharmaceutical companies 
and scientists chose to stress two other problems: firstly, there was the predicted 
shortage of animal insulins, and secondly, the claim that complications could be 
caused by the more immunogenic, compared with human insulin, animal insulin. 
With claims of a predicted shortage of insulin the research groups and Eli Lilly were 
able to stress the need for alternative sources of insulin. In particular, it was human 
insulin that they wanted to be the alternative. However, if supply was the only 
problem to be solved then other sources of insulin could have been found. For 
example, since the development of insulin there has long been interest in using fish 
insulin. Indeed, the Japanese made insulin from whales briefly during World War 
Two (Bliss, 1983: 246). Yet it was not just because of the predicted problems in 
supply that researchers wanted to develop human insulin. There were also concerns 
over the immunogenicity of animal insulins compared with human insulin. 
Obviously, the use of fish insulin would not address this concern. The research 
groups also wanted to develop genetic engineering techniques, and human insulin 
seemed a vehicle through which this would be possible. 
It should be clear that Eli Lilly were carrying out more than one problematization. 
They were not only problematizing the supply of insulin, but also the adequacy of any 
insulin that did not have the same amino acid sequence as `natural' pancreatic human 
insulin. Further, not all problematizations were distributed evenly to all actors. To 
regulatory authorities, Eli Lilly were problematizing the predicted shortage in the 
supply of insulin, with such a problematization Eli Lilly hoped to speed up the 
licensing of human insulin. To the medical profession, Eli Lilly were problematizing 
the adequacy of current animal insulins. 
Eli Lilly did not distribute problematizations directly to diabetics, although they were 
present in the network by implication. Problematizations dispersed through 
intermediaries represented potentially `tragic' effects, if the problematizations, 
defined by Eli Lilly, were not accepted by other important actors: What would happen 
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to diabetics if there was a shortage of insulin? Wouldn't diabetics be better off if 
insulins were purer? Therefore, through the problematization of various parts of the 
current insulin network, diabetics were being constructed as `prospective consuming 
bodies' of human insulin. In order for human insulin to be consumed by diabetics, it 
was necessary for Eli Lilly to distribute, and have accepted, a number of different 
definitions and identities. 
One interesting act of problematization was conducted by Eli Lilly, over Novo 
Industri's highly purified porcine insulin. I outlined above that Novo Industri had 
developed a highly purified porcine insulin - that would prevent insulin allergies. Eli 
Lilly claimed that a large amount of porcine insulin was lost in the process of 
purification, and subsequently, this would increase the predicted shortage of animal 
insulin. However Eli Lilly in the early 1980s, had themselves developed their own 
purified insulin as well as their human insulin. Although Eli Lilly may have 
problematized purified porcine insulins, they still wanted to have a similar range 
available to medical practitioners and diabetics to that of Novo Industri. 
Novo Industri were playing a similar `game' with human insulin. They were 
attempting to `demote' the predicted benefits of human insulin, while also developing 
their own human insulin preparation. Eli Lilly claimed that one reason for developing 
human insulin was that porcine insulin differed by one amino acid to human insulin. 
Eli Lilly claimed that this difference may cause allergies. However, Novo Industri 
claimed that the slight difference in amino acid structure was too minor to cause 
serious allergies. Instead, Novo Industri claimed that the cause was contaminants 
present in conventional insulin preparations. As a result, Novo Industri had 
developed their purified animal insulins. However, Novo Industri were also 
developing a human insulin. The strategies of the two companies can be summarised 
as follows. Eli Lilly were problematizing purified animal insulins and promoting 
human insulin, while also developing a purified porcine insulin. Novo Industri for 
their part, were problematizing the benefits of human insulin and promoting their 
purified insulins, while also developing a human insulin. 
It should be clear that the problematizations of both Eli Lilly and Novo Industri 
appear to have some contradictions. I would suggest that we can outline the `surface' 
problematizations of an actor, but these only tell half the story (simplified in Figure 3- 
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5). Both companies were problematizing, on the surface, a certain area of the insulin 
network, whether it was the supply of animal insulin or the impurities of conventional 
animal insulins. Each then offered a solution to their problernatizations, whether it 
was genetically engineered human insulin or purified animal insulin. This can be 
defined as an overt strategy: it is overt since it is the main strategy of the network, or 
the one that other networks are aware of. 
Compan Surface 
Problematization 
Overt Strategy Covert Strategy 
Eli Lilly " predicted shortages of " development of " development of 
animal insulin. genetically purified animal 
" problems with engineered human insulins. 
immunogenicity of insulin. 
animal insulins. 
Novo " it is conventional " development of " development of a 
Industri animal insulins that purified animal converted human 
are the problem, due Insulins. insulin. 
to their impurities. " later development of 
genetically 
engineered human 
insulin. 
Figure 3-5: Surface problematizations, overt and covert strategies 
However, we can also derive a covert strategy. The covert strategy is one that is 
perused in parallel with the overt strategy, but does not have the same prominence. 
Interestingly, a covert strategy may contradict the surface problematization. In this 
case, Eli Lilly had a covert strategy that was to develop purified animal Insulins, and 
so, was in contradiction to their problematization of a shortage in supplies of animal 
insulin. Novo Industri, on the other hand, had problematized conventional insulins in 
favour of their purified animal insulins. At the same time, they were developing a 
human insulin, in the first place converting animal insulin, and then later a genetically 
engineered human insulin. 
Of course, such actions are not unexpected. There are a number of reasons for this. 
Pharmaceutical companies need to maintain the image of innovation, for Eli Lilly it 
was by using genetic engineering, and for Novo Industri, it was by purifying animal 
insulins. By adopting overtly different innovative methods the companies were 
stressing their individual innovation. Pharmaceutical companies also need to look 
forward to the future. What would be the effect on the pharmaceutical companies if: 
Genetic engineering was not successful? If supplies of animal insulin were vastly 
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improved? Or, if predictions of a shortage in animal insulin were correct? 
The movement between the overt and covert strategy also has to be managed 
carefully, indeed, it may only be in retrospect that the contradictions within a 
particular problematization became apparent. As already mentioned, within the 
pharmaceutical industry there is a stress on innovation. However, companies also 
need to `hedge their bets' in case one innovation is unsuccessful. 
With existing insulin problematized it was then necessary for the enrolling actors to 
define different identities and wants of different actors. Those groups who were 
attempting to define the key players, such as the pharmaceutical companies, wanted to 
define the aims of various other groups. For example, diabetics were defined as 
wanting a `new and modern' insulin and the medical profession were defined as 
wanting an insulin that would reduce diabetic complications. In teens of the program 
of action, the enrolling actors wanted to define a program of action for those involved. 
The aim was for the defined program of action to be adopted by those networks that 
the enrolling actors defined as important. If they were accepted, then there would be 
no obvious antiprogram. In general terms, a program was defined in which human 
insulin was to be developed, produced and regulated. Actors, such as scientists and 
regulatory bodies, were to agree with this program. However, if scientists questioned 
the benefits of human insulin, and regulatory bodies refused to regulate it, then a 
antiprogram may have developed. 
From the point of view of phannaceutical companies, there were a number of reasons 
why they wanted to develop human insulin. Phannaceutical companies wanted to be 
able to: capture particular insulin markets; control the supply of insulin; be at the 
forefront of medical technology; produce cheaper insulins; reduce some of the 
complications of diabetes; and serve diabetics better. The enrolling actors' aims were 
to make their aims `compatible' with those networks that they wished to enrol. 
Of course these aims did not apply to all the involved networks. Diabetics are 
unlikely to be concerned that some pharmaceutical companies wanted to capture 
another company's insulin market. Importantly, different aims were applicable to 
different networks. As long as the pharmaceutical companies multiple aims did not 
conflict with specific aims, defined as relevant to a particular network, then enrolment 
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was likely to be successful. For example, as long as diabetics were still receiving an 
insulin that they felt happy with, they would not necessarily mind who was supplying 
that insulin. 
This suggests that human insulin had a variable geometry (Law and Callon, 1992: 24) 
or interpretative flexibility (Pinch and Bijker, 1987: 40) before and after its 
development. By this I mean that human insulin meant different things to different 
networks. For the pharmaceutical companies it was a way to break into new markets, 
for some scientists it was a means to carry out genetic engineering work, and for 
diabetics it was, perhaps, a more efficient insulin. 
Throughout the development and production of human insulin the medical profession 
were defined as wanting to have pure and regular supplies of insulin. The medical 
profession were initially on the outskirts of the development and production network 
of human insulin. However, without the medical profession enrolled, human insulin 
would not be an option for diabetics - it would not be within the diabetics' network 
body. Although on the outskirts during development and production of human 
insulin, the medical profession would gradually become a central actor as human 
insulin moved from production to use by diabetics. 
The medical profession became involved through the clinical trials that were 
necessary for human insulin to be approved as safe. Without passing through clinical 
trials, an obligatory passage point, human insulin could not be certified as safe. The 
medical profession are a crucial part of this process. As time passed the role of the 
medical profession was extended even further. Doctors were to be one of the crucial 
points by which diabetics would be able to use human insulin. As a result, advertising 
campaigns were directed towards doctors informing them of the benefits of human 
insulin. 
I described above that diabetics were being constructed as `prospective consuming 
bodies' of human insulin. As such, it was hoped that human insulin would easily 
replace animal Insulins in the network body of diabetics. The important point is that 
there was already a group or network of people who consumed animal insulin. We 
can outline two types of consumption. On the one hand, there were actors who 
physically consumed insulin, namely diabetics. On the other hand, there were actors 
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within the `consumption path', such as doctors and pharmacists. Importantly, it was 
believed that human insulin could be `slotted' into the place where animal insulins 
were. Added to this, there would be benefits for the diabetic, and others within the 
network body. For example, family members would benefit as the diabetic may not 
suffer from diabetic complications in later life. 
Of course some antiprograms to the development of human insulin by genetic 
engineering did exist. Ruth Hubbard for example, was worried about, "the hazards of 
looking for technological fixes as solutions to complicated diseases of metabolic 
control and other complicated problems" (Hall, 1987: 130). However, these concerns 
did not form a dominant antiprogram. Those who believed that the genetic 
engineering of human insulin was a `quick fix', were unable to enrol the appropriate 
actors to be able to oppose the research groups. One reason why they were unable to 
do this was undoubtedly the existing meaning of insulin as a `life saving drug'. 
Added to this, human insulin had been presented as the solution to a number of other 
problems, such as problems of immunogenicity and supply of animal insulin. 
An important feature of problematization and interessement is the way in which an 
enrolling network is able to fulfil its own research interests. In the case of the 
Harvard University and UCSF groups, they wanted to carry out genetic engineering 
work. By attaching human insulin to this work, and defining why this was important 
to other networks, they were able to negate the concerns over genetic engineering. 
Indeed, as pointed out, much thought was given by the research teams to what would 
be the first genetically engineered protein. Human insulin appeared as a prime 
candidate, not only because a lot was already known about it, but also because of 
insulin's identity. It could be argued therefore, that the development of human insulin 
acted as a `carrier network', or key to further research into genetic engineering. Or to 
look at it another way, human insulin was the obligatory passage point by which 
scientists could further their own goals. The genetic engineering techniques 
developed for human insulin would not just be used for human insulin. They would 
also be applied to, and were always intended to be applied to, the production of other 
drugs. 
There is then a coming together of the aims of the enrolling actor and those whom 
they wish to enrol. The aim of the enrolling actor is to make themselves, or what they 
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can offer, the only way to achieve the wants that have been defined for the various 
actors. In actor network terms, actors want to become the obligatory passage point. It 
is notable that the research groups set themselves up with slightly different aims. 
Genentech defined themselves as being able to produce human insulin for commercial 
production. On the other hand, Harvard University and UCSF also wanted to know 
more about human insulin itself. 
When the research groups had contact with the pharmaceutical companies, the 
companies were interested in what the groups' aims were. As I have pointed out, Eli 
Lilly were interested in all the research groups. Before the contract with Genentech 
had been signed, Eli Lilly had already made arrangements with UCSF to develop 
human insulin. UCSF had claimed that they were the obligatory passage point by 
which human insulin could be produced. Eli Lilly accepted this claim, and offered to 
build a new laboratory for them to carry out their work in Strasbourg. 
However, as Genentech's work progressed, Eli Lilly believed that Genentech would 
be able to commercially produce human insulin quicker than the other research 
groups. One reason for this was that the methods that Genentech were using to 
produce human insulin were less complicated, since the insulin A and B chains were 
engineered separately. 
By keeping their options open Eli Lilly were maintaining a number of multiple and 
simultaneous obligatory passage points. Eli Lilly wanted to have access to whichever 
centre of calculation would be the first to produce a commercially viable human 
insulin. However, they also wanted to have access to the techniques that would 
produce the most efficient human insulin. By maintaining the links with a number of 
research teams Eli Lilly were more likely to achieve these goals. It is also important 
to realise that by maintaining a link between themselves and the research groups, Eli 
Lilly were able to access the knowledge produced by both research groups. Of course 
these links are symbiotic. The research groups needed the financial support that Eli 
Lilly could offer, and Eli Lilly needed the scientific know-how from the research 
groups, or at least preferred to use this source of knowledge rather than develop their 
own research techniques. 
It was therefore very important for Eli Lilly to manage a number of obligatory 
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passage points. In theory, other actors, other pharmaceutical companies, could have 
been more eager to form more concrete relations with Genentech or UCSF, or the two 
research teams may have decided to develop human insulin on their own. 
Through interessement existing links with various actors were broken. In order to 
overcome the restrictions of carrying out genetic engineering work individuals 
presented various reasons why they should be lifted. For example, at the Cambridge 
City Council meeting in Massachusetts, Walter Gilbert attempted to interest and 
reassure various groups over the benefit and safety of genetic engineering. The links 
that were being broken were of a negative order, i. e. worries over the threat of genetic 
engineered organisms, such as E. coli, entering the environment. These links were 
broken through the presentation of work protocols and other inscriptions which aimed 
to reassure those who had negatives attitudes towards genetic engineering. 
Interessement for Genentech involved proving to Eli Lilly that human insulin could be 
produced in the laboratory, and later, that it could be scaled up. By doing so, links 
that Eli Lilly had with other human insulin research groups were reduced. One reason 
why links were reduced is because the cost of R&D is high, and so a pharmaceutical 
company will be very selective over the projects they fund (Davis, 1997). During the 
1980s the cost of the R&D process was put at $65 million (in 1990 dollars) (Office of 
Technological Assessment, 1993). This was one reason why Eli Lilly were happy to 
let others carry out the early developmental work. If they had originally funded one 
group, and that group had been unsuccessful, it would have been costly, and perhaps 
disastrous, for the company. 
It was also necessary for the research groups to carry out interessement within the 
laboratory. The scientists had to enrol the methods used for the production of the 
insulin chains. In order to purify human insulin the scientists had to break the 
proteins' link with various impurities. This was done by laboratory protocol, where 
`pollutants' attachment to various entities was reduced (scientific instruments, 
scientists and the environment). Or by removing the already attached protein 
impurities to human insulin, through the enrolment of other entities to form 
purification devices. 
Interessement also occurred within the medical and scientific community. At the 
112 
3.6 Applying some theory 
symposium held by Eli Lilly, Irving Johnson presented data and graphs that showed 
the predicted shortages of insulin. Such inscriptions, or immutable mobiles, 
combined a lot of information to form clear `proof' that there would be a shortage of 
animal insulin. For example, one graph that was circulating at the time showed two 
lines. One line showed the predicted increase in the diabetic population each year 
(estimated at 5%), the other line showed the predicted supply of animal insulin. The 
graph showed a crossover point, where demand would outstrip supply (Hall, 1987). 
It is only when an actor's pre-existing associations with other entities have been 
severed (interessement) that enrolment, albeit temporarily, can be said to be 
successful. In this study this was evident when contracts were signed and regulatory 
bodies passed human insulin. In the case of human insulin itself, techniques and 
enzymes were enrolled when human insulin was actually produced. Importantly, 
enrolment occurred a number of times, in different situations. It was one thing to 
enrol the techniques to produce human insulin in the laboratory, but for the 
commercial production of human insulin, it was necessary to use other techniques in 
order to produce human insulin in appropriate commercial quantities. 
Finally, mobilization referred to the way that some entities were able to silence and 
speak in the name of others. Indeed, I have shown how Eli Lilly silenced the 
laboratory development of human insulin by Genentech. It was Eli Lilly's human 
insulin and not Genentech's. When human insulin was finally marketed as Humulin, 
a large number of other networks had been silenced, such as the scientists and 
production processes involved in the production of human insulin. 
3.6.3 The Black Boxing of Human Insulin 
Throughout the process of translation there were many elements that came to be black 
boxed. For example, there was no mention of the regulatory procedures and clinical 
trials that had been carried out that enabled human insulin to be marketed. 
Importantly, such features are still present, it is just that they are no longer visible. 
However, as I will show in subsequent chapters, where there is a crisis in the current 
setting or network, black boxed features such as clinical trials may become visible 
again. For example, one response by the pharmaceutical companies to the claim that 
human insulin caused side effects was to refer to the successful completion of clinical 
113 
3. The development of human insulin 
trials, that showed that human insulin was safe and efficient (Keen et al., 1980; Clark 
et al., 1982). In my theoretical chapter this was described as a feature of the 
inoculation of artefacts 
In Section 3.5 1 described how human insulin had to pass a number of clinical trials 
and regulations (Figure 3-3) before it could be marketed for use by diabetics, and 
became part of the network body. It is the role of regulatory authorities to outline the 
tests that have to be conducted. Through this process the drug, in this case human 
insulin, became defined as edible. As stated in Chapter 2 the classification of a 
substance as edible/inedible can be applied to prescription drugs. By going through 
the `ritual' of clinical trials a drug is defined as edible, although there are restrictions 
under what circumstances the prescription drug can be consumed. 
The prescription drug does not become edible for all, rather, there are particular 
restrictions on who, and under what conditions, the drug can be consumed. In the 
case of human insulin, consumption is under the guidance of the doctor. Referring 
back to my theoretical chapter - the process of regulation allowed human insulin to be 
available at particular consumption sites (the pharmacy), through a particular 
consumption path (consisting minimally of the diabetic, doctor, a diagnosis and 
pharmacist). Crucially, the consumption path is culturally defined: it draws upon 
existing cultural practices and standards, in this case the authority of the doctor. 
Further, human insulin became inscribed with particular prescriptions and 
proscriptions. It wasn't just defined as edible, but also as superior to other insulins. I 
argued above that throughout the development of human insulin frequent reference 
was made to the prescriptions of pancreatic human insulin. Through the clinical tests 
and regulatory procedures these claims were put to the test. 
I would now like to make some comments on the regulatory procedures that I 
described in Section 3.5.17 It is obvious that clinical trials cannot be carried out on all 
individuals. Tests are initially carried out on healthy individuals and then on the 
intended users of the drug. Therefore, those who used human insulin in the clinical 
trials were acting as representatives of a larger population. Healthy individuals were 
17 These comments will not be comprehensive, however, see Abraham (1997) for a more 
comprehensive discussion. 
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acting as representatives of `human beings', while diabetics were acting as 
representatives of the larger diabetic population. I have termed such bodies 
`exemplar' bodies or simplified network bodies. 
It is expected that results from these `exemplar' bodies can be generalised to the wider 
population. However, we have to be aware that only a small percentage of those who 
will eventually use a particular drug, will actually be involved in clinical trials. 
Furthennore, certain patients will be excluded from such trials because their multiple 
pathologies or their use of other medications may interfere with the scientific 
demands of controlled comparison (Abraham, 1997: p. 129). Therefore, the process 
by which results from clinical trials are extrapolated to the wider populations may be 
problematic. 
There are not just scientific pressures on regulating new drugs. As should be clear 
from this chapter, the two pharmaceutical companies had a commercial interest in 
getting their human insulin through regulatory procedures and marketed as quickly as 
possible (Abraham, 1997). This was especially the case since the insulin market is 
very competitive, albeit only between a small number of companies. Due to the 
interest in human insulin, the first company to have a marketable product would have 
an advantage over the other. Since Novo Industri were using less controversial 
techniques it could be argued that their progression through the regulatory process 
would be quicker. Eli Lilly, on the other hand, were the first to use genetic 
engineering, which was in its infancy. 
However, because of the interest and promise of genetic engineering, it can be argued 
that human insulin was a special case. According to the Food and Drug 
Administration (FDA), who regulate drugs in America, human insulin was on the `fast 
track' for approval (Yanchinski, 1980). It was also argued that the same commitment 
existed with the Committee on the Safety of Medicine, the UK drug regulatory body 
(New Scientist, 1980). Therefore, there are many factors that effect the approval of 
particular drugs. If the perceived societal need and importance of a drug is great, then 
there is a likelihood that regulatory bodies will respond to this. 18 Of course, the issue 
of `perceived societal need and importance' is the result of translation, and as in this 
18 See Epstein (1996) for an example of how activism within the AIDS community accelarated the 
approval of various drugs. 
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case, involves the enrolment of many actants. 
3.7 CONCLUDING REMARKS 
When the scientists at Genentech were developing human insulin they saw it as a set 
of exciting scientific experiments that would produce socially useful results. As Eli 
Lilly became involved, Genentech had deadlines to meet and finally disappeared from 
the commercial production of human insulin - Humulin is produced by Eli Lilly and 
not Genentech. However, Genentech are still present in some respects. In accounts 
of the history of genetic engineering, Genentech are referred to as the first to use 
genetic engineering to produce a human protein. 
It is interesting how original definitions of problems can change. Eli Lilly had 
presented a picture where the supply of animal insulin was problematic, and problems 
existed with animal Insulins. However, when one of the scientists from the 
Genentech group went on a tour of an Eli Lilly insulin production plant, in December 
1979, he saw another side to these problematizations. He realised that: highly 
purified animal insulins were not impure; they did not cause allergic reactions; and 
there was not a shortage in animal pancreases. Although the DNA method was 
elegant and less messy, it was not necessarily simpler or cheaper than the method for 
producing animal insulin (Hall, 1987: 298). It was also complicated to produce the 
starting material for human insulin, compared with that for animal insulin, which was 
a by-product of the meat industry. 
This example illustrates that translation, and particularly problematization, are 
variable. Power is possessed by those who are able to define a particular 
problematization, and have it accepted by particular networks, and so enrol a number 
of allies, both human and nonhuman. These definitions do not have to apply to all 
networks, and as such, a network may have multiple definitions of a situation which 
are then selectively applied to different networks. Eli Lilly had defined shortages and 
impurities with animal insulins, and these had been accepted by scientists and 
regulatory bodies. However, as the Genentech scientist found out, another 
interpretation of the situation was possible. It was not so much that there were 
problems with the supply and production of animal insulin, rather, this was the way 
Eli Lilly wanted others to perceive the situation. 
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In future chapters I will show that the constructed prescription of human insulin was 
called into question. 
In particular, the superiority of human insulin over animal insulin was problematized. 
I have already shown that human insulin was not necessarily more bio-efficient than 
purified animal insulins, as was theoretically suggested. I will show in later chapters 
that some diabetics experienced adverse effects on human insulin, and a significant 
number returned to their `less modern' animal insulin. 
In the next chapter (Chapter 4) I will describe some of the initial reactions of 
diabetics, care groups, and those in the scientific and medical community, to problems 
experienced by some diabetics on human insulin. In particular, I will look at the 
change in warning signs of approaching hypoglycaemia that were experienced by 
some diabetics. This chapter will set the scene for future chapters, where I will look 
at the long term reactions of the scientific community and pharmaceutical companies 
(Chapter 5), and diabetics and care groups (Chapter 6). 
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4. INITIAL PROBLEMS ON HUMAN INSULIN - SYMPTOMS AND INITIAL REACTIONS 
4.1 INTRODUCTION 
In Chapter 3I outlined the development and promise of human insulin. In this 
chapter, I wish to discuss some of the problems that a number of diabetics 
experienced on human insulin. I am particularly interested in how diabetics initially 
voiced their concerns regarding a change in some of the characteristics of diabetes, 
namely hypoglycaemia, that they (eventually) attributed to human insulin. This 
chapter also sets the scene for the following 2 chapters. In the next chapter (Chapter 
5), I will look at the reactions of the scientific community and pharmaceutical 
companies in the human insulin debate. Then, in Chapter 6,1 will look at what 
actions were taken by diabetics and care groups in the human insulin debate. 
In this chapter, I will first describe the meaning of hypoglycaemia in `normal' 
circumstances for a diabetic. I will then go on to address how hypoglycaemia should 
be seen as a disruption of the everyday activities of diabetics. Next, I describe some 
of the problems encountered by some diabetics on human insulin, particularly in 
relation to hypoglycaemia. In the next sections I examine how various groups (care 
groups, the scientific community and the medical profession) responded to the claims 
of diabetics on human insulin. Finally, I will consider how the work outlined in the 
previous sections can be related to my theoretical base. 
4.2 WHAT IS HYPOGLYCAEMIA? ITS ROLE IN DIABETES 
For some diabetics, human insulin did not fit unproblematically within the existing 
management of their diabetes. One particular problem reported by diabetics was that 
they experienced a change in the warning signs of approaching hypoglycaemia. 
Before I look at this change in symptoms, I would first like to describe the place of 
hypoglycaemia in the management of diabetes. 
From the first discovery and use of insulin, diabetics have experienced hypoglycaemia 
(Bliss, 1983). Peter J. Watkins argues that: 
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"Hypoglycaemia is the major hazard of insulin treatment... All diabetics on 
insulin who are reasonably well controlled will experience hypoglycaemia at 
some stage. At its mildest it is no more than a slight inconvenience, but at its 
severest, when unconsciousness can occur, it is both a hazard and an 
embarrassment.. . 
Ali diabetics must be carefully taught about the causes, 
symptoms and treatment of hypoglycaemia. Ideally, new diabetics should be 
made to experience hypoglycaemia during their initial education. " 
(Watkins, 1982: 278) 
Hypoglycaemia is therefore a very important characteristic of diabetes. 
Hypoglycaemia, or low blood sugar, occurs when a diabetic's glucose level drops too 
low to be able to fuel the body's activity. During the digestion of carbohydrates 
glucose is absorbed into the blood stream, with unused glucose being stored in the 
body as glycogen. Blood glucose levels are measured in mmol/L (millimols per 
litre)' 9, with a normal blood sugar level being between 3.33 to 6.66, depending on 
when the person last ate (see Figure 4-1). The amount of glucose in the blood stream 
is mainly regulated by the hormones insulin and glucagon. Too much or too little of 
these hormones circulating in the body, at any one time, can cause blood sugar levels 
to fall too low (hypoglycaemia) or rise too high (hyperglycaemia). 
Classification mmol/1 mg/dl State 
2.0 35 Extremely low, danger of unconsciousness 
Hypoglycaemia 2.8 50 Severe hypoglycaemia as defined by DCCT 
(American Journal of Medicine, 1991) 
3.0 55 Low, marginal insulin reaction 
3.33 60 
Normoglycaemia I I Normal range for blood sugar 
6.66 120 
Hyperglycaemia 7 130 High blood sugar 
Figure 4-1: Blood sugar levels 
Figure 4-2 shows the approximate biological process by which the body responds to a 
fall in blood glucose (Gale, 1989). It is important to be aware that failure in the 
process can occur at any level, in which case, the diabetic may not (or may be unable 
to) take appropriate action. In many cases the appropriate action is eating 
carbohydrates, in the form of a chocolate bar or a biscuit, and in severe cases the 
administration of glycogen. 
19 This is the SI (Systeme International) unit. However, the United states use mg/dl (milligrams per 
decilitre). To convert blood sugar from mmol/L to mg/dl, multiply by 18 and to convert blood sugar 
from mg/dl to mmol/L, divide by 18. 
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Low glucose concentration sensed by brain 
Triggers a sympathomedullary response 
(Includes secretion of adrenaline and other 
counterregulatory hormones which buffer the fall in blood 
glucose) 
4 
The neurohumoral response in turn causes physical 
changes 
(E. g. sweating and tremor) 
4 
Perceived by patient and prompted to take appropriate 
action of finding and eating carbohydrates 
Figure 4-2: The process of hypoglycaemia 
The initial symptoms of approaching hypoglycaemia are known as sympathoadrenal 
symptoms (Figure 4-3). When a diabetic experiences these symptoms it is likely that 
they will be able to take action in the form of eating carbohydrates. Neuroglycopenic 
symptoms come later. When a diabetic experiences these secondary symptoms, they 
are less likely to be able to take action themselves because they may be confused or 
experiencing seizure. It has been suggested that sensations of hypoglycaemia are 
experienced by as many as 50% of insulin-dependent diabetics, as frequently as once 
a month (Goldgewicht et al., 1983). 
Sympathoadrenal Neuroglycopenic 
Sweating Headache 
Palpitations Confusion 
Tremor Visual disturbances 
Nervousness Amnesia 
Irritability Seizure 
Hunger Focal signs, e. g. hemiplegia 
Excessive heart rate Coma 
Figure 4-3: Typical symptoms of hypoglycaemia 
Since hypoglycaemia is part of diabetes, diabetics are taught how to manage their 
diabetes in order to avoid, and cope with, hypoglycaemia. Through experience, a 
diabetic will also learn how to detect approaching hypoglycaemia by being aware of 
sympathoadrenal symptoms. 
In order to prevent hypoglycaemia, diabetics are taught the possible causes (see 
Figure 4-4). A large part of the management of diabetes is to maintain a balance20, in 
the case of hypoglycaemia, it is between insulin and glucose intake. For example, if a 
20 Indeed, the full title of the magazine of the BDA, is ` Living with diabetes - Balance a lifestyle'. 
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diabetic takes exercise then it is important that they also consume extra glucose. 
" Taking more exercise than usual 
" Delay or omission of a snack or main meal 
" Administration of too much insulin 
" Eating insufficient carbohydrate 
" Over-indulgence in alcohol 
Mistake in sulphonylurea (tablets used to stimulate the production of insulin in the 
pancreas) dosage 
Figure 4-4: Some causes of hypoglycaemia 
There are a number of classifications of hypoglycaemia, depending on the severity. 
In normal circumstances these occur in the following order. Mild hypoglycaemia can 
easily be treated by the patient, and is often referred to as `having a low blood sugar'. 
This type of hypoglycaemia will probably not be reported to the doctor. A moderate 
hypoglycaemic episode occurs when someone else has to intervene to bring the 
diabetic to nonnoglycaemia (normal blood glucose concentration). The diabetic may 
be unable to consume glucose themselves because they are confused or unconscious 
(neuroglycopenic symptoms). Severe reactions often cause stupor, coma, fits or focal 
neurological signs, such as a herniparesis (muscle weakness down one side of the 
body). With such reactions hospital treatment may be needed. Indicators for hospital 
admission include: poor or incomplete recovery from severe hypoglycaemia; 
recurrent severe reactions; or poor home circumstances, such as an elderly patient 
living alone who has had a severe reaction for no obvious reason. 
There are a number of factors that make hypoglycaemia particularly distressing for 
diabetics and their families, as Rajaram writes: 
"The intensity, unpredictability, and risk of physical harre of an insulin reaction, 
all contribute to the complexity of illness experience. Management of an 
insulin reaction involves an ongoing discourse between patients and their 
physical states, their partners, the medical professionals, and the social and 
ideological constraints, within a social and cultural context. " 
(Rajaram, 1997: 281) 
Hypoglycaemia is a complicated biographical disruption in the management of 
diabetes. Bury (1982) describes a `biographical disruption' as a disruption of taken- 
21 for-granted assumptions of one's self concept caused by chronic illness. It is worth 
21 Interestingly, the IDDT made a proposal to the World Health Organisation for an amendment to the 
St. Vincent Declaration. The declaration sets general goals for those adults and children with 
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pointing out that there has been a movement away from focusing solely on 
biographical disruptions. Attempts have been made to "extend the theoretical and 
methodological frameworks that link illness and disability with self-identity, social 
interaction and critical features of the life course and social structure" (Bury, 1997: 
136). One particular area is the active responses that people make in order to manage 
the possible changes in lifestyle and identity that those with illness may experience 
(Bury, 1997). Bury (1991) has characterised these responses in terms of coping, 
strategy and style. Further, there has also been an interest in studying the changes in 
patterns of illness and the cultural contexts in which they occur. As a result, 
individuals who have the same illness, for example those with HIV/AIDS 
(Carricaburu and Pierret, 1995), may adopt different strategies to minimise the 
influence that the illness has on their identity. Moreover, strategies may change over 
time for the same group as societal views of a particularly group or illness change. 
Moving back to biographical disruption, the taken-for-granted assumptions that are 
disrupted in times of illness are part of the network body. When the network is 
durable the body is hidden, yet, in the case of chronic illness the network body is 
initially opened up or becomes `unblack boxed'. There are a number of reasons why 
a hypoglycaemic biographical disruption can be particularly problematic for a 
diabetic. Rajaram (1997) outlines five: 
1) The uncertainty and unpredictability of a hypoglycaemic episode. 
2) The suddenness and intensity of the onset of an insulin reaction. 
3) The disorientation and loss of cognitive-motor functioning. 
4) The risk of physical harm to themselves and others. 
5) The possibility of death due to an accident or failure to take timely corrective 
medical action. 
Diabetics are encouraged to understand the day-to-day management of their illness, to 
prevent biographical disruptions, and to be able to carry out a `normal' life. They are 
encouraged to understand the importance of diet, insulin dose and self-monitoring of 
blood glucose levels. Through experience and education the network body may 
expand. A newly diagnosed diabetic network body will consist of new artefacts and 
knowledge. Over time, the network body will not only consist of insulin, syringes, 
diabetes, and also sets 5 year targets to improve education, general awareness, independence of those 
with diabetes, support facilities, and further, sets targets for the reduction of complications. The 
IDDT wanted to amend the declaration to include hypoglycaemia, and the fear of it, as a 
complication (1995c: 11). 
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blood glucose monitoring equipment, but also knowledge of diabetes and 
hypoglycaemia. However, because of the uncertainty and unpredictability of 
hypoglycaemia, a diabetic's efforts may not be enough to prevent a hypoglycaemic 
episode. 
I have described here the characteristics of hypoglycaemia. In normal circumstances 
the onset of hypoglycaemia is usually recognisable. However, a number of diabetics 
claimed that they lost their traditional warning signs when transferred from animal to 
human insulin. This is where my attention now turns. 
4.3 CHANGING WARNING SYMPTOMS OF HYPOGLYCAEMIA 
In 1985-6 only about 6% of insulin sold in Britain was human insulin. By 1989 about 
80% of insulin dependent diabetics used human insulin (Balance, 1989a: 8), even 
though "diabetologists agreed that human insulin in general has no advantages over 
highly purified porcine insulins. " (Egger et al., 1992: 351). Although many studies 
showed that human insulin was comparable to animal insulin, they did not show that 
it was better than purified porcine Insulins. 
In the following sections I will outline some of the symptoms that were reported by a 
number of diabetics. I will also describe what effect these experiences had on a 
diabetics' body as a network. 
4.3.1 Symptoms 
The British Diabetic Association first heard about problems with human insulin in 
1987 and looked at it seriously, with the Professional Advisory Committee and the 
Executive Council (Balance, 1991 a: 22). While the Insulin Dependent Diabetic Trust 
(IDDT) reports, in retrospect, that within a year or so of human insulin being used 
people were reporting problems with human insulin (1994: 2). 
The British Diabetic Association, through their magazine Balance, first reported 
possible problems on human insulin in October 1987 (1987d). 22 One possible reason 
for the gap between the introduction of human insulin, and reports of side-effects 
could be due to the steady increase in use of human insulin between 1986-89. There 
22 Another concern, that was expressed earlier, was of the possibility of catching AIDS from human 
insulin (Balance, 1987b: 51). 
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were a number of reasons for the increase in use: between 1986-87 a number of 
porcine insulins were withdrawn and replaced by a human equivalent; many bovine 
Insulins were replaced with human long acting insulin zinc suspensions; there was an 
increasing popularity for multiple injection regimes, that used human insulin; and, 
there was an increased promotion of human insulin by pharmaceutical companies 
(Pickup, 1989). By the end of 1989, the BDA had received 60 unsolicited letters from 
diabetics reporting a change in the nature of hypoglycaemia while on human insulin. 
It is also interesting that the pharmaceutical companies received few reports of 
problems on human insulin. From 1987 to the middle of 1989, Novo Nordisk, who 
had the largest share of the insulin market in Britain, only received reports of 28 
events in relation to hypoglycaemia and hypoglycaemia unawareness. Of those 28 
events, only 4 were coded as unexpected. Eli Lilly received a similar number of 
reports of an adverse reaction to human insulin (Pickup, 1989: 992). It is likely that 
such a lack of reporting to pharmaceutical companies was due to diabetics reporting 
their effects to other networks, such as doctors or care groups. 
Although the number of reported cases may have been small, it is important to realise 
that the experience of unexpected hypoglycaemia has important consequences for a 
diabetic. Typical reported problems on human insulin were: 
" Loss of hypo warnings (hypoglycaemia unawareness). 
" Increase in weight especially under multiple daily injection routines. 
" Extreme tiredness. 
" Loss of memory. 
" Change in personality. 
" Less stable diabetic control, more hypoglycaemic episodes, some severe. 
The most frequently reported change was in the warning signs of approaching 
hypoglycaemia. Teuscher and Berger termed this change in symptoms 
`hypoglycaemia unawareness' (1987), or loss of warnings. Some diabetics claimed 
that their hypoglycaemic symptoms changed from those associated with 
sympathoadrenal activation (sweating, tremor, palpitations, and so on) to those of 
neuroglycopenia (inability to concentrate, speech and visual disturbances, headache 
and so on). This change in symptoms meant that a diabetic was sometimes unable to 
take action to correct low blood glucose levels. This is worrying for a diabetic 
because they may feel they are losing control of their lives. They may also feel afraid 
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of losing their jobs and becoming a nuisance to others (Balance, 1991 b). It was not 
clear however, whether this change in symptoms was due to human insulin or some 
other cause. There was also some suggestion in the media, that human insulin could 
trigger neurological disorders such as multiple sclerosis (Balance, 1994). 
The naming of a change in the symptoms of hypoglycaernia as `hypoglycaemia 
unawareness' is important because it represents the symbolic legitimation of an 
ideology of expertise (Habermas, 1971: 81). Cooper (1997) describes the naming of 
ME, arguing that: 
"... those who wish to `psychologise' the condition have been accused of 
constructing the term Chronic Fatigue Syndrome in order to sustain this belief, 
whilst those who wish to construct ME as a physical disease insist on calling it 
`Myalgic Encephalomyelitis' (the term translates into inflammation of the 
brain)... the label ME has come to serve as a symbol for the usurpation of power 
from doctors to patients. " 
(Cooper, 1997: 188) 
However, in this case, the term `hypoglycaemia unawareness' is used by both care 
groups, doctors and scientists. There are therefore no competing claims to the 
`correct' terminology between the `experts' and the `public'. From my investigations 
there is no alternative term, although loss of warnings is used with `hypoglycaemia 
unawareness'. 23 Yet there was not a consensus that hypoglycaemia existed in relation 
to human insulin. Loss of warnings however, has been found in both diabetics and 
non-diabetics. Hypoglycaemia unawareness has been noted in patients with 
insulinoma, spinal cord section and ganglionic blockade (Gerich, 1992). In insulin 
dependent diabetic patients, it "has been accepted as a textbook feature of diabetic 
autonomic neuropathy" (Ryder et al., 1990: 786). 24 
There is not, on the whole, a battleground as to whether hypoglycaemia unawareness 
has a biological or psychological basis, as in the case of ME. Instead, care groups and 
diabetics were attempting to link hypoglycaemia unawareness to a possible side effect 
of the use of human insulin. Importantly, the symptoms of hypoglycaemia 
unawareness are difficult to assess, from a medical point of view. Therefore, it is 
23 It is interesting to note that `hypoglycaemia unawareness' suggests that, diabetics who experienced a 
change in warning signs missed the sympathoadrenal symptoms. However, it should be noted that in 
some diabetics the sympathoadrenal symptoms existed, but were not as pronounced, or diabetics did 
not experience these symptoms for the same length of time, that they had previously. 
24 Although Ryder et al. (1990) call this into question. 
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perhaps sensible, following Cooper (1997) on ME, that when I refer to sufferers of 
hypoglycaemia unawareness, I am referring to those who believe that their bodily 
experiences should be labelled as `hypoglycaemia unawareness'. It is the ability of 
various actors to have their symptoms diagnosed as hypoglycaemia unawareness that 
is one of the issues at hand. 
When hypoglycaemia is unexpected, or action cannot be taken to correct the 
imbalance of glucose, it should be seen as a `severe biographical disruption'. I use 
the term `severe biographical disruption', to signify a disruption of the taken-for- 
granted assumptions of the illness. For example, the onset of hypoglycaemia 25 is 
usually accompanied by particular sympathoadrenal symptoms such as sweating, 
tremor, palpitations, and so on (Figure 4-3). A severe biographical disruption occurs 
when a diabetic is unaware of the initial sympathoadrenal symptoms. The 
management of chronic illness can be seen as an attempt to manage the biographical 
disruption; in severe cases, the disruption is difficult to manage because it is 
unexpected (even in retrospect, the diabetic may not be able to account for their 
hypoglycaemia). The important point is that the hypoglycaemic episode cannot be 
accounted for within the existing management of diabetes. To talk again in terms of 
the network body, the network body becomes threatened; the current network body is 
unable to cope with the new situation. As Rajaram argues: 
"It is through a process of communication that the significance and justification 
of these experiences become an integral part of the illness experience, 
embedded with the ideological context of everyday existence. " 
(Raj araln, 1997: 290) 
I would now like to look at the effect that these symptoms may have on a diabetic. 
4.3.2 Experiencing Symptoms 
The aim of this section is to indicate the ways in which diabetics were influenced to 
produce narratives which described their own experiences. In doing so, I will also 
indicate that the notion of narrative is complex since actors produce narratives and are 
also subject to them. 
25 Hypoglycaemia is termed a `non-disease' or `illegitimate illness' because it is generally defined in 
terms of symptoms, with an uncertain aetiology and pathogenesis (Cooper, 1997). Also see Singer et 
al. (1984). 
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When a diabetic experiences an unpredictable hypoglycaemic episode, it can affect 
the diabetic's identity. The diabetic may no longer see themselves as being someone 
able to lead a `normal' life despite their illness. Further, when such disruptions 
become public disruptions, questions may be raised about the ability of the diabetic to 
look after themselves. Importantly here, it is not that the diabetic did something `out 
of the ordinary' in their normal routine. In cases of severe biographical disruptions, 
diabetics have to deal with stigmatising reactions and a discredited identity, but not 
because there was a failed performance (Goffinan, 1963). In cases of a failed 
performance a diabetic is able to account for the discredited identity within the 
network body, for example, a delayed snack or meal. However, where there is no 
(known) failed performance, a diabetic is likely to search for a reason for such 
biographical disruption in order to understand why they had the hypoglycaemic 
episode. This search for meaning comes through an interaction with existing and new 
networks that reconfigures the network body. 
To reiterate, the network body includes many different entities, not only artefacts and 
knowledge, but also the meanings attached to these entities. For example, where a 
diabetic experiences problems on human insulin, they may no longer consider human 
insulin to be a wonderful modem drug. Where once it was viewed as a technological 
advancement by the diabetic, it is now viewed with suspicion. It is also important to 
realise that the meaning of animal insulin, the `old' insulin, may also change. Animal 
insulin may now be viewed as something to be returned to, indeed, the diabetic may 
feel that animal insulin is better than the `new' human insulin. 
Further, "the body is not merely the location of disease but is that through which one 
continues to apprehend the world and oneself in it" (Radley, 1989: 232). Therefore, 
we cannot separate `the body' from `the world'. The experience of hypoglycaemia 
can be seen as being mediated, and justified, through a number of networks. Rajaram 
(1997) argues that the management of a hypoglycaemic episode involves an ongoing 
discourse between: 
a) Patients' relationships with their illness. 
b) Patients' relationship with their intimates. 
c) Patients' relationships with the medical profession. 
d) Relationship of diabetic partners to the world at large. 
In the case of a severe hypoglycaemic biographical disruption these networks are even 
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more important. Moreover, because reasons for the episode cannot be easily found 
within the existing relationships, the diabetic may draw upon other networks. 
Therefore, in the case of a severe biographical disruption, we should also add: 
e) Patients' relationships with other diabetics. 
f) Patients' relationships with care groups. 
g) Patient and family relationship with the media. 
It is through interaction with these networks that sufferers' generate narratives. As 
Somers has argued, it is "through narrativity that we come to know, understand, and 
make sense of the social world" (1994: 606). Importantly, narratives are intimately 
related to identity. There is a stress here on the plurality of narratives; it is not the 
case that we simply pick from one narrative and that defines our identity. Rather, it is 
important to stress "the embeddedness of identity in overlapping networks of relations 
that shift over space and time" (Somers, 1994: 607). Identities change because our 
relations between various networks change. These networks include not only family, 
friends, care groups and the medical profession, but also the body itself. 
In keeping with ANT, narratives will be seen as an intermediary or inscription (in the 
form of letter or conversation) that passes from one network to another (for example, 
a diabetic may tell a doctor that they are feeling ill on human insulin). In this case 
study, narratives are the way in which diabetics share their experience of 
hypoglycaemia: that is, how they describe their symptoms. More specifically, it is 
through narratives that diabetics describe the state of their network body. Importantly 
however, it is possible that as a result of becoming aware of narratives, a diabetic may 
then produce new or altered narratives describing their own experiences. As a result, 
narratives and experiences are closely related, not only because they are used to 
describe experiences, but also, because they may have a role in prompting actors to 
describe their own experiences. 
It is also interesting to look at the point where narratives meet. As such, in what 
follows, I explore what happens when a diabetic reports problems to their doctor, or 
writes to the BDA. This is important because a diabetic, who reports their problems 
to their doctor, may be satisfied with the solution presented to them, and as a result, 
will be unlikely to direct a narrative towards the BDA or IDDT. However, a diabetic 
who is dissatisfied with the solution presented to them by their doctor may then direct 
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narratives to other actors, such as care groups. 
Different narratives also have a different authority. Those networks that already have 
a large measure of authority are likely to produce powerful narratives. This stresses 
the relational nature of power. For example, a warning from the medical profession 
over the efficiency of a particular drug will probably have more of an effect than from 
a care group. Indeed, it is interesting to look at how one narrative can produce others, 
which become more authoritative, either because they are backed up by other 
networks, or because the number of similar narratives increases. This will be 
illustrated in Chapter 6, where I describe how care groups were able to collect many 
similar narratives of those who were having problems on human insulin. 
It is possible to outline at least two broad forms of narrative. Narratives produced by 
patients, which relate to their illness, can be classed as `illness as narrative' (Hyden, 
1997). This form of narrative should be seen as personal experience, since it comes 
from the body, and it is about the body. This should be contrasted with `narratives 
about illness' (1997), which refers to those narratives that convey knowledge and 
ideas about illness. The concept of narratives about illness stresses that actors, who 
do not have a particular illness, can produce narratives about illness. The source of 
these narratives includes not just doctors, but also family members, care groups and 
the media. 
It is not just the origin of narratives that is important: there are both different forms of 
narrative (such as oral or written forms) and different types (such as interviews, letters 
or magazine articles and formal reports). The form of narratives are important 
because written narratives have the possibility of possessing greater immutability 
compared with oral forms. The type of the narrative is also important because they 
may be received in different ways. Letters, published in Balance, from diabetics may 
not have the same authority as magazine articles or formal reports. 
It is also possible to outline an `institutional context', which refers to narratives that 
are produced and shared in a medical environment, such as within the doctor-patient 
relationship or where professionals talk about the symptoms of their patients (Agar, 
1985). Early points to illness narratives that occur in `everyday contexts', such as 
when a patients tells another person about their illness (1984). In this situation, the 
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type of narrative produced may be variable, depending on the shared experiences of 
those involved, or the `others' positioning. There are likely to be different narratives 
produced when one diabetic talks to another, compared with a diabetic talking to a 
non-diabetic. Similarly, narratives produced through contact with sympathetic care 
groups are likely to be of a different order to less sympathetic care groups. Hyden 
points to another context, called `elicited contexts', where a researcher interviews 
subjects about their illness (1997). 
It is also important to understand that narratives are rarely stable, as Hyden argues: 
"... illness narratives are constantly changing and being renegotiated, depending 
on changing perspectives and other changes in the illness process. " 
(Hyden, 1997: 61) 
This again stresses that narratives do not exist in isolation from other factors. Not 
only are narratives dependent on the context in which they are expressed, but also on 
changing perspectives. For example, a diabetic who is experiencing problems on 
human insulin may feel that they are alone, or through interaction with their doctor 
they may feel let down. Narratives at this point are likely to be `down beat'. 
However, through interaction with others who have had similar experiences, future 
narratives may be more positive. These issues will be dealt with in Chapter 6. 
The notion of narratives is therefore complex. Importantly, narratives do not simply 
pass from one actor to another. Instead, narratives may have an influence on actors, 
indeed, this is the aim of many of the narratives that are passed between actors. 
Narratives become even more complex when they become collectivized, since choices 
have to be made as to what information is included in the collectivized narratives. 
Through collectivization actors have a degree of flexibility as to which experiences 
are included within narratives, and as a result, what they wish to represent. For 
example, there were differences in the narratives that the BDA and the IDDT 
collectivized. In particular, the IDDT was far more hostile towards human insulin 
than the BDA. This will be explored in Chapter 6. 
It seems sensible at this point to give an illustration of how meanings come to be 
generated through the network body. A diabetic may produce a narrative about 
themselves to their doctor, for example, that they are experiencing a change in 
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hypoglycaemic symptoms on human insulin. The doctor may then tell the patient 
about possible side effects of human insulin, or possible causes of their change in 
symptoms. Through this interaction, a diabetic is likely to experience a shift in self- 
identity, perhaps from a diabetic coping with their illness, to one that is not. 
However, it is very rarely the case that the doctor-patient relationship is isolated from 
other networks. For example, part of the reason for a diabetic talking to the doctor 
may be due to encouragement from close family members or from contact with other 
diabetics. Of course, there is continual feedback here, the diabetic may not agree with 
the doctor and produce other narratives to other networks, such as care groups. 
When a diabetic experiences a change in the symptoms of hypoglycaemia, either 
through self-monitoring or because they were unable to take action themselves, they 
may reassess a number of meanings. They may reassess their own identity, the role of 
others, and of their diabetic management, as well as the meaning of objects within the 
network body. As Good (1994) has pointed out, a central problem with illness 
narrative is often a lack of an ending. That is, how will the situation develop in the 
future. For a diabetic, the new characteristic of their diabetes, `hypoglycaemia 
unawareness', increases the feeling of a lack of an ending because the diabetic has to 
redefine what it means to be a diabetic. 
When an existing network breaks down there may be both a motivation to re-engage 
with existing networks and to engage with new ones. This motivation may come 
from individual experiences, or from other networks, such as close family members 
encouraging the diabetic to search out information. 
I would now like to look at how diabetics initially interacted with other networks. 
4.4 INITIAL REACTIONS 
I have dealt above with a number of rather abstract issues concerning the experience 
of some diabetics on human insulin. In this section I would like to look more closely 
at the way diabetics expressed their experiences on human insulin. I have a number 
of broad aims. Firstly, to look at the initial responses of various groups to patients' 
experiences, their illness as narrative. Secondly, to look at how patients' narratives 
were initially represented within certain groups, that is, narrative about illness 
(Hyden, 1997). This type of narrative deals with situations in which doctors and 
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professionals talk about patients' illness. 
Frank (1994) argues that modern illness narratives are based around three central 
tensions: to gain a public voice that relates a private experience; to sustain the 
primacy of one's own voice in relation to the voice of medicine; and, to balance the 
illness experience against the scheme of one's own life. This section aims to illustrate 
how diabetics gained a public voice. 
One important area of study is how a private narrative becomes public, and how 
private narratives come to be collectivized into a coherent narrative. By collectivized 
I mean the process by which individuals come to realise that they are not the only one 
experiencing a particular problem. Part of this process entails how individuals come 
to be supported and represented by other networks. This collectivization occurs 
through the production and accumulation of narratives, and becoming aware of 
narratives already in circulation, such as news reports of the experiences of others. 
One particular type of `other' narrative is what we can call a grand narrative26, such as 
those printed in the `popular' diabetic press (e. g. Balance) and the popular press (e. g. 
national newspapers). Grand narratives differ from other narratives by their diversity 
and density. That is, their content will come from a range of networks (e. g. scientific 
community, care groups and regulatory authorities), and from a variety of sources 
from within these networks (e. g. those scientists who felt that human insulin did cause 
negative side effects and those who did not). For example, the media may bring 
together diabetics who have experienced problems on human insulin and narratives 
from doctors and care groups. 
This collectivization of narrative is intimately tied to the ways in which `issues' arise. 
Cobb et al. (1976 taken from Scambler, 1998) outline three models through which 
political issues emerge. They distinguish between: 
26 Apologies to Lyotard (1984). 
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1) The inside access model - where the initiative is generated and pursued by 
office holders or political leaders, while the broader public is either excluded 
altogether or able to exercise only scant influence. 
2) The mobilization model - again the initiative is taken from within the 
political system, but where the support of a mobilized public sphere is 
required to effect change. 
3) The outside initiative model - where it is a mobilized public sphere, or 
pressure of public opinion, that promotes an issue to the point of salience and 
concern in the political system. 
Rather than looking at the political system, these models may be generalised to look 
at other groups or networks, such as scientists and care groups. For example, the 
inside access model would refer to an issue generated by scientists, while the outside 
initiative model would refer to `lay' sufferers or interested individuals taking the 
initiative. Pictured on a continuum doctors may be placed nearer to scientists, while 
care groups nearer to interested individuals or patients. Since scientists are already 
within the generalised institution of medicine, they are able to take the initiative from 
within this network. This is also the case for doctors. However, we have to be aware 
that single scientists are unlikely to be able to start an initiative, unless backed by part 
of their institutional network. Patients on the other hand, are outside of this 
institutional network. Patients are likely to have to go through care groups in order to 
take some form of initiative. Importantly, some care groups act as a bridge between 
patients and doctors. However, some care groups are able to do this more than others. 
For example, the BDA are more able to bridge this gap than the IDDT because of 
their existing links with a variety of medical actors. Although rather simplistic, this 
continuum may be a useful tool to look at how various issues are generated, and dealt 
with, within wider society. 
inside access mobilization outside initiative 
model model model 
4 10 
scientists doctors care groups public 
Figure 4-5: Initiative types and various groups 
In the next sub-sections I will deal with three areas. In the first sub-section I will look 
at help groups, and how they became aware of some of the problems experienced by 
some diabetics on human insulin. In the second sub-section I will deal with the 
scientific community, and look at how interest in human insulin and its possible 
133 
4. Initial problems on human insulin - symptoms and initial reactions 
problems arose. In the third sub-section, I will look at why the medical profession 
drastically increased the prescription of human insulin between 1986 and 1989. For 
clarity these areas have been separated, however, as will be shown in each sub-section 
they are not distinct. These sections are important because they will `set the scene' 
for the following chapters, which will describe the long term actions of some of the 
key actors in the human insulin debate. 
4.4.1 Help Groups 
In this section 1 will look at some of the reactions of the popular diabetic press. I will 
first describe and compare the two main groups that are of interest in this study, the 
British Diabetic Association (BDA) and the Insulin Dependent Diabetes Trust 
(IDDT). 27 I will then look at some of the initial reactions of these groups. 
Comparisons between these two groups will be made in greater depth in Chapter 6. A 
comparison will not be made in this chapter because, in the initial stages of the human 
insulin debate, the IDDT did not exist. 
Throughout this thesis the two main patient help groups, the British Diabetic 
Association (BDA) and the Insulin Dependent Diabetic Trust (IDDT), will be 
collectively referred to as `care groups'. My justification for this is that although both 
these groups include diabetics, they also include non-diabetics, such as members of 
the medical community. It could be argued however, that the term `patient group' 
could be used to describe the IDDT. Indeed, they describe themselves as a 
`patient/carer organisation' (1995c) or as a `patient-centred organisation' (1994). 
However, both groups aim to `care for' diabetics, it therefore seems sensible to use 
the term `care groups' to apply to both groups. 
4.4.1.1 British Diabetic Association (BDA) 
The British Diabetic Association (BDA), 28 founded in 1934, was the first medical 
self-help charity in Britain, and also the first to have both lay and professional 
members. The Association was founded by R. D. Lawrence, a diabetologist who had 
diabetes himself, and the author, H. G. Wells who is famous for books including The 
27 It should however be noted that the IDDT started over 10 years after the introduction of human 
insulin. 
28 BDA, 10 Queen Anne Street, London, WIM OBD, UK. 
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Time Machine and War of the Worlds. The aims of the BDA are: to help and care for 
people with diabetes and those close to them; to represent and campaign for their 
interests; and, to fund research into diabetes. 
The association produces a magazine called Balance, once every two months. 
4.4.1.2 The Insulin Dependent Diabetes Trust (JDDT) 
The Insulin Dependent Diabetes Trust (IDDT)29, a registered charity, was started in 
1994 with its first newsletter being printed in April of that year (1994). It was set up 
to be a "patient centred' organisation based on true self-help', and had the following 
aims: 
" To offer care and support to people with diabetes and their carers, especially 
those experiencing difficulty with 'human insulin. ' 
" To influence appropriate bodies to ensure that all insulin users have a 
continued supply of their chosen insulin. 
" To ensure all patients/carers are properly informed of the alternative 
treatments available to them. 
" An equal choice of injection devices, including a pen injection system for 
animal insulin. 
" To collect information and experiences from those with diabetes and their 
carers, to use the results of this, to help others in the same situation and to 
pass it to professionals to create a greater understanding of `life with 
diabetes. ' 
9 To inform its members and others through a quarterly newsletter. 
" In the longer term, to promote research and surveys into 'human insulin' and 
its effects. 
With the exception of the trust's medical advisor, Dr Laurence Gerlis, the initial 
trustees all lived with diabetes -3 had diabetes and 3 were carers. They came 
together because they had experienced problems with 'human' insulin, either directly 
or indirectly. Further, the problems appeared to disappear when they changed back to 
animal insulin. Interestingly one of the co-founders, Jenny Hirst, was a former vice- 
chairman of the executive council of the BDA (Rogers, 1995). One of the reasons 
why Jenny Hirst and Dr Matt Kiln formed the IDDT was because they felt that the 
BDA were not representing and supporting diabetics adequately, in respect of 
differences between animal and human insulin (personal email). In particular, they 
were aware that the BDA were receiving a large number of letters from diabetics who 
29 IDDT, PO Box 294, Northampton, NN3 2BN, UK. 
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were experiencing problems on human insulin. Jenny Hirst claims that the BDA had 
up to 3,000 letters of complaint (IDDT, 1997). 
Due to their experiences, the initial IDDT trustees, wondered how many more people 
were experiencing problems on human insulin. They were especially interested in 
those who had not thought about moving back to animal insulin, to see if that helped 
remove the problems. They also wanted to ensure that animal insulins continued to 
be available for all who wished to use them. 
The IDDT is different from the BDA in so far as it was set up specifically because of 
the problems diabetics experienced on human insulin. As a result, it had a particular 
set of concerns for those diabetics who used human insulin. Their concerns can be 
summarised as follows: 
" Those who have only used human insulin have no comparison to make about 
how they feel. They may accept erratic diabetic control as the best they can 
achieve, and may also put how they feel down to just being diabetic. 
" Those who have symptoms that appear gradually may not think about 
changing their insulin species. 
" Although scientific evidence shows no difference, anecdotal evidence is 
valuable, and people with diabetes do know how they feel and their carers 
are valuable observers in any changes. Those who live with diabetes, need to 
be assured that the professionals looking after them are fully aware of this. 
" Those who want to change insulin species should be able to do so. 
" Those living with diabetes should feel secure that their chosen insulin will 
continue to be produced, and that animal insulins will not be withdrawn in 
the UK. 
" People should not be dissuaded from using animal Insulins because they are 
not available in cartridges for pen-injection devices. 
(IDDT, 1994) 
Although some of these concerns are the same as those of the BDA, it is obvious that 
the IDDT took a more aggressive stance towards the introduction and use of human 
insulin than the BDA. One example is the naming of human insulin. The IDDT 
claimed that the naming of human insulin was "clever and misleading" because "It is 
NOT human insulin" (1995a). The BDA did not have such a concern. 
I will return to these groups throughout this work. 
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4.4.1.3 Reactions, from the care groups 
In 1987 the first letter on problems with human insulin was published in Balance, the 
magazine of the BDA. A family member explained the change in symptoms of their 
mother. When she was changed to human insulin from bovine insulin, the family felt 
that she was getting more `hypos' without warning, and often felt confused and 
disorientated. The letter also asks if Balance had received any other such reports, 
which they had. In reply to the letter, Balance describes the study by `two Swiss 
doctors' (Teuscher and Berger, 1987). The study showed that 66 out of 176 people, 
who were switched from animal insulin to human insulin, claimed that their 
symptoms had changed. Some of the 66 were not aware of their low blood sugars, 
and a few experienced hypoglycaemic coma. 
The reply in Balance concludes: 
"Clearly this report means that anyone changing from beef or pork to human 
insulin should be very careful, monitoring their blood sugars frequently and 
reporting any changes immediately to their diabetic clinic. For those who prefer 
to stay on animal-derived insulin, we can reassure you that beef and pork 
insulins will continue to be available for the time being. " 
(Balance, 1987d: 50) 
At the end of 1987, Balance (1987e) requested that diabetics who had been transferred 
to human insulin from animal insulin, in the last year, should contact them if they 
would be willing to fill in a confidential questionnaire. The results were published 8 
months later (Balance, 1988c). 
Another letter asks readers for their help. A mother tells of how her son was 
experiencing problems on human insulin, on which: 
"Not only did he become ill physically his whole personality changed, 
becoming aggressive, tearful and lethargic. " 
(Balance, 1988d: 7) 
The letter describes how it took nearly a year for her son to be diagnosed as being 
unable to use human insulin. She asks that other parents and diabetics contact her if 
they were experiencing similar problems. 
This suggests that it is possible to outline two broad types of help groups. One 
organised on a large scale, and another on a more personal level. Katz and Bender 
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(1976) suggest that help groups can be divided into two basic kinds: 
1) Inner-focused, groups primarily aimed at providing an arena where members 
can share their personal problems with fellow sufferers, likely to be 
organised on a local level and meet regularly. 
2) Outer focused, groups that are likely to act as pressure groups, who represent 
the needs of many. They act to disseminate information to district 
authorities, professionals and suffers, and also carry out fundraising. 
My focus here is on outer focused care groups. Both the BDA and the IDDT act as 
pressure groups that disseminate information. Although the above letter, asking for 
others to contact the author if they were experiencing problems, can be allocated to 
the inner-focused group, to a large extent the BDA took over the role of helping those 
with problems. 
The issue of a loss of warnings was generated by diabetics themselves, what Cobb et 
al. would allocate to the outside initiative model. Such initiative, through the 
interaction of the public and help groups, enables a `popular epidemiology' to form. 
A popular epidemiology is defined by Williams and Popay (1994) as: 
"... situations in which lay people conceptualise and gather information on health 
problems and risks about which orthodox experts are silent or unreliable... lay 
knowledge moves beyond individual complaint to develop a public voice and 
provide the basis for collective action for change in policy. " 
(Williams and Popay, 1994: 120) 
However, we also have to be aware that the nature of medical knowledge has 
changed. For example, Comaroff and Maguire (1981) point out that as explanations 
become more biologically sophisticated, patients find it more difficult to relate 
scientific knowledge to their experience of illness. They become more alienated from 
that knowledge compared to their experiences (Williams and Popay, 1994) 
If this is the case, self-help groups play an important role in bridging feelings of 
alienation. Self help groups give patients a degree of comfort, since patients become 
aware that they are not the only ones suffering a particular illness or set of symptoms. 
The important point is that self help groups place value on experiential knowledge. 
Added to this, outer-focused groups share scientific knowledge. Help groups are 
likely to bring one (sanitised) form of scientific knowledge into their publications. 
For example, Balance referred to the 1987 study by Teuscher and Berger in one of 
their letters (1987d) and to other studies in a number of other articles (1992b; 1994). 
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Balance also have a regular `research round up-section'. The IDDT also refers to 
studies (1996), although not as regularly. Help groups then, reduce an individuals 
feeling of alienation that may exist as a result of differences between their experiences 
and scientific knowledge. 
In outer-focused groups knowledge is disseminated to diabetics (amongst others). 
The BDA, for example, acts to raise issues that are of general concern to diabetics, 
that are usually suggested by diabetics themselves. They frequently discussed the 
problems that were experienced by diabetics on human insulin in Balance. In 1988 
the BDA, via their magazine Balance, asked for diabetics to contact them and 
complete a questionnaire on their experiences of using human insulin (1987e). They 
also set up, and funded, various pieces of research and working groups. For example, 
in October 1989, the BDA set up the Human Insulin Working Group (HIWG) to look 
at the issue of human insulin and deaths in young people. Many questioned the make- 
up of this group because it was medically biased, and did not contain any patients who 
experienced difficulties on human insulin (Balance, 1994: v). This was corrected in 
1991, when the BDA set up the Loss of Warnings (LOW) Task Force to help and 
support those who had been experiencing a loss of hypoglycaemia warning signs 
(Balance, 1991 a). 
Outer-focused groups act as a channel of knowledge by producing press releases. For 
example, the LOW Task Force printed 40,000 copies of a special leaflet, mailed 
professional advice sheets and a copy of the leaflet to all the medical professionals on 
the BDA's mailing list. Leaflets were also sent to BDA branches; adverts of the new 
leaflet were placed in many national newspapers; a press conference was held; and, 
extra resources were made available to the Diabetes Care Department and the BDA 
telephone helpline (Balance, 1991 a: 46). 
Before I end this section, I would like to say something more about the experiences of 
diabetics on human insulin. In particular, I would like to look at `semi-legitimised' 
symptoms and those reported by diabetics. Semi-legitimised symptoms are those 
frequently reported in the media. The most frequently reported symptom was 
hypoglycaemia unawareness. However, if we look at symptoms that have been 
reported by patients on the whole, rather than the semi-legitimised symptoms, we can 
produce a longer list. For example, the IDDT (IDDT, 1995b) listed the symptoms 
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that had been reported by its members (Figure 4-6). Most patients experiencing 3 or 4 
symptoms. 
Loss of warnings Depression 
Extreme tiredness or lethargy Blood sugars dip and peak wildly 
Sleeping all the time Not the same person 
Weight increase of 1.5 stones or above Mood changes - difficult to live with 
Feeling unwell all the time Pains, especially in legs 
Memory loss/confusion Late or irregular periods 
Figure 4-6: Reported problem on human insulin 
Although loss of warnings and changes in blood sugar levels are in the list, the other 8 
problems were not regularly associated, by non-diabetic actors such as medical 
commentators and doctors, with human insulin. It is possible to outline a number of 
reasons for this. On the one hand, the label 'hypoglycaemia unawareness' is simple 
(although its diagnosis is not) and can be used as a `catch all' term. Hypoglycaemia 
unawareness has also been shown to be related to other factors of diabetes, and so 
already had a degree of `facticity' and credibility. According to Turner (1990), some 
health disorders (such as anorexia nervosa) are more socially constructed and over- 
determined than others (such as goitre and gout). As a result, it may be possible to 
outline a continuum (Arksey, 1998) with `troubles' on one end of the line and `well- 
established, respectable' illnesses on the other end of the line (Turner, 1992: 106). 
Taking a lead from Arksey (1998), there are also differences in the extent to which 
particular conditions have been taken up by professional bodies. Although 
hypoglycaemia unawareness is not necessarily well established in physiological 
terms, it has been taken up by medical professionals. Therefore, for those who 
wished to claim that problems existed on human insulin, it would be less of a political 
struggle if the claim was based on an established category. 
Another reason could be that, in theory, hypoglycaemia unawareness could be tested 
and assessed in the laboratory, whereas the other symptoms could not. Perhaps then, 
the division between hypoglycaemia unawareness and other symptoms, can be 
compared against `expert' and `lay' classifications. That is, by referring to 
hypoglycaemia unawareness, media articles could refer to scientific studies and 
patient experiences. However, by referring to other symptoms, the media could only 
draw upon `lay' knowledge. Another important consideration is that the original 
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study looking at human insulin, claimed that, in some cases, human insulin caused 
hypoglycaemia unawareness. 
I would argue, then, that the problems experienced by some on human insulin had 
been simplified and `black boxed'. Through the simplification of the problems 
experienced by some diabetics, the media were able to `deal' with particular positions. 
For example, in most discussions in the human insulin debate there were just two 
questions, related to the negative symptoms experienced by diabetics on human 
insulin, that needed to be answered. These questions were: Does human insulin 
increase an unawareness of approaching hypoglycaemia? and, Does human insulin 
cause sharp changes in blood glucose levels?. When the media dealt with scientific 
evidence and the negative symptoms experienced by diabetics, they talked in terms of 
these two questions. 
In this section I have aimed to outline some of the initial concerns of care groups, 
particularly the BDA. Rather than look in-depth at some of the issues, I have mainly 
concentrated on describing some of the features of help groups. In Chapter 6, I will 
look more closely at a number of concerns that existed around the use of human 
insulin, such as increased unawareness of hypoglycaemia and the withdrawal of a 
number of animal insulins. 
4.4.2 Scientific Community 
As implied above, one of the questions that I am interested in is the origin of issues, in 
particular, whether human insulin caused a change in the warning signs of 
approaching hypoglycaemia. More generally, I am asking the question: Where did 
the pressure to look into human insulin come from? I explained in Chapter 3 how 
human insulin was shown to be a safe alternative to animal insulin (Clark et al., 
1982). However, other studies were carried out that called this into question. Others 
still agreed with the original findings. The original studies were carried out before the 
drug was marketed as a requirement of regulatory bodies. Later studies, however, 
were carried out due to an interest in the possible side-effects experienced by some 
diabetics. 
In this section I would like to describe some of the initial reactions from the scientific 
community. I do not intend to look at the results of specific studies; rather, I will 
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illustrate how possible problems with human insulin entered the scientific community. 
In the next chapter (Chapter 5) 1 will discuss some of the studies and their results in 
detail. 
The first study to look at the link between human insulin and a change in warning 
symptoms, was carried out by two Swiss investigators in 1987 (Teuscher and Berger, 
1987). The study described 3 case studies, and then a follow up study, in which 176 
patients who had switched to human insulin were questioned. This study was 
prompted by an awareness by the investigators that their patients were experiencing 
problems on human insulin. Further, in response to a criticism of their study, 
Teuscher and Berger, argued that one reason for publishing the study was to inform 
physicians of the decreased awareness of hypoglycaemia, experienced by some 
patients, who were transferred to human insulin. They also wanted to show that 
hypoglycaemia unawareness was a potentially important clinical problem (Egger et 
al., 1988). Letters in the medical press were also prompted by doctors' experiences of 
patients transferring to human insulin (Turner et al., 1988). 
Studies were carried out by insulin manufacturers who were concerned about the 
suggested negative effects of human insulin. For example, Eli Lilly carried out an 
assessment study in 1988 (Lancet, 1989). Another insulin manufacturer, Novo 
Nordisk, started clinical trials in co-operation with the BDA in 1989 (Prentice, 1989). 
The BDA, through the Human Insulin Working Group, also recommended that 
studies be carried out to see if there were any differences between animal and human 
insulin. An article in Balance pointed out that normally research takes a long time to 
set up, but this research was commissioned and set up within three months of an 
advertisement appearing in the medical press (Balance, 1991b). In total, the BDA 
would spend over £250,000 on funding research into the effects of human insulin 
(Hope, 1995). The studies aimed: 
"... to meet the concerns shown by members about the loss of hypoglycaemia 
warnings following the change to human insulin. " 
(Balance, 1994: iv) 
In one study funded by the BDA, a research group from the Royal Infirmary in 
Edinburgh (Hepburn et al., 1992), studied the differences in the symptoms of 
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hypoglycaemia experienced by diabetics on human and porcine insulin. In another, 
Dr Simon Heller (1992) was given £53,000 to cover a two year research project to 
look at the switch to human insulin, especially a diabetic's ability to detect 
hypoglycaemic reactions (Balance, I992b). Another study led by Dr A Swerdlow 
looked into diabetic death, especially in relation to insulin type. The study aimed to 
follow more than 30,000 patients with diabetes throughout the UK (Balance, 1994). 
In this section I have described some of the initial actions taken by the scientific 
community as a result of concerns over possible side effects of human insulin. I have 
outlined a number of influences on the scientific community in bringing problems on 
human insulin to the attention of the scientific community. I have also described how 
a number of studies were carried out, some funded by the BDA. I would now like to 
sketch the role that the medical played in the use of human insulin. 
4.4.3 Medical Community 
Obviously the medical community play an important role in this study. In this section 
I would like to look at their position within the evolving human insulin network. In 
the first sub-section I will suggest a number of reasons why doctors transferred 
diabetics to human insulin. Then, in the sub-second section, I will look at some of the 
initial responses of doctors when diabetics reported problems on human insulin. 
4.43.1 Transferring to human insulin 
As prescribers of human insulin, doctors have a crucial role in the consumption path 
of human insulin. Therefore, it seems wise to look at some reasons why large 
numbers of diabetics were prescribed human insulin between 1986 and 1989. It has 
been argued that, from the point of view of doctors, there were three main reasons for 
transferring a diabetic to human insulin (Wolff, 1992). Firstly, promotional literature 
claimed that human insulin was far less immunogenic than animal insulin. Secondly, 
advertising campaigns made the new insulin sound superior to existing insulins, so 
patients asked for human insulin. Thirdly, physicians and pharmacists were under the 
impression that animal insulins were being discontinued. 
As already pointed out in Chapter 3, one of the claims made about human insulin was 
its reduced immunogenicity. In Chapter 51 will look at this claim in more detail. 
143 
4. Initial problems on human insulin - symptoms and initial reactions 
However, it may be useful to point out that, in retrospect, it has been argued that the 
transfer to human insulin was not necessarily for clinical benefit, rather it was for 
commercial reasons (Egger et al., 1992). In Chapter 31 described how by developing 
a new insulin Eli Lilly would be able to `break into' European markets. I also argued 
in Chapter 3 that the marketing of human insulin began before it was available for 
sale (Yoxen, 1983). Indeed, new drugs need to be energetically promoted to doctors 
if pharmaceutical companies are to recuperate their development costs (Burstall, 
1990). 
Although for Eli Lilly human insulin may have been a way to `break into' other 
insulin markets, this was obviously not the identity of human insulin presented to 
doctors and diabetics. Instead, human insulin was defined as being superior and 
`healthier' than existing animal insulins. Indeed, the exact amino acid sequence of the 
human insulin produced by the pharmaceutical companies to natural pancreatic 
human insulin was used as a marketing tool by the pharmaceutical companies 
(Datamonitor, 1997). 
On the issue of advertising campaigns it should be pointed out that insulin is not 
widely advertised. For example, when an advert was placed in the British Medical 
Journal for Humulin, claiming that it was less immunogenic than other insulins, there 
was some concern over its accuracy. However, another concern was over the advert's 
language. It was argued that: 
"The advertisement, which is written as though directed to the patient rather 
than to the doctor, is rich in emotive innuendo and lacks any explicit 
experimental or clinical basis. " 
(Collier and Pilkington, 1984: 191) 
However, in reply it was argued that: 
"The advertisement has been placed in journals whose contents are aimed at 
doctors. It has never been placed in any journal to which patients have access. " 
(Knight and Gennery, 1984: 191) 
Others have argued that it is more likely that patients may have asked for human 
insulin due to news reports in the popular media (Drug and Therapeutics Bulletin, 
1989). This is an example of the public consuming the public representation of 
science. As Lambert and Rose have argued, "The public representation of science is 
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generally mediated through its application or its promised application" (1996: 74). In 
the case of human insulin, there was a representation of human insulin based on its 
promised application and benefits. In actor network terms, diabetics were aligning 
themselves with the prescription of human insulin, that is, what it was claimed that 
human insulin would allow. 
On the third point of animal Insulins being withdrawn, the results of a BDA survey 
found that some patients had been changed to human insulin with the explanation that 
`Your old insulin is no longer being made. This is the modem one' (Redmond, 1988). 
Other doctors were under the impression that all animal insulins were soon to 
disappear, so began to change their patients over to human insulin (Drug and 
Therapeutics Bulletin, 1989). The survey by the BDA also found that a number of 
patients had simply been given the new insulin without any guidance from their 
doctor. In such cases, patients may not have been alerted to possible changes in their 
sensitivity to the new insulin (Pickup, 1989). 
4.4.3.2 Responding to problems 
In this section I will look at some of the initial responses from doctors when patients 
reported problems on human insulin. The reports come from patients' accounts and 
those reported in the media. The aim here, is to outline some of the responses, given 
by doctors, to diabetics who reported ill effects on human insulin. In Chapter 6I will 
look more closely at this area. 
When a diabetic presents themselves to their doctor, claiming that they are having 
problems with human insulin, the doctor could do one of three things: 
1) Accept the patient's view, and change them back to animal insulin. 
2) Reject the patient's view, and maintain the same insulin regime. 
3) Change some part of the insulin regime, but not the insulin species. 
A consistent complaint from diabetics was that doctors refused to acknowledge that 
they were having problems on human insulin (Pickup, 1989: 993). When patients 
asked to be changed back to animal insulin, many doctors replied that: pork insulin 
was no longer available; human insulin is better for you, it would be a step backward 
to use animal insulin; you've been on human insulin too long to change; and, the 
different species cannot be used in the same syringe (IDDT, 1995b: 9). 
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In relation to this final point, it was argued that diabetics should not be dissuaded 
from using animal insulins because they are not available in cartridges for pen- 
injection devices (IDDT, 1994: 2), Insulin pens are small pen like injection systems 
which use cartridges to deliver a set amount of insulin. Insulin pens remove the need 
to take insulin into a syringe from an insulin vial. As well as being small and 
convenient, it is also possible to adjust the administered dose by use of a selector at 
the top of the pen. The development of insulin pens went hand-in-hand with the 
development of human insulin, and initially, were only available for use with human 
insulin. 
Before a diabetic could ask to change insulin they had to attribute changes in their 
diabetic management to human insulin. One possible reason why patients may have 
attributed a change in the management of their diabetes to human insulin, could have 
been media publicity. It has been argued that the media worried many diabetics on 
human insulin, and as a result, even though a diabetic did not have particular 
problems, they requested to be put back on animal insulin (Balance, 1992b: 18; Gale, 
1989). 30 Wolff points out that some television programmes featured articulate and 
concerned diabetics who presented their symptoms as caused, without doubt, by 
human insulin (1992: 376). 31 Motivation to change insulin therefore, may not come 
from a `real' side effect of human insulin, but rather the perception, by a diabetic, that 
human insulin is the cause of their problems. Gale points out that some diabetics have 
run in to problems: 
"Some unlucky patients have run into trouble at the same time of changing to 
human insulin, but it seem likely that many have simply attributed all their 
problems to it. " 
(Gale, 1989: 1266) 
I have looked here at some of the reasons for the change to human insulin and some 
initial responses to problems experienced by some diabetics, from the point of view of 
30 Gabe et al. describes a similar case for tranquilliser dependence. They argue that some users of 
tranquillisers are influenced by the media to such an extent that they define themselves as dependent 
on tranquillisers simply because they use them (Gabe et al., 1991: 334). Also see Montagne (1988). 
3i Interestingly in August 1991 it was reported that lawyers were putting together a case to represent 
400 diabetics who claimed to have experienced negative effects on human insulin (Hall, 1991 a). By 
September, it was reported in The Times that the number had risen to 700 (Times, The, 1991). Indeed 
it was argued that the number could rise to 25,000. Some argued that the press coverage over the 
case enormously increased the numbers who felt injured or litigious. Indeed, it was argued that the 
`real' cases of human insulin related hypoglycaemia unawareness would be hidden under a large 
number of `me-too' complaints (Wolff, 1992: 376). 
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4.5 CONCLUDING REMARKS 
In the previous sections I outlined the process by which a number of issues were 
brought to the attention of various groups. I have utilised the concept of narratives to 
illustrate that it is not only a matter of producing narratives, whether it be illness as 
narrative or narratives about illness, but of gaining support for a particular narrative. 
Diabetics were crucial in producing the initial narratives of a change in symptoms on 
human insulin; narratives were then (re)produced by other actors, such as the BDA. 
In this final section I intend to bring together some of the issues outlined in the 
previous sections. I intend to relate the previous sections to work outlined in my 
theoretical chapter (Chapter 2). I will also provide some pointers to the content of the 
next two chapters. 
As I illustrated above, the BDA acted to gather information on the possible symptoms 
of human insulin, through questionnaires and the funding of studies. Relating this to 
ANT, the BDA became the representatives of diabetics who were experiencing 
problems on human insulin. However, some were unhappy with the way that the 
BDA were representing them, and so started their own alternative network - that 
eventually took the form of the IDDT. 
Through the production of various narratives the prescription of human insulin was 
being changed for some. Rather than seeing human insulin as a `safe alternative to 
animal insulin' (Clark et al., 1982), a number of diabetics saw human insulin as a less 
effective insulin than animal insulin. Indeed, some actors, such as doctors and 
diabetics, were beginning to form an antiprogram against human insulin. Further, 
some diabetics not only developed an antiprograrn to human insulin but also to other 
elements of the diabetic network, such as doctors and the pharmaceutical companies. 
It is important to note however, that these responses were not universal. For many 
diabetics human insulin was still a safe alternative to animal insulin. I will look at 
this more closely in the next chapter, when I consider the many scientific studies that 
were prompted by the experiences of those on human insulin. 
There are many reasons why some diabetics may have claimed to experience negative 
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effects on human insulin. An obvious cause is that they were experiencing side 
effects. However, diabetics do not use insulin in a vacuum: as argued in this, and in 
Chapter 2, we can conceive of the diabetic as living through a number of other 
networks, such as family, the media, doctors and various artefacts. These other 
networks will influence the actions of diabetics, just as these networks are influenced 
by the actions of diabetics. 
Through interaction with other actors, such as the media and other diabetics, diabetics 
may have linked human insulin with their current experiences. There may then be a 
breaking of the identification of human insulin as `modern' and `healthy'. These 
`other' actors may therefore affect perceptions of risk. 
It is also important to realise that these `other' actors can be enrolled by diabetics 
themselves. For example, by making issues `newsworthy', delegitimated actors are 
able to bring their perspectives into the public eye (Epstein, 1996). As Klandermans 
has described, by diffusing particular beliefs various groups are able to gain 
credibility that they would not have been able to gain on their own (1988). The ways 
in which diabetics enrolled other actors will be expanded in Chapters 5 and 6. 
As I have stressed throughout this chapter, the key actors/networks should not be seen 
as discrete actors/networks, rather there is constant interaction between these 
actors/networks. Further, groups or networks may need to balance a number of 
relationships between different groups. For example, the BDA felt that the reports in 
the media about possible litigation by those experiencing problems on human insulin 
caused difficulties for the BDA. They argued that they needed to support and 
represent those who were having problems on human insulin, but did not want to 
cause unnecessary distress to people who did not have problems with human insulin 
(Balance, 1994: v). 
Before I end this chapter, it is worth making reference to what I have called the 
network body. If we remember, the network body consists of all those entities that 
make up the experience of illness, whether it be doctors, the media or artefacts. Over 
time patients come to a negotiated settlement with their illness. This settlement 
involves the coming together, and an understanding of, the features of the network 
body. Yet, where new symptoms emerge new relationships need to be formed with 
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parts of the network body. In some cases new entities or networks may need to be 
introduced. 
Human insulin was introduced into this network body with the aim that it would 
replace existing animal insulin. Further, at the same time other artefacts may have 
been introduced into the network body, such as pen injection systems which further 
re-shaped the network body. As already noted, in some cases diabetics were 
discouraged from changing back to animal insulin because it could not be used with 
pen injection systems - now not only an integral part of the network body, but also 
closely linked to human insulin. 
Therefore, the selection of one entity, in this case the convenient insulin pen, is 
closely tied to the use of human insulin: it is not possible to use an insulin pen without 
also using human insulin. This led care groups to pressure pharmaceutical companies 
to ensure the supply of animal Insulins, so that doctors and diabetics had a choice of 
the insulin species they wished to use with the insulin pen. 
In sum, when human insulin was introduced into the network body, it was initially 
believed that there was no need to change other parts of the network, such as insulin 
dose. However, over time it was realised that a number of changes had to be made to 
existing networks within the network body. 
In the next two chapters I will look at the long term actions taken by a number of 
important actors. I will begin Chapter 5 by giving a chronological outline of some of 
the issues that were discussed in the human insulin debate, which will encompass both 
institutional and patient centred points of view. I will then go on to discuss the ways 
in which various institutional actors attempted to position themselves as central actors 
in the human insulin debate. Chapter 5 will therefore look at the scientific community 
and pharmaceutical companies. Then, in Chapter 6, I will look at the way patient 
centred actors attempted to define certain issues as important in the human insulin 
debate. 
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5. AFTER THE INITIAL REACTIONS - SCIENCE AND THE PHARMACEUTICAL COMPANIES 
5.1 INTRODUCTION 
In this, and the following chapter, I intend to describe how various actors attempted to 
render meaningful, the claims by diabetics, that they were experiencing problems on 
human insulin. I am interested in such groups as: pharmaceutical companies, the 
scientific community, the medical profession, care groups, and diabetics themselves. 
Outlining and describing these actors will not be an easy task since there are a great 
number of strands and interconnections between these groups. 
If we take a look at Figure 5-1 we can see that the key actors are linked to, and 
through, each other. By this I mean that actors are dependent on each other. For 
example, in order for pharmaceutical companies to have a relation with GPs, 
pharmaceutical companies and their products need to be registered and cleared 
through a number of regulatory bodies. As another example, GPs are likely to gain 
information from the scientific community through the scientific and medical media. 
GPs may also report to regulatory bodies, and report observations to both the medical 
and popular media. 
It will not be possible to deal with all the possible connections and strands in this 
study. As such, this chapter will inevitably be comprised of a constructed narrative, 
since it is not possible to do justice to all the `moments' linking the numerous actors 
involved. I have therefore had to make choices as to which moments to describe, and 
thus, which to leave out. Consequently, I do not consider this to be the only possible 
account of the issues within the human insulin debate. 
What I will attempt to do, in this and the following chapter, is to bring out some of the 
key issues of the human insulin debate in order to form one possible narrative. In the 
first section of this chapter I have chronologically outlined some of these key issues 
and moments. The aim of this outline is to provide a grounding for future sections. I 
have also summarised the key issues, and how they related to various central actors, in 
a chronological table (Figure 5-2). 
Once I have provided an account of some of the key issues in the human insulin 
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debate, I will then go on to look at the roles of a number of important actors. To bring 
some structure to the narrative I have divided them into two thematic chapters. This 
chapter can be seen as being institutionally centred, in that I will look at the scientific 
community and pharmaceutical companies. Chapter 6 on the other hand, can be seen 
as being patient centred. That is, I will look at issues that are of direct concern to 
diabetics, such as: patient knowledge; the doctor-patient relationship; the role of care 
groups; and, factors in the choice of insulin species. 
Scientific Media 
-Science 
-Nature 
Regulatoii Bodies 
-MCA 
-FDA 
IF IF 
Scientific 
Conunurzit\ 
ýº Medical Media 
-British Medical Journal 
-The Lancet 
f--' GP Patient 
, l--v . ly 14 
Popular Media 
-The Times 
-The Independet 
-Daily Mail 
British 
Diabetic 
Association I 
iI 
Care Urouts 
I, 
. 
'-, 
--- 
Pharmaceutical Companies 
-Novo Nordisk 
-Eli Lill, 
-CP Pharmaceuticals 
v1 
Family and 
Relatives 
4 
Insulin I 
Dependent I 
Diabetic 
Trust 
AL 
The schema above shows the main actors and their 
relationship to each other. Although rather 
simplistic. it illustrates how different actors Have 
different links to each other. As can be seen, the 
GP-patient relationship is an important one, since 
interaction between various groups often 'goes 
through' this relationship. 
Key 
4--- Strong one way link 
t--º Strong two way link 
.--º Weaker two Nvav link 
Figure 5-1: Schematic to show how the various actors are linked to each other 
Although I have separated these two broad areas, this does not mean that the 
institutional and patient centred chapters are not linked in their content. Looking at 
Figure 5- 1, we can see that care groups do have some link to pharmaceutical 
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companies. For example, care groups, through their publications, will pass on 
information about current medical thinking to diabetics. 
In order to bring these two chapters together, in Chapter 7I will bring out some of the 
linkages between the actors described in these two chapters. There are two areas that I 
am particularly interested in. Firstly, the different ways in which a multiple of actors 
attempted to bring some form of closure to the human insulin controversy. Secondly, 
I am interested in how the various forms of knowledge discussed in the following 
chapters can be related to each other. 
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Date Science Care Groups Patients Companies 
1981 . Human insulin approved for 
sale 
1982 
1983 
"Novo Laboratories are to 
discontinue the production 
of some porcine insulin 
1984 
1985 'investigation of diabetic . Only 6% of insulin sold of 
deaths begin human type 
1986 
1987 "Teuscher and Berger's "Questionnaire request . Diabetics first start to report 
paper on unawareness of printed in Balance problems 
hypoglycaemia 
1988 . Questionnaire results 
published 
1989 . The Human Insulin . About 80% of diabetics "Nordisk Wellcome in 
Working Party (BDA) meets using human insulin Britain introduce a warning 
for the first time for the first time in 
connection with marketing 
of a new human insulin. 
Followed discussions with 
the British government's 
Committee on Safety of 
Medicines 
1990 "BDA issue first statement 
on human insulin, being the 
result of more than two years 
scientific and clinical study 
1991 . interest in outlining the 'interest in outlining the , First news of possible legal 
ideal study ideal study action 
*First study on diabetics who "BDA set up the Loss of 
had experienced problems Warnings (LOW) Task 
on human insulin Force 
'Pair of studies by Egger et *Leaflets produced and sent 
al to medical profession 
. Letters written by the BDA 
to pharmaceutical 
companies asking for better 
labelling of their insulins 
1992 "Study by Colagiiuii et al . BDA still receiving letters 
,, 'For Debate' summaries from patients about their 
*Liverpool Symposium on experiences on human 
human insulin and insulin 
hypoglycaemia held 
1993 . Court case collapses 
1994 . First newsletter of the "BDA petition started "Novo Nordisks Insulin 
Insulin Dependent Diabetes Simplification Programme 
Trust . Novo Nordisk stated that 
"BDA's Insulin Campaign animal insulin will remain in 
petition presented to production at least until the 
pharmaceutical companies turn of the century 
. The BDA produces a 
special supplement on 
human insulin - The Insulin 
Debate' 
1995 . Study by Meneilly et al on "84% of people with 
NIDDM subjects diabetes use human insulin 
1996 
1997 'Number of diabetics on "CP Pharmaceuticals Ltd 
animal insulins put at announce they are extending 
50,000 their range of animal 
insulins to include cartridges 
1998 "Insulin becomes a 
prescription only drug 
Figure 5-2: Chronological outline 
153 
5. After the initial reactions - science and the pharmaceutical companies 
5.2 A CHRONOLOGICAL OUTLINE 
In the previous chapter I outlined a number of reasons why the prescription of human 
insulin rose from 6% in 1985 to about 80% in 1989. I suggested that advertising 
aimed at the medical profession, media attention toward human insulin, and the belief 
that animal insulins were being withdrawn, all affected the transfer of diabetics from 
animal to human insulin. 
Soon after the initial introduction of human insulin in 1982, various animal insulins 
were also being withdrawn, and a number of these were being replaced with 
equivalent human insulins. For example, in 1986 it was announced that beef Ultratard 
was to be withdrawn in July (Balance, 1987a: 5). In December 1986, Novo 
Laboratories announced that they were replacing two of their Monocomponent (MC) 
pork insulins32 with human equivalents (Balance, 1986: 4). As the use of human 
insulin increased the BDA received many letters regarding the withdrawal of these 
insulins. As a result of these letters the BDA were constantly seeking reassurances 
from the pharmaceutical companies over the availability of animal insulins (Balance, 
1987). 
In Chapter 4I also described some of the initial reactions of diabetics who were 
experiencing problems on human insulin. In particular, I pointed to the request by the 
BDA, in 1987, for those diabetics who were experiencing problems on human insulin 
to contact them. Another important date was the publication of the first study, in 
1987, that showed that human insulin did cause a change in the warning signs of 
approaching hypoglycaemia. I ended that chapter by describing some of the initial 
reactions of diabetics and doctors, to claims of a change in the warning signs of 
approaching hypoglycaemia. 
The initial study by Teuscher and Berger in 1987 (1987) prompted many other studies. 
These tested two main hypotheses: 1) whether human insulin caused a change in the 
warning signs of approaching hypoglycaemia, and 2) whether human insulin increased 
the number of severe hypoglycaemic episodes. Although there were many studies that 
were carried out, it is possible to pick out a number that were important. These 
studies were important for a number of different reasons: a new study design was used 
32 The initials `MC' signify highly purified insulins. 
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that improved on a previous study; two papers were published close together that 
showed different sides of the argument; and, as a result of a published study, the 
medical media received, and published, letters. 
What is important about these studies is that they were not carried out to satisfy 
regulatory bodies, as were the initial studies but were, rather, prompted by concerns 
within the medical community over problems experienced by some diabetics who 
were using human insulin. Reports were then published in the medical press, which 
fed back to the medical community. 
Some studies that looked at the issues that surrounded the possible negative effects of 
human insulin showed contradictory results. Studies showed both that human insulin 
did, and did not, effect the awareness and number of hypoglycaemic episodes, 
compared with animal insulin. From a clinical point of view, there were a number of 
suggested reasons for the effects experienced by some diabetics who were on human 
insulin. It was suggested that the cause of the experiences may have something to do 
with the natural biography of diabetes or to some other therapeutic change, rather than 
human insulin (Pickup, 1989). 
Throughout the human insulin debate there were a number of reasons suggested for 
the problems experienced by some diabetics that were not strictly scientific or 
medical. For example, there was a concern that some diabetics were changed to 
human insulin without proper advice and monitoring. Turner et al. argued that: 
"Advertisements have led general practitioners to alter the insulin brand their 
patients receive without the diabetic clinic knowing about the change and 
therefore being unable to monitor or adjust the dose. " 
(Turner et al., 1988: 1150) 
This was backed up by the BDA's survey of diabetics: 
"[one group of people]... who have had difficulties are those transferred, 
unknowingly, from pork to human by the pharmacist. " 
(Alexander, 1989: 157) 
Despite the fact that by 1989 there was still no scientific `proof that human insulin 
caused a change in the nature of hypoglycaemia, insulin manufactures printed 
warnings on their human insulin packaging. The warnings stated that some diabetics 
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had experienced problems on changing from animal to human insulin. These 
warnings were produced in consultation with the Committee on the Safety of 
Medicines. 
As would be expected, the BDA were aware of the problems that some diabetics were 
experiencing on human insulin. However, it was only in 1989 that they investigated 
the problem by setting up the Human Insulin Working Party (HIWG). The HIWG's 
task was to monitor the human insulin situation, gather data, and keep abreast of any 
new developments. The group comprised a number of recognised experts on 
hypoglycaemia, a number of BDA staff members, and representatives of the insulin 
manufacturers. 
One criticism of the HIWG was that there were no diabetics in the group (Balance, 
1994: v). In response to this criticism, the BDA set up a Loss of Warnings (LOW) 
Task Force in 1991. The task force aimed to bring to the attention of doctors some of 
the problems that diabetics were experiencing on human insulin (Balance, 1991b). 
They also wanted to encourage better communication between patients and doctors. 
They took a number of practical steps in order to achieve this. For example, they 
produced a special leaflet - People with Diabetes and Changes in Hypoglycaemic 
Warnings - which outlined some of the problems experienced by diabetics (see 
Appendix 2). This leaflet was circulated to medical professionals, placed in various 
national newspapers and printed in an issue of Balance. At the end of 1991, Dr Ward 
of the BDA, wrote to the insulin manufacturers asking them to clarify the labelling of 
their insulin types (Balance, 199 1 b). 
Requests for further information for diabetics and doctors did not just come from 
diabetic care groups. In a study that showed no difference in awareness of 
hypoglycaemia between porcine and human insulin, the researchers concluded that: 
"Clear advice is urgently required for the many patients who are anxious about 
the possible risks of hypoglycaemia with human insulin. " 
(Patrick et al., 1991: 531) 
One problem in obtaining clear advice was that the scientific community were in 
disagreement over the possible negative effects of human insulin. One solution to this 
would be in designing an ideal study. It was in 1991 that there was the most interest 
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in outlining an ideal study capable of determining definitively the impact of human 
insulin, and so resolving the human insulin debate. However, within the scientific 
community there was no agreement as to the size and format of such a study. 
Also in 1991, a steering committee was formed in which lawyers and diabetics had 
got together in order to look into the possibility of taking legal action over the side 
effects that they had experienced on human insulin. There was a lot of interest from 
diabetics and solicitors over the possibility of legal action. However, it was unclear 
who the action would be against, and in March 1993, the legal case was dropped since 
claimants were unlikely to get legal aid, and there were insufficient scientific grounds 
for the claim. 
Although there had been warnings and advice over the possibilities of problems on 
human insulin for over 5 years, the BDA were still receiving letters from diabetics 
concerning the negative effects of human insulin. In particular, letters from diabetics 
described how, despite experiencing problems on human insulin, their doctors were 
refusing to change them to back to animal insulin (Balance, 1992c). However, it is 
important to point out that the number of letters of complaint had fallen considerably 
since the activities of the LOW Task Force had begun (Balance, 1992c). 
As already pointed out, there had been some confusion over the availability of animal 
Insulins. In order to clarify the situation the BDA began their animal insulin 
campaign in 1994. The aim of the campaign was to make animal insulins available 
indefinitely (previously the BDA had argued that any withdrawal of animal insulins 
had to be accepted). In September and October 1994, the BDA presented a petition, 
with 140,000 signatures, to the three main insulin manufacturers. Novo Nordisk said 
that they remained committed to animal insulins, and assured the BDA that they 
would be available until the year 2000. However, they could not commit themselves 
after this, since it would depend on the economic viability of animal insulins. 
Although Eli Lilly had never marketed animal insulins in the UK, they expressed their 
support for a choice of insulin species for diabetics. As for CP Pharmaceuticals, they 
made an ongoing commitment to the production of beef insulin. 
Also in 1994, the BDA produced a special supplement on human insulin. The 
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supplement outlined some of the issues that surrounded the human insulin 
controversy. The supplement was printed in an issue of Balance. 
One important moment was the setting up of the Insulin Dependent Diabetic Trust 
(IDDT) in 1994. One of the prime aims of the trust was to offer care and support to 
diabetics, particularly those on human insulin. Indeed, one of the reasons for the 
setting up of the trust was because its members felt that the BDA, and other 
organisations, were not offering adequate support to diabetics who were experiencing 
problems on human insulin. 
Between 1995 and 1996 Novo Nordisk began their Insulin Simplification programme. 
The aim of the programme was to simplify the number of insulins that the company 
supplied, as many of the Insulins were duplicated. Throughout the simplification 
programme the BDA had frequent contact with Novo Nordisk over the structure of the 
programme. In particular, they were influential in gaining a number of concessions, 
such as assurances that clinical trials would be carried out looking at how diabetics 
dealt with the switch from the discontinued insulins. 
In 1997 CP Phannaceuticals announced that they were extending their range of animal 
insulins. Some of their existing beef insulins would be produced in cartridges, for use 
with insulin pens. Insulin pens are pen like devices that carry set insulin doses that 
can be administered quickly and conveniently. They were also going to produce some 
new porcine insulins in cartridges. For the BDA and the IDDT this was a major 
boost. The BDA felt that their 1994 campaign had helped persuade CP 
Pharmaceuticals that there was a market for animal insulins in pen fommn. 
Both the BDA and the IDDT had argued that since human Insulins were available for 
use with both syringes and insulin pens, this should also be the case for animal 
insulin. Some had argued that since human insulins were available in cartridges, 
many diabetics had been dissuaded from transferring back to animal insulin, despite 
experiencing problems, because they wanted to use this convenient method of insulin 
administration (IDDT, 1996a: 10). With animal insulins available in pen form, 
diabetics and the medical profession, had a full choice of insulin and administration 
devices. 
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At present, the human insulin debate is still unresolved. However, through greater 
awareness by both the medical profession and diabetics, it can be argued that human 
insulin is less of an issue than it was. The IDDT does still exist, and receives many 
letters from diabetics who are still experiencing problems on human insulin. The 
IDDT has established strong links with diabetic populations in other countries who are 
experiencing problems on human insulin. 
In this overview I hope that I have adequately outlined some of the important points in 
the human insulin debate. There are a number of particular elements that I intend to 
bring out in future sections, these will be organised under the thematic chapters 
institutionally and patient centred. In this institutionally centred chapter I will first 
look at some of the studies that have been carried out to look into whether human 
insulin is to blame for the problems experienced by some diabetics. I will then go on 
to consider the argument for other possible causes for these experiences. I will then 
address attempts, by both sides of the debate, to outline the criteria of the ideal study 
that would close the human insulin debate. I will also refer to some non-scientific 
elements of the human insulin debate. Finally, I will look at how the pharmaceutical 
companies responded to concerns over human insulin, in particular, warning diabetics 
of problems on human insulin. 
These issues are important for a number of reasons. By describing the studies that 
took place within the scientific community, and claims that it was not human insulin 
that caused negative effects but an unrelated therapeutic change, I hope to illustrate 
the complexity of assessing whether the use of human insulin does cause negative 
effects. Discussion of the ideal study is also important because it is an illustration of 
how scientists attempted to close the human insulin debate, and this should be 
contrasted with the following sub-section, which describes more rhetorical attempts at 
closure. The final sub-section, on the pharmaceutical companies, is interesting 
because it describes actions taken by human insulin manufactures that were not forced 
upon them by the scientific community. 
5.3 SCIENTIFIC COMMUNITY 
The scientific community had an important role in the regulatory process by which 
human insulin was certified as `safe and efficient'. The trials which were organised 
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and funded by pharmaceutical companies, enabled human insulin to be approved for 
use by diabetics. After the introduction of human insulin other trials were still carried 
out, however, these trials were more interested in assessing the benefits of human 
insulin, rather than its safety. In the majority of cases, rather than being funded by 
pharmaceutical companies, the studies were organised within the scientific 
community, prompted by the experiences of some diabetics on human insulin. In this 
section I am interested in these latter studies. Before I look at these however, it might 
be helpful to give some background to the introduction of human insulin from a 
scientific standpoint. 
When human insulin was first introduced there were concerns over the commercial 
versus scientific aspects of human insulin. In 1983 it was pointed out that there were 
a large number of commercially sponsored symposia, unreviewed papers and reports 
in books and supplements to well-known journals. By comparison, there were only a 
small number of original papers on human insulin that had passed a peer review 
system (Sonnenberg and Berger, 1983: 458). Indeed, as noted in Chapter 3, some 
have argued that the introduction of human insulin was very speedy compared with 
other drugs. Hall has argued that the time frame, in which human insulin was 
regulated, was very short because there was pressure from a number of areas to have 
human insulin available for use as soon as possible (Hall, 1987). The interest in, and 
speed by which, human insulin passed through the regulatory authorities was due to 
the ability of key actors, such as scientists and the phannaceutical companies, to 
define other insulins as problematic, and human insulin as the solution to these 
defined problems. 
When human insulin was introduced there were a number of suggested benefits, such 
as it being less immunogenic than animal insulin. When an insulin is less 
immunogenic it means that there are less circulating insulin anti-bodies. The 
reduction of insulin antibodies is important because insulin antibodies can cause 
lipoatrophy (pock marks) at the site of injection, and insulin resistance. 
33 Studies 
have shown that human insulin is less immunogenic than conventional animal insulins 
(Fineberg et al., 1983; Collier and Pilkington, 1984). However, when human insulin 
33 However, insulin resistance is rare now that purified porcine insulins are now in common use 
(Pickup, 1989). 
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is compared with highly purified porcine insulin the picture becomes less clear 
(Peacock et al., 1983; Pickup, 1986). Therefore, looking at the issue as a whole, there 
seemed to be little justification for the massive transferral of diabetics to human 
insulin. This led Sonnenberg and Berger to argue that, in 1983 that the "present vogue 
for human insulin is not matched by comparable benefits in clinical practice" (1983: 
458). 
Since human insulin had not been shown to be clinically advantageous, it was argued 
in the scientific community, that there was no reason to transfer diabetics to human 
insulin who were well controlled on animal insulin (Amiel, 1995: 258). Indeed, it was 
argued that only those who suffered from insulin allergy or who needed insulin 
treatment intermittently would benefit from human insulin (Pickup, 1986). However, 
it was argued that human insulin should be the logical choice for newly diagnosed 
diabetics (Pickup, 1986). 
The first trial to suggest that human insulin had particular side effects, rather than 
being comparable with porcine insulin, was that carried out by Teuscher and Berger in 
1987 (1987). As I described in the previous chapter, Teuscher and Berger claimed 
that human insulin caused `hypoglycaemia unawareness'. That is, some diabetics 
lacked the early warning signs of approaching hypoglycaemia that they usually 
experienced when they were on animal insulin. After the study by Teuscher and 
Berger there were a large number of studies, letters and editorials printed in the 
scientific press concerning the possible problems that some diabetics experienced on 
human insulin. Therefore, I would argue that it was the paper by Teuscher and Berger 
that, at least in part, initiated the `scientific controversy'. 
Although for purposes of exposition I have separated out some of the important actors 
in this and the following chapter, it is important to be aware that they should not be 
seen as entirely distinct. For example, work carried out within the scientific 
community influenced how the medical profession treated the issue. Care groups also 
draw upon work carried out by scientists. 
In order to bring some structure to this section I will base it around a number of key 
studies that have been carried out. I will look at these studies and the letters that 
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resulted from their publication. I do not claim that the studies that I will deal with are 
the only possible key studies. However, by keeping to a relatively small number of 
studies and responses to, and criticisms of these studies, I hope that I will be able to 
clearly outline some of the issues involved. For example, I will show how there was 
some debate over which type of study would be able to show whether human insulin 
did or did not cause negative effects. I will also show how, over time, the selection of 
the study population was reassessed. 
So, in the following sections, I will consider a number of scientific studies that looked 
at the possible side effects of human insulin (as initially suggested by Teuscher and 
Berger). In the next section, I will look at other possible causes for an increase in the 
frequency of severe hypoglycaemia and a change in the symptoms of hypoglycaemia. 
Whereas the first section will look at causes that can be `studied scientifically', the 
second section will be concerned with claims about a number of more `wide-ranging' 
causes. Explanations in this section put the experiences of diabetics down to either 
the `natural' biography of diabetes or to problems in the management of diabetes. 
From this point of view, it is not human insulin per se that is to blame, but rather 
aspects of clinical practice. I will then go on to look at how scientists attempted to 
define the `ideal study', that would, in theory, be able to show whether human insulin 
did or did not cause side effects. In the final section, I will draw together some of the 
points made, in particular, how the scientific community perceived the human insulin 
debate. 
5.3.1 The Studies 
The first study to look specifically at the possible side effects of human insulin, rather 
than looking at its benefits, was published in 1987 by Teuscher and Berger (1987). 
The study was the first in which the term `hypoglycaemia unawareness' was used to 
refer to some of the symptoms experienced by some diabetics on human 
insulin. 
The conclusion of the study by Teuscher and Berger was that the use of 
human insulin 
can effect the onset of the classic early warning signs of approaching 
hypoglycaemia. 
They argued that warnings signs of approaching hypoglycaemia tended to 
be of an 
neuroglycopenic nature, rather than the classical sympathoadrenal warnings. 
If we 
remember from Chapter 4 (Figure 4-3), with sympathoadrenal symptoms 
(sweating, 
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hunger and irritability) a diabetic is likely to be aware of approaching hypoglycaemia, 
and be able to take appropriate action. Neuroglycopenic signs on the other hand, are 
secondary signs, and due to their nature (confusion and seizure) they may prevent a 
diabetic from taking appropriate action. 
Teuscher and Berger stressed that, for the majority of diabetics, there would be no 
benefit in transferring patients from animal to human insulin. They further stressed 
that they were concerned over the "apparent marketing effort of manufacturers to 
influence physicians and patients to switch from animal to human insulin" (Teuscher 
and Berger, 1987: 385). As a result of their findings, they stressed the need for the 
continued availability of beef and pork insulins. 
Type of study: 
" the study was looking at frequency of hypoglycaemic episodes and not unawareness of 
hypoglycaemia. 
" studies carried out on healthy subjects not diabetics. 
" `one-off laboratory studies may not be powerful enough to detect differences between 
insulins. 
" retrospective studies - relies on accounts of diabetics after the fact. 
Failure to exclude certain subjects: 
" those who experienced a loss of warnings before being transferred to human insulin. 
" those with long duration of diabetes. 
Problems with studies: 
" the study was too small to detect a statistically relevant result. 
" variations in recall periods. 
" lack of a control group. 
" varying criteria in the definitions, assessment and classification of `severe 
hypoglycaemia'. 
" issues of variability of biological responses within subjects when hypoglycaemia is 
induced. 
" incomplete records. 
" statistical validity. 
" comparing results from various studies is difficult. 
" selective transfer of patients to human insulin. 
Figure 5-3: Summary of possible problems with human insulin studies 
There were however, a number of criticisms of this study (see Figure 5-3 for a 
summary of various criticisms of studies carried out looking into human insulin). 
Hepburn and Frier (1989) point out that Teuscher and Berger did not exclude those 
patients who experienced a loss of warnings before being transferred to human 
insulin. By not excluding these subjects, the study would exaggerate the prevalence of 
the problem of hypoglycaemia unawareness in the study population. The study also 
consisted of diabetics with a long duration of diabetes (Gale, 1989). This is important 
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because long duration of diabetes has been shown to increase the occurrence of 
hypoglycaemia unawareness in diabetics (Drug and Therapeutics Bulletin, 1989: 22). 
Again, this would affect the prevalence of hypoglycaemia unawareness in the study 
study population. 
Another criticism was that the study was designed to reach a particular conclusion, 
and did not warrant statistical analysis (Lean, 1987). An editorial, written quite a few 
years after the study, cast strong aspersions on the original paper by Teuscher and 
Berger, claiming that it was `evidently unscientific' and should never have been 
published (Home, 1991: 799). Although Wolff responded to the editorial by arguing 
that it was "an interesting and publishable preliminary study" (1992: 376). 
As already indicated the paper written by Teuscher and Berger was the first to 
associate hypoglycaemia unawareness with human insulin. 34 Although there had been 
concerns over the marketing and clinical benefit (compared with purified animal 
insulin) of human insulin, there had not been concerns over a negative effect of human 
insulin. Looking at all the subsequent scientific papers, they all referred to the paper 
by Teuscher and Berger. Therefore, if we wish to define a `starting point', at least in a 
codified way, of the human insulin controversy, this would be it. 
A possible cause, suggested by Teuscher and Berger, for a change in the classic 
warning signs of approaching hypoglycaemia, was due to decreased neurotransmitter 
secretion. One type of neurotransmitter that has interested scientists are 
catecholamines. As Pickup points out: 
"... absent or reduced release of catecholamines in response to hypoglycaemia 
correlates with unawareness of hypoglycaemia, a well established and extremely 
hazardous complication of insulin dependent diabetes. " 
(Pickup, 1989: 991) 
Studies that have investigated the size of catecholamine response to hypoglycaemia 
induced by porcine or human insulin have found conflicting results. Some studies 
have found that there is a decreased catecholamine response in healthy subjects (Heine 
34 However, Teuscher and Berger argued that some other studies should be reassessed. They point to a 
study by Clark et al. (Clark et al., 1982) which claimed that biosynthetic human insulin was a safe 
alternative to porcine or bovine insulin. However, Teuscher and Berger (Teuscher and Berger, 1987), 
point out that 6 out of 94 patients withdrew from the study due to severe hypoglycaemia. 
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et al., 1989). Others have found that there is no difference (Kern et al., 1989). In 
1989, Tattersall and Macdonald reviewed the issue of human insulin and the release of 
neurotransmitters and concluded that the issue remained controversial (1989). 
Another suggested reason for the difference in warning signs of hypoglycaemia was 
due to the absorption rates of human insulin compared to pork insulin - their 
pharmacokinetics. It has been found that the pharmacokinetics of pork and human 
Insulins have indistinguishable biological actions after intravenous administration 
(Pickup, 1989). However, when human and porcine Insulins are injected 
subcutaneously, human insulin is absorbed slightly faster than the equivalent pork 
insulin (Sonnenberg and Berger, 1983). Both human and porcine insulin are absorbed 
faster than bovine insulin. This means that although human insulin has a faster onset 
of action, it has a shorter duration of action. It has been argued that this difference in 
absorption may be more noticeable in some patients, which results in a 
hypervari ability of glycaemic control in these patients (Pickup, 1989). 
it has also been suggested that because porcine insulin is slightly more lipophilic than 
human insulin, it is able to cross the blood brain barrier faster than human insulin 
(Heine et al., 1989). This effect may lead to high concentrations of insulin in the 
brain, and so have a differential effect on the central nervous system. 
What is noticeable at this stage is that there are only a small number of suggested 
possible causes for a change in the symptoms exhibited by some diabetics on human 
insulin. Although future studies would look into these possible causes, the main 
concentration was in assessing whether human insulin did cause negative effects, 
rather than the origin of the effect. There were two effects or hypotheses that were 
investigated by researchers. One hypothesis was that human insulin increased the 
occurrence of severe hypoglycaemia in diabetics. A second was that human insulin 
altered the warning signs of approaching hypoglycaemia. 
As I will show, some studies agreed with the findings of Teuscher and Berger, and 
others showed no negative effect of human insulin. However, some studies have 
found that diabetics have experienced an increased awareness of hypoglycaemia on 
human insulin (Hepburn et al., 1989). For this very feature, some diabetics preferred 
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human insulin to animal insulin. 
There were other reasons why some diabetics preferred human insulin. In a follow up 
study to the original study by Teuscher and Berger (1987) 59 (89%) patients were 
available for re-examination. From these 59,25 had remained on human insulin. 
Reasons given by these 25 diabetics for their continued use of human insulin were: 
insulin type "`does not matter' (n=12); human insulin `must be [a] better insulin' 
(n=7); human insulin can be used in an insulin pen, but animal insulin can't (n=3); 
and, `no sweating in hypoglycaemia' (n=3)" (Teuscher and Egger, 1989: 1072). 
Berger et al. also noted that some patients saw the lack of sweating, which is normally 
experienced as a warning of approaching hypoglycaemia, as a positive feature of 
human insulin. They argued that: 
"... a few patients preferred human insulin because they found the symptoms of 
sweating (common on porcine insulin) disturbing. " 
(Berger et al., 1989: 1044) 
However, we have to be careful to distinguish between the frequency of severe 
hypoglycaemia and the quality of warning signs. Tattersall and Macdonald have 
pointed out that, "in early trials some patients reported feeling better because they did 
not get the unpleasant hypoglycaemia symptoms, and the conclusion was that the risk 
of hypoglycaemia was lower" (1989). However, it may be the case that these 
diabetics were clinically hypoglycaemic, but due to the lack of warning signs, they 
were unaware of their low blood sugars. In such cases, the diabetic may have felt able 
to carry out normal activities, such as driving, however, this would have been 
dangerous for the diabetic and others. 
None of the studies described so far have studied diabetics who had reported a loss of 
awareness of hypoglycaemia after the change from animal to human insulin. 
However, in August 1991, a paper was published that studied this population (Patrick 
et a1., 1991). The researchers compared the awareness of acute hypoglycaemia 
symptoms for diabetics on porcine and human insulin. They concluded that 
symptomatic responses to hypoglycaemia were not impaired by the use of human 
insulin. 
166 
5.3 Scientific community 
As would be expected this study was criticised. Egger et al. argued that the study was 
too small to be able to conclude any clinically important result. They also argued that 
there may have been some misclassification of symptoms as either symptomatic or 
neuroglycopenic (Egger et al., 1991). Another criticism was that the subjects had not 
been treated with each insulin for long enough. David Kerr argued that, 
"Comparisons between insulin species should be made after patients have been treated 
for a reasonable time with each type of insulin" (1991: 951). Although this study was 
supposed to help close the controversy, since it was carried out on those very diabetics 
who were experiencing problems on human insulin, Kerr concluded that: "The human 
insulin/perception of hypoglycaemia debate is unresolved" (1991: 951). 
A pair of studies that attempted to resolve the human insulin debate were carried out 
by Egger et al. in 1991 (1991 c; 1991 b). These studies are interesting because they 
tested the two hypotheses that I outlined earlier. One study showed that human 
insulin was associated with an increased risk of hypoglycaemia (Egger et al., 1991 c). 
The second study concluded that human insulin could impair a diabetic's ability to 
take appropriate steps to avoid severe hypoglycaemia (Egger et al., 1991 b). 
In response to these studies, a whole string of letters were published in the British 
Medical Journal. In one letter, Matthews wrote: 
"The two papers by Dr Matthias Egger and colleagues on the risk of 
hypoglycaemia associated with treatment with human insulin reopen a debate 
that British doctors with diabetic patients had hoped was closed. " 
(Matthews, 1991: 1265) 
In particular, Matthews points out that it should not be a particular concern of 
scientists and the medical profession to seek to "prove or refute potentially litigious 
differences between porcine and human insulin" but to make sure that patients and 
families are aware of the possibility and educate them accordingly (1991: 1265). 
Others argued that, just because some studies showed that there was a rise in hospital 
admissions, for severe hypoglycaemia in the area of study, and the increased use of 
human insulin, it did "not necessarily impute a causal relation" (Frier et al., 1991: 
1667). Indeed, as I will show in a following section, there are a number of other 
possible causes of hypoglycaemia unawareness and increased frequency of severe 
hypoglycaemia. These other causes include such factors as the movement towards 
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tight blood glucose control, that occurred at a similar time as the transferral to human 
insulin, and features of the `natural' biography of diabetes. 
Another criticism was put forward by Frier et al. (1991). They pointed out that the 
patients in the studies were transferred from animal to human insulin at equivalent 
doses. Yet, research had shown that a dose reduction may be necessary when 
diabetics were transferred to human insulin from animal insulin. They especially 
point out that: 
"Because of an expected reduction in insulin requirement after transfer from 
animal to human insulin diabetic patients in the United Kingdom were 
instructed to reduce their dose by at least 10% and few subsequently 
experienced increased hypoglycaemia. " 
(Frier et al., 1991: 1667) 
As outlined above, there were some strands that were continually present through the 
human insulin controversy. One such strand was the transferral of diabetics back to 
animal insulin if they experienced problems on human insulin. Even those studies 
that showed that there were no negative effects for diabetics on human insulin, did not 
advocate that human insulin should be the only insulin available to doctors and 
diabetics. This was also expressed by authors of editorials. For example: 
"In our opinion the balance of available evidence does not suggest that human 
insulin specifically impairs perception of hypoglycaemic symptoms or that its 
use predisposes to severe hypoglycaernia.. . [however].. . we 
have no hesitation in 
transferring patients back to animal Insulins if they so wish... " 
(Williams and Patrick, 1992b: 356) 
Indeed, at the Liverpool Symposium on Human Insulin and Hypoglycaemia (Patrick 
and Williams, 1992), held in January 1992, there was general agreement, from both 
sides of the human insulin debate, that a number of guidelines should be followed (see 
Figure 5-4, taken from Williams and Patrick (1992b)). Those at the symposium 
included, Dr Matthias Egger, Professor Arthur Teuscher, Dr Alan Patrick and Dr 
Gareth Williams who have all been prominent in the human insulin debate. 
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1) Patients who are satisfactorily treated with animal insulin should not be transferred 
routinely to human insulin. If transfer is indicated on medical grounds (for example 
hypersensitivity to animal insulin) the doctor should discuss this fully with the patient 
and monitor the change over carefully. It is not acceptable for patients to be 
transferred to human insulin by pharmacists. 
2) Patients receiving human insulin should be transferred back to animal insulin if they so 
wish. 
3) Animal insulin preparations must therefore remain available, they should include 
cartridges for the pen injection devices which are increasingly popular with patients 
(only human insulin cartridges are available for the most widely used devices). 
4) Adequately designed studies should be performed as a matter of urgency to determine 
conclusively whether human insulin has specific adverse effects. 
Figure 5-4: Suggested strategy for managing diabetic patients with 
insulin 
In a quite well received study by Colagiuri et al, the research group found that human 
insulin did not have a negative effect (1992a). This study was particularly crucial 
because it involved diabetics who had been referred by their doctors because they 
experienced ill effects on human insulin. The study was therefore similar to that 
carried out by Patrick et al. (1991). However, one criticism of the study by Patrick et 
al. was that the findings were not applicable outside of the laboratory setting (Egger et 
al., 1991). The study by Colagiuri et al. attempted to correct this criticism. 
The study found that there was no difference between porcine and human insulin in 
glycaemic control or the frequency, timing, severity, or awareness of hypoglycaemia 
(Colagiuri et al., 1992a: 1434). For Colagiuri et al. it appears that any change in 
warnings in the diabetic population are slight. Indeed, they conclude their paper by 
arguing: 
"Hypoglycaemia is the most common and distressing side-effect of insulin 
therapy. Hypoglycaemia unawareness is frequent and deserves more attention 
in clinical practice. It is common during treatment with both human insulin and 
porcine insulin. " 
(Colagiuri et al., 1992a: 1435) 
As with the majority of papers published concerning the human insulin debate, 
subsequent letters were printed in the scientific and medical press. Egger and Davey 
Smith (1992) for example, argued that the study did not match a number of standards 
that have been defined as important for clinical trials (Altman and Dore, 1990). These 
are based on the calculation of. sample size; method of randomisation; and, statistical 
analysis which explores any discrepancies between different treatment groups. Egger 
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and Davey Smith argued that "Colagiuri and colleagues' report fails on all three 
counts" (1992: 301). As a result, they concluded that the study was of little help to the 
human insulin debate. Colagiuri et al. responded by arguing that Egger and Davey 
Smith, "... make spurious comments on the design of our study and inappropriate 
reanalysis of our data" (1992b). 
Such comments can be seen as typical rhetorical moves in scientific controversies 
(Collins, 1985). In addition to criticising the methodology of a study, the criticisms 
are directed towards the credibility and authority of an individual author. Similar to 
above, when Dr. Kiln (1992) dismissed the study by Colagiuri et al. (1992a) as 
`worthless', due to serious flaws in the design of their study, they replied: 
"Mr R Kiln dismisses our study on insulin species and awareness of 
hypoglycaemia as worthless. Kiln's comments reflect a less than careful 
reading of our paper. " 
(Colagiuri et al., 1992c: 957) 
Other responses would state the current state of the controversy. Again, this should be 
seen as a kind of attempted rhetorical closure. For example, Von Kriegstein argued 
that: 
"... Colagiuri's study should neither end the scientific debate, nor end the need 
for porcine insulin to be kept available for our patients who, we remain 
convinced, have difficulties with human insulin. " 
(Von Kriegstein, 1992: 302) 
In 1992, an editorial (Gerich, 1992) and a pair of discussion papers (Egger et al., 
1992; Williams and Patrick, 1992b) were published in the British Medical Journal. 
As may be evident so far, the authors Egger, Davey Smith and Teuscher were 
frequently having material published in the scientific press concerning problems on 
human insulin. Similarly, but to a lesser extent, Williams and Patrick frequently had 
articles published in which they claimed that human insulin did not have any negative 
effects. Therefore, the publication of these two discussion papers is interesting since 
it puts the `for and against' groups in a space in which they can easily be compared. I 
should point out that the formulation of two sides in human insulin debate is not just 
mine, but was quite prevalent in the scientific and medical media (Patrick and 
Williams, 1992). 
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No new evidence was presented in either of the discussion papers. Rather, each paper 
reviewed other studies that had been carried out in order to assess whether human 
insulin had any negative effects. They came to the following conclusions: 
"... a different symptom pattern seems to exist in at least one important group of 
adult insulin-dependent patients - those with tight glycaemic control and a 
history of diabetes of several years. " 
(Egger et al., 1992: 354) 
"In our opinion the balance of available evidence does not suggest that human 
insulin specifically impairs perception of hypoglycaemia symptoms or that its 
use predisposes to severe hypoglycaemia. " 
('Williams and Patrick, 1992b: 356 
So, although both sets of authors had the same material to review, since they were 
published at the same time, they came to different conclusions. From the outset the 
two groups of authors came from different stand points, indeed, this is probably why 
they were chosen. There are however a number of differences in the content of the 
two papers. 
The paper by Egger et al. (1992) provides a comprehensive review of the studies that 
had already been carried out. They argued that, from their reading, a number of these 
studies had shown that human insulin does act differently compared with animal 
insulin. In particular, they point to a change in the symptoms of hypoglycaemia. The 
review by Williams and Patrick (I 992b) points more to other possibilities, such as a 
diabetic's change to tight glycaemic control, which may have occurred at a similar 
time to the transferral to human insulin; Williams and Patrick point to the complexity 
of diabetes in general, rather than human insulin. 
There were however some points of agreement. The authors of the two discussion 
papers agreed that future studies should be aimed at those who have experienced a 
change in the warning signs of approaching hypoglycaemia, which have returned 
when patients were transferred back to animal insulin. The papers also reiterated that 
those patients who experienced problems on human insulin, and wished to change 
back to animal insulin, should be able to do so. 
Another point of agreement was that both sets of authors proposed the need for a large 
multicentre randomised trial (Gerich, 1992). However, the specifics of such a trial 
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were not outlined. One important criterion would be the size of the study. Egger et 
al. talk of a study of `adequate size', while Williams and Patrick defer the decision of 
the size and duration of the study to the statisticians. On the other hand, John Gerich, 
the author of the editorial, rejected the need for a large trial. Instead, he argued that 
the study by Colagiuri et al, which showed "no statistically significant differences 
between insulin species" (1992a: 1432), should be repeated, as their "combined power 
could exclude a clinically important effect" (Gerich, 1992: 325). From looking at 
articles in the scientific media it does appear that 1992 was a period when there was a 
great deal of interest in the outlining of an ideal study. Since this is an important part 
of any attempt to scientifically close the human insulin debate, I have dealt with issues 
concerning the `ideal study' in a following section (5.3.3 The Ideal Study). 
In 1995 a new study was carried out by Meneilly et al. (1995), that looked at the effect 
of human insulin on non-insulin dependent diabetics. This study is important because, 
although human insulin had been administered to healthy subjects and diabetics, it had 
not been given to non-insulin independent diabetics. This study then, had the 
possibility to extend the human insulin debate into a different area (Amiel, 1995). 
The study found that "... beef/pork insulin results in greater awareness of 
hypoglycemic warning symptoms than does human insulin in elderly patients with 
NIDDM" (Meneilly et al., 1995: Abstract). Indeed, these results were similar to many 
others in the debate that showed a difference in symptoms of hypoglycaemia on 
human insulin. 
As part of the review of the study by Meneilly et al, Amie! (1995) considers some of 
the literature on human insulin in general. She argues that the majority of formal 
investigations have shown that human insulin does not specifically alter the 
psychological responses to hypoglycaemia induced in a laboratory setting. In terms of 
clinical practice, she also argued that there seemed to be no increase in the frequency 
of severe hypoglycaemia. 
In the editorial Amiel also asks the question: Is the debate now to be rehearsed for 
patients with NIDDM? (1995: 258). She points out that due to a number of reasons, 
such as the treatment period being rather short, the clinical significance of the study 
was not clear. This is especially the case since a large number of studies on insulin 
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dependent diabetics have shown conflicting results. Indeed, Amiel calls for another 
similar study to be conducted where preceding glycaemic experiences of the patients 
is known, and so can be compared over the study. 
In this section I have illustrated how attempts to close the human insulin debate by 
clinical trials have largely failed. As each study was published, various criticisms 
were lodged (Figure 5-3). However, as each new study was carried out it was hoped 
that it would improve on previous studies. Indeed, looking at the criteria by which 
subjects were selected, we can see that they were narrowed down from an unselected 
population, consisting of diabetics with a long duration of diabetes, to one where 
subjects were selected because they claimed to be experiencing problems on human 
insulin. This is important because long duration of diabetes has been shown to reduce 
a diabetic's awareness of approaching hypoglycaemia. As a result, by including such 
a sub-population in a study, it would not be possible to assess whether the occurrence 
of hypoglycaemia unawareness was due to human insulin or to a long duration of 
diabetes. 
In the next section I will look at other explanations for the experiences of some 
diabetics on human insulin. Here, the issue is no longer whether human insulin is, or 
is not, the cause of the negative experiences of diabetics. Rather, the focus shifts to 
other areas of the network body, such as therapeutic changes. 
5.3.2 Other Possible Causes 
In this section I would like to look at claims for other possible reasons for the effects 
experienced by diabetics on human insulin. These are factors that have already been 
shown to affect the perception of hypoglycaemia. What will emerge are the 
difficulties in apportioning blame to human insulin. Indeed, since one of the 
symptoms exhibited by some on human insulin is an unawareness of hypoglycaemia, 
it is important to realise that an estimated 1.5% of diabetics lose awareness of 
hypoglycaemia each year under `normal' circumstances (Colagiuri et al., 1992a; Gale, 
1989). 
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Summary of other possible causes of a perception of increased severe hypoglycaemia 
or hypoglycaemia unawareness 
" One hypoglycaemic episode may prejudice responses to subsequent episodes. 
" Part of the `natural' biography of diabetes. 
" Perception of hypoglycaemia can be dulled by alcohol and medications. 
" Tight glycaemic control may increase the chance of hypoglycaemia. 
" Perception of hypoglycaemia is notoriously difficult. 
Figure 5-5: Summary of causes of hypoglycaemic 
For those who believed that human insulin was not to blame there were many other 
possible causes for the change in awareness (see Figure 5-5). Indeed: 
"It could be argued that hypoglycaemia is fairly common in insulin dependent 
diabetes, whatever the treatment, and that on a few occasions patients could well 
attribute a chance increase in hypoglycaemia to come recent therapeutic 
manipulation. " 
(Pickup, 1989: 992) 
In the past a number of changes in the management of diabetes have resulted in claims 
by patients that their hypoglycaemic symptoms had changed. Changes were noted 
when patients have switched from beef to pork insulin (Gale, 1989); when patients 
were changed from conventional animal insulins to highly purified animal insulins in 
the 1970s (Home, 1991); when insulin strengths were changed from U40 and U80 
insulin to U100 in the early 1980s35 (Pickup, 1989); with the introduction of insulin 
pump therapy (Home, 1991); and even changes in colour coding of insulin vials 
(Dejgaard, 1991). 
In many cases, at the time of transfer to human insulin, the chance was also taken to 
alter a patients management of diabetes. Many doctors and clinics implemented 
changes to a diabetic's routine; there were attempts to improve overall glycaemic 
control; intensified injection regimes were introduced; diabetics were encouraged to 
increase self monitoring of blood glucose concentrations; and, there was also a 
renewed program of diabetes education for patients. 
The importance of glycaeric control was shown in the Diabetes Control and 
Complications Trial (DCCT) where tighter glycaemic control was shown to reduce the 
chance of diabetic complications in later life (Drug and Therapeutics Bulletin, 1989). 
35 Pickup notes that the extent of any such change due to insulin strength is poorly documented (Pickup, 
1989). 
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However, these measures also increase the chance of low blood sugars occurring, and 
subsequently, there is an increased risk of hypoglycaemia (Lesser, 1989a). It has been 
suggested that strict control in itself can reduce the warning signs of hypoglycaemia, 
possibly by lowering the glycaemic threshold at which catecholamines are released 
(Arniel et al., 1987; Amiel et al., 1988; Pickup, 1989: 992). As noted above, one 
suggested cause for some of the negative effects experienced by some diabetics on 
human insulin was that human insulin reduced the release of neurotransmitters, such 
as catecholamines (Teuscher and Berger, 1987). 
Since the management of diabetes can be complicated, it is important to be aware that 
even slight changes in routines may affect the health of a diabetic. Pickup has argued 
that, "on a few occasions patients could well attribute a chance increase in 
hypoglycaemia to some recent therapeutic manipulation" (1989: 992). That is, a 
diabetic may devise a common-sense aetiology, based on knowledge of the change to 
human insulin (or any other therapeutic change). For example, in some studies no 
clinical difference has been found in patients who reported hypoglycaemia 
unawareness, although they themselves had attributed their unawareness to human 
insulin (Maran et al., 1993; Patrick et al., 1991). Also, in studies that showed no 
significant differences between human and porcine insulin, patients still remained 
convinced that human insulin interfered with their awareness of hypoglycaemia and 
chose to be treated with animal insulins (Williams and Patrick, 1992b: 356). 
It is also known that one hypoglycaemic episode may prejudice responses to 
subsequent episodes (Ovalle et al., 1998; Amiel, 1995: 258). Therefore, no matter 
what insulin is used, if a diabetic is already badly controlled, then human insulin will 
make little difference to the management of diabetes. Linked to this are the findings 
that hypoglycaemia unawareness is known to occur in diabetics as part of the general 
biography of diabetes. For example, as a feature of a diabetic's age, duration of 
diabetes and the presence of autonomic neuropathy (Drug and Therapeutics Bulletin, 
1989: 22). These are all factors that are part of the biography of diabetes, with or 
without human insulin. Therefore, any study that looks at hypoglycaemia 
unawareness must take into account the nature of the study population. Indeed, some 
studies were criticised because they did not exclude particular diabetic sub- 
populations, such as those diabetics with a long duration of diabetes (Teuscher and 
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Berger, 1987). 
On a much more general front, it is known that the perception of hypoglycaemia can 
be dulled by alcohol and other medications, such as beta blockers used for treatment 
of high blood pressure and angina (Williams and Patrick, 1992b: 355). Therefore, 
before apportioning blame to human insulin, it is important to consider a number of 
factors which may cause `hypoglycaemia unawareness'. Everett and Kerr (1994) have 
suggested a number of practical steps that should be taken before changing a diabetic 
back to animal insulin (Figure 5-6). 
Hypogly caenlia unawareness I 
Long duration of diabetes ------- Explanation and education 
Tight glvcaemic control --------- Relax glvcaemic targets 
Alcohol --------------------- Education 
Hypoglycaemia per se ---------- Education 
Frequent monitoring 
? Alter insulin regime 
'Change in insulin species ------------ ? Change back to 
animal insulin 
I Tn, caffeine 
Figure 5-6: Treatment options for patients who experience hypoglycaemia, but 
lack awareness of its occurrence 
One important finding that has an effect on apportioning blame to human insulin, is 
that when diabetics, who are experiencing problems on human insulin, are transferred 
back to animal insulin, the changes in the management of diabetes that they 
experienced on human insulin disappear. Teuscher and Berger in 1987 (1'987) found 
that for a "... substantial number of diabetic patients there is a substantial loss of the 
classical warning symptoms, which is reversible after transfer back to animal insulin 
despite improved diabetes control" (Teuscher and Egger, 1989: 1072). 
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Therefore, it has been argued that it is not the case that diabetics who have 
experienced negative effects on human insulin, have experienced chronic and 
irreversible unawareness of hypoglycaemia (Patrick et al., 1991; Maran et al., 1993). 
In such cases then, the argument would be that the experience of diabetics on human 
insulin, cannot be part of the biography of diabetes, i. e. due to the long duration of 
diabetes or a diabetic's age. Neither could it be due to a therapeutic change, as long as 
the same conditions exist before and after the transfer back to animal insulin. 
However, not all diabetics that were on human insulin and had experienced problems, 
and were then transferred back to animal insulin regained their original warning signs 
(Home, 1991). It has also been found that a loss of warnings of hypoglycaemia could 
be reduced over time on human insulin, what is known as desensitisation (Cranston et 
al., 1994). In another study, it was found that only a very small number of diabetic 
patients could identify the species of insulin that had been administered. This led the 
researchers to conclude that: 
"The fact that only two of 50 patients could do so [identify insulin species] is 
convincing evidence against a species effect on hypoglycaemia awareness. " 
(Colagiuri et al., 1992c: 957) 
This adds to some of the evidence outlined in the previous section that showed that 
studies of patients who have reported a change in the warning signs of approaching 
hypoglycaemia on human insulin, have not shown any scientific reason why this may 
happen (Patrick et al., 1991; Maran et al., 1993). This was my argument in the 
previous section: although scientific studies have suggested reasons why diabetics 
may have experienced problems on human insulin they could not be `proved'. 
It is also important to be aware that the perception of hypoglycaemia is problematic. 
There are a whole number of possible symptoms of hypoglycaemia and these vary 
between individuals (Figure 5-7). One study found that well educated and motivated 
patients wrongly judged that they were clinically hypoglycaemic in a quarter of 
episodes (Egger et al., 1991 c). There is then, a divide between what may be defined 
as clinically hypoglycaemia and what signs of approaching hypoglycaemia exist 
in 
practice. In day-to-day life it is a diabetic's experiences that will affect the way they 
conduct themselves. It is these experiences that will be the subject of Chapter 6. 
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Symptoms of mild to moderate hypoglycaemia may occur suddenly and can include: 
" sweating 
" dizziness 
" palpitation 
" tremor 
" hunger 
" restlessness 
" tingling in the hands, feet, lips, or tongue 
" lightheadedness 
" inability to concentrate 
" headache 
Signs of severe hypoglycaemia can include: 
" disorientation 
* unconsciousness 
" drowsiness 
" sleep disturbances 
" anxiety 
" blurred vision 
" slurred speech 
" depressed mood 
" irritability 
" abnormal behaviour 
" unsteady movement 
" personality changes 
seizures 
" death 
Figure 5-7: Signs of hypoglycaemia from Eli Lilly 
I hope that in this section I have indicated how the scientific assessment of whether 
human insulin is the cause of some of the problems exhibited by some diabetics has 
been problematized. It is not only the case that many of the studies that have been 
carried out have been criticised for their methodological flaws, there have also been 
claims that there are other possible causes of the relevant symptoms. In order to 
apportion blame to human insulin it would be necessary to filter out this noisy 
background; this can be very difficult (Williams and Patrick, 1992b: 355). One 
attempt to do this was through the discussion of an ideal study. This discussion is 
interesting because it involves both sides of the human insulin debate, who discussed 
the structure of a possible study before it was carried out and published, rather than 
after publication, as is usually the case. 
5.3.3 The Ideal Study 
With all these problems then: What is the ideal study? Further, if there is an ideal 
study: Why has not it been carried out? As already described there are a number of 
problems in assessing the possible negative effects of human insulin, such as the 
selection of subjects, methodology used, and the applicability of results in clinical 
practice. Although, as Williams and Patrick point out, "previous work has been useful 
in identifying important pitfalls which must be avoided in future [studies]" (1992b: 
356). 
As already mentioned, two main hypotheses need to be tested when looking at 
possible negative effects of human insulin. The first, is that human insulin impairs the 
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warning signs of hypoglycaemic symptoms. The second, is that human insulin 
increases the risk of severe hypoglycaemia. It has been argued that previous studies 
have not been powerful enough to test one or both of these hypotheses, and have thus 
not produced valid conclusions (Williams and Patrick, 1992b). During 1991/92 there 
was a large degree of interest in outlining what would be the ideal study by which 
some resolution of the human insulin controversy could be achieved, and this is where 
my attention now turns. 
Discussion of the ideal study was not just restricted to the medical and scientific 
community. The BDA also looked into what the ideal study would be. They asked 
the question: Why don't scientists get together and carry out one big study to sort the 
problem out once and for all? (Balance, 1992a). As part of the BDA's Loss Of 
Warnings (LOW) Task Force, which was set up in 1991 to look into and clarify issues 
around human insulin (Balance, 1991 b), a special workshop was organised to consider 
the feasibility of carrying out a large scale study. 
The BDA point out that one of the factors that has added to the confusion over human 
insulin, is the inability of scientists to decide clearly whether or not human insulin is 
in any way to blame for the loss of hypoglycaemia warnings (Balance, 1992a). 
Although many studies have been carried out to compare the way diabetics react to 
human and animal insulin in terms of warning symptoms, these studies have usually 
been small in scale. As already mentioned, some of these studies have shown that 
there is a difference, while others have shown that there is no difference between 
animal (especially pork) and human insulin. The BDA suggest that there are two 
main reasons, which I have already indicated above, for the inconclusive results over 
the possible negative effects of human insulin: 
" Warning symptoms are very personal and vary between diabetics, as a result, 
they are difficult to measure. 
" There are many possible reasons for experiencing a loss of warnings of 
hypoglycaemia. 
So what type of study should be conducted to deal with these problems? 
There 
appeared to be a general acceptance that the hypotheses that human insulin 
increases 
the frequency of severe hypoglycaemic episodes could only be tested in field studies 
(Williams and Patrick, 1992b: 356). It had been argued that field studies would be 
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necessary since `one off laboratory studies are not powerful enough, due to individual 
differences, to detect a genuine effect. But if this is the ideal study, there are still a 
number of questions that need to be answered. 
One of the crucial factors in any study is the selection of subjects. It had been 
suggested that the selection of diabetics should be restricted to those diabetics who 
had experienced problems on human insulin, and when returned to animal insulin, 
their awareness returned (such as that by Colagiuri et al. (1992a)). This would reduce 
the number of subjects that would be needed if taken from an unselected population, 
since the selection would be based on those very subjects that were exhibiting 
problems on human insulin, and not as part of the `natural' biography of diabetes. 
Another problem is that there is already a `background' occurrence of severe 
hypoglycaemia. On any type of insulin species, the average number of diabetics 
having a severe hypoglycaemic episode is estimated at about 5% each year (Balance, 
1992a). Looking at new cases of hypoglycaemia unawareness, Gale has argued that if 
100 patients were followed for 20 years, 30 patients would be expected to develop 
signs of hypoglycaemic unawareness -a rate of 1.5 per year. If 100,000 patients 
switched to a new insulin preparation, 1500 can be expected to develop altered 
symptoms, even if the new insulin was blameless (Gale, 1989). Therefore, any study 
would have to be able to look beyond this background rate of hypoglycaemia. 
Background rate of severe hypoglycaemia 
per annum (%) 
Size of study Size of year 
follow up 
1 6200 3100 
5 1160 580 
10 540 270 
Figure 5-8: Size needed to detect a doubling of the risk of severe 
hypoglycaemia 
It has been argued that for a study to pick up a small increase in hypoglycaemia, say 
from about 5% up to 6.25%, would require 10,000 insulin dependent volunteers, if 
they could be found (Balance, 1992a). Earlier in 1988, Egger et al. (1988) had also 
looked into the size of any possible study. They considered the number of subjects 
that would be needed to detect a doubling of the risk of severe hypoglycaemia when 
assuming 5% (1 %, 10%) of unexposed patients, having at least one episode per year 
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(see Figure 5-8). 
Although Egger et al's figure is not as large as that of the BDA (since this was for an 
unselected population), it is still a large figure. Such large numbers of subjects are 
needed due to the background rate of severe hypoglycaemia experienced by diabetics. 
Indeed, even the background rate of severe hypoglycaemia is not certain. Balance 
claimed it is 5%, while others have claimed that it is 10% (Egger et al., 1988; Gale, 
1989). In an overview by a group of scientists, the estimated frequency of severe 
hypoglycaemia in daily life ranged from 4% to 29% (Amiel et al., 1991). 
Williams and Patrick argued that because of the rarity of patients, who matched their 
criteria (those suffering from hypoglycaemia unawareness which abated after 
transferring back to animal insulin), it may be necessary to carry out a multi-centre 
survey (1992b). Although they do not give an idea of the size of such a study, they do 
say that: 
"No doubt the statisticians, who have been vocal in the debate so far, will be 
able to give precise details of the necessary size and duration of such a study. " 
(Williams and Patrick, 1992b: 356) 
The BDA agreed that multicentre field studies would be needed. However, they were 
more precise over its details. I have already pointed out that the BDA believed that 
they would need 10,000 diabetics, although again, it should be noted that these 
subjects would be from an unselected population. The BDA point to a number of 
logistical problems with such a study: 
" Estimated that it would need to be a 3-5 year study. 
" Data would have to be analysed in over 100 centres, with a person employed 
in each centre. 
" Both on practical and ethical grounds it would not be possible to carry out 
the study in the UK (or Australia). 
" The cost of carrying it out in North America or Asia would be high. 
" One possibility would be Eastern Europe, however in this part of the world 
health care is generally poorer. 
" Estimated that it would cost a minimum of £ 1.5 million to carry out the 
study, over half the BDA's annual research budget. 
The BDA and the LOW Task Force concluded that such a study would not be 
possible, and that even if it was, the current cost would make it impractical (Balance, 
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1992a). 
Some have also argued that the "manufacturers who profit from the sale of human 
insulin should fund this enterprise: this is surely an ethical imperative. " (Egger et al., 
1992: 354). However, the pharmaceutical companies were not keen to do this. In 
another article, Egger and Davey Smith point out that it is up to those who propose a 
therapeutic change, in this case the pharmaceutical companies, to demonstrate the 
complete safety of what they propose before it is implemented (1992). This had been 
done, at least to the satisfaction of the regulatory bodies. 
Egger et al. (1988; 1992) argued that there was a need for a large randomised trial of 
adequate size. 36 Although small scale studies had been carried out, they had not been 
specifically designed to test for an increased risk of severe hypoglycaemia (Egger et 
al., 1992). The trial would need to be a randomised double-blind trial, with carefully 
constructed questionnaires and case control studies, with the aim of determining the 
relative risk of severe hypoglycaemia and human insulin (Egger et al., 1988). 
Williams and Patrick also stressed that the study would have to be `blinded' in some 
way. They argued that: 
"Because of general awareness of the debate and (regrettably) the possible 
motive of compensation claims insulin species can now be compared only under 
at least single blind conditions. " 
(Williams and Patrick, 1992b: 356) 
However, there was not total agreement that a multi-centre study would be needed. 
John Gerich argued that many studies have shown there to be no clinically significant 
differences between human and porcine insulin. As a result, he questions the need for 
an expensive large scale multicentre study (1992). Instead, he argues that the 
double 
blind crossover trial carried out by Colagiuri et al. (1992a) should be repeated. 
The 
study by Colagiuri et al. consisted of 50 diabetics who had been selected because they 
had reported reduced awareness of hypoglycaemia after transferring to human 
insulin. 
The group found that human insulin did not reduce the risk of hypoglycaemic 
unawareness, neither did it increase the incidence of severe hypoglycaemia. 
Although 
this study was criticised on a number of levels (see Teuscher, 1992; Von Kriegstein, 
36 This was also recommended during a symposium on human insulin and hypoglycaemia in Munich 
in 
1990 (Von Kriegstein, 1992). 
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1992), Gerich argued that with an additional study, with a design identical to that used 
by Colagiuri et al, "their combined power would exclude a clinically important effect" 
of human insulin having negative side effects (1992: 325). 
Indeed, it was argued by some that a large study would not be needed since, according 
to Dr Matthias Egger and his team, unawareness of hypoglycaemia was a common 
occurrence. As Patrick and Williams argued: 
"If affected patients are as common in Switzerland as the work of the Berne 
group suggest the group should be able to test its hypothesis easily in a 
rigorously controlled setting, rather than simply adding to the existing confusing 
reports. " 
(Patrick and Williams, 1991: 1266) 
In summary then, there was interest in looking at the ideal study from both sides of the 
human insulin debate. Since previous studies could always be criticised on a number 
of points, such as the selection of subjects or the assessment of hypoglycaemia, there 
was discussion over the organisation of the ideal study. However, all researchers did 
not agree on the size or method of this ideal study. As a result an `ideal study' was 
never carried out, although as shown above, many studies were carried out after the 
main interest in outlining the `ideal study'. 
5.3.4 Some General Strands 
In this final section I would like to make some general comments on how the 
scientific community perceived the human insulin debate. As with many scientific 
debates, issues do not simply remain in one area, in this case human insulin. Some 
have argued that the debate over human insulin has helped to illustrate the problems 
with hypoglycaemia (Teuscher, 1992; Wolff, 1992). It has been argued that due to the 
human insulin debate, a lot more has come to be known about diabetes, 
hypoglycaemia unawareness, and human insulin, than would have been the case 
otherwise. 
On the other hand, some authors felt that the human insulin debate was drawing 
attention away from other areas of the management of diabetes. Colagiuri and 
colleagues argued that the "continuing focus on insulin species distracts attention 
from 
the serious clinical problem of hypoglycaemia unawareness. " (1992b: 303). Gale 
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argued that the "real problem is the inadequacy of current insulin therapy, not the 
insulin species in use" (Gale, 1989: 1266). Another concern was over the image that 
the development of human insulin gave to diabetics. As Sonnenberg and Berger 
argued 
"... there is a risk that the mere change to human insulin might lead some 
physicians and patients to the superficial and wrong impression that everything 
possible has been done to optimise the treatment of diabetes... " 
(Sonnenberg and Berger, 1983: 458) 
As should be evident in the above sections, there were continual attempts to `limit' the 
effect of a particular study. By this I mean that when a study was published scientists 
criticised particular elements of the study, such as the selection of subjects, treatment 
periods, or the statistical tests that were used. Some editorials were also criticised in 
this way. After the publication of an editorial concerning human insulin in 1992 
(Wolff, 1992), which had the general tone that the human insulin controversy was to 
some extent `created', one subsequent letter argued that "we are still sitting on a 
human insulin timebomb" (Kiln and Sugarman, 1992 : p. 10). This led Williams and 
Patrick, in reply to Kiln and Sugarman, to argue that: 
"... it is now time to turn attention to the many other pressing problems of 
diabetes. Kiln and Sugarman are worried that `we are still sitting on a human 
insulin timebomb'. If they listen carefully, they may well discover that this 
particular timebomb has stopped ticking. " 
(Williams and Patrick, 1992a: 355) 
Some authors, who were sceptical of any possible case against human insulin, were 
accused of being in the pay of human insulin manufacturers (Wolff, 1992: 376). On a 
wider level, reports in the medical press have made some strong claims. Home argued 
that some journals encouraged the controversy by giving space to articles about the 
controversy with the aim of serving their "own interests before those of patients and 
the medical community" (1991: 799). In particular, Home points to the Lancet: 
"Even journalists and media commentators have been led to ask whether some 
of the heavily criticized contributions in the field, and in particular the self 
evidently unscientific study which began the controversy, should have been 
published in reputable medical journals at all. " 
(Home, 1991: 799) 
Throughout the debate various groups attempted to claim some form of closure in the 
184 
5.3 Scientific community 
human insulin debate. On the one hand, reports from authors such as Arthur Teuscher 
and Matthias Egger, showed that human insulin did cause some change in the warning 
signs of hypoglycaernia. On the other, studies showed that human insulin did not 
impair a diabetics control of their diabetes. Instead, a diabetic's experience on human 
insulin was seen to be due to a parallel change in the management of diabetes or to 
some part of the `natural' biography of diabetes. 
As usual in scientific controversies, closure was attempted through the use of 
rhetorical criticisms or claims. As outlined above, some authors were criticised for 
their lack of understanding of the methods used in a particular study or due to their 
less than careful reading of the study. In other cases, some authors claimed that the 
controversy was still open or closed, without necessarily fully supporting their claim. 
Although there was no agreement between the two sides of the debate, over the 
possible side effects of human insulin, there was agreement that those diabetics who 
wished to change back to animal insulins should be able to do so. Studies had shown 
that when diabetics, who had claimed to have experienced problems on human 
insulin, were transferred back to animal insulin their awareness returned (Patrick et 
al., 1991; Colagiuri et al., 1992a). There was therefore a general agreement that 
animal insulins should be available for those diabetics who wished to change back to 
them (Maran et al., 1993: 171: Figure 5-4). Obviously then, those within the scientific 
community supported the availability and choice of different insulin species. 
Therefore, although scientifically no `proof could be demonstrated either way, and no 
clinical consensus reached, the scientific and medical community did reach general 
agreement that animal Insulins should remain available for those diabetics who 
wished to remain on animal insulin (Egger et al., 1992: 354). 
In Chapter 7I intend to bring some of the issues discussed above together, while 
referring to theoretical work. In particular, I am interested in the ways in which 
scientists attempted to `close' the human insulin controversy, both on a scientific 
(clinical studies) and non-scientific (rhetorical claims) level. The scientific 
community were attempting to define the grounds under which closure would be 
achieved, whether this was through an experimental study or the continued availability 
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of animal insulin. Those scientists attempting to do this can be seen as being part of 
the core set (Collins, 1985). However, other groups were attempting to enter this core 
set. These included pharmaceutical companies and care groups. This complicated 
matters, since these other groups were competing with others to define the grounds 
under which closure of the human insulin debate could be achieved. These grounds 
may not be the same for all groups. One complication was the involvement of the 
pharmaceutical companies, and this is where lny attention now turns. 
5.4 THE PHARMACEUTICAL COMPANIES 
As argued in Chapter 3, describing the commercial development and production of 
human insulin, the pharmaceutical companies were able to pass human insulin 
through regulatory bodies relatively quickly. I argued in Chapter 4 that one reason for 
the mass transfer of diabetics from animal to human insulin was due to pressure from 
the pharmaceutical companies. The pharmaceutical companies argued that there were 
benefits to patients in using human insulin, usually because of the claimed reduced 
immunogenicity of human over animal insulin. 
However, the choice by doctors and pharmacists between animal and human insulin 
could not always be made on a `level playing field', since some animal insulins were 
being withdrawn. The withdrawal of some animal Insulins occurred in parallel with 
the introduction of human insulin. As early as 1986, it was announced that beef 
Ultratard was to be withdrawn (Balance, 1987a: 5). In December 1986, Novo 
Laboratories announced that they were replacing two of their Monocomponent (MC) 
pork insulins with human equivalents (Balance, 1986: 4). 
The BDA warned that although Novo Laboratories were the first pharmaceutical 
company to discontinue animal insulins, and replace them with a human equivalent, 
they would not be the only ones to do so. Balance believed that diabetics had to 
accept that some insulin manufacturers were going to standardise their insulins 
because it made commercial sense (Balance, 1986: 4). The BDA's medical advisor 
wrote: 
"... it is likely that all manufacturers will `rationalise' their Insulins to human 
only in the near future, and we have no choice but to accept this. " 
(Balance, 1986: 4) 
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Although pharmaceutical companies' strategy of withdrawing animal insulins 
continued through the 1980s and into the 1990s, the reasons behind the marketing of 
human insulin, and the withdrawal of animal insulins, did seem to change. Gale has 
argued that, as the lack of a clear benefit of human insulin, especially its 
immunogenicity, over purified animal insulins (especially porcine insulin) became 
apparent, claims by pharmaceutical companies for the superiority of human insulins 
were quietly dropped (1989). The argument then became one in which, since both 
human and porcine insulins were so very similar, porcine insulin was no longer 
needed (Gale, 1989). 
So was it the case that pharmaceutical companies argued that human insulin did not 
cause noticeable side-effects in diabetics? One way in which this can be gauged is 
through patient information leaflets. Since original studies showed that human insulin 
was `safe and efficient', no warnings were originally placed on human insulin patient 
information leaflets. However, it has been noted that warnings appeared as early as 
1983 on Eli Lilly human insulins that were marketed in the United States (Dejgaard, 
1991). These warnings alerted diabetics to possible changes in the signs of 
approaching hypoglycaemia (Drug and Therapeutics Bulletin, 1989). 
In the United Kingdom there were initially no such warnings. This led Teuscher and 
Egger to write: 
"... we are disturbed that insulin manufacturers have not yet produced more 
precise information on this important issue [the change in warning signs] in the 
inserts of their human insulin packages, both for physicians and diabetic 
patients. " 
(Teuscher and Egger, 1989: 1072) 
However, as concern began to grow in the United Kingdom, pressure was exerted on 
the pharmaceutical companies to put some warning on their human insulins. In 
August 1989, Nordisk Wellcome in Britain, announced that they were to introduce 
warnings with the marketing of their new genetically engineered human insulin (see 
Figure 5-9. Taken from Novo Nordisk). Nordisk said that the warnings followed 
discussions with the Committee on the Safety of Medicines (Lesser, 1989b: 22). 
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Changing to human insulin 
" You should only change to human insulin on your doctor's advice. 
" Transfer from porcine to human insulin of the same type, does not normally require a 
change in dose. 
" Transfer from bovine or mixed bovine/porcine insulins to human insulin may require a 
dosage adjustment; follow your doctor's advice on this. 
"A few patients have reported that after being transferred to human insulin, the early 
warning symptoms of hypoglycaemia were less pronounced than they were with animal 
source insulins. 
Figure 5-9: Example of a Novo Nordisk human insulin insert 
The British Licensing Authority also wrote to all insulin manufacturers: 
"... suggesting that the patient leaflets and the data sheets for human insulin 
should contain a specific warning that some patients have noticed less 
pronounced symptoms of hypoglycaemia on transferring to human insulin from 
animal insulin. " 
(Pickup, 1989: 993) 
All manufacturers made this change in their insulin packaging, which the BDA 
welcomed (Balance, 1989a). However, Frank Lesser pointed out that it was unclear 
whether diabetics themselves would be aware of the warnings. He argued that many 
pharmacists remove manufacturers inserts before passing the insulin on to diabetics. 
He also argued that the leaflets seemed to be aimed more at specialists than at patients 
(Lesser, 1989b: 22). 
Although the BDA initially accepted the withdrawal of a number of animal insulins, 
in 1994 the BDA began a campaign to maintain choice for diabetics as to the species 
of insulin they wished to use. They collected 140,000 signatures that were then 
presented to three UK insulin manufacturers in September and October 1994 (Hope, 
1994). The aim was to ensure that animal insulins were made available indefinitely, 
and to secure the availability of animal insulin pen devices. 
The Insulin Campaign petition was presented to Novo Nordisk on the 29th of 
September 1994. Novo Nordisk reiterated their commitment to animal Insulins into 
the next millennium, indeed, they pointed out that new investment was being made to 
ensure this. They also stated that this did not mean that animal insulins would be 
discontinued after the year 2000, rather, no indefinite commitments could be made. 
With regard to pen devices, Novo Nordisk said that they had no plans to produce 
porcine insulin pen cartridges as it was not economically viable to do so (Hope, 1994). 
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The petition was presented to Eli Lilly Industries on the 13 th of October. Eli Lilly 
have never marketed animal Insulins in the UK, but expressed their support for a 
choice of insulin species for diabetics. However, they pointed out that more than 80% 
of insulin users were on human insulin, which had been proved scientifically, to be 
safe and effective. As to the future, they said that they had no plans to apply for an 
animal insulin product licence, but would keep the situation under review (Hope, 
1994). 
On the 26th of October the petition was presented to CP Pharmaceuticals Ltd who only 
manufactured beef insulin, after having recently discontinued the production of human 
insulin for commercial reasons. They made a substantial commitment to the ongoing 
availability of beef Insulins (Hope, 1994). So while other companies were 
withdrawing their animal insulins, CP Pharmaceuticals had withdrawn their human 
insulin. CP Pharmaceuticals were therefore becoming a specialist in the market of 
animal insulin production. 
One important point in the withdrawal of animal Insulins was Novo Nordisk's insulin 
`Simplification Programme'. The Simplification Programme aimed to reduce 
confusion that occurred due to the merger between two Danish Companies, Novo and 
Nordisk in 1989, to form Novo Nordisk. When these companies came together they 
kept all their insulins, which led to a duplication in many insulins. 
The programme consisted of two phases. The first phase began in 1995, with the 
second beginning in April 1996. When the BDA became aware of the simplification 
programme they began discussions with Novo Nordisk to gain a number of alterations 
in the programme. 
The first phase is not of great interest to this thesis, since it only concerned the 
withdrawal of some duplicate human insulins. However, it should be pointed out that 
the BDA managed to: lengthen the timetable of implementation of the changes; 
improve the content of information provided to diabetics and health care professionals 
concerning the changes; and, set up a telephone helpline to deal with queries (Balance, 
1995: 42). 
In April 1996 Novo Nordisk announced the second phase of their simplification 
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program, in which the naming of some insulins would change and some insulins 
would be withdrawn. The BDA said that they were particularly concerned that other 
such commercial decisions may be made, even though only a year ago the BDA 
gained a commitment from the company that they would continue to produce animal 
Insulins (Balance, 1996). Again, the BDA had meetings with Novo Nordisk and 
gained a number of assurances: 
" They would continue to produce their `core group' of animal insulins as long 
as there was demand. 
" They would re-invest in an animal insulin manufacturing plant. 
" Clinical trials would be conducted in different parts of the country looking at 
the switch from the discontinued insulins. The data gathered would be used 
to help others make the change in the future. 
The renaming of some animal insulins, where they had human equivalents, took place 
in April/May 1996. Patients were warned of the forthcoming change through a flash 
on the insulin packaging, and after the change, the insulin had different packaging to 
reflect the change. The production method of two of these insulins was also going to 
be changed, and patients were advised to carry out more frequent blood glucose 
testing (Balance, 1996). 
Those insulins that were withdrawn were two of Novo Nordisk's lesser used MC 
animal insulins. The packaging of these insulins incorporated a flash saying that they 
would not be available after September 1997. Novo Nordisk was also carrying out 
studies to find an appropriate alternative (Balance, 1996). 
In 1997 CP pharmaceuticals announced that they were extending their range of animal 
insulins, to include cartridge administered ones (to be used with pen devices). The 
BDA claimed that this was a major victory for them (Balance, 1997). CP 
pharmaceuticals were not only going to produce some of their existing bovine insulins 
in cartridge form, but also some new porcine insulins. I will return to this in Chapter 
6. 
The campaign by the BDA had aimed to ensure the availability of animal insulins and 
to ensure that animal Insulins were available in pen devices, to some extent then, this 
campaign had been successful. CP Pharmaceuticals said that they were committed to 
supplying animal insulin in vials and cartridges indefinitely. 
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In conclusion, there was a tendency for phannaceutical companies to withdraw a 
number of animal Insulins. However, CP Pharmaceuticals Ltd began to expand their 
animal Insulins and also developed animal insulin pen cartridges. Those producing 
human Insulins did include warnings on their human insulins, however some were 
concerned with the wording of these warnings. In general, the production and use of 
human insulin increased after its initial introduction. 
5.5 CONCLUDING REMARKS 
In this chapter I have looked at some of the issues that were of concern to the 
scientific community and pharmaceutical companies. Work carried out within the 
scientific community was unable to show whether human insulin was or was not the 
cause of changes in the awareness of, and number of, hypoglycaemic episodes. 
However, there was an agreement that those diabetics who wished to be transferred 
back to, or stay on, human insulin should be able to do so. 
Pharmaceutical companies wanted to maintain human insulin as the primary insulin. 
The two main players, Eli Lilly and Novo Nordisk, had withdrawn a large number of 
their animal insulins, and replaced them with human equivalents. CP Pharmaceuticals 
on the other hand, had increased the range of animal insulins that they were 
manufacturing and had invested heavily in animal insulins. 
There is then an element of choice. The scientific community argued that animal 
insulins should be available, and CP Pharmaceuticals were manufacturing animal 
insulins. I also pointed out that the other two pharmaceutical companies did support a 
choice of insulin species. However, these pharmaceutical companies were not going 
to provide the opportunity for choice themselves. I will return to the idea of `choice' 
in Chapter 6. 
There was some interaction between the scientific community and pharmaceutical 
companies, with one result being that the pharmaceutical companies had produced 
warnings on their human insulins about a possible change in the nature of 
hypoglycaemia. Other actors also had links with these two main actors. For example, 
the BDA had consulted with the pharmaceutical companies, and some patients did 
write to the pharmaceutical companies about their experiences. In Chapter 61 will 
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look at some of these other actors in more detail. 
It is in Chapter 7 that I will bring some of the key actors together under a theoretical 
framework. In particular, I will be interested in attempts by various groups to bring 
some form of closure to the human insulin debate. When I have dealt with issues 
from a patient centred point of view I will then be in a position to compare the 
differing attempts at closure, between those actors that may be defined as being 
institutionally centred and those being patient centred. 
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6. AFTER THE INITIAL REACTIONS - DIABETICS AND CARE 
GROUPS 
6.1 INTRODUCTION 
In Chapter 51 gave a chronological outline of some of the key moments in the human 
insulin debate. I then went on to describe in more depth some of the important 
moments in the human insulin debate from an institutionally centred point of view. In 
this chapter I would like to look at human insulin from the perspective of the patients. 
Rather than being interested in large organisations or communities, this chapter will 
look at what role patients and care groups had to play in the human insulin debate. 
I will first describe some of the experiences of diabetics on human insulin. I have 
already described some of these initial experiences in Chapter 4, but it will be helpful 
to summarise these experiences here in order to set the scene for future sections. 
Then, in Section 6.3 I will look at the role of two mediating actors, families and the 
media, and their role in the human insulin debate. The following section will look at 
the interaction between doctors and diabetics. In particular, I am interested in how 
solutions and resolutions, presented by doctors, were accepted or rejected by diabetics 
themselves. Section 6.5 will then go on to look at issues around the `choice' of 
insulin. Finally, in Section 6.6 I will compare the way in which the BDA and the 
IDDT approached the human insulin debate. 
6.2 SOME EXPERIENCES 
Before I go on to look at issues in the human insulin debate that can be seen as patient 
centred, I will first set the scene by recalling some practical experiences of diabetics 
on human insulin. 
Some diabetics described how, when transferred to human insulin, they no longer felt 
that they were in control of their diabetes. I described in Chapter 4 how some 
diabetics found that on human insulin they no longer had the usual warning signs of 
approaching hypoglycaemia. A number of diabetics described how these changes, in 
the management of their diabetes, had a detrimental effect on the conduct of everyday 
life. Diabetics described how it was only due to paramedics, neighbours, family 
members and the casualty department at the local hospital that they did not suffer 
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detrimental effects on human insulin (Balance, 1991 d). 
The experience of diabetics on human insulin therefore affected a number of areas of 
their social life. For example, one diabetic describes how: 
"... since starting on Human Monotard Insulins around 1986, I have suffered 
many embarrassing and dangerous hypos, with doctors being called to treat me 
on several occasions. " 
(Balance, 1991 c) 
As a result of these problems, the diabetic describes how, when on an animal insulin 
mixture, he was employed in a position of responsibility, being able to manage his 
diabetes through an in-built `early warning system' of threatening hypoglycaemia. 
Due to problems on human insulin, he asked for, and was given, early retirement. His 
experiences were therefore impinging on his `normal' life (Balance, 1991 c). 
I described in Chapter 2 how those who have recently been diagnosed with an illness, 
in this case diabetes, come to a negotiated settlement over their illness. In this 
negotiated settlement, new relations are set up with doctors and family members, and 
with artefacts such as syringes. However, in times of `new' biographical disruptions, 
this newly configured network body comes to be questioned. Many diabetics 
described how a change in their diabetes not only affected their employment, but also 
their relationship with their families. Indeed, as Alexander has pointed out: 
"Hypoglycaemia, especially if it is severe or without warning, can be most 
frightening, and can threaten normal living and employment. " 
(Alexander, 1989: 156) 
There are plenty of examples of this from the diabetic literature, for example: 
"My memory loss has been particularly distressing because it affects my job. " 
(IDDT, 1995b: 5) 
"In my job, work with which I had been familiar for nearly ten years became a 
major task; as my memory began to fail, each piece of work required much more 
time as I had to spend so much time trying to remember how to deal with it. 
Not surprisingly, within a year, I was retired on ill-health grounds. By virtue of 
this I lost my home that I was buying and was forced to return to my parents'. " 
(IDDT, 1996c: 9) 
Another area that caused concern for diabetics on human insulin was driving. The 
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results from the BDA questionnaire (Redmond, 1988) of those on human insulin, 
found that a typical response to a change in the symptoms of hypoglycaemia, on 
human insulin, included the statement: 
"I find the lack of symptoms of hypoglycaemia a bit worrying, especially 
regarding driving, as I no longer get the early warning symptoms. " 
(Redmond, 1988: 67) 
Indeed, two respondents claimed to have been involved in road traffic accidents as a 
result of losing their usual warning signs of approaching hypoglycaemia (Redmond, 
1988: 67). In their original study, Teuscher and Berger described the case of a 
diabetic who had had a car accident while on human insulin, even through he had 
eaten half an hour before and so should not have experienced low blood sugar (1987). 
Others also stressed caution for diabetics who were on human insulin and drove (Drug 
and Therapeutics Bulletin, 1989). Indeed Pickup argued that: 
"It is particularly necessary to warn patients of the danger of hypoglycaemia 
while driving and remind them of the need for checking blood glucose 
concentrations before the journey and at about two hourly intervals during long 
periods of driving. " 
(Pickup, 1989: 993) 
In the following sections I will describe the ways in which diabetics sought to remove 
the uncertainty that existed around their problems on human insulin. In Chapter 5, I 
described this `reduction of uncertainty' from an institutionally centred point of view. 
I did not, on the whole, look at how the reactions, both physical and cognitive, to 
human insulin affected the practical management of diabetes. In this patient centred 
chapter, I will look at the ways in which patients attempted to bring some form of 
resolution to their problems on human insulin. Obviously, any attempt at resolving 
problems on human insulin involves interaction with the medical profession, and 
again we should refer to the schema in the previous chapter (Figure 5-1). 
6.3 MEDIATING OTHERS 
In this section I would like to look at the role played by two important groups in 
mediating the experiences of diabetics. Referring back to my schematic (Figure 5-1) 
we can see that the family and the popular media have a direct link to the patient. I 
also refer to care groups as a form of media in this section, since I will be talking 
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about the way information was passed from care groups to diabetics through 
newsletters and magazines. 
My interest here is in the way that these two groups mediated the experiences of 
diabetics. I am therefore interested in a number of questions: What role did carers 
play in the management of `another's' diabetes? Did family members notice a change 
in the symptoms of hypoglycaemia, while the diabetic did not? How did the popular 
media influence diabetics? What issues did the popular media bring up? How was 
the popular media `used' by diabetics to influence others? 
6.3.1 Family 
The IDDT point out that carers are observers in any change in the management of 
diabetes, and therefore, have an important role to play in the management of diabetes 
(1994). This is especially the case for changes in the warning signs of hypoglycaemia, 
since some of the symptoms (such as confusion) may inhibit the diabetic from being 
able to take notice of, and appropriate action to correct, approaching hypoglycaemia. 
In a number of cases, it was family members who noticed changes in diabetics. One 
letter printed in an IDDT newsletter says: 
"The real problem is that these conditions are subjective and gradual - meaning 
that a slow descent over many years appears quite normal. It is only when 
somebody remarks on this personality change `you were never like that before'. " 
(IDDT, 1995b: 5) 
Another letter, written by the mother of a diabetic in her early twenties, tells of how 
her daughter was getting more frequent episodes of hypoglycaemia and had become 
moody and depressed. Although the mother noticed these changes the daughter 
didn't. More importantly, the mother could not make her daughter to see that her 
personality had changed (IDDT, 1996c: 10). Another diabetic, through blood glucose 
monitoring, was aware that he was experiencing low blood sugar, however, he was 
unable to spot the warning signs himself, but his wife could. He writes: 
"Soon after changing to human insulin, however, I noticed the absence of those 
symptoms [clear warning signals of low blood sugar]. 
function quite normally on very low blood sugar levels 
spot my warning signals, I am unable to do so. " 
I seem to be able to 
. Although my wife can 
(Balance, 1991e) 
196 
6. After the initial reactions - diabetics and care groups 
A recurring theme in letters received by the BDA and the IDDT was that relatives 
noted that patients no longer recognised hypoglycaemia, and so did not report a 
change to their diabetic clinic. This led some to request that: 
"We would urge doctors to question relatives rather than rely on self reports 
when trying to decide whether a patient does or does not get adequate warnings 
of hypoglycaemia. " 
(Tattersall and Macdonald, 1989: 1338) 
As well as arguing that doctors should take notice of carers, it was also suggested that 
carers may be able to add to the scientific body of knowledge. One doctor suggested 
that: 
"Now that the validity of previous studies looking at problems experienced with 
human insulin have been questioned we must rely on the hundreds of case 
reports about human insulin from patients and their carers. These suggest that 
many patients have problems when using human insulin. The patients and their 
carers confirm an improvement when the patients change to animal insulin. " 
(Kiln, 1995: 1407) 
It can be extremely dangerous for a diabetic if they are not aware that they are 
approaching hypoglycaemia. In such cases the importance of `others' is even more 
dramatic. For example, a diabetic may feel that they are able to carry out normal 
activities, like drive and operate machinery, however they may actually be unable to 
do so safely. Indeed, this is one reason why Pickup stressed that diabetics should be 
warned of possible problems on human insulin, and encouraged to carry out more 
frequent blood glucose monitoring, especially when driving (1989: 993). 
The observations from others are not just important at particular times, such as 
approaching hypoglycaemia, but also in the long term. From observations of a 
diabetic, family members may encourage and motivate a diabetic to consult their 
doctor. Therefore, knowledge from family and friends can play an important role in a 
diabetic's understanding of their own diabetes. 
On a wider front, family and friends may come across information that they feel will 
be useful to the diabetic and/or their family. For example, a mother of a diabetic 
describes how a friend had telephoned her after watching an edition of Newsnight. 
The programme featured the IDDT, and described symptoms that mirrored those of 
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the daughter. In particular, it was the first time that the mother had heard of animal 
insulin (IDDT, 1995d: 7). Such information may also be useful in enabling `choice', 
since diabetics may become aware of what options are available to them. This is 
something that I will return to in a later section. 
As I will show in the next section, the media, especially the diabetic media, played an 
important role in collectivising issues around human insulin. 
6.3.2 Media 
Throughout the human insulin debate articles and news items were published in the 
popular media which described the problems experienced by some diabetics on human 
insulin. Some articles were concerned with the portrayal of the human insulin issue. 
One article, in The Independent, described how a diabetic smashed up his home, 
which was put down to being on human insulin (1991). However, a subsequent letter 
from a physician, argued that the article made a `serious factual error', in saying that 
those on animal insulin `invariably' retain appropriate warning signs. The letter 
further states that: 
"It would be wrong to suggest, as your article does, that the problem [lack of 
awareness of approaching hypoglycaemia] has come about solely as a result of 
the introduction of human insulin. " 
(Watkins, 1991: 18) 
There were other articles that caused distress. In 1992, an article was published in The 
Sunday Times entitled, `The Cure that Went Wrong' (Shannon, 1992). The article 
recounted the experiences of one diabetic who was on human insulin. In particular, 
the article alleged that the BDA was funded by major pharmaceutical companies, so 
wouldn't speak out about the problems. The BDA responded by pointing out that 
their funding comes entirely from legacies, donations, and fundraising efforts 
(Balance, 1994). 
A news item in The Sunday Times in 1995 linked the deaths of a number of diabetics 
with the use of human insulin (Rogers, 1995). Again the BDA responded, referring 
directly to the article, they wrote that they wanted to "reassure the very large number 
of people who may have been caused stress by the contents of this article" 
(Independent on Sunday, 1995). The statement and advert - Human Insulin - reality 
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and myths - was placed in a number of newspapers. The Sunday Times refused to 
include the advert, but they did include a letter from Michael Cooper, the BDA's 
Director General, which was an edited version of the advertisement (Cooper, 1995). 
The hope was that the advert would reduce the anxieties raised by The Sunday Times 
article. However, other letters in response to the original article, commented on the 
`infonnative nature' of the article (Norton, 1995), and that it highlighted an important 
issue (Hill, 1995). 
Letters and articles in the media made diabetics aware that their experiences of 
problems on human insulin were not isolated instances. This was especially the case 
for the IDDT. Many letters from diabetics, printed in the IDDT newsletter, described 
how they felt reassured after reading letters or articles in the newsletters. For 
example: 
"Dear Jenny [a member of the IDDT], Many thanks for talking to me on the 
telephone and for your useful Newsletters. It made me realise that I really had 
to do something about my diabetes... " 
(IDDT, 1995c: 10) 
"After reading your letter in our local paper I finally raised the courage to 
approach my doctor and he agreed to put me back on pork insulin. " 
(IDDT, 1996b: 11) 
"Dear Jenny, Thank you for your letter. I am pleased to say I've now benefited 
from changing back to pork insulin. I'm feeling much more comfortable and 
happy. Many thanks for your help and for the Newsletter which is most 
interesting and well put together. " 
(IDDT, 1996c: 11) 
"Dear Jenny, Thank you for all your newsletters. I could hardly believe my eyes 
when I read them because I now know that I am not making a fuss. " 
(IDT, 1997: 9) 
As can be seen from the above quotes, the IDDT also encouraged diabetics to take 
action over the symptoms that they were experiencing. In particular, the IDDT made 
constant reference to the Patients Charter. The charter states that patients have the 
right to be aware of alternatives and to a second opinion. In one letter, the mother of a 
diabetic tells of how, after speaking to the IDDT, she became aware that she had the 
right to a second opinion. After a second opinion, her child was changed to animal 
insulin (IDDT, 1995d: 7). 
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As should be obvious, there was frequent two-way contact between the media and 
diabetics, this was not only the case in the specialised diabetic media, but also in the 
popular media. Importantly, what I have tried to show in this section is that diabetics 
do gain their information from a number of sources, whether it be family and friends, 
or the media. Therefore, when a diabetic forms narratives about their experiences, in 
whatever context, they are drawing on a range of emergent sources and resources, 
such as biographical accounts and larger `factual' claims (grand narratives), that come 
from both the family and the media. These `other knowledges' may have an important 
impact on what choices are accepted by diabetics, in the resolution of problems on 
human insulin. It is this set of issues that I now wish to turn to. 
6.4 SOLUTIONS WITHIN MEDICAL PRACTICE 
As implied in Chapter 4, there are a number of responses that can be made by the 
medical profession in resolving problems exhibited by some diabetics on human 
insulin. Moreover, it is not just the resolution of problems by the doctor that is 
important, but also the acceptance of these resolutions by patients. In this section 
therefore, I am interested in the ways that individuals resolved the problems that they 
were experiencing on human insulin. The focus is in the ways that patients accepted 
or rejected solutions given to them by the medical profession. One of the important 
features here will be the possession of knowledge by diabetics, not just of their 
experiences, but also of the experiences of other diabetics. 
In the following sections I will describe some of the explanations and resolutions that 
were given to diabetics when they reported problems to their doctor, while on human 
insulin. By looking at these `suggested' resolutions, I also intend to bring out further 
some of the experiences of diabetics. I intend to look at the following resolutions: 
psychological explanations; the experiences were part of the `natural' biography of 
diabetes; a dose reduction would correct any problems; increased blood glucose 
monitoring would help the diabetic correct any problems; and, a change back to 
animal insulin would resolve the diabetic's problems. 
It is important to note that these `resolutions' should not be seen as being distinct from 
each other. In some cases one resolution may have been tried and may have worked, 
in other cases, many possibilities may have been tried. The resolutions that I will 
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describe should also not be seen as being in any particular order. Some diabetics, 
claiming a change in their symptoms of hypoglycaemia, may have been transferred 
back to animal insulin with little or no negotiation with the doctor. On the other hand, 
others may have had to battle hard to have their own wishes met. Again, one of the 
important features is the knowledge that is possessed by both the diabetic and the 
individual doctor. 
6.4.1 Psychological Explanations 
In some cases, when a diabetic reported problems on human insulin, their experiences 
were not put down to any feature of diabetes, but rather to a psychological cause. 
There were a number of complaints from diabetics that their experiences were being 
ignored (Balance, 1994). Indeed, there were a number of cases in which diabetics 
were told, after seeing their diabetic consultant or GP, that they "must have been 
imagining it [their unawareness of hypoglycaemia]" (Balance, 1991 a: 20. Also see 
IDDT, 1995a: 5). One mother describes the experiences of her daughter. After being 
prescribed human insulin the daughter experienced an increase in the number of 
severe hypoglycaemic episodes, and also a change in her personality. The mother 
writes: 
"After over nine changes of human insulin I was told `there is nowhere else to 
go' and we were advised that her problems were due to her hormonal changes 
and something she was doing - it was `suggested' she was drawing up large 
doses of insulin so she could eat chocolate in large amounts and that the 
aggression accompanying the hypo was pretence. " 
(IDDT, 1995d: 7) 
Such replies are interesting because they are neither based around the `natural' 
biography of diabetes, in which case the exhibited symptoms may `naturally' occur, 
nor are they put down to human insulin, in which case some change in the 
management of diabetes would be needed. Rather, they are directed at the individual, 
it is he/she that is to blame, rather than some other part of the body network. In such 
cases, resolution of the experiences of diabetes can not be carried out by a change in 
the management of diabetes, but rather to changes in some psychological facet of the 
individual. Indeed, in the case above, the whole family were sent off for 
psychological assessment (IDDT, 1995d: 7). 
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In the majority of cases however, reasons for, and resolutions of, the experiences of 
diabetics on human insulin were put down to causes within the management of 
diabetes. I will now look at a number of these resolutions in turn. 
6.4.2 A Part of the 'Natural' Biogfraphv of Diabetes 
One well known complication of diabetes is that the awareness of hypoglycaemia can 
diminish over time. In such cases then, the problem is not the insulin species, but 
rather, part of diabetes itself. One diabetic writes: 
"All I got from my diabetic consultant was `it's your age and you can't go back 
onto animal insulin'. " 
(Balance, 1991d) 
The important feature is the acceptance of diagnosis. In some cases a diabetic may 
accept these explanations and so adapt their own lifestyle to cope with these changing 
circumstances. 
A similar situation existed for newly diagnosed patients. Human insulin is generally 
accepted to be the standard treatment for newly diagnosed diabetics (Gale, 1989: 
1266). However, one of the concerns of the IDDT was that newly diagnosed diabetics 
may experience problems on human insulin, but accept it as part of diabetes (IDDT, 
1994). In such cases, a diabetic may not place their experiences as part of the 
`natural' biography of diabetes or due to some therapeutic change, but rather as part of 
diabetes in general. Although existing diabetics may have been aware that diagnosis 
of diabetes does not have to affect the way that they carry out their social life, newly 
diagnosed diabetics on human insulin may not be aware of this. To put it more 
simply, diabetics transferred to human insulin from animal insulin have past 
experiences to compare their current experiences with. Newly diagnosed diabetics on 
human insulin only have the experiences of being healthy to compare their current 
experiences with. For newly diagnosed diabetics, there may also not be an awareness 
of possible options that are available to them. The IDDT point out that some diabetics 
claimed that they were not aware that animal insulin existed (IDDT, 1995b: 8-9). 
Newly diagnosed diabetics may therefore lack the knowledge of the traditional 
warnings signs of approaching hypoglycaemia, and of the existence of animal insulins. 
These are all features of the network body for a long term diabetic. 
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Therefore, one of the criteria for the acceptance or rejection of a diagnosis, by a 
diabetic, may be the knowledge that is possessed by the diabetic. As I have already 
indicated, the family, help groups, and media play an important role in this. 
6.4.3 Dose Reduction 
Another suggested resolution was a reduction in dose. By reducing the amount of 
human insulin taken, compared with animal insulin, some problems on human insulin 
were reduced. One reason for this is that using animal insulins causes the body to 
produce insulin antibodies, which are specific to the insulin species. These antibodies 
reduce the efficiency of the specific insulin, and as a result, more of this specific 
insulin is needed. When diabetics change to another insulin species, in this case 
human insulin, there are no human insulin antibodies, and so the body has potentially 
more insulin than it needs. 
However, it has been claimed that early guidelines from Wellcome and Nordisk 
suggested that, "transfer of patients from Wellcome beef insulins to 
WellcomelNordisk human insulins [can occur] on a unit-for-unit basis, as advised in 
the promotional literature" (Turner et al., 1988: 1150; Pickup, 1989). This advice may 
have led to some confusion. 
However, Nordisk argued that the full guidelines suggest that: 
"(1) Most patients may be transferred on a unit-for-unit basis. Those who make 
dosage adjustments according to the results of blood or urine tests should 
continue to do so. (2) A minority of patients currently on a high daily dose of 
beef insulin ... may require 
dosage reduction. " 
(Harrison and Nick, 1988: 1305) 
As already noted, many studies have shown that a dose reduction would be necessary, 
especially for the more immunogenic bovine insulin (Gill and Jones, 1988). Some 
manufacturers suggested reductions by up to one fifth (Pickup, 1989). Yet there was 
still some concern. Manufacturers warned that although a dose reduction may be 
necessary for those changing from bovine to human insulin, the impression given was 
that this would only be necessary for those on high doses (Drug and Therapeutics 
Bulletin, 1989). Indeed, from letters received by the BDA, it appears that many 
diabetics had not been warned that they might have to alter their dose (Balance, 1994). 
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The results of the BDA survey, carried out in 1987-8, found that a number of patients 
appeared to have been changed to human insulin by their pharmacists and not their 
doctor (Redmond, 1988). Robert Tattersall recommended that prescribers should not 
change Insulins without good reason, and that patients should know that it may be 
necessary to fine tune their insulin dose and that their warnings of hypoglycaemia may 
change (Lesser, 1989a). Indeed, Amiel points out that some patients were transferred 
en masse and without consultation (1995: 258). It was also found that, when diabetics 
were transferred to human insulin in their pharmacies and without any medical 
supervision or information, there was an increased risk of severe hypoglycaemia 
during the transition to human insulin (Egger et al., 1992). 
Frier et al. (1991) point out that when patients were transferred from animal to human 
insulin with a dose reduction, complaints of unexpected severe hypoglycaemia 
reduced. They argued that: 
"Because of an expected reduction in insulin requirement after transfer from 
animal to human insulin diabetic patients in the United Kingdom were 
instructed to reduce their dose by at least 10% and few subsequently 
experienced increased hypoglycaemia. " 
(Frier et al., 1991: 1667) 
However, for some, the reduction in dose was not the answer. The argument that `few 
subsequently experienced increased hypoglycaemia' would be questioned by a number 
of researchers and diabetics, such as Berger and Teuscher, and members of the IDDT. 
For example, after being transferred to human insulin one diabetic experienced leg 
cramps. His doctor suggested a reduction in dose. However, the diabetic writes: 
"When I reduced the dose of insulin I became very lethargic and my urine and 
blood tests showed my diabetes was no longer under control. " 
(Balance, 1988a) 
Where doctors refused to acknowledge that human insulin was the problem, many 
patients felt let down by their doctor. A consistent complaint was that doctors refused 
to recognise that patients were having problems on human insulin despite adjustments 
in dose (Pickup, 1989: 993). 
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6.4.4 Increased Monitorring of'Blood Glucose Levels 
One suggested alteration to the diabetic regime, for those experiencing problems on 
human insulin, was to increase the monitoring of their blood glucose levels. 
Typically, when diabetics are changed to a new insulin (no matter what the species) or 
to a new insulin regime, they carry out more blood glucose monitoring. Of course, if 
diabetics were not told that they were on a different type of insulin, they would be 
unaware that they should carry out more frequent blood glucose monitoring. This led 
Amiel to argue that the recommendations of the early studies, that conversion to the 
use of human insulin should be carefully monitored and changes in doses and/or 
injection times should be considered, were not followed (Amiel, 1995: 258). 
Although it was argued that when diabetics transferred to human insulin they should 
carry out more frequent blood glucose monitoring, in the early days, this was usually 
only stressed when changing from beef to human insulin (Balance, 1987a: 5; Muir et 
al., 1988). This is because there is more difference in beef insulin's amino acid 
composition than pork insulin. 
So problems could have existed where diabetics did not keep a close enough eye on 
their blood glucose levels. Interestingly, some diabetics did lay the blame for a 
change in the warnings of hypoglycaemia at the door of diabetics themselves. A letter 
from a diabetic of 35 years argued that: 
"Before we blame the drug companies too strongly, maybe the individual 
diabetic needs to take some responsibility for not checking the possibility of 
their symptoms changing when they were first put on the new insulin. " 
(Balance, 1991d: 49) 
This letter is interesting because the author of the letter was involved in the clinical 
trials of human insulin, in which they were frequently monitored. Further, he did 
experience some change in symptoms, but because of the regular testing, this could be 
detected. Of course, in everyday life this is not always possible, and it is likely that 
more care will be taken by both the medical care team and the diabetic, while they are 
under observation. 
Through the use of human insulin therefore, new objects may have come to be 
involved within the network body. I have already described how diabetics were 
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encouraged to carry out more blood glucose monitoring, either at the time of 
transferral to human insulin or because they were having problems. There were other 
changes that may have also occurred. For example, one diabetic tells of how glucagon 
became a regular prescription for him (Balance, 1991 c). Glucagon is a protein that 
when injected into the body increases blood glucose levels. It is used when a diabetic 
has become unconscious due to hypoglycaemia, and so is unable to consume food. 
Glucagon has to be injected and is supplied in kit form, to be injected by a family 
member. After the injection of glucagon the diabetic is likely to regain consciousness. 
Glucagon therefore, becomes inserted into the network body in order to help maintain 
health. However, rather than preventing hypoglycaemia as blood glucose monitoring 
does, glucagon is used when the network body breaks down, or, in other words, 
diabetic coma. Of course this is not satisfactory. Glucagon is supposed to be used for 
emergencies, rather than on a regular basis. If glucagon is used frequently then this 
should be reported to a diabetic's doctor, so that changes can be made to the patient's 
management of their diabetes. 
The three explanations/resolutions described above can be seen as accommodations in 
which there is a continued use of human insulin. These ranged from a simple 
dispelling of any problems that a diabetic described, to changes in the management of 
diabetes, whether through a reduction in dose or greater blood glucose monitoring. 
What is important is a diabetic's reaction to a particular resolution. Although a 
change in dose or increased blood glucose monitoring resolved some diabetics' 
problems, others were still not happy with the control of their diabetes. Where 
diabetics were still not happy, another possible resolution involved a return to the 
original species of animal insulin. 
6.4.5 A Change Back to Animal Insulin 
As already mentioned, the changes above should be seen as being within the context 
of treatment with human insulin. However, in a large number of cases, more was 
needed than simply a change in dose or increased blood glucose monitoring. As 
outlined in Chapter 5, it was found that when diabetics changed back to their original 
animal insulin the majority regained their awareness of approaching hypoglycaemia 
(Maran et al., 1993). However, there were a number of reasons why diabetics would 
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not be automatically returned to animal insulin. These reasons ranged from an 
unawareness of the availability of animal insulins on the part of either the doctor or 
the diabetic, to a disbelief that human insulin was to blame for the problems. 
When looking at controversies there is a temptation to see only the negative cases, 
where less `powerful' individuals are marginalised by a more powerful group or 
individual. However, it is important to be aware that doctors were not always 
unsympathetic to the experiences of diabetics. For example, one diabetic writes that 
when she went to the diabetic clinic `determined to return to animal insulin': 
"We [her and her husband] were prepared to dig our heels in but, surprise, 
surprise, I made the request and the doctor was most co-operative and 
immediately found a pork insulin he thought would suit me. " 
(IDDT, 1995a: 11) 
Another diabetic describes how, after experiencing an increase in severe 
hypoglycaemia on human insulin, he reported his problems to his doctor, who 
dismissed his concerns. However, after falling down a pair of concrete stairs, he had 
`had enough' and went back to his doctor. He writes: 
"That was it, I had had enough! I went to the clinic and `the boss' was there, not 
my usual doctor. I explained my problems and within two minutes he changed 
my insulin back to pork. " 
(IDDT, 1995a: 5) 
However, there were many cases where diabetics were unable to change back to their 
original animal insulin. Letters to the BDA's Diabetes Care Department, from 
diabetics, spoke of doctors who refused to change them back to animal insulin, even 
though their letters suggested they had problems (Balance, 1992c: 18). Many 
diabetics described how they had to fight to be able to change their insulin species. 
For example: 
"After many requests to the consultant at the diabetic clinic, he has changed me 
back onto bovine insulin and after a short settling in period, I am now back to 
the way I was before, with hypos detected sufficiently early for self treatment. " 
(Balance, 1991 c) 
As well as the scientific evidence, there was much anecdotal evidence that when 
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diabetics returned to their original insulin, their symptoms returned. 37 For example: 
"I have clear cut, recognisable diabetic warnings of hypos. The warnings are 
not quite a early as I remember them on soluble insulin, but there is no doubt 
about them and I have quite enough time to react. " 
(O'Nions, 1988) 
"Now I feel wonderful; no longer do I have a fuzzy head and my husband tells 
me I am back to how I used to be before human insulin. I never want to use 
human insulin again. " 
(IDDT, 1995a: 11) 
"I have now changed my insulin from human to pork and feel much better! The 
hypos have stopped, my mood-swings have stopped and my skin cleared up. I 
feel as if a heavy `cloud ' has been removed and that I am now back in control 
of my life again! My family has commented that I now seem more like I used to 
be -I am delighted at this, but also angry that my family, friends, and colleagues 
should have had to `put up' with my character changes. " 
(IDDT, 1995b: 10) 
Although one diabetic was aware that some diabetics would not regain their warning 
signs, when returned to animal insulin, he also points out that it becomes more 
compelling when added to other evidence: 
"I feel as sure as I can be that human insulin has materially adverse effects in 
terms of the warning signals of the approach of hypoglycaemia. Although I 
cannot definitely prove this from my own experience, I believe that the 
coincidence is simply too strong to ignore even in my case alone. When it is 
added to the anecdotal evidence, which I have heard and which you must have 
collated from diabetics and their doctors throughout the country, I believe that 
the case becomes compelling. " 
(IDDT, 1995c: 11) 
From the view of doctors, there were a number of reasons why diabetics were not 
automatically changed to another insulin species. Some doctors believed that existing 
animal Insulins were being discontinued. For example, one diabetic wrote to Balance 
(1988a) saying that they had been transferred to human insulin because their doctor 
said that their existing animal insulin was being discontinued. On human insulin he 
had experienced problems, despite an adjustment in dose. As a result, the diabetic 
wanted to return to their existing animal insulin, and wanted to know if it was still 
possible to obtain supplies. Balance responded, saying that they had been in touch 
37 Although this was not always the case (Home, 1991). 
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with the medical advisor of Novo Laboratories, and they had responded saying that 
Lentard insulin was still available. 
This example suggests that some doctors were not fully aware of the situation 
regarding animal insulin, although we do have to be aware of the possibility that the 
doctor was lying. One source of information for doctors is the British National 
Formulary. It is produced jointly by the British Medical Association and the Royal 
Pharmaceutical Society and gives information on drugs, their costs and details of 
adverse effects. In the September 1995 edition, it gave the following information on 
human insulin: 
"Preparations of human sequence insulin should theoretically be less 
immunogenic, but in trials no real advantage has been shown... some patients 
have reported a loss of warnings of hypoglycaemia after transfer to human 
insulin . Patients should be warned of this possibility and if they believe that human insulin is responsible for their loss of warnings it is reasonable to 
transfer them back to porcine insulins. " 
(British National Formulary, 1995: 280) 
As well as the belief that some animal insulins were no longer available, the IDDT 
found a number of other reasons why doctors would not return diabetics to animal 
insulin when they reported problems on human insulin. These included claims that: 
human insulin was a better insulin; that using animal insulin would be a step 
backwards; and that they had been on human insulin too long to change. With this 
last point, the IDDT asked the question: Why was there then a change to human 
insulin? (IDDT, 1995b: 9). 
One option available to those who wanted to obtain animal insulin, but where their 
doctor would not sanction it, was through the named patient system. In special 
circumstances drugs that are not available in the UK can be obtained through the NHS 
with a `named patient prescription' that is obtained through a doctor. Of course such 
an option would require the doctor to accept that a particular (animal) insulin is 
necessary for the health of the diabetic, 
Where diabetics were unable to obtain animal insulin through their doctors, another 
way of obtaining animal insulin was by going outside of the existing doctor-patient 
relationship. One letter, printed in an IDDT newsletter, described how a diabetic was 
209 
6.4 Solutions within medical practice 
concerned with the "blinkered attitude of some of the medical profession" (1995a: 5). 
He was particularly concerned, as happened with him, that doctors simply dismissed 
any problems that diabetics were having on human insulin. The diabetic encourages 
others, who have problems on human insulin and where their doctor does not accept 
their problems, to go over the doctor's head until they get a sympathetic hearing. 
Another way of going temporarily outside of the existing doctor-patient relationship 
was by obtaining animal insulin independently from the doctor. For example: 
"Dear Jenny, My husband did very badly on both animal and human insulins 
when he was forced to change from 40 strength concentration to the U 100 
strength. He managed thanks only to the imported 40 strength insulin which he 
uses to the present day. 
(IDDT, 1995a: 11) 
"I have recently secured porcine insulin U 40 u/cc strength from France and 
over a few weeks my old well known visual warning signs of hypos have 
returned. " 
(IDDT, 1996d: 11) 
Prior to August 1998, insulin was a `class P drug', which meant that it could be 
bought over the counter without prescription, it was however, expensive, and 
pharmacists were expected to only sell it to diabetics. 38 The IDDT gave advice on 
how to obtain animal insulin from a source other than their own doctor. They also 
printed the name and address of a pharmacist who would sell animal insulin to 
diabetics (IDDT, 1996d: 11). However, diabetics were always warned that they 
should consult their own doctor before any change of insulin. We should also be 
aware that the diabetic would have to pay for the cost of the animal insulin, since it 
was not acquired through the legitimised consumption path. A months supply of pork 
insulin costs between £7-8 from pharmaceutical companies (Prescription Pricing 
Authority, 1997). 
The IDDT also pointed out that animal insulin pens were available before 1994 in 
other countries, but were not available in the UK for an unknown reason. They 
38 From August 1998 insulin became a prescription only drug (POM) (Statutory Instrument, 1998). 
There were a number of reasons for this change. One was due to concerns over the use of human 
insulin by non-diabetics such as body builders (Hall, 1998). The change also brought the United 
Kingdom in line with the European Union (Balance, 1998). 
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describe how to obtain the pens and cartridges through a `named patient prescription' 
or, failing that, from IDIS World Medicines (a global supplier of internationally 
licensed medicines) (IDDT, 1994: 3). Although they do point out that such equipment 
is expensive. However, some insulin pens were also being withdrawn in other 
countries. As shown in Chapter 5, they were however, introduced into the UK in 
1997. 
In the next section I would like to relate further some of the experiences of diabetics 
to the doctor-patient relationship. In particular, I am interested in how the relationship 
between the doctor and the patient can change over time, and how, in some cases 
patients can be motivated to search out further information when they are dissatisfied 
with their treatment. 
6.4.6 Some Notes on the Doctor-Patient relationship 
Clearly, then, some diabetics sought information from sources other than their 
immediate medical practitioner. Importantly, there were various triggers to seeking 
more information both from existing sources, and also through `new' and `alternative' 
sources. One diabetic wrote that after having problems on human insulin, and not 
receiving much information from her doctor, she decided to search out information 
herself (IDDT, 1995d: 10). After 5 or 6 months of feeling more and more ill every 
week, and her doctor not taking any notice of her, she writes: 
"I HAD HAD ENOUGH and having continuously researched information about 
diabetes I decided that human insulin could be the cause and I asked the clinic if 
I could change to pork insulin to which they said fine. " 
(IDDT, 1995d: 10) 
Whether an individual searches out further information will be based on a number of 
different criteria. It is what both the patient and the doctor bring to the doctor-patient 
that is of importance. It is possible to outline a number of beliefs or positions that 
doctors and diabetics may hold with regard to human insulin. For example: 
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" The doctor may not believe that human insulin is the cause of symptoms 
exhibited by their patient. 
" The doctor may not be aware that animal insulins are still available. 
" The patient may not be aware that animal insulins are still available. 
" The patient may not attribute their problems to human insulin. 
" The patient may not be aware that other diabetics are exhibiting similar 
problems that have been put down to human insulin. 
The approach taken by both the doctor and the patient, will affect the outcome of any 
negotiation between the doctor and the patient. In some cases a doctor may accept 
that the diabetic is experiencing problems on human insulin and change them back to 
animal insulin. In other cases, the doctor may believe that human insulin is not the 
cause of any side effects. The diabetic may accept this assessment, however in other 
cases, through a belief that human insulin is to blame, a diabetic may search out 
further information themselves. I will return to analyse this array of possibilities 
within a theoretical framework in Chapter 7. 
However, just because an individual gathers knowledge, does not necessarily mean 
that it will be put into practice, and this brings me to issues of the doctor-patient 
relationship. It is unlikely that there is only one formulation of the doctor-patient 
relationship. Stewart and Roter look at the doctor-patient relationship in terms of the 
degree of control exhibited in the encounter by each party (1989). A paternalist one 
occurs where the doctor is in control, and a consumerist relationship where the patient 
is in control. Tuckett et al. argue that a mutual control relationship is desirable 
(1985). 
Of course, the nature of any relationship can change over time. Gabe et al. (1991) 
point out that when patients experienced tranquilliser dependence, the doctor-patient 
relationship changed from a Parsonian model of reciprocity (Parsons, 1951) to one 
based around a Freidsonian conflict model (Freidson, 1970). In such cases the 
patients may the feel let down by the doctor, who was supposed to maintain their 
health. The patient may then search out further knowledge. Cooper (1997), looking 
at sufferers of ME, describes their experiences of the medical profession. She tells of 
how, in some cases, individuals were dismissed and disbelieved, and were often 
labelled as bored housewives or depressed adolescents, when they attempted to gain a 
diagnosis. As a result of this `rejection', Cooper describes how: 
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"... acting no longer as passive agents when their needs were not met, 
respondents actively pursued their own paths to knowledge and challenged the 
authority and status of their GPs and consultants. " 
(Cooper, 1997: 190) 
There are similarities here with some of the psychological explanations that I outlined 
above, where diabetics were told that they must be imagining their problems (Balance, 
1991 a; IDDT, 1995a) and as with above, such responses encouraged diabetics to 
search out other information. 
One of the important features of all the responses outline above is that those who are 
exhibiting problems on human insulin want to be diagnosed `adequately'. Therefore, 
if the response from the doctor was adequate for them, a diabetic may not pursue the 
matter further. Thompson39 has looked at how doctors are `idealised' by patients 
when they give the `correct' diagnosis to the patient, that is, it matched with their own 
diagnosis. However, where doctors denied the existence of `the illness', and were 
unable to name and heal the disease, and so legitimate it, then patients `demonised' 
these doctors. 
As I have shown, it was argued that some problems on human insulin could be solved 
by a reduction in the dose of human insulin. For others, it was felt, by either diabetics 
or doctors, that a change to animal insulin was the answer. In looking at chronic 
fatigue syndrome (CFS), Woodward et al. found that patients were much happier after 
a diagnosis of CFS. They argue that after diagnosis, sufferers were provided with a 
rational and structured meaning system for their experiences of disability and illness 
(Woodward et al., 1995). The important feature is the acceptance of a particular 
diagnosis. For example, some diabetics may accept that their experiences are part of 
the biography of diabetes and others may believe that such a diagnosis is inadequate. 
Now, these are individual choices and strategies. However, that there is choice at all 
is arguably because of the efforts of care groups 
6.5 CHOICE OF INSULIN 
It is to their role that I now turn. 
As indicated in Chapter 5, animal insulins were withdrawn as early as 1986 by Novo 
39 Reference unknown, although see Cooper (1997: 200) for original reference. 
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Laboratories. Initially, withdrawal was accepted by the BDA. The BDA argued that 
companies would want to standardise their insulins since it made commercial sense 
(Balance, 1986: 4). They also argued that diabetics and care groups had "no choice 
but to accept this" (Balance, 1986: 4). 
The BDA did however give advice to their readers. When Novo Laboratories were 
replacing their MC pork insulin with a human equivalent, the medical advisor to the 
BDA said that people should be able to transfer from pork to the human insulin 
without any problems. However, the advisor pointed out that if diabetics noticed a 
significant change in the action of the insulin, which could not be corrected by dose 
adjustments, or were not happy about the principle, they should contact their doctor 
(Balance, 1986: 4). 
A number of articles, that dealt with the withdrawal of animal insulins, also stressed 
which animal insulins were still available. The BDA often sought reassurances from 
pharmaceutical companies on their current animal insulin policy. In August 1987, CP 
Pharmaceuticals Ltd announced that they would continue supplying their Hypurin 
range of highly purified beef Insulins for the foreseeable future while demand existed. 
Evans Medical Ltd also stated that their range of beef insulins would remain available 
as long as economically viable for them to be produced (Balance, 1987c: 4). During 
the late 1980s the BDA acted to gain reassurances of the availability of animal 
insulins from the manufacturers. Also through their magazine, the BDA acted to 
inform diabetics of the continued availability of various animal insulins. 
Throughout the late 1980s and early 1990s, other animal insulins were also withdrawn 
from production. Some, however, argued that reducing the number of insulins 
available would be beneficial. Robert Tattersall pointed out that between 1983 and 
1989 the number of branded human insulin preparations increased from 4 to 17, which 
was a source of confusion to medical staff, pharmacists and patients alike (Lesser, 
1989a). Some argued that in the UK the classification of insulins as short, 
intermediate, and long was too confusing and should be simplified (Bonn, 1996). 
Others however, disagreed with this (Kreigstein et al., 1997). The Drugs and 
Therapeutics Bulletin claimed that there was an argument for reducing the number of 
Insulins available, however a range of pork, beef and human insulin should always be 
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available (Drug and Therapeutics Bulletin, 1996). 
Whenever the diabetic media reported that an insulin was being withdrawn it was 
always stressed that there were similar animal Insulins available for diabetics. 
However, this did not always mean that diabetics would be given the appropriate 
insulin. Various letters were printed in Balance telling of cases where diabetics had 
been given the wrong insulin (Balance, 1988b) or where patients had been transferred 
to another insulin without their knowledge (Redmond, 1988). I referred to this above, 
where diabetics were more likely to experience problems when they were not told of 
the change of insulin species. 
As a result of some of these concerns over the transferring of some diabetics to human 
insulin, the BDA's medical adviser gave advice to all diabetics - see Figure 6-1 
(Redmond, 1988). 
Advice given to diabetics when receiving their insulin: 
1) Be sure you are aware what insulin you are using. 
2) Note the manufacturer, species and the name of your insulin, as well as your doses. 
3) Always take sample vials with you whenever you see your doctor, nurse or chemist. 
4) NEVER LET A CHEMIST GIVE YOU DIFFERENT INSULIN, unless your doctor 
has explained it. 
5) Read the paper insert that comes in the box with your insulin. 
6) Find out whether it is likely your insulin will need to be changed. 
7) Ensure any change is adequately explained by your diabetes medical advisor. 
8) If you do have your insulin changed and you experience problems, make an 
appointment to see your doctor so that you can discuss the problems fully. 
Figure 6-1: Advice given to diabetics when receiving their insulin 
In 1991 the BDA set up the Loss of Warnings Task Force which had the aim to bring 
to the attention of doctors some of the problems experienced by some diabetics 
(Figure 6-2). Due to criticisms of the Human Insulin Working Group (HIWG), that 
was set up in 1989, the LOW Task Force also included diabetics, particularly those 
grappling with hypoglycaemia unawareness. The HIWG had included health care 
professionals and members of insulin manufactures, but did not include diabetics 
(Balance, 1994). The LOW Task Force wished to encourage communication between 
the patient and the doctor on the issue of problems with the use of human insulin. The 
BDA felt that it was important that doctors were flexible to the wishes of diabetics, 
especially if they wanted to change back to animal insulin (Balance, 1991b). 
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There are many factors therefore, that are important in the choice of insulin - not just 
concerning the availability of animal insulins. On the one hand it is based around the 
knowledge and desire of the doctor. Some doctors changed patients over to human 
insulin because they were not aware that there were other animal Insulins available, or 
that they were under the impression that existing animal insulins were being 
discontinued. It also seems that many diabetics were transferred to human insulin, by 
their doctor, due to the marketing techniques of the pharmaceutical companies. On 
the other hand, diabetics themselves may have needed information on the availability 
of animal insulins in order to `push' for animal insulin. 
Steps taken by the BDA's LOW Task Force 
"A special leaflet - People with Diabetes and Changes in Hypoglycaemic Warnings - was 
printed and reproduced in an issue of Balance (see Appendix 2). 
"A copy of the leaflet and professional advice sheets were sent to all the medical 
professionals on the BDA mailing lists 
"A copy of the leaflet was sent to all BDA branches 
" An advertisement for the new leaflet was placed in many national newspapers. Local 
branches were also encouraged to put adverts in their local newspapers. 
"A press conference was held, and a press statement and copies of the leaflet were sent to 
national newspapers 
" Extra resources were made available to help the Diabetes Care Department answer 
queries on hypoglycaemia and human insulin. In particular extra resources were made 
available to the BDA telephone helpline. 
Figure 6-2: Steps taken by the BDA's LOW Task Force 
Before 1994 the BDA had simply sought reassurances for the continued availability of 
animal insulins from the pharmaceutical companies. However, in 1994 the BDA 
attempted to stem the flow of withdrawals of animal insulin by beginning its 
campaign to maintain a choice for diabetics, as to the species of insulin they wished to 
use. They collected 140,000 signatures that were then presented to three UK insulin 
manufacturers in September and October 1994 (Hope, 1994). The aim was to ensure 
that animal Insulins would be available indefinitely, and to make animal insulin 
available for pen devices. 
As outlined in Chapter 5, Eli Lilly have never marketed animal insulins in the United 
Kingdom, but supported the availability of animal Insulins. Novo Nordisk, said that 
they would continue to produce some animal insulins as long as it was economically 
viable. CP Pharmaceuticals only manufactured beef insulins and made a continued 
commitment to them (Hope, 1994). 
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Later, in 1996, the BDA embarked on a European wide survey to check out the 
strength of market demand for animal insulin, and so monitor the user patterns that 
influence insulin suppliers (Balance, 1996: 12). It was also hoped that greater links 
with European partners would help groups campaign more efficiently. 
Although some animals insulins were being withdrawn, and others simplified, we 
have to be aware that there was a general agreement that there should be a continued 
availability of animal insulins. As I showed in Chapter 5, scientists also agreed with 
this. Simon Hope, of the BDA, argued that the Insulin Campaign was underpinned by 
freedom of choice, so that people with diabetes may use the insulin that suits them 
(1995: 10-11). The pharmaceutical companies also seemed to support choice, at least 
while demand made it economically feasible (Hope, 1994). 
The IDDT did have some concerns about the Simplification Programme that was 
being carried out by Novo Nordisk in 1995/96. Although changes were only being to 
human insulins, they were concerned that other changes may also be carried out by 
doctors, they frequently argued that: 
"This programme only affects human Insulins and there will be no changes in 
the animal insulins, so don't let anyone persuade you otherwise! 
(This has already started to happen to some of our members - perhaps an excuse 
to change them to human insulin! ) 
The changes will not affect animal Insulins. " 
(IDDT, 1995a: 4) 
Again, from the point of view of the IDDT, it was the knowledge that was possessed 
by diabetics that was important. If diabetics were unaware that the simplification 
programme was only aimed at human insulins, and did not affect animal 
insulins, they 
may have accepted that their animal insulins were being withdrawn. 
The IDDT also believed in the availability of choice so that doctors and 
diabetics 
could choose which insulin species they wished to use. However, 
from reading some 
of their newsletters the point was not always made clear. For example, one 
letter 
printed in the newsletter began: 
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"Please remove my name from your mailing list. I originally joined IDDT 
because of my belief in choice. However I find some of your articles alarming 
and unnecessarily frightening. " 
(IDDT, 1997: 15) 
In answer to the letter, the editor pointed out that they did believe in choice, but that 
they were concerned that choice was only possible if diabetics had all the information. 
As the editor writes: 
"An INFORMED choice means having sufficient information to be able to look 
at the pros and cons of an action or decision and, when this applies to diabetes, 
it sometimes means having information which may be upsetting or frightening. " 
(IDDT, 1997: 15) 
Choice, according to this perspective, is not just about the availability of different 
insulin species, but also knowledge of the available insulins. In other cases choice is 
tied up with other actants. From the view of diabetics, one reason why they may have 
wanted to continue to use human insulin was because it was available for pen 
injection systems, but animal insulin wasn't. Care groups argued that diabetics should 
not be dissuaded from using animal insulins just because they were not available in 
cartridges for pen-injection devices (IDDT, 1994: 2). This is especially the case if a 
diabetic had been on human insulin and used an insulin pen. If a diabetic used this 
convenient method, then they may have been reluctant to change back to animal 
insulin, and so lose this method. As this quote illustrates: 
"After trying pork insulin I am convinced that the human insulin has a definite 
detrimental effect on my moods causing deep, dark (sometimes suicidal) periods 
whereas the same thoughts whilst on pork insulin are almost insignificant. I 
have switched back to human insulin twice during the 3 months, initially 
because I wasn't convinced it was the cause of the difference and then, because 
of the convenience of the pen. Both times I noticed the `moods' return within a 
week. " 
(IDDT, 1996c: 11) 
However, in April 1997 CP Pharmaceuticals announced that they were going to 
produce some animal insulins (both pork and beef). Victory for the change was 
claimed by both the BDA (Balance, 1997) and the IDDT (IDDT, 1997c). The IDDT 
also gave credit to the directors of CP Pharmaceuticals (IDDT, 1997e). The IDDT 
argued that the development of the animal insulins gave diabetics equal choice of 
insulins, totally uninfluenced by the lack of an insulin pen. From the point of view of 
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doctors, the IDDT argued that doctors would not now be `forced' into prescribing 
human insulin as a first line treatment (IDDT, 1997e). 
As would be expected, the IDDT newsletters, after the announcement that animal 
insulins were going to be available in cartridges, contained a number of letters about 
animal insulin cartridges. 
"Good news about CP Insulins. Nice to know we no longer have to succumb to 
the 'take it or leave it' attitude and the hide bound refusal to listen by the 
'human' insulin school'. " 
(IDDT, 1997c: 5) 
"I just wanted to congratulate all of you on your success with CP 
Pharmaceuticals. It is reassuring that pressure can persuade common sense to 
prevail. Keep up the good work. Although my daughter appears to have no 
particular problems with 'human' insulin I feel for those who do. " 
(IDDT, 1997c: 5) 
"My specialist nurse ordered 30 pens - her estimation of how many she would 
need for the clinic and within 2 or 3 days she had to make a second list because 
that wasn't enough. She couldn't understand where all the people were coming 
from. " 
(IDDT, 1997c: 5) 
"My specialist nurse told me they were discovering patients in the area they 
didn't know existed until CP introduced their pen cartridges for animal 
insulins. " 
(IDDT, 1997c: 5) 
Although animal insulin pens and cartridges had been introduced, the IDDT were 
concerned that diabetics may not know about them. They argued that since 
pharmaceutical companies can only directly advertise to the medical profession, a 
diabetics knowledge of new products is dependent on the medical profession (IDDT, 
1997d). The IDDT point out that since they are only a small organisation, there is no 
way that they can reach large number of diabetics, but the BDA could. However, the 
initial introduction of animal insulin cartridges did get quite a lot of attention in the 
diabetic media. 
Throughout this section I have indicated how the IDDT believed that diabetics needed 
more information in order to be able to make choices over the species of insulin that 
they wished to use. However, as already indicated elsewhere, some diabetics were 
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transferred to human insulin without their knowledge (IDDT, 1995b). In order to 
counter this possibility, the IDDT produced stickers which said, `This patient does not 
give consent for human insulin to be administered' (IDDT, 1995d). The idea was that 
these stickers could be stuck on medical notes, so that human insulin was not 
`mistakenly' given to diabetics against their wishes. Although some diabetics thought 
these were a good idea (IDDT, 1997) others felt that they were `adversarial' (IDDT, 
1997). 
In this section I hope that I have indicated the various actions that were taken by both 
the BDA and the IDDT, in the maintenance of choice of insulin species. The main 
difference between the BDA and the IDDT is that while the BDA lobbied 
pharmaceutical companies over the availability of animal insulins, the IDDT worked 
on an `individual' level. The IDDT were more concerned with giving information to 
individual diabetics, so that they themselves could utilise the choice of insulin. 
6.6 COMPARING THE BDA AND THE IDDT 
It should be obvious that there are a number of differences between the BDA and the 
IDDT. In this section I would like to expand on some of these differences. One 
difference between the two groups is in the way in which they were set up. As 
outlined in Chapter 4, the IDDT is a relatively new organisation, being set-up in 1994. 
One of the reasons why the IDDT was set-up was to offer help and support for 
diabetics and carers, who were experiencing problems on human insulin. 
Another difference between the two groups was the resources that they had available. 
The BDA is a larger group than the IDDT, and was able to fund a number of research 
studies into human insulin and its possible negative effects (Balance, 1992a: 16). 
They were also able to carry out more country wide publicity, as shown by the BDA's 
letter to medical professionals (Balance, 1991b). They were also able to afford 
adverts in the popular press (Independent on Sunday, 1995). 
The IDDT were less powerful in this sense. Rather than attempting to place adverts in 
national newspapers, which they themselves admitted they could not afford, the IDDT 
trustees wrote letters to national and local newspapers. In one case, Jenny Hirst, of the 
IDDT, wrote a letter to a number of local and national newspapers describing the 
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experiences of her husband and daughter, who both had problems on human insulin 
(IDDT, 1995b: 8). In an article, entitled `No big advertising campaign - just one 
letter', Jenny Hirst describes how the letter had been printed in a large number of 
these newspapers (IDDT, 1995b: 8). 
The IDDT also encouraged other diabetics, who were having problems on human 
insulin, to write to their own local newspapers (IDDT, 1995d: 7). Further, they 
managed to publicise themselves through news programmes (IDDT, 1995d: 7). From 
reading the IDDT newsletters, such methods did seem to get themselves noticed, with 
some diabetics contacting the IDDT after reading or hearing about their work from the 
media (IDDT, 1996b: 11). The IDDT also had a number of letters published in the 
medical press (British Medical Journal, Diabetologia, Diabetic Medicine and The 
Lancet) which outlined some of the problems that were experienced by some 
diabetics. Some of these letters were by non-medical members of the trust (Hirst and 
Hill, 1996a; Hirst and Hill, 1996b; Hirst, 1998) and other by medical members (Kiln, 
1995; Kiln, 1996a; Kiln, 1996b). 
Another difference between the BDA and the IDDT was in the content of the material 
that each group produced. The BDA produced material that was less antagonistic than 
that of the IDDT. Indeed, the IDDT were so antagonistic towards human insulin that 
some were under the impression that the IDDT wanted human insulin to be totally 
removed (IDDT, 1995d: 5). As a result, in July 1995, the IDDT issued a press release 
that re-stated their aims, particularly that they wished for the continued availability of 
animal insulins, and that human insulin shouldn't automatically be seen as the first 
choice of insulin treatment (IDDT, 1995d: 5). 
The IDDT were also very keen for those diabetics experiencing problems on human 
insulin to speak with the media and write letters, they also encouraged diabetics to 
report problems on human insulin through the Yellow Card Scheme. Indeed, the 
IDDT were very critical of the current way in which adverse effects of drugs were 
reported. 
In the UK, part of post-marketing surveillance, is the Yellow Card Scheme. In the 
scheme, adverse drug reactions are reported to the Committee on Safety of Medicines 
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(CSM). The IDDT described how a new drug is on trial from its discovery to its final 
demise, and that it is through pharmacovigilance (watching over drugs in use) that 
adverse reactions can be reported (IDDT, 1995a). The Yellow Card Scheme is 
however, based on spontaneous reporting by doctors, and as a result, is dependent on 
the vigilance and enthusiasm of doctors. Studies have shown that in any one year 11- 
13% of all UK doctors sent in at least on Yellow card, with the cumulative number 
over four years being about 35% (Medicines Control Agency, 1997). The IDDT 
pointed out that in 1994, very few adverse drug reactions on human insulin had been 
reported to the CSM, with the consequence that the CSM had not been sufficiently 
alerted to the frequency of problems on human insulin (IDDT, 1994). 
Although patients are unable to report problems direct to the CSM, the IDDT 
encouraged patients to ask their doctor to report their problems. They gave the 
following advice: 
"Simply book a long appointment with your GP and ask him or her kindly to 
report your case. Say that you know he or she is very busy but please could they 
do it especially if you have changed to animal insulin and things have 
improved. " 
(IDDT, 1994: 2) 
In 1995 the Royal Pharmaceutical Society and the Patients Association had talks with 
the MCA about the possibility of expanding the Yellow Card Scheme to allow 
pharmacists, and possibly patients, to report adverse drug reactions. 
This is not to say that the BDA were not keen that diabetics should be well informed. 
For example, the Hypoglycaemia Workshop, which met in 1994 and was organised by 
the BDA, argued that knowledge for people with diabetes, and those who care for 
them, leads to empowerment (Balance, 1994: vi). This was not just knowledge of 
their bodies and their diabetes, but also of their current treatment. 
It is also notable that initially the BDA began by informing health care professionals 
of some of the concerns of diabetics, and asked these care professionals to be aware of 
possible problems on human insulin. The BDA were concerned not to "invoke undue 
distress to people who were not having problems by publicising a matter on which 
there was only anecdotal evidence" (Balance, 1994: xi). 
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However, in retrospect, Suzanne Redmond, who was the Director of the BDA Care 
Division, believed that: 
"Our experiences since then have led us to believe that we should have taken the 
risk of provoking anxiety and made the considerations and responses of the 
BDA more public. " 
(Balance, 1994: xi) 
Suzanne Redmond went further and argued that the BDA were aware that many 
diabetics, who were having problems on human insulin, felt that they were not being 
listened to, because they did not see their problems being discussed in issues of 
Balance. 
The IDDT on the other hand, had always had an approach in which they were more 
`open' in their discussion of human insulin. However, for some, the content of the 
IDDT newsletters was too "alarming and unnecessarily frightening" (IDDT, 1997: 
15). Some doctors thought that the IDDT were a bunch of `eccentrics'( IDDT, 1996c: 
2). In a book written by doctors, and to be used by GPs, the IDDT was described as 
having "set out to raise fears about human insulin which may increase the insecurity 
of GPs" (Fox and Pickering, 1995). However, others took a different view: 
"I, like many of your readers, look forward to reading your Newsletters. I love 
reading them, you are so outspoken and tell the truth, which some people in 
authority do not like; we who are unfortunate to have diabetes know you and 
your colleagues are doing your utmost to ease our burden and to assist us in any 
way you can. " 
(IDDT, 1996c: 11) 
Others saw the IDDT as a body that was campaigning against larger more powerful 
bodies. For example, one diabetic wrote: 
"Dear Jenny, I would just like to say how much I look forward to reading the 
newsletters; the ongoing story of your battle against drug companies and BDA 
and the professional way in which you edit the paper... I feel that the Trustees are 
unsung and unpaid heroes. " 
(IDDT, 1998: 10) 
In response, the editor of the newsletter points out that they do not see themselves as 
being in a battle with the BDA. That is not to say that they agreed completely with the 
BDA. The IDDT argued that the BDA did not use their resources in a way that would 
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benefit diabetics who were having problems on human insulin. They argued that: 
"The BDA has the power, the information amongst its members and the funds to 
really ensure that animal Insulins remain available, if it chose to use that 
power. " 
(IDDT, 1998: 10) 
The IDDT also argued that they wished that the BDA "had a more open attitude to the 
`human' vs animal insulin issue and that they would truly recognise that some people 
with diabetes are better using natural animal Insulins" (IDDT, 1998: 10). 
In summary then, there were a number of differences between the BDA and the IDDT. 
The main difference related to the two groups attitude towards human insulin. The 
BDA believed that, although human insulin may cause some adverse symptoms, on 
the whole human insulin should be the insulin of choice. On the other hand, the IDDT 
believed that human insulin did cause adverse effects, and that these effects should be 
widely publicised. 
6.7 CONCLUDING REMARKS 
In this chapter I have described some of the concerns of diabetics and care groups in 
the human insulin debate. I described the important role played by two mediating 
others: the family and the media. The family had an important role to play in alerting 
some diabetics to changes that they observed in the diabetics behaviour. Crucially, 
due to the nature of some of the symptoms exhibited by some diabetics on human 
insulin, diabetics themselves were sometimes unaware that their behaviour changed 
on human insulin. The media, and to a lesser extent family members, had a role to 
play in circulating information about the experiences of some diabetics on human 
insulin. In many cases, it was through the media that diabetics became aware that 
other diabetics were experiencing problems on human insulin. 
A large part of this chapter has described the different solutions that were presented to 
diabetics, by doctors, when they reported problems on human insulin. What was 
important about the presentation and acceptance of solutions to diabetics was the 
knowledge that both doctors and diabetic possessed. In particular, I stressed that a 
diabetic may have been presented with a number of different solutions before they 
came to a settlement with their network body. I will theorise this issue in Chapter 7. 
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One important issue that was dealt with in this chapter was the availability of animal 
insulins. In particular, I argued that there was some agreement that doctors and 
diabetics should have a choice of insulin species. However, it was not just the 
availability of animal insulins that was important, but also, that doctors and diabetics 
were aware that animal insulins were available. Again, the issue of insulin choice will 
be theorised in Chapter 7. 
I concluded this chapter by looking at the differences and similarities of the two main 
care groups in this study: the BDA and the IDDT. The main difference between these 
two groups was that the IDDT saw human insulin as the cause of some of the 
experiences of diabetics who were using human insulin. However, the BDA were less 
confident on this score. This main difference reflected and influenced the way that the 
two groups conducted themselves in the human insulin debate. The IDDT were vocal 
in informing diabetics of their rights, and the problems experienced by some diabetics. 
On the other hand, the BDA produced material that was less antagonistic, with much 
of their work being carried out `behind the scenes' in scientific studies and within 
research groups. 
In the following chapter I will bring together some of the issues discussed in this and 
the previous chapters. 
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7. THEORETICAL PERSPECTIVES AND HUMAN INSULIN 
7.1 INTRODUCTION 
One of my central concerns in this thesis is the application of a number of theoretical 
approaches (actor network theory, the public understanding of science and the 
sociology of the body) to the development, introduction and use of human insulin. It 
is now time to draw out some of the theoretical implications of the present case study. 
However, before I do this, it will be beneficial to provide an overview of the thesis. 
In Chapter 31 described the development and commercial production of human 
insulin. There were a number of features of the development and production of 
human insulin that made it interesting. Human insulin was the first protein for human 
use to be produced by genetic engineering, and as a consequence, it generated a lot of 
scientific and media interest. Before 1982 diabetics used animal insulin to control 
their diabetes. However, there were two main concerns (or problematizations) within 
some areas of the scientific and medical community concerning animal insulin. The 
first concern was that the demand for insulin would outstrip the supply of animal 
insulin. Secondly, it was suggested that animal insulins may be the cause of some of 
the complications of diabetes, due to the differences in the amino acid sequence of 
animal and human insulin (Figure 2-3). 
In the latter half of the 1970s work began on producing a human insulin that would 
allay both of these concerns. It was hoped that through genetic engineering it would 
be possible to produce endless amounts of pure human insulin. Between 1976 and 
1979 the development of human insulin was represented by the media as a `race' 
between three research teams - to be won by the first to produce human insulin within 
the laboratory using genetic engineering. In 1979 Genentech successful produced 
human insulin using genetic engineering and so `won' the human insulin `race'. Eli 
Lilly had for a long time been interested in the work being carried out by the research 
teams, and when it became obvious that human insulin could be commercially 
produced, they took over the development of human insulin from Genentech. 
It was also pointed out in Chapter 3 that Novo lndustri were also interested in 
developing a human insulin, although their method originally converted animal insulin 
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to human insulin. With both Eli Lilly and Novo Industri attempting to commercially 
produce human insulin the media reported that there was a `battle' or `war' as to 
which company would be the first to market human insulin. It was Novo Industri who 
won this `battle', with Eli Lilly not far behind. It was also noted that human insulin 
passed through clinical trials relatively quickly, with human insulin being available in 
pharmacies by 1982. 
One notable finding of Chapter 3 was that both Eli Lilly and Novo Industri carried out 
multiple and `contradictory' strategies towards new developments in insulin (Figure 3- 
5). Although Novo Industri were claiming that their purified animal insulins would 
prevent diabetic complications (their overt strategy), and so human insulin would not 
be necessary, they were themselves developing a human insulin (their covert strategy). 
On the other hand, Eli Lilly were claiming that there was a shortage of animal 
insulins, and so human insulin was necessary (their overt strategy), yet they were also 
developing a purified animal insulin (their covert strategy). 
As human insulin passed through the regulatory process it became endowed with 
particular characteristics, specifically, that it was superior to existing animal Insulins. 
It was believed that human insulin could be inserted into a diabetic's existing network 
body without the need for changes in their network body. In terms of a program of 
action, pharmaceutical companies presented a program of action to doctors, who 
subsequently presented it to diabetics, in which human insulin was to be 
unproblematically used. 
Once passed through regulatory bodies, human insulin was forcefully marketed by 
both pharmaceutical companies, with many diabetics being transferred from animal 
insulin to human insulin in a relatively short period of time. There were other reasons, 
apart from the marketing of human insulin, that caused many diabetics to be 
transferred from animal to human insulin. These included: claims that human insulin 
was superior to animal insulin; the withdrawal of a number of animal Insulins; and, as 
a result of media interest, some diabetics requested to be transferred to human insulin 
(Chapter 4). 
By 1987 the BDA. had become aware that some diabetics were experiencing problems 
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on human insulin. Two particular problems arose: some diabetics felt that their 
`traditional' warning signs of approaching hypoglycaemia were no longer present 
when using human insulin; and, some diabetics experienced an increased incidence of 
severe hypoglycaemia. 
It was in Chapter 5 that I described some of the scientific studies that were carried out 
to study the possible adverse effects of human insulin. What was interesting 
(although in the context of SSK, very typical) about the findings in this chapter was 
that although some studies showed that human insulin did not have any negative 
effects, other studies, carried out by different researchers, showed that human insulin 
did have some negative effect. 
At the present time there is still no definitive scientific evidence as to whether human 
insulin does or does not cause adverse effects in some diabetics, in SSK terms there 
has been no `closure' of the debate. However, it is accepted that a number of 
diabetics have experienced problems while using human insulin (although human 
insulin may not have been the cause). As a result of the human insulin debate, there is 
now a consensus within the scientific and medical community (and care groups) that 
diabetics should have a choice of the species of insulin they wish to use. 
In Chapter 6I began to describe in more detail the experiences of diabetics, not just in 
using human insulin, but also their experiences within the doctor-patient setting. 
What particularly came out in this section was that doctors differed in the solutions 
that they presented to diabetics, with some doctors being sympathetic to a diabetic's 
experiences, and others being much more dismissive of similar experiences. 
Depending on the medical `solutions' offered, some diabetics came to a re-settlement 
with their network body while others did not. Those who were unable to come to a 
negotiated settlement, that is, those whose negative symptoms on human insulin 
continued, contacted other actors, such as care groups and the media. 
As the number of diabetics using human insulin increased, care groups became aware 
of a significant number of diabetics who were experiencing problems on human 
insulin. As textual evidence (of possible adverse effects) mounted, care groups began 
to circulate intermediaries through a number of different networks. For example, the 
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BDA sent a number of letters to the medical profession and began their animal insulin 
campaign, which asked for assurances from pharmaceutical companies for the 
continued availability of animal Insulins. It was through the actions of care groups 
and those in the medical profession that the identity of human insulin began to change. 
For some diabetics and members of the medical community, the use of human insulin 
was no longer seen as unproblematic. In some cases changes would have to be made 
to a diabetic's existing network body in order to enable human insulin to `fit' within 
the network body. These changes, e. g. increased blood glucose monitoring, enabled a 
diabetic to come to a re-negotiated settlement with their body. In other cases, it was 
only by transferring a diabetic back to animal insulin that the body could once again 
become settled. 
One particular finding of Chapter 6 was that the two care groups - the BDA and IDDT 
- treated the human insulin issue differently. The IDDT was formed as a result of 
dissatisfaction with the way in which the BDA initially conducted itself in the human 
insulin debate. The original members of the IDDT were concerned that diabetics were 
not being represented adequately by the BDA, and that diabetics were not being given 
enough information about the possible adverse effects of human insulin. As brought 
out in Chapter 6, the main difference between the two groups was that the IDDT were 
more critical of the place of human insulin within the treatment of diabetes than the 
BDA. 
Now that I have presented an overview of the thesis, it is now time to draw out some 
of the key theoretical implications of this thesis. 
7.2 CONSTRUCTING A TENTATIVE THEORETICAL FRAMEWORK 
I now wish to bring together, within a tentative theoretical framework, the issues that I 
have dealt with in the previous chapters. This section will be structured around the 
ways in which actors produced and circulated texts within a number of networks. As 
a starting point we have to keep in mind the initial identity of human insulin as 
brought about by the development of human insulin. I will then look at the circulation 
of texts by diabetics to a number of actors, in particular, care groups. The circulation 
of texts by diabetics is important because they were one way in which a diabetic was 
able to `represent' their experiences. I will then move on to the circulation of texts by 
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other actors, such as care groups and the scientific community, to diabetics and those 
within the medical community. As noted in Chapter 2, texts are important because 
they can (sometimes) easily move from their point of origin, and as they move from 
one actor to another, their (possible) immutability allows them to align actors to 
(re)produce a network - they are able to act at a distance. 
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I" side - refers to the doctor patient setting and the production of a text by a diabetic 
2°(I side - refers to the collectivization by others to produce (possibly) more persuasive texts 
3" side - refers to the circulation of texts to other actors 
Figure 7-1: Schematization of the production, collectivization and dissemination 
of texts on human insulin 
In order to conceptualise the circulation of texts it will be helpful to refer to Figure 7- 
1. Inevitably, given the complexity of the case, this is a tentative and simplified 
schematization. However, by beginning with the first intimation of a problem, in this 
case from the individual diabetic body, and `building up', I hope to be able to bring 
out these complexities. Although the schematization represented in Figure 7-1 will 
provide the backbone to the theoretical discussion, a number of issues need to be 
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brought out of the discussion of Figure 7-1. Although these issues will be alluded to 
in the discussion of the circulation texts, they will be dealt with in greater depth in 
separate sections (see Section 7.3). 
7.2.1 Initial Identities of'Huinan Insulin 
In Chapter 31 described how, throughout the development and production of human 
insulin, existing animal insulins were problematized, and at the same time, human 
insulin was presented as the solution to these problematizations. Identities were also 
being distributed, through the circulation of texts, to a number of actors. For example, 
human insulin was defined as the solution to the complications experienced by some 
diabetics on animal insulin. Other actors were also defined: diabetics were defined as 
what I have called `prospective consuming bodies' of human insulin and doctors as 
those who would prescribe human insulin. 
However, diabetics were not just defined as `prospective consuming bodies'. They 
were also defined as being able to transfer from animal to human insulin without the 
need for changes in the management of their diabetes. One of the concepts that I used 
to illustrate this was the network body. To recap, the diabetic network body includes 
such artefacts as insulin (originally animal insulin), syringes, doctors and other 
diabetics. It is the makeup of this network body that affects how an individual acts 
towards other networks. Although all bodies, not just `ill' bodies, should be seen in 
this way, it is when a body is in crisis that elements of the network body become 
particularly visible. Over time, `ill' bodies come to a negotiated settlement as new 
artefacts are incorporated into the network body and existing ones are redefined. The 
network body of a newly diagnosed diabetic comes to a negotiated settlement through 
the use of insulin, care over their diet, and other management techniques. These 
features then come to re-constitute the settled network body. 
In terms of the network body, human insulin was defined as being able to slot into the 
existing (settled) diabetic network body - the starting apex of Figure 7-1. In ANT 
terms, it would not be necessary to enrol new actors within the network body, or re- 
inscribe existing ones, in order for human insulin to be `successfully' used by 
diabetics. Further, the existing pre-inscriptions of diabetics were expected to be 
sufficient to enable the unproblematic use of human insulin. Referring to my 
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schematization, it was not believed that the use of human insulin would directly lead 
to adverse bodily experiences. The bodily experiences would be `hidden', since it was 
expected that there would be a more or less `straight substitution of animal insulin 
with human insulin. As a result of this straight substitution, there would be no need 
for a diabetic to represent these experiences in either talk or texts. 
Referring directly to human insulin, it was believed that the prescriptions and 
proscriptions of human insulin would be no different to those for animal insulin. 
Further, it was suggested that human insulin would `prescribe' or `enable' more than 
animal insulin, since it was predicted that human insulin would reduce the occurrence 
of diabetic complications, which would then lead to an increase in a diabetic's quality 
of life. Human insulin was therefore inscribed with characteristics that gave it an 
identity of being superior to existing animal insulins. 
It was also expected that the program of action, defined by pharmaceutical companies, 
would be accepted and followed by those involved with human insulin. Through the 
development and production of human insulin, human insulin had become black 
boxed, and was presented unproblematically to doctors, care groups and diabetics. A 
program was presented to doctors, by the pharmaceutical companies, that human 
insulin should be the insulin of choice, due to its claimed superiority over animal 
insulin. In turn, doctors prescribed human insulin to diabetics, claiming that human 
insulin was the `modem' and `best' insulin. These initial identities of doctors, as 
prescribers of human insulin, and diabetics as users of human insulin, were accepted. 
This was shown by the `speedy' increase in the use of human insulin from 6% to 80% 
between 1985-1989 (Balance, 1989). 
Those diabetics who used human insulin, without experiencing any changes in the 
management of their diabetes, accepted, perhaps unknowingly, the program of action 
that human insulin was superior, or at least equal to, animal insulin, and used human 
insulin without experiencing any change in the management of their diabetes. 
Referring to my schernatization (Figure 7-1), a diabetic did not experience a change in 
the way that their diabetes was managed. 
However, many actors did not accept these distributed identities. Using my 
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schematization (Figure 7-1) as a basis, I will describe the means by which diabetics 
expressed their concerns over human insulin. However, it is not just the rejection of 
these identities that has been 1ny interest in this thesis. I have also been interested in 
the way in which one particular actor, such as a diabetic, attempted to re-inscribe the 
meaning of human insulin, and in turn, how other actors, such as doctors, responded 
to this complication. At this point it is worth recalling that Akrich and Latour 
described re-inscription as defining the drama (Akrich and Latour, 1992), and Latour 
has argued that re-inscription is the transformation of a silent artefact into a polemical 
process (Latour, 1992). One of the aims of this thesis has been in describing this 
drama. 
7.2.2 Textualization of Problems in the Network Body 
For a significant number of diabetics human insulin did not fit unproblematically 
within their existing network body. As a result of a `fitting' artefact40 being replaced 
by a `non-fitting' one, many diabetics produced intermediaries which expressed their 
new bodily experiences. Looking at Figure 7-2, diabetics have a varying degree of 
experiential knowledge depending on their duration of diabetes. It was because a 
diabetic's existing experiential knowledge was unable to accommodate changes in the 
management of their diabetes that a diabetic produced and circulated intermediaries. 
These intermediaries expressed the nature of the artefact's `non-fittingness'. 
When experiencing problems on human insulin, it was likely that a diabetic would 
have initially consulted their doctor. The doctor-patient setting is a good place to start 
because the medical practice is the legitimised source from which diabetics are 
encouraged to seek solutions to problems in the management of their diabetes. 
However, within this site of expertise, the actors involved have different knowledge 
bases from which they draw. A diabetic's primary source of `knowledge' comes from 
interpreting their own experiences. On the other hand, a doctor's primary source of 
`knowledge' comes from institutional sources, in particular the British National 
Formulary. 
40 Importantly, `fitting' artefacts may have at one time been `non-fitting'. As illustrated in chapter three, 
there were a number of reports of diabetics experiencing problems on animal insulin when they 
changed from porcine insulin to highly purified porcine insulin. 
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The bottom right part of the figure shows those actors that have little or no scientific or 
experiential knowledge of diabetes. such as a newly diagnosed diabetic. However, as a newly 
diagnosed diabetic learns. through experience, about their diabetes they begin to gain experiential 
knowledge, and move into the bottom left part of the figure. 
The top right part of the figure shows those actors who have knowledge of the science behind 
diabetes, but are not diabetic themselves, so lack experiential knowledge. However, a scientist 
who is a diabetic, will have both the experience of living with diabetes, and may know something 
about the science behind diabetes. 
Figure 7-2: Illustration of the dimensions of experiential and scientific 
knowledge 
Within the doctor-patient setting the doctor has often been classed as an `expert', 
while the patient is `lay', that is belonging to a group referred to as the `public'. The 
label of an actor as an `expert', refers to the classification of that actor, as an 
acknowledged professional in their field, "by virtue of formal accreditation, 
knowledge, training and experience" (Arksey, 1998: 15). On the other hand, `lay' 
actors are those who are not seen as professionals but nonetheless may be interested 
by a particular topic. As described in Chapter 2, one of the important differences 
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between these two actor types is the main source from which knowledge is drawn. An 
`expert' relies on those texts that have been deemed legitimate within their medical 
field. By contrast, `lay' actors largely, although certainly not always, draw from their 
own experiences and from those sources that have textualized the experiences of 
similar actors with which they identify. 
I noted in Chapter 2 that the divide between `expert' and `lay' knowledge is 
problematic. As Davison et al. have argued: 
"The two strands [lay and scientific], though, are rarely if ever entirely 
separable, indeed the range of thought and belief in both the professional and 
public domains is so broad that the traditional lay/scientific dichotomy may well 
have outlived its usefulness. " 
(Davison et al., 1991: 5) 
So, if the distinction between `lay' and `expert' is too simplistic, what other 
dimensions are there? I suggest that we should view this case as based on two criteria, 
the `scientific' and `experiential' (Figure 7-2). The tenn `scientific' refers to those 
actors who possess what is tenned scientific or expert knowledge within a particular 
field. By contrast, the teen `experiential' refers to knowledge that is gained by 
experiencing illness in the first person, or by being in contact, and identifying with, 
those who are experiencing illness. Experiential knowledge will draw upon cultural 
representations, just as scientific knowledge does, but, and this is the key point, these 
are not `accredited' or seen as `scientifically objective'. 
In any particular situation, and around any particular issue, actors within a site of 
expertise will possess differing degrees of `scientific' and `experiential' knowledge 
(classified as low and high). The importance of this classification is that actors can 
possess both types of knowledge simultaneously. Through the doctor-patient setting, 
a doctor may gain an understanding of what a diabetic is experiencing. On the other 
hand, a diabetic may gain an understanding of the scientific basis for their 
experiences. Actors will attempt to persuade other actors of the validity of the 
knowledge that they possess, and it is the value that actors give to both their own, and 
the knowledge of others, that is important to the outcome of the doctor-patient setting. 
It was negotiations that took place within the doctor-patient setting that may have 
235 
7. Theoretical perspectives and human insulin 
affected whether a diabetic produced texts for networks outside of the doctor-patient 
setting. Importantly, there were many possible influences that may have affected 
whether a diabetic was satisfied with solutions presented to them by their doctor (first 
side of schematization). 
These influences include: the popular and diabetic media; family and friends; and 
other diabetics. For an antiprogram to exist, however preliminary, towards a 
particular program, a link has to be made between artefacts, actors and networks. In 
many cases, it is the circulation of texts that enable actors to link what are possibly 
disparate actors and experiences. For example: What caused some actors to link 
hypoglycaemia unawareness to human insulin, and not to the long duration of their 
diabetes? The observation that actors are influenced by a large number of texts, 
shown throughout this thesis, illustrates that actors are subject to the influence of a 
multiplicity of networks (Singleton and Michael, 1993). 
When a diabetic reported problems with the management of their diabetes to a doctor, 
whether or not they had attributed it to human insulin, the doctor had a number of 
possible actions s/he could take (see Section 7.3.1). The possible actions included: a 
dismissal of the problems; changes made to the management of diabetes, within the 
use of human insulin; and, a transferral of the diabetic back to animal insulin. As 
outlined in Chapter 2, it is through the circulation of intermediaries that actors attempt 
to enrol other actors into a particular program of action. The circulation of various 
intermediaries, realised in these different options, defined the frontline of the 
controversy. The negotiations that took place within this site of expertise had an 
influence on whether a diabetic produced texts which articulated their condition. 
Many diabetics who had not attributed their symptoms to a particular origin, accepted 
solutions which brought them to a re-negotiated settlement with their network body. 
Some diabetics, who had attributed their hypoglycaemia unawareness to human 
insulin, also came to a negotiated settlement as doctors presented solutions to them 
which they in turn accepted. In ANT terms, the intermediaries that were circulated by 
doctors, in order for a diabetic to continue to use human insulin, had been successfully 
accepted by diabetics. As a result, diabetics were still enrolled within the human 
insulin network. This group of diabetics were unlikely to have contributed to the 
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production of texts which criticised human insulin. It has to be remembered however, 
that some diabetics originally accepted solutions presented to them, and later, possibly 
due to other critical texts, questioned these initial solutions. 
However, if a diabetic was unhappy with the solutions that were presented to them in 
the doctor-patient setting, they may have produced texts which expressed their 
experiences. In many cases, doctors did not accept that human insulin was the cause 
of the symptoms exhibited by patients. Other doctors, who attributed human insulin 
as the cause, were nevertheless unwilling to return patients to animal insulin. In both 
these cases, doctors expressed counter narratives to those of the patient, and it is as a 
result of these counter narratives that diabetics may have written to newspapers or the 
diabetic media, in other words, produced texts that expressed their experiences. 
Importantly, the production of these texts may have been due to a dissatisfaction with 
a number of different solutions or negotiations within the doctor-patient setting. A 
diabetic may have visited their doctor on a number of occasions, reporting their 
problems, without the diabetic feeling that an adequate solution had been found - the 
intermediaries that were being circulated, to reduce the frontline, were unsuccessful. 
When a doctor was unable to bring a diabetic to a satisfactory negotiated settlement, a 
diabetic may have produced texts for other networks. From the diabetic's point of 
view, it is the doctor who has the identity of being able to solve bodily problems. 
However, if an actor, in this case the doctor, is no longer able to maintain a particular 
identity then it is likely that there will be some crisis between the actors involved, in 
this case, between the doctor and the diabetic. Therefore, for those diabetics who did 
not come to a negotiated settlement within the doctor-patient setting, there was a 
`personal necessity' (Lambert and Rose, 1996) to understand their unsettled network 
body. One way in which this understanding could be gained was through seeking out 
other actors. 
For a diabetic experiencing problems with the management of their diabetes, and 
wishing to understand their experiences, an obvious starting point was to seek 
information from care groups. Initially, diabetics wrote to the BDA (since the IDDT 
wasn't yet formed) describing some of their experiences. These experiences were not 
just those on human insulin (such as an unawareness of hypoglycaemia), but also 
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describing their contact with doctors (such as claims that doctors were unsympathetic 
or that they denied the existence of particular animal insulins). From this body of 
texts care groups chose which to include within their magazines and newsletters. 
7. ?. 3 Collectivization of'Texts 
With regard to my schernatization (Figure 7- l ), the collectivization of texts is key in 
showing the discussions around the human insulin debate. When texts become 
`collectivized' they may include texts from a number of different sources. These 
sources may not be just from a similar type (letters describing the experiences of 
diabetics or reviews of the scientific literature) but also from different types of sources 
(evidence of the experiences of diabetics from both scientific studies and diabetic 
reports). This is one of the points where texts from other networks, such as scientific 
evidence, comes into contact with other sorts of understanding; that is, where different 
types of knowledge are differentiated and/or combined. Such differentiation and 
combination rests, at least in part, on the relation between `expert' and `non-expert' 
actors. This is because, what texts become collectivizable within other texts depends 
on the sort of trustworthiness that is attached to the initial texts. Such trustworthiness 
(or authority) will reflect the relation between different actors, such as experts, 
doctors, scientists, care groups and diabetics etc. 
Before I continue, it is worth differentiating between Latour's idea of the combination 
or integration of texts (Latour, 1987), and my notion of collectivization. Latour talks 
of the process by which texts of a similar kind are integrated, and then reduced to 
form an immutable mobile. Take for example the calculation of gross national 
product (GNP). In order to calculate a countries' GNP it is necessary for statisticians 
to accumulate data relating to income earned by domestic citizens, regardless of the 
country in which their services were supplied. As a result, statistical data will be 
gathered from a number of sources and then reduced to a final figure. However, 
collectivization involves the accumulation of texts of different types and content. For 
example, editorials included quantitative texts (e. g. scientific studies), qualitative 
evidence (e. g. case studies) and biographical texts (e. g. personal accounts). The 
resulting narrative did not attempt to reduce the data, rather, the data was juxtaposed 
without integration. 
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The two concepts should not however be seen in opposition. Instead, they should be 
viewed as existing on a spectrum, with combination at one end and collectivization at 
the other. Although the texts dealt with in this study are the result of collectivization, 
they may also involve elements of combination. For example, some editorials 
presented data from many scientific studies, which was then reduced to a prediction of 
how many diabetics may be experiencing hypoglycaemia unawareness. As well as 
this data however, editorials also included biographical evidence. 
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Figure 7-3: Extending the core set 
It should also be stressed that collectivization is not about sharing texts. Instead, 
through collectivization, texts are integrated with others. It is not the case that whole 
texts are collectivized, rather, particular issues, within texts, are `pulled out' and then 
(re-)interpreted by actors. Texts will be (re-)interpreted in terns of the network that 
the collectivizing actor is part. 
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Returning to collectivization, it is important to be able to formalise the relations 
between members of the scientific community and other actors (such as care groups 
and individual diabetics). One way to do this, is through the notion of the core set 
(Collins, 1981; Collins, 1985; Collins, 1988). It is necessary therefore, to take a slight 
detour from Figure 7-1 and describe the core set, before returning to Figure 7-1. 
7.2.3.1 The core set 
Those scientific actors, who were attempting to produce facts within the human 
insulin debate, can be seen as comprising what Collins calls a core set. Collins 
(Collins, 1981; Collins, 1985; Collins, 1988) describes a core set as consisting of 
`insiders' and `others'. In a scientific controversy, according to Collins, there is an 
elite group of insiders who possess the necessary technical and practical knowledge to 
formulate and judge competing truth claims. Of course, in a particular controversy the 
`experts' will be different. For Collins: 
"... the core-set of scientists are those who are actively involved in 
experimentation or observation, or making contributions to the theory of the 
phenomenon, or the experiment, such that they have an effect on the outcome of 
the controversy. " 
(Collins, 1981: 8) 
Within the core set there is also a penumbra of would-be contributors. Work carried 
out by this group is not significant to the controversy as far as the core set members 
are concerned (Collins, 1981: 11). Collins has argued that it is an actor's association 
with the less prestigious institutions and actors which prevents them from entering the 
core set. As a result, the experimental material produced by these actors is seen as 
being of a'low level'. 
One important feature of the core set is that it includes both `allies' and `enemies'. 
That is, within a core set there is likely to be animosity and conflict, especially if 
members come from different scientific disciplines. Indeed, Collins points out that 
some members of the core set may be intent on destroying a particular interpretation 
of `truth' that others have staked their scientific reputation on (Collins, 1985). This 
was shown in Chapter 5, where many researchers did not accept the claims of 
`facticity' put forward by other researchers. Many studies were criticised on scientific 
grounds, and the authors of letters, written in response to these studies, were criticised 
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for their reading and understanding of the studies they were commentating on. These 
criticisms attempted to problematize the texts that were being circulated by scientists. 
Another important feature of the core set is that actors within it need to maintain a 
degree of `privacy' or exclusivity. By doing so, experts can maintain the illusion that 
they are able to produce relative certainties. When knowledge is then produced from 
within the core set it becomes purified (Latour, 1993). Any social, political or 
economic interests that once existed within the set are `removed', and only a version 
of the `science' conducted within the core set is produced. It is the use of this 
`purified' knowledge, within wider circles, that feeds back into the core set and so 
justifies its authority (Arksey, 1998). What is at stake within core sets is the ability of 
actors, within the core set, to claim `facticity' about some part of nature. Within the 
core set there is also a core group which embodies what comes to be known as the 
dominant view (Collins, 1999). In this study, the core group claimed that human 
insulin was safe as long as certain considerations were observed. One such 
consideration was that there may be a need for a reduction in insulin dose compared 
with animal insulin. 
Those on the outside of the core set can be described as the `lay' public. According to 
the notion of the core set, this `lay' public are unable to appreciate the complexity of 
the science that is discussed within the core set, and as a result, can be justifiably 
marginalised. In one article, Collins has argued that: "it would be a strange world if 
there were no experts. It would be a strange world and one I would not welcome if 
`the public [had] its own and legitimate interests in the very content of science"' 
(Collins and Pinch, 1994: 335). 
In some instances, lay individuals are invited, if only in a restricted sense, to be 
members of the core set. In Collins' case study of the UK's Central Electricity 
Generating Board's demonstration of the `safety' of its nuclear fuel flasks, members 
of the public were invited to attend, through the media, an experiment which 
demonstrated the safety of the flasks (Collins, 1988). The members of the `public', 
who were invited to be observers, were temporarily defined as `experimenters' who 
were able to judge the science that they were observing - in this case the testing of 
nuclear fuel flasks. In reality, it was not an open experiment that the public were 
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observing, but a display of post-closure knowledge (Michael and Birke, 1994). By 
accepting the identity defined for them, the actors had become allied to the work of 
the experimenters. 
However, in this example actors were also being given other identities, as well as the 
temporary identity of `experimenter'. They were also given the identity of someone 
interested in `Britain's economic well being' (Michael and Birke, 1994). Without this 
supplementary identity, the demonstration may be rejected, on such grounds as: `What 
happens when the flasks reach the power station? What are we doing with the nuclear 
waste? ' With these other identities, the `experiment' could have been rejected on 
broader political, ethical or economic grounds, rather than simply on technical 
grounds. With these other identities the core set can potentially be extended to 
encompass any actor with a view on the relevant subject, whether the view is 
politically or morally based (Michael and Birke, 1994). 
Another problem with the conception of the core set, as outlined by Collins, is that not 
all disputes are confined to scientists and scientific institutions. The work of Collins 
has mostly been concerned with scientific controversies that involve experimentation 
and observation (Collins, 1981). As indicated above, Collins would oppose extending 
the core set beyond `expert professionals'. However, a large number of controversies 
involve a public element. In such cases, Collins would argue that the public should be 
represented by their own experts. In such cases these `experts' will still be using the 
existing pathways to knowledge - the scientific method. Collins offers no "discussion 
of the process by which laypeople can construct alternative ways of knowing or new 
varieties of expertise that-sometimes-alter the pathways of knowledge construction" 
(Epstein, 1996: 17). In this case, looking at a `simplistic' core set does not help us: 
"where who get to count as an expert is one of the issues at hand and which set of 
characteristics qualify one as such" (Epstein, 1996: 17). It is not just important to 
look at which `experts' are able to claim facticity, but also how `non-experts' are able 
to claim that their knowledge is just as credible as scientific knowledge. 
As shown throughout this study, other actors were involved within the scientific 
debate. As a consequence, the boundaries of the debate were more problematic than 
implied by the work of Collins. As Arksey has argued, when the `public' are involved 
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in a scientific debate, there is a need for more politicking in order to stabilise the 
enquiry, that is, in deciding what the central issues are to be (Arksey, 1998). In this 
study, it was not just scientists that were attempting to define the important issues, but 
also other actors, such as care groups. In Section 7.3.3 I will look more closely at how 
this was done. 
In this study, the traditional core set consisted of researchers such as Teuscher, Berger 
and Williams. There was also a group of commentators who did not carry out 
experimental work themselves, but wrote review articles and interpreted findings. To 
this groups, we can add authors such as Pickup and Amiel. However, we need to 
extend the notion of the core set further (Figure 7-3). 
Michael and Birke (Michael and Birke, 1994) claim that by developing the concept of 
the core set it can become more useful to understanding scientific controversies. They 
argue that scientists are increasingly aware that there is a need for `non-scientists' to 
be involved within scientific debate, at least on the surface. These `other' actors 
comprise what they call a `generalized agonistic set', which is open to anyone wishing 
to express a view. However, there is a censoring of those who are allowed into this 
newly constructed core set. Michael and Birke used the term `envelopment' to 
describe how "target actors are invited and manoeuvred into an argumentational 
envelope in which there is space for a limited number of opposing or antagonistic 
positions" (Michael and Birke, 1994: 92). These actors are not enrolled, since the 
identities of the actors are not being definitively formulated, rather the associations are 
flexible or agonistic. 
Actors within the scientific core set, define a set of minimal characteristics that groups 
within the `generalized agonistic set' must follow to be part of a debate - to become 
part of the argumentational envelope. In the case of the anti-vivisection debate, these 
characteristics were: rationality, non-violence, civility, and so on (Michael and Birke, 
1994: 84). I will look at the minimal characteristics for the human insulin agonistic 
core set in Section 7.3.2. 
Figure 7-3 shows one way in which the `new' core set can be represented. Those that 
are further away from the inner ring are less influenced by the texts that are circulated 
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from within the scientific core set. Importantly, those actors in these outer rings are 
influenced much more by other texts, such as those from `lay' individuals. A 
comparison can also be drawn between the penumbra in Collins' version of the core 
set and these outer rings. Work carried out by the outer rings, particularly when it is 
`non-scientific', is not seen as significant by members of the scientific core set. As I 
will show in Section 7.3.3, care groups attempted to break this boundary, by stressing 
the value of their own knowledge. 
Returning to Figure 7-1, the collectivization of texts does not just include texts of a 
similar kind, but can include a whole variety of texts from different networks - 
different parts of the core set (both scientific and lay). For example, one set of texts 
that were produced by diabetics described how they were told by their doctor that 
animal insulins were no longer available. Care groups then contacted pharmaceutical 
companies to discover which animal insulins had been withdrawn. In a significant 
number of cases equivalent animal Insulins were still available, and care groups 
reported this fact through their magazines. 
In other acts of collectivization, actors had a degree of flexibility to which texts they 
selected. As pointed out above, one of the important features of the scientific core set 
is that not all actors within this set will agree. As a consequence, when an actor 
attempts to collectivize texts, which include those from within the scientific set, they 
have a degree of flexibility to which scientific texts they use and collectivize. As 
Epstein has argued, the definitiveness of a study is "a negotiated outcome and one that 
may be actively resisted by some members of the controversy" (Epstein, 1996: 334). 
Similarly, Shapin and Schaffer (Shapin and Schaffer, 1985) argue that scientists 
negotiate what counts as evidence and which experiments represent the accurate 
testing of a hypothesis. 
When an actor is collectivizing texts, they do not just have a degree of flexibility of 
which experiments adequately represent reality. There is also a degree of flexibility of 
which texts within the rings of the core set represent reality. For example, 
pharmaceutical companies- stressed that the majority of diabetics on human insulin did 
not experience any problems. On the other hand, the IDDT stressed that there were a 
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significant minority who had experienced problems. 
As part of the collectivization of texts, the IDDT tended to draw on scientific texts 
that backed up the possibility of adverse effects on human insulin. This reflected the 
IDDT's initial position, gained from experiential evidence, that human insulin did 
cause adverse effects. On the other hand, pharmaceutical companies, who had 
invested a large amount of resources in human insulin, selected texts which backed up 
their position that human insulin was safe and efficient. Importantly, from the point 
of view of the pharmaceutical companies, the dominant view within the core set, what 
Collins calls the core group (Collins, 1999), was that human insulin was the insulin of 
choice. This was important because it allowed the continued regulation of human 
insulin (had the dominant view been that human insulin did cause negative effects 
then it may have resulted in the withdrawal of human insulin). Since the 
pharmaceutical companies had invested a large amount of resources into human 
insulin, this would have been a major upset for them. 
The selection and collectivization of texts by actors is therefore shaped by the wider 
networks of which an actor is part: the IDDT were representing those diabetics that 
were having problems on human insulin, and it was those studies that `reified' these 
experiences that were seen as credible. On the other hand, the BDA had built up links 
with pharmaceutical companies and the medical profession. These links may have 
been one reason why, when the BDA were contacting other actors (such as the 
pharmaceutical companies), they did not keep their readers informed of their actions. 
It may have been the case that they did not want to strain their relationship with these 
other actors when the negative effect of human insulin was unproven. The IDDT 
had 
no such links with other actors. 
7.2.4 Dissemination of Collectivized Texts 
Collectivized texts should be seen as describing the relation that the producing actor 
has to other actors. These collectivized texts are then disseminated with the aim of 
persuading others of their `facticity'. Different texts (scientific reviews, care group 
articles and medical reviews), produced by different actors (scientists, IDDT and the 
BDA), were directed towards different actors (doctors, diabetics and regulatory 
bodies) within any part of the core set. The important point is that actors can, 
in 
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theory, collectivize texts from any part of the core set, whether from the scientific set 
or the generalized agonistic set, and disseminate these texts to any other part of the 
core set. 
In many cases, it was through receiving disseminated texts, from care groups and the 
popular media, that diabetics became aware of the human insulin controversy and the 
problems experienced by other diabetics. The importance of these texts is that it may 
have enabled a diabetic to link their own experiences to those of others. For example, 
a diabetic experiencing a change in their warning signs of approaching hypoglycaemia 
may have attributed it to their duration of diabetes, perhaps through consultation with 
their doctor. In this situation, there may be no antiprograrn to human insulin even 
though a diabetic is experiencing some form of biographical disruption, or `crisis', in 
their network body. However, as a diabetic became aware of popularized texts that 
described the experiences of others, they may have re-interpreted their original 
diagnosis and solution, and linked their symptoms to human insulin. In such 
scenarios a diabetic may have formed an antiprogram towards human insulin. 
When a diabetic accepted and used disseminated texts the `knowledge' contained 
within them then became part of the diabetic's network body. It is this knowledge that 
may have been used to bring themselves to a negotiated settlement. In Chapter 6, I 
described how some diabetics used information about the availability of animal 
insulins to `persuade' their doctor to transfer them from human to animal insulin. In 
some cases, using texts from the IDDT, diabetics went outside of the doctor-patient 
setting to gain animal insulin independently. Other diabetics used texts which 
described the experiences of other diabetics. These texts attempted to reduce the 
frontline between the doctor's dismissal of problems and the diabetic's experience of 
problems on human insulin. However, rather than the doctor presenting solutions, to 
enrol the diabetic into their program, it was the diabetic who was attempting to enrol 
the doctor to their program of action. 
Care groups also directed texts towards other networks. For example, the BDA's 
petition was directed towards pharmaceutical companies, while the IDDT often wrote 
to the regulatory bodies about the experiences of diabetics on human insulin. 
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I have already stressed that texts were used by diabetics to bring themselves to a 
negotiated settlement. However, there was another function of texts that were 
circulated by care groups. The IDDT encouraged diabetics to produce and circulate 
texts themselves. In particular, they asked diabetics to contact their local media and 
describe their experiences on human insulin. They also informed diabetics of their 
patient rights. 
We must not forget that doctors also received disseminated texts. The main source of 
these texts was of an institutional nature, that is, the bedrock of any diagnosis is based 
upon certified knowledge (Collins, 1985) produced from within the scientific core set. 
This includes such texts as those from the British National Formulary and prescription 
guidelines. However, Phillips has argued that "the direct transmission of information 
in the medical literature... is enhanced or amplified by secondary amplification in the 
lay press... " (Phillips et al. (1991) quoted in Epstein, 1996: 22). Therefore, it may be 
through the `lay' or non-medical media that doctors are provided with a sense of 
which scientific findings are important (Epstein, 1996). In the case of human insulin, 
doctors may have read about the experiences of some diabetics on human insulin. 
Doctors may also have come into contact with other diabetics who had experienced 
problems. These other experiences may have been tacitly influential in the way 
doctors treated subsequent patients. As doctors built up their experiential knowledge, 
it may have become a more credible challenge to their institutional knowledge. It may 
have even been the case that they themselves had experienced problems with human 
insulin, such as Dr. Kiln. 4' As a result of these other influences, it is possible that 
`institutional' knowledge will be re-interpreted within local conditions. Having an 
amalgamated notion of lay and expert knowledge (Figure 7-2), enables us to 
accommodate for the fact that actors are influenced by both `expert' and `lay' 
knowledge. Indeed, it is questionable whether actors ever possess solely `expert' or 
`lay' knowledge. 
As actors disseminated texts they attempted to move themselves into more credible 
41 As Dr Kiln admitted, he found it difficult to comprehend that while scientifically there should be no 
problem with human insulin, through his own experience, he felt there was a problem with human 
insulin. 
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positions, both in relation to members of the scientific core set, and with members of 
the `generalized agonistic set'. For example, the pharmaceutical companies wanted to 
be seen to be acting on the problems experienced by some diabetics, and as a result 
changed their patient information leaflets. Both the BDA and the IDDT wanted to be 
seen to be acting in the interests of diabetics, and as a result to be seen as the 
obligatory passage point by which diabetics sought information. However, as shown 
in Chapter 6, the method by which this was done differed between the two groups. 
Initially the BDA directed texts towards the medical profession. This led to the claim 
that the BDA were not actually doing anything for the benefit of patients, when in 
fact, they were working behind the scenes. On the other hand, the IDDT were very 
open about what they were doing, in particular that they were very interested in 
empowering diabetics. For example, they aimed to `educate' diabetics regarding their 
rights. In particular, they explained how diabetics could obtain animal insulin, 
without going through their own doctor. 
As the debate over the safety of human insulin progressed, those carrying out 
scientific work attempted to give the texts that they were disseminating credibility by 
mixing both scientific and experiential knowledge. Studies that were carried out later 
in the debate included not only biological evidence (such as changes in blood glucose 
levels), but also experiential evidence (such as a diabetic's awareness of approaching 
hypoglycaemia). By carrying out such work, it was hoped that care groups would 
view the studies with more credibility since they were taking account of the 
experiences of diabetics, albeit in artificial conditions. Scientific studies are to some 
extent artificial because they are unable to duplicate all the possible influences that a 
diabetic may experience in everyday life. Care groups also disseminated scientific 
evidence that used to give support to experiential evidence (this will be studied more 
closely in Section 7.3.3). 
It should be clear therefore, that through the dissemination of texts an identity of the 
producing actor, and its relation to other actors, is formed. For example, some 
diabetics and doctors felt that the IDDT was too aggressive, while others believed that 
the BDA wasn't aggressive enough. It was due to these different identities that 
diabetics and other actors (scientists and doctors) allied differently with the two 
groups. 
248 
7.2 Constructing a tentative theoretical framework 
As well as the identity of the actor who is disseminating texts, there are other factors 
which determine whether a text will be accepted. Michael (Michael, 1996) talks 
about ignorance, represented discursively, as a result of a division of labour. This 
kind of ignorance is constructed due to a belief that `credible' others are `looking 
after' and protecting one. Ignorance as a division of labour then, refers to elements of 
the cultural (and institutional) backdrop, and how they affect the interpretation of texts 
- these texts may include those that represented the ill-fitted network body. For 
example, although diabetics may have been aware that other diabetics were 
experiencing problems while on human insulin, there may have been a belief that the 
problems were not directly related to human insulin. Some actors believed that other 
actors (regulatory bodies) would not allow a dangerous drug to be marketed. Indeed, 
some diabetics claimed that the responsibility for problems on human insulin may rest 
with the diabetic, since they may not be carrying out adequate blood glucose 
monitoring. 
Before I go on to look at some particular issues, it is worth pointing out that once texts 
are disseminated to actors, it is by no means the `end of the life' of the text. I have 
already stressed that some texts that were circulated to diabetics, by the IDDT, were 
used by diabetics to illustrate to doctors that other diabetics were having similar 
experiences to themselves. Certain scientific texts were also drawn upon time and 
time again, such as the initial paper by Teuscher and Berger (1987). The 
collectivization of texts is therefore a continual process, in which texts are chosen to 
support an actor's position within the debate. 
Once texts have been circulated, they are added to a body of texts which may be 
drawn upon by other actors in the process of collectivization. Collectivization is 
therefore always a dynamic and unfinished process. At any time actors may draw 
upon disseminated texts. Importantly, the texts that are seen as credible by actors may 
change as other texts are circulated. For example, as texts were circulated criticising 
the paper by Teuscher and Berger (1987) on methodological grounds, scientists tended 
to draw less (collectivize less) on this study. However, the IDDT still drew heavily on 
this study as it was, for them at least, the study that `proved' that human insulin did 
cause negative effects. 
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In this section 1 have suggested one way in which the collectivization and 
dissemination of texts can be theorised. As an initial starting point I looked at the way 
a diabetic, experiencing disruption in their network body, produced texts to care 
groups which expressed their own experiences. These texts were then collectivized by 
care groups in order to forrnalise a position within the human insulin debate. 
Although I began with the collectivization of texts by care groups, I also stressed that 
other actors, such as those within the scientific and medical community, also 
collectivized texts. These collectivized texts, which may have included both 
experiential and scientific evidence, were then disseminated to other actors (e. g. 
diabetics and doctors) with the hope of persuading these actors of their `facticity'. 
At a number of points in this section I indicated that there were issues that I would 
deal with separately, it is to these issues that I now turn. 
7.3 OTHER ISSUES 
In this section I would like to deal with three issues that were alluded to in the 
previous section. In Section 7.3.1 I will look at how the various solutions presented to 
diabetics can be related to the network body. Then in Section 7.3.2, I will look at the 
set of minimal characteristics that allowed actors to be members, and remain within, 
the agonistic core set. Finally, in Section 7.3.3, I will look at some of the actions of 
care groups with members of the scientific core set. 
7.3.1 Solutions to the Problems Experienced by Diabetics 
I argued in Section 7.2.2 that the negotiations that took place within the doctor-patient 
setting affected whether a diabetic textualized their experiences. I argued that within 
the doctor-patient setting intermediaries were circulated which attempted to bring the 
diabetic to a negotiated settlement. In this section I would like to theorise these 
various solutions in terms of ANT and the concept of the network body. 
There were a `stock of solutions' that were available to the doctor in order to bring a 
diabetic to a negotiated settlement over human insulin. One approach was to redefine 
the `state of a diabetic's network body. In the regulation of human insulin various 
scientific studies were carried out to assess the safety and efficiency of human insulin. 
I argued in Chapter three, that these studies were carried out on subjects that could be 
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called exemplar bodies, since these bodies were acting as representatives of the 
diabetic population. These studies showed that human insulin was safe and efficient. 
However, in some cases individual diabetics did not act in the same way as the 
exemplar bodies. Since exemplar bodies should be seen as `normal' diabetics, some 
doctors attempted to redefine those diabetics, who were having problems with human 
insulin, as being `not-normal'. There were many examples of this in the literature. 
For example, where diabetics were defined, by their doctor, as having psychological 
problems or imagining their problems. In this case, doctors did not accept the 
`facticity' of a diabetic's experiences, and denied the existence of a diabetic's 
symptoms. It may be possible, as Arksey (Arksey, 1998) has suggested, that such 
actions to `discredit' patients, are a way in which a doctor attempts to disguise their 
own lack of knowledge. 
In other cases, symptoms were verified and the `facticity' of a diabetic's experiences 
accepted, but the symptoms were defined as being part of diabetes, in particular, that 
changes in an awareness of approaching hypoglycaemia were due to a patient's long 
duration of diabetes. These experiences were defined as `natural', in terms of 
diabetes, and independent of the species of insulin being used. In these cases human 
insulin was still defined as unproblematic. 
Another group of solutions was based on the verification of a diabetic's symptoms, 
and an attribution of these symptoms to human insulin. In this approach, solutions 
were taken in which the diabetic's network body was reconfigured within human 
insulin treatment. Approaches taken here included such actions as, reducing the dose 
of human insulin administered and encouraging a diabetic to carry out increased blood 
glucose monitoring. In this case, there was an acceptance that the existing pre- 
inscriptions of the diabetic, generated through the use of animal insulin, were 
inadequate for the healthy use of human insulin. These pre-inscriptions needed to be 
changed, or in ANT terminology, re-inscribed. 
In these cases, it was through the circulation of intermediaries (such as medical 
advice) that the frontline was to be reduced (Akrich and Latour, 1992). Importantly, 
human insulin was still to be used, by accommodating it within the network body - the 
use of human insulin was being re-inscribed. Although human insulin may have been 
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problematized, it was by reconfiguring the user, to use human insulin `properly', that a 
solution was to be found. Further, any changes that were made were defined as being 
those that may have been necessary with any therapeutic change, not just human 
insulin. For example, in Chapter 5,1 described how reports of a loss of awareness 
were made when diabetics were changed from conventional animal insulin to highly 
purified animal insulin. In this case, as with the transferral to human insulin, changes 
were defined as `fine-tuning'. 
In these two cases, the intermediaries that were circulated by the doctor, in order to 
continue the use of human insulin, had been accepted by diabetics. However, as 
indicated in the previous section, it was by no means certain that the solutions 
presented by doctors would be on-goingly accepted by diabetics. Through coming 
into contact with other texts, such as from the IDDT, a diabetic may have questioned 
the solution presented to them, and thus may have questioned the management of their 
diabetes. 
A third solution was to transfer the diabetic back to animal insulin. In this case, there 
was a verification of a diabetic's symptoms which were then attributed to human 
insulin, but the solution was not seen to lie within the human insulin network. 
Instead, human insulin was to be removed from the network body and replaced with 
animal insulin - it was not the user that was being reconfigured, but one artefact was 
being replaced by another within the network body. In this case, the pre-inscriptions 
gained through the use of animal insulin were accepted as still being credible and it 
was human insulin that was seen as problematic. 
In the other solutions, the program that human insulin was superior may not have been 
accepted, but the diabetic did not have the resources to be aware of alternatives. In 
this final solution however, a diabetic may have had the resources to reject the 
program that human insulin was superior. 
The fact that there were a number of possible solutions emphasises that actors, 
especially doctors, are subject to a number different texts. Some doctors were more 
likely to change their patients to animal insulin than others. This also suggests that 
there may have been an extended process through which a diabetic may have gone 
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through in order for their network body to come to settlement. Over time, as an actor, 
whether a diabetic or a doctor, received disseminated texts they may have become 
aware of diabetics who were experiencing similar problems on human insulin. This 
awareness may have altered the solutions presented by doctors, and the solutions 
accepted by diabetics 
In conclusion then, the circulation of intermediaries by a doctor may have brought a 
diabetic to a negotiated settlement with their body. Some diabetics did not have an 
antiprogram to human insulin, and accepted one of the solutions which brought them 
to a settlement with their body. Those diabetics who had an antiprogram to human 
insulin, as a result of disseminated texts, also came to a settlement with their body. 
the solutions however, rather different, entailing either a switch back to animal, or an 
`extended' switch which included further textualization, the circulation of 
intermediaries, and the collectivization of texts within the human insulin network. 
7.3.2 Agreement within the Core Set 
As described in Section 7.2.3.1, actors within the scientific core set, define a set of 
minimal characteristics that groups within the `generalized agonistic set' must follow 
to be part of a debate. In the case of the anti-vivisection debate, these characteristics 
were: rationality, non-violence, civility, and so on (Michael and Birke, 1994: 84). 
In this study, the characteristics for entry into the core set are not easy to define. One 
possible criterion for inclusion into the core set can be deduced: members of the 
`generalized agonistic set' had to act `responsibly' towards diabetics. Yet what is 
meant by `responsible' is not set. For the IDDT, responsible meant the general and 
uncensored spread of information about human insulin; for the BDA, `responsible' 
meant not sharing all the information at their disposal, due to a concern of causing 
stress to diabetics. Yet it is possible to outline one specific meaning of 'responsible' 
that all appeared to agree on - that diabetics should not change their insulin without 
consultation with a medical practitioner. The doctor was seen as having a central role 
in the management of diabetes, because of their direct access to medical texts. To 
question whether the doctor had a role at all would bring castigation not just from the 
medical community, but also from the scientific community and governmental bodies, 
and importantly, from other care groups. For both the care groups then, negotiations 
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over solutions to a diabetics problems were to take place within the doctor-patient 
setting. Importantly, the IDDT did encourage the inclusion of various texts into these 
negotiations. For example, the IDDT suggested that diabetics bring evidence of 
possible side effects, in the form of the IDDT newsletter, to the doctor-patient setting. 
This illustrates how some texts are `channelled' back. In particular, it stresses that by 
using collectivized texts diabetics were able to illustrate to their doctor that there were 
other diabetics experiencing similar adverse effects on human insulin. It was hoped 
that through the use of such texts, diabetics would be able to illustrate to their doctor 
that there were other solutions than those that they were currently using. 
The pharmaceutical companies can also be seen as acting responsibly. When 
scientific evidence was mounting that human insulin may cause adverse effects, but it 
was by no means conclusive, pharmaceutical companies changed their patient 
information leaflets to warn of possible changes in awareness of hypoglycaemia. 
Pressure to make this change had come from care groups and regulatory bodies. The 
companies can be seen as attempting to reduce any potentialfi°ontline with members 
of the core set, in particular, the regulatory bodies. Further, since this strategy kept the 
pharmaceutical companies in a `favourable' position within the core set, it allowed 
them to claim that they were doing everything they could to warn diabetics of possible 
adverse effects. The stress here is on the `possible', since the view of the dominant 
group was that human insulin was safe. There was no pressure from regulatory bodies 
to withdraw human insulin, and so pharmaceutical companies only had to advise on 
possible adverse effects. 
Membership of the generalized agonistic set also necessitated that actors believed in 
the principle of a choice of insulin species. For example, the IDDT were concerned 
that the wrong impression was being given that it wished for all human insulin to be 
withdrawn. They clarified their belief that human insulin should not be seen as the 
insulin of first choice, but that human insulin should still be available. There were no 
scientific grounds for human insulin being withdrawn, and for an actor to claim that 
human insulin should be withdrawn, would give the impression that an actor was 
acting irrationally. 
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Pharmaceutical companies also accepted the need for the continued availability of 
animal insulins, and consequently, for insulin choice. However, Eli Lilly did not 
market an animal insulin in the UK, and Novo Nordisk were discontinuing a number 
of their animal insulins. Therefore, both Eli Lilly and Novo Nordisk left the 
`possibility' of choice, that is the production of animal insulin, to other actors. 
Importantly in the issue of choice, pharmaceutical actors did not have to enable choice 
themselves, that is produce animal insulin, rather just support choice. 
What is interesting about the issue of insulin choice is that the criterion for inclusion 
into the debate over human insulin was mutual. The core set consisted of scientists, 
commentators, regulatory bodies, doctors, pharmaceutical companies and care groups. 
It was not the case that those within the scientific set, such as scientists and 
commentators, were defining the criteria for inclusion into the generalized agonistic 
set, which consisted of care groups and pharmaceutical companies etc. Instead, the 
criterion of choice was agreed upon by all members of the core set. Any actor who 
disagreed with this criterion would not just be rejected by the scientific set, but by 
members of the generalized agonistic set as well. Therefore, on the issue of insulin 
choice, all actors can be seen as forming, what we might tentatively call, a 
`generalized consensus-orientated set', where the consensus is focused on choice. 
7.3.3 Actions of Care Groups with Members of 'the Core Set 
In a number of instances, the care groups in this study attempted to question the 
boundaries between themselves, and the scientific and medical community. One way 
in which the boundaries were questioned was through the collection and 
dissemination of texts, as illustrated in Figure 7-1. Many texts questioned the 
authority of the studies that were carried out, or the exclusivity of scientific 
knowledge. Figure 7-4 shows three basic strategies of how care groups attempted to 
blur or question the boundaries between care groups and the scientific and medical 
community. These strategies were: care groups stressed the value of experiential 
knowledge; they became actively involved in how scientific work was conducted; and, 
they gathered scientific knowledge and enrolled scientific actors. 
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Figure 7-4: Care group strategies 
In the concept of the core set outlined by Collins, the public are not seen as having the 
credentials to enter the scientific core set. However, in the new formulation of the 
core set the public do have a greater role. In controversies where the public are 
involved the public themselves should be seen as `experts' (Arksey, 1998). This study 
can be seen as illustrating `popular epidemiology', defined by Brown as: 
"... the process whereby laypersons gather scientific data and other information, 
and also direct and marshall the resources of experts in order to understand the 
epidemiology of disease. " 
(Brown, 1992: 269) 
It is not a simple task to be able to carry out scientific work. As Latour points out, 
dissent is not possible without "a huge accumulation of resources which permits the 
collection of relevant inscriptions" (Latour, 1987: 70). Although it is possible for care 
groups to collect scientific inscriptions, through reading scientific literature, it is less 
likely that care groups will be able to gather the many devices, artefacts and people 
(and the many other intermediaries) that enable the production of scientific 
knowledge. However, one way to counter this `lack', is to stress and champion the 
credibility of other types of knowledge, in this case experiential expertise. By 
collectivizing and stressing the value of experiential narratives, it was hoped that 
patients' narratives would stand against the narratives from biomedicine (Hyden, 
1997). Evelleen Richards has argued that the myth that clinical trials can produce 
definitive knowledge primarily serves the interests of professional legitimation. 
Instead, she argues for a more prominent role for the public in the decision making 
process (Richards, 1991). In this case study care groups were attempting to bring 
about this more central role, by claiming the value of experiential knowledge. As the 
IDDT pointed out, even if patients don't have scientific and medical knowledge, they 
have something valuable to offer - the experience of living with diabetes (IDDT, 
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1995a). 
So care groups attempted to give a central role to experiential knowledge, by 
circulating collectivized texts detailing the experiences of diabetics on human insulin, 
to the scientific and medical profession (Figure 7-1). It was hoped these texts would 
`educate' doctors, and ensure that patients suffering on human insulin would be 
`properly' treated. Care groups were attempting to `move' doctors into a position of 
higher experiential knowledge (Figure 7-2). Not only did the texts circulated by care 
groups describe the experiences of diabetics' network bodies on human insulin, they 
also described the experiences of these bodies within a number of networks. For 
example, they described how the experiences of some diabetics were dismissed by 
some doctors, and how other doctors claimed that animal insulins had been 
discontinued. 
Care groups also attempted to affect the way in which devices, artefact and people 
were gathered to produce scientific work - they wanted to become actively involved in 
how scientific work was conducted. For example, the BDA funded a number of 
research projects and investigated the possibility of an ideal study. The IDDT had 
questioned the characteristics of the exemplar body that was used in various studies, 
arguing that, subjects were removed from the network in which they would normally 
be placed, meaning that the studies were `overly artificial'. The IDDT also had letters 
published in the scientific media, criticising studies and suggesting how future studies 
should be carried out. The groups were therefore accepting the place of science as a 
key resource, but not accepting its "automatic authority in framing what the issues 
are" (Irwin and Wynne, 1996: 9). In relation to the core set, care groups were 
attempting to have active involvement in the work being carried out with the scientific 
core set. 
Care groups also had contact with scientists. Actor network theory argues that just as 
scientists are able to enrol the public, so the `public' are, in theory, able to enrol 
scientists. 42 Indeed, some groups set up by the BDA, consisted of scientists, as well as 
care professionals, members of the pharmaceutical companies, and diabetics. In a 
42 Although, as some have argued, these implications have not been fully developed (see Epstein, 
1996). 
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similar way, Arthur Teuscher, one of the main members of the scientific core set, but 
not one of the core group, was closely linked to the IDDT. Such activities conferred a 
measure of scientific credibility to these care groups. The care groups were 
attempting to gain access to the core set. 
As well as having contact with members of the scientific core set, care groups, and to 
a lesser extent individual diabetics who were experiencing problems on human 
insulin, also gathered and distributed knowledge that was produced within the 
scientific core set. By assessing these texts, care groups not only attempted to become 
in some degree competent themselves, but by distributing versions of these texts to 
other diabetics, they attempted to confer competence onto other diabetics. The `other' 
versions, distributed by care groups, `selectively' mixed both scientific and 
experiential knowledge. Importantly, it was because a group of actors felt that the 
BDA were not adequately representing diabetics, that they constructed their own 
network to form the IDDT. They then became competent themselves. This is one 
element of popular epidemiology, where medical and scientific knowledge is tested by 
bringing it out into the public sphere for debate (Habermas, 1989). In particular, 
scientific work was compared with the `real life' experiences of diabetics. The 
articles produced by the IDDT were therefore comparing scientific knowledge with 
experiential knowledge. 
These actions, by the care groups, were an attempt to reduce the exclusivity of 
scientific knowledge. On the one hand, care groups were arguing that experiential 
knowledge was valuable, and on the other, they were selectively utilising elements of 
science. The aim was not only to break the boundary between `lay' and `expert' 
knowledge, but also to reassess the value of exclusively relying on scientific 
knowledge. 
7.4 DRAWING OUT THE MAIN FINDINGS 
It is now time to draw out some of the main findings of this thesis. As human insulin 
was being developed, existing Insulins were problematized and the links that various 
actors, such as the medical profession, had with these existing Insulins were broken. 
In the most part, the translations that occurred through the development and 
production of human insulin were successful, and human insulin came to be seen as 
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the superior insulin. 
It was initially argued that human insulin would be able to slot into the existing 
diabetic network body. It was believed that for human insulin to be unproblematically 
used by diabetics, there would be no need to change the existing pre-inscriptions that a 
diabetic had gained through the use of animal insulin. 
However, for some diabetics existing pre-inscriptions were not adequate for the 
unproblematic use of human insulin, and as a result they experienced severe 
biographical disruptions in their once settled body. These disruptions led to a crisis in 
the identity of human insulin. This demonstrated that the identity and meaning of an 
artefact, in this case human insulin, is never fixed. Negotiations are constantly taking 
place in which the meaning of an artefact is re-negotiated by a number of actors. For 
example, for some diabetics human insulin was not a `modern' and `superior' insulin, 
instead animal insulin was superior to the more `technologically advanced' human 
insulin. Similarly, individual doctors and scientists also questioned the superiority of 
human insulin. 
Another important finding concerned the ways in which actors attempted to have their 
own program of action accepted by those actors who had a contradictory program of 
action. For example, when a diabetic wished to transfer back to animal insulin, it may 
have been necessary for the diabetic to circulate intermediaries in order to reduce the 
frontline that existed between the doctor and the diabetic. Similarly, when a doctor 
believed that human insulin was the `best' insulin, the doctor may have circulated 
various intermediaries, such as educating the diabetic, in order to reduce the frontline 
in which the body was unsettled while on human insulin. 
Hopefully I have also demonstrated that the body should be seen as being `made up 
of many different actors. I used the concept of the network body to illustrate this 
point. In particular, I have shown that there are many influences on the way in which 
a diabetic, or any actor, makes sense of the world, and in particular, makes sense of 
biographical disruptions. For example, as a diabetic became aware of the experiences 
of other diabetics, they were able to understand their own experiences. 
Importantly, it is negotiations within the network body that brings the body to 
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settlement. In many cases, diabetics rejected certain knowledges used in negotiations 
that attempted to bring the body to settlement, not least because their network body 
was in possession of alternative knowledges. For example, some diabetics rejected 
the claim, by their doctor, that animal insulins had been discontinued because they 
were aware that some animal insulins, in fact, were still available. However, other 
diabetics would have accepted that animal insulins were no longer available, because 
their network body was comprised of different actors and relations. 
Within this thesis I have also shown that texts from individuals become collectivized, 
and it is these texts that are circulated to key actors. Within this study there is a sense 
in which texts become accumulated by care groups, who then generalise from these 
texts. Care groups very rarely quantified the texts which they received, instead care 
groups claimed that they had received `many letters', but not the exact number. 
Arguably, the vagueness of such statements is not problematic because of care groups' 
authority as the representatives of diabetics. 
The texts that actors circulate attempt to persuade others, within the core set (both the 
scientific and the agonistic set), of their facticity. For example, the IDDT were 
attempting to persuade the medical profession, particularly regulatory bodies, that 
human insulin produced adverse effects in some diabetics. On the other hand, some 
scientists circulated intermediaries which claimed that human insulin did not cause 
adverse effects. For the IDDT, the reality was that human insulin was unsafe for some 
diabetics, but for the scientists, the reality was that human insulin was equal to animal 
insulin. 
For actors, the collectivization of texts did not just involve the use of texts from 
within their own ring of the core set. Instead, in order for an actor, within one ring, to 
persuade an actor in another, it is necessary to bring texts together from 
different parts 
of the core set. The potency of texts therefore lies in the ability of actors to combine 
texts from a number of sources, such as results from scientific studies and texts which 
describe the experiences of patients. This relates closely to the argument in ANT that 
durable networks are composed of actors from a number of disparate networks. 
However, the texts that are being collectivized have to be perceived by the receiving 
actors as important and authoritative. 
260 
7.4 Drawing out the main findings 
It is also important for those actors in the agonistic set to form allies with members of 
the scientific core set. For example, the 1DDT formed links with Arthur Teuscher. 
Actors within the agonistic core set also form links with other members of the 
agonistic set, for example, the BDA had links with the pharmaceutical companies. 
However, these links are reciprocal. Arthur Teuscher was able to gain much needed 
anecdotal evidence from the IDDT to support his scientific claims, and the 
pharmaceutical companies, through the BDA, were able to represent themselves to 
diabetics as being concerned and flexible actors. 
As a result, the formulation of the core set, as outlined in Figure 7-3, is (inevitably) 
simplistic. Actors do not simply exist in one ring and one ring only. Instead, actors 
move between rings depending on who they are attempting to persuade. The other 
important point is that actors within rings of the agonistic or scientific set are not 
necessarily homogeneous. For example, some actors within the scientific set 
identified with the IDDT and others didn't. 
One important finding of this study was that the notion of the core set should be 
supplemented by a `consensus-orientated set'. This new set not only crosses the 
scientific and agonistic set, but it is a precondition of membership of the core set that 
all members support a particular position. In this case the precondition was that actors 
should support a choice of insulin species, although actors did not have to be actively 
involved in the production of animal insulin. 
As a final note, throughout this study I have been aware that it is not possible to 
produce hard and fast descriptions of the actors involved. Not only are actors 
constantly slipping and merging, but actors simultaneously belong to a number of 
different networks. For example, doctors are members of different networks; the 
general view within the medical community was that human insulin is safe and 
efficient, yet due to contact with diabetics, doctors may be led to think otherwise. 
Another example is the position of some medical scientists. On the one hand they 
carry out medical work, and at the same time may have close links with care groups, 
such as Teuscher and the IDDT. As a consequence of this movement, the core set 
should be viewed as having a degree of fluidity. 
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7.5 SOME IMPLICATIONS OF THE HUMAN INSULIN CASE 
In this section I would like to suggest some possible practical implications of my 
research. As argued in Chapter 3, the regulation of human insulin occurred relatively 
quickly compared with other drugs. There were a number of reasons for this: a great 
deal was already known about insulin; human insulin was the first drug for human use 
to be produced using genetic engineering and so human insulin was seen as `trial run' 
for the genetic engineering of other drugs; and, there were concerns that supplies of 
animal insulin would not meet demand. It can be argued therefore, that regulatory 
bodies were under social pressure to regulate human insulin quickly. In retrospect it 
can be argued that adequate clinical trials had not been carried out, before human 
insulin was regulated. More careful consideration should be given to how drugs are to 
be used in `practical' or `real' situations. Criticisms of some of the studies that were 
carried out during the clinical testing of human insulin claimed that the studies were 
`overly artificial'. The main criticism was that the majority of the clinical studies 
concentrated on biological factors, rather than the experiences of diabetics. 
I would therefore suggest that more careful assessment of the claims of `interested' 
actors be made by regulatory bodies. However, we live in a commercial world where 
companies do compete to be able to produce the most technologically advanced drugs, 
so there are bound to be pressures from these actors to produce and regulate `novel' 
drugs. It is my belief that this commercial pressure affected the speed by which 
human insulin passed through clinical trials. Although perhaps impractical in the 
commercial world, it may have been more prudent for a small number of diabetics to 
have been prescribed human insulin as a `trial run', instead of the mass transfer that 
actually occurred. 
Of course, just because a particular drug is available it does not mean that doctors 
have to prescribe these drugs. However, since it is likely that pharmaceutical 
companies have invested large amounts of resources to produce new drugs, they are 
likely to advertise these new drugs to doctors above existing ones. In the case of 
human insulin, some doctors were also under the impression that existing animal 
insulins had been withdrawn, and so transferred their patients to human insulin. Due 
to these factors, it may be wise to reconsider the ways in which doctors become aware 
of current treatments. 
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On transferring patients to new, but similar, pharmaceutical drugs it should not be 
taken for granted that the treatment will go smoothly. This is particularly the case 
when the new drug bears a close resemblance to `natural' bodily products. One of the 
important points in this study was that when diabetics were transferred to human 
insulin, after using animal insulin for a long period of time, many diabetics 
experienced problems. In these cases, closer attention should be given to these 
patients. Linked to this, is a warning that just because a drug appears to be more 
technologically advanced, does not mean that patients will feel the same. 
Another consideration is the information that is available to patients. Although 
patients receive basic descriptive information on the drugs they are following, through 
patient information leaflets, this is often of a very low level. Indeed, in this study, it 
was claimed that the information warning of possible side effects was more aimed at 
professionals (and in some cases removed from drug packaging by pharmacists). 
Patients should also be clearly warned when changes are made to their drug treatment, 
or when changes are made to patient information leaflets. In this study, some 
diabetics believed that they had not changed their insulin species when in fact they 
had. In some cases diabetics were not told of these changes by their doctor, and in 
others their pharmacist had changed then without consultation with either the patient 
or the doctor. One reason for this was the similarity in the names of the insulins. 
Many Insulins simply had `human' placed in front of their existing name. This 
evidently caused some confusion. Although Novo Nordisk made changes to the 
names of their human insulin in 1996 to avoid this confusion, it would have been 
preferable for this change to have been made when human insulins were first 
marketed. Where changes in drugs are made it may also be prudent to issue clearer 
warnings that the drug has changed. For example, similar drugs could be colour 
coded, in this case so that diabetics would be aware that they were using human and 
not animal insulin. 
Diabetics also received information from the BDA and the IDDT. However, one 
criticism of the BDA was that it did not appear to be representing diabetics who were 
experiencing problems on human insulin, when in fact they were carrying out work 
`behind the scenes'. The BDA claimed that it did not want to worry diabetics 
unnecessarily, and so refrained from describing their actions. In retrospect, the BDA 
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have argued that this policy was mistaken. I would suggest that other care groups 
should learn from this mistake, and inform others of the work that they are carrying 
out. Care groups should give more credit to `interested publics' when outlining any 
possible controversy. By doing so, it may avoid actors being subjected to 
`sensationalist accounts' from the popular media, which may only be reported when 
there is a greater body of evidence against a particular drug. Such sensationalist 
accounts are far more likely to worry interested publics, than evidence that is 
presented, by care groups, as a particular debate is unfolding. This is particularly the 
case with the management of diabetes, since diabetics are encouraged to become 
actively involved with the management of their diabetes. 
One of the notable findings of this study was that doctors differed in the solutions that 
they presented to their patients. For some doctors, changes were made to a diabetic's 
management of diabetes within human insulin treatment, for others the solution was to 
transfer their patients to animal insulin. It was not necessarily the fault of doctors that 
patients were not transferred back to animal insulin, since the dominant view was that 
human insulin was safe. It may therefore be useful to consider changes that can be 
made to the way adverse reactions on drugs are reported. If the pathways by which 
doctors became aware of adverse reactions were more flexible, then it is likely that so 
too would the dominant view. 
When those diabetics who were experiencing problems on human insulin reported 
their problems to their doctor, the diabetic was then treated as an individual case. 
Although doctors had the ability to report the adverse effects of human insulin to the 
Medicines Control Agency, through the Yellow Card Scheme, this was very rarely 
done. However, it has been suggested that patients should be able to report these 
adverse effects themselves. One effect of this suggestion could be that patients feel 
that their experiential knowledge becomes valued. Although there may be some 
problems with this suggestion, such as what the definition of a negative effect is, 
it 
appears to me that this suggestion should be taken seriously. 
On a more practical level, I would also suggest that in future research groups should 
join together to carry out an `ideal study' early on in a controversy. However, the 
notion of the ideal study should be broadened, not just to include those actors within 
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the scientific set, but also those within the agonistic set. The criterion by which an 
ideal study is conduct should include contributions from a range of experts, such as 
from care groups. The knowledge possessed by care groups is important since they 
will be able to inform research teams of the practical implications of any study. In this 
case study, an ideal study was only suggested late on in the controversy. Although 
speculative, I suggest that an ideal study may have brought the human insulin debate 
to closure more quickly. One reason for this is that members of the insulin debate 
would more likely to be in agreement as to the way diabetics should be treated when 
on human insulin. This may then have avoided diabetics being presented with a 
number of solutions, before an adequate one was found. Such an approach may have 
also helped the credibility of science, since care groups would have been aware that 
scientists were doing their best to help sufferers. 
However, one word of warning has to be voiced before we accept that an 'ideal study' 
would have conclusively 'proved' whether human insulin did or did not cause negative 
effects. A study is conclusive when actors agree that a particular study is definitive. 
As indicated in Chapter 5, there was much disagreement on the nature of an ideal 
study, such as the size and method of the ideal study. Therefore, although, in theory, 
an ideal study may have brought some closure earlier on to the human insulin debate, 
an ideal study is, inevitably, elusive. 
7.6 SHORTCOMINGS AND RECTIFICATIONS 
As with any piece of research, there are a number of shortcomings of this work that I 
have become aware of. In this section I would like to describe some of these 
shortcomings. 
In terms of the collectivization of texts, it may have been useful to study, in more 
depth, the process by which collectivization occurred. In particular, it may have been 
productive to study the choices that were made by the BDA and the IDDT when they 
were deciding which texts, in particular letters, were to be included in their 
magazines. It would also have been useful to look at the choices made by care groups 
as to which `scientific data' was to be included in their magazines. 
Early on in the beginning of this research I took the decision to use published texts as 
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my data source (see Appendix 1). Therefore, any conclusions made, are dependent 
upon those diabetics who produced texts. However, it may have been useful to 
conduct interviews with diabetics who had experienced problems on human insulin. 
With data from these interviews, it would have been possible to compare the 
`textualized controversy' with these very personal accounts. 
Interviews could also have been carried out with doctors. An image may have been 
presented in this thesis that doctors were one of the `villains' in the human insulin 
debate, because they did not always transfer diabetics who were experiencing 
problems on human insulin back to animal insulin. However, as pointed out in this 
thesis, doctors were subject to pressure from the pharmaceutical companies to 
prescribe human insulin. By interviewing doctors, I would also have been able to 
study in more detail the differing information that was available to doctors. These 
interviews would have revealed the factors which affected the prescription of human 
insulin, and the presentation of solutions to diabetics. 
7.7 FUTURE RESEARCH 
As I have carried out this case study there have been a number of areas that I could 
have investigated further, however due to limitations of space and direct relevance, I 
have refrained from doing so. In this section I would like to point to these areas, and 
to other wider areas where future research could be carried out. 
One particular direction of future research is looking at the human insulin debate in 
different countries. For example, in America it was argued that there was not a 
controversy over human insulin, even though there was a similar transferral to human 
insulin. This led one author to ask: 
"In the United States, the `land of litigation, ' the problem does not seems to 
exist, or if it does it is of little consequence and not reported. Why should there 
be such a transatlantic difference? There is no obvious answer.. . The 
lack of an 
American experience of this problem calls into question its true validity. " 
(Walker, 1991: 1265-1266) 
One suggested reason for the difference was that in America there were warnings 
printed on human insulin packaging in 1989 (Wolff, 1992). However, some 
have 
argued that diabetics in America are experiencing problems, but the authorities 
do not 
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admit that there is a problem. It is also argued that another reason why there is not a 
debate in some countries (such as Holland, Australia and America) is because these 
countries do not have a method of collecting evidence of adverse effects, or that 
patients are not being listened to (Kiln and Sugarman, 1992). 
Another area of future research could be in looking more closely at the role of 
mediating others. In this study I have only briefly indicated that other actors, such as 
family and friends, do have a role in making diabetics aware of changes in their 
personality, while on human insulin. In some cases, family and friends, became 
aware, through the media, of other diabetics who were experiencing similar problems 
on human insulin to their relative or friend. It would be interesting to study the role of 
these actors more closely. 
One of the interests of this thesis has been in looking at what happens when diabetics 
meet with doctors. Future research could be carried out looking more closely at what 
happens within the doctor-patient setting. In particular, it will be interesting to look at 
how doctors re-interpret expert knowledge due to coming into contact with 
experiential knowledge. Work in this area would extend my formulation of scientific 
and experiential knowledge (Figure 7-2), to map the process by which movement 
from one quadrant to another occurred. 
One interesting feature of this case study was that when human insulin was introduced 
it was expected to replace existing insulin treatment. Importantly, this was to be done 
without the need for changes in the way a diabetic carried out the management of their 
diabetes. By looking at similar cases, where one drug was replaced by another, I 
would be able to see how ideas behind the network body could be applied further. It 
would particularly interesting to look at other genetically engineered drugs. 
Human insulin also aimed to benefit patients by reducing complications. It was 
therefore seen as a technological advancement. It would be interesting to look at other 
drugs that are seen a technological advance, for example, the MMR vaccine. 
There are also some specific theoretical areas that could be elaborated. In Chapter 3I 
argued that the two main pharmaceutical companies, Eli Lilly and Novo Industri, had 
multiple strategies concerning the development of new insulins. Eli Lilly were 
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stressing the need for human insulin (overt strategy) while also developing a purified 
porcine insulin (covert strategy), and Novo Industri were arguing that their purified 
porcine insulin prevented diabetic complications (overt strategy), while also 
developing a human insulin (covert strategy). It would be interesting to study whether 
this was the norm within phannaceutical companies. 
Another area of further theoretical interest would be in developing the idea of the core 
set. I described above that within the core set there was evidence of a `generalized 
consensus-orientated set' which revolved around the issue of insulin choice. Rather 
than the scientific core set defining what characteristics were necessary to be a 
member of the' agonistic generalized set, there was a mutual consensus by all 
members of the core set. It would be interesting to investigate whether this was the 
same in other controversies, in particular what happens when some members of the 
core set veer from this mutual consensus. It would also be interesting to study what 
conditions ensure that choice of a particular drug is maintained. In particular I would 
be interest in looking at cases where the availability of an `old' drug is maintained, 
even though a new drug is supposedly superior. We could outline a number of 
factors: commercial viability, scientific necessity or patient demand. 
Finally, it would also be interesting to study more closely the disagreements within the 
rings of the core set. I have already argued that there were differences in the way in 
which the BDA and the IDDT conducted themselves in the human insulin debate. It 
may be productive to look at how certain actors, within the rings of the cores set, 
become marginalised. 
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APPENDIX 1- METHODOLOGY 
By glancing at any handbook on methodology we soon become aware that there are a 
large number of possible approaches that a researcher can adopt. Approaches that can 
be used include: observational methods, interviews, questionnaires and unobtrusive 
methods (Robson, 1993). 
In this thesis I opted to use an unobtrusive method. My main body of evidence was in 
the form of documented evidence. The evidence that I collected related to two 
periods. The first was between 1976-1981, which texts detailed the development and 
introduction of human insulin, and a second, between 1982 to 1999, which described 
the problems experienced by diabetics on human insulin. However, it should be 
pointed out that after 1992 the number of scientific articles published on the human 
insulin debate did diminish significantly, since the scientific community had come to 
some agreement. 
The documented evidence can be divided into two broad types: scientific/medical and 
`lay'/experiential. Scientific and medical evidence came in a range of scientific and 
medical journals, such as the British Medical Journal and The Lancet, and were in the 
form of formal studies, review articles and letters. Experiential and `lay' evidence 
came from those documents that were aimed at diabetics, mostly from Balance - the 
magazine of the British Diabetic Association - and the Insulin Dependent Diabetic 
Trust's newsletter. Experiential/'lay' evidence also came from newspaper articles. 
What all the sources had in common was that they were, in theory, public documents, 
that is, they could be accessed by anyone. Most libraries hold copies of the major 
science journals, and anyone can subscribe to Balance or obtain copies of the Insulin 
Dependent Diabetic Trust's newsletter. 
When initially approaching the human insulin debate my first step was to form a 
database of articles. Using two bibliographic databases (Bids and Medline) I gathered 
references to a large number of scientific and medical articles. By reading abstracts I 
identified documents that were relevant to my case study, and then, using the 
university library I photocopied the important articles. This systematic search formed 
the backbone of my scientific evidence. While reading the selected articles I 
familiarised myself with the human insulin debate and I identified which of my 
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selected articles were most important. While reading the articles I also identified 
articles that were not included in my initial reference list, but appeared to be 
important. In the process of this, I soon became aware of the key authors, papers and 
issues within the human insulin debate. 
In order to collect experiential and `lay' evidence I contacted two care groups. I made 
an appointment to meet with members of staff at the BDA, and was also able to read 
through, and photocopy, articles and letters in back issues of Balance. I also 
contacted the Insulin Dependent Diabetic Trust and obtained back issues of their 
newsletter. Added to this source, I referred to newspaper indexes. 
Since my interest was in the human insulin debate within the United Kingdom, all 
experiential and `lay' evidence related to the debate within the UK. In terms of 
scientific and medical evidence some studies were conducted in other countries, 
notably Switzerland, but because their content was relevant to the human insulin 
debate, this evidence was referred to in the study. 
By using these two types of documentary evidence, scientific/medical and 
'lay'/experiential, I was able to build up a picture of the human insulin debate. The 
use of multiple documentary sources meant that I was able to corroborate certain 
features of the human insulin debate. However, as well as corroborating `facts', the 
use of multiple sources allowed me to draw out conflicting features of the human 
insulin debate. In all this, my aim was to build up a picture that was not biased toward 
one particular point of view, whether of the medical community or care groups. The 
other important point was that I was able to assess which issues were important to 
which actors, and further, how actors responded to the issues that were deemed 
important by other actors. 
Throughout the study I kept in mind that the documents that I was studying were 
written with specific purposes in mind. For example, evidence from the IDDT aimed 
to stress the `reality' of diabetics' negative experiences on human insulin. It was also 
important to identify the position of authors within the human insulin debate. For 
example, Teuscher and Berger believed that human insulin caused negative effects 
in 
some diabetics, and as a result, any scientific paper written by them had to 
be read 
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with this in mind. 
My analytical strategy was to examine critically evidence from different networks. By 
investigating the evidence, in the form of documents produced by different networks, I 
have been able to reconstruct the human insulin debate. When approaching the 
documented evidence I adopted a principle of symmetry, that is, I used the same 
conceptual tools to explain `true' and `false' beliefs. The principle of symmetry is one 
of the guiding principles of the sociology of scientific knowledge, and requires 
researchers to "bend over backwards to consider the arguments of scientific 
`underdogs"' (]Epstein, 1996). However, my approach to symmetry went further. In 
keeping with ANT, I adopted a neutral vocabulary to understand the conflicting roles 
of the actors, both human and nonhuman, involved in the debate. 
The thesis shows the ways in which actors attempt organised the important issues in 
the human insulin debate. It could be argued that an interest-based conceptual 
framework (Shapin, 1979; Barnes and MacKenzie, 1979) would have been 
appropriate for this study. The interest approach argues that, "knowledge-claims 
made by scientists will embody or be informed by certain social, sometimes political 
interest" (Webster, 1991: 16). Space does not allow a full discussion of the interest 
approach here, but see Woolgar (1981), Barnes (1981) and MacKenzie (1981) for two 
possible positions. Rather than go into the intricacies of the interests approach I wish 
to indicate why an actor network approach was more appropriate for this case study. 
One strong objection to the interest approach is that it pre-defines a set of 
`background' interests. By ascribing interests to groups, which are then used to 
explain the actions of actors, researchers attribute a `special (stable) status' to a 
backcloth of prior interests (Callon and Law, 1982). Importantly, social interests are 
"temporarily stabilized outcomes of previous processes of enrolment" (Callon and 
Law, 1982: 622). At any time an actor's interests are subject to change since other 
actors may be attempting to enrol actors. From this point of view, interests (and other 
categories such as desires, motives and wishes) are not in the background, but rather, 
are used to define the roles of actors within a particular social world (Callon and Law, 
1982). The role of a researcher should be to describe the ways in which some 
stability, however temporary, is achieved through the process of enrolment. 
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This then, is the main analytical difference between an interests and actor network 
approach. Whereas an interests approach begins with a predetermined `backcloth' and 
set of interests, an actor network approach studies the way in which the interests of 
actors are transformed. As a result, the interests of actors are revealed in the action of 
actors, and thus, researchers need to `follow the actors' of every new case study. 
The aim of my analytical strategy was to gain an in-depth understanding of the human 
insulin debate in order to understand the key events in the debate. Rather than using 
quantitative data analysis, my approach was to immerse myself within the data rather 
than reduce it to abstract codes and clusters. The method is therefore one in which I 
followed the actors and their negotiations, even if this was at a distance, through their 
texts. In Chapter 3 this was carried out in a more or less chronological manner: I first 
outlined the reasons behind the development of human insulin; I then went on to 
describe the progress of the research groups; and then the commercial development 
and introduction of human insulin. The aim of Chapter 4 was to set the scene for 
future chapters by outlining the initial use of human insulin, and was therefore 
presented in a descriptive manner. Chapters 5 and 6 on the other hand, were 
organised around a comparative structure, where I described issues of the human 
insulin debate from two perspectives: Chapter 5 concerned itself with issues within 
science and the pharmaceutical companies, and Chapter 6, looked at issues deemed 
important by diabetics and care groups. 
Although published sources may only tell part of the story, by using a variety of 
sources, from the influential to the less well known, I believe that I have been able to 
produce a reasonably comprehensive and accurate representation of the human insulin 
debate. Further, by using different forms of narrative, such as scientific studies, 
editorials, articles and published letters, I have been able to produce an account of the 
human insulin debate from a number of positions. 
Problems do exist with documentary evidence, and as a result, it could be argued that, 
in order to produce a rounded account of the human insulin debate I should have 
carried out interviews to add to the documented evidence. Some of the problems 
associated with the use of documented evidence include: their retrievability may be 
low due to access being blocked; the documents may be biased; or, the documents 
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may be inaccurate. On the whole, these problems did not arise in this study since I 
was interested in how the human insulin debate was played out in the `public' domain 
- that is, it is possible for any individual to access the documents. The other important 
point is that there was an abundance of documented evidence from a large number of 
resources, and as a result, any possible document inaccuracies could be overcome by 
using multiple sources. 
Another reason why documented evidence was preferred was that, on the whole, the 
human insulin debate was played out between 1982-1992. Within the scientific 
community some closure of the debate had occurred in that scientists, and those in the 
medical community, had come to an agreement that diabetics expressing problems on 
human insulin should be transferred back to animal insulin. One of the potential 
problems with using interview data is that retrospective accounts might be directed to 
issues in the present, though of course, it could be argued that with time, more 
`rounded' or less `charged' accounts from the main actors might have been 
forthcoming. 
Finally, it is worth assessing the advantages and limitations of using textual analysis 
to explain the network body: that is, using textual analysis to decide what `makes-up' 
the network body. Some of the main advantages have already been discussed in this 
appendix, namely those associated with the accessibility of texts. The other important 
point is that this study focuses on the circulation and textualization of texts, and as a 
result, the make-up of the network body that is represented in texts. Ironically, this 
leads me to a limitation of using textual analysis to explicate the network body. I have 
described the network body as represented in texts, and is therefore, to some extent, a 
sanitised version of the network body. Direct contact with diabetics, scientists and 
doctors may have produced another formulation of the network body. In particular, 
such an analysis may have revealed the different emphasises that different actors place 
on entities within the network body. For example, diabetics may place more emphasis 
on the role of close family members than scientists would, especially when a diabetic 
is experiencing problems with the management of their diabetes. One way in which 
such an analysis could be approached is by talking to individuals, and bringing out the 
elements that they feel are important to them in the management of diabetes. 
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" BRITISH DIABETIC ASSOCIATION " 
People with Diabetes and Changes in Hypo Warnings 
There has been a lot of publicity in the 
newspapers and on TV recently about human 
insulin. This has understandably caused a lot of 
distress for people living with diabetes. We 
hope that this leaflet will be helpful and 
reassuring. 
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WHAT ARE THE PROBLEMS? 
Some people are saying that their hypo symptoms 
have changed. Instead of having their usual 
symptoms of sweating, trembling, hunger, 
weakness, anxiety and palpitations they find their 
symptoms have changed to lack of concentration, 
confusion, and personality change, and it takes 
some while to learn to recognise the new 
symptoms. Others find that they have no or very 
little warning of hypos or that they happen so 
quickly they do not have time to take action. As a 
result they wake up and find themselves being 
given sugary 
food or drink. They cannot remember 
going into the hypoglycaemic. 
This is an extremely worrying and frightening 
situation for anyone living with diabetes because 
people feel they are no longer in charge of their 
lives. They are afraid of losing their jobs and 
becoming a nuisance to others. It should be 
emphasised that all these problems with 
hypoglycaemia can occur in people on any type of 
insulin. 
WHY SHOULD THESE PROBLEMS 
HAPPEN? 
Loss of warning symptoms of hypos is not a new 
problem. Even before human insulin was 
introduced some people with diabetes had this 
problem. Many research studies have been carried 
out in Europe during the past 3 years, but no one 
can explain exactly what is happening or why 
some people are affected when others are not. 
Improving control of diabetes can cause changes 
in hypo warnings. This is because if blood sugars 
are usually kept at a low level there isn't far to go 
before a hypo occurs, and there may be loss of 
hypo symptoms. Some people who have had 
diabetes for a long time unfortunately lose their 
warnings anyway, partly because of the effects of 
long term diabetes on their nervous system. 
WHAT IS THE DIFFERENCE BETWEEN 
HUMAN AND ANIMAL INSULINS? 
Animal insulins are extracted from the pancreas of 
pigs or cattle and they do not have exactly the 
same chemical make up as the insulin which is 
normally produced in the human body. Human 
insulin is not prepared from the human pancreas. 
Scientists have been able to find a way to get 
bacteria to make insulin which is chemically 
exactly the same as the insulin made in the human 
body. So when this type of insulin was first 
produced it was natural to expect that it would suit 
people better than animal insulin. About 8 in every 
10 people who use insulin are on human insulin. 
IF I HAVE LOST MY HYPO WARNINGS 
WHAT CAN I DO ABOUT IT? 
Do not stop your injections! Remember that 
insulin keeps you alive and there is no substitute 
for it. 
Check out your diabetes control by doing frequent 
blood tests and discuss the results and 
management of your diabetes with your doctor or 
diabetes specialist nurse. If adjustments to 
management do not help THE ANIMAL 
INSULINS ARE STILL AVAILABLE, and if you 
need to change back to them you can do so. 
Discuss this with your diabetes doctor or diabetes 
specialist nurse. The BDA can tell you which 
animal insulins are available and the correct name 
for them if necessary. Many people with diabetes 
who are treated with human insulin and have been 
experiencing no problems are concerned that their 
warning symptoms may change in the future. 
There is no guarantee that your warning symptoms 
will not change with time. However, only a small 
percentage of people experience this problem and 
it is unlikely that human insulin will be the cause 
so there is no reason to change your insulin. 
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WHAT HAS THE BDA DONE TO HELP 
PEOPLE ON HUMAN INSULIN WHO ARE 
HAVING PROBLEMS? 
1) In 1989 the BDA set up a Human Insulin 
Working Party of experts in diabetes. Some are 
people with diabetes and others are doctors and 
scientists or diabetes specialist nurses. The 
Committee on Safety of Medicines has a 
representative on the Working Party. The 
Working Party has listened very closely to the 
problems and studied them, and recommended 
carrying out research into how people react to 
human and pig insulin to see if there is any 
difference. Normally research takes a long time 
to commission and set up but this research was 
commissioned and set up within 3 months of an 
advertisement appearing in the Medical Press. 
The BDA is paying for the research. 
2) Companies who make insulin have assured us 
that animal insulins will not be withdrawn. 
3) BDA staff have answered many thousands of 
enquiries from insulin users and their families 
and from doctors and nurses about human 
insulin and its effects. In 1988 the staff sent a 
questionnaire to people who had been put on to 
human insulin and the results were published in 
the BDA magazine Balance. Quite a lot of 
people had had some difficulties 
over the transfer. In many instances these were 
due to a lack of understanding of the change to 
a new insulin or to other in the way diabetes 
was managed. At that time BDA Medical 
Advisor advised that people should be aware of 
the insulin they are using and that any change in 
insulin should be fully explained by their 
medical adviser. 
PROPOSALS FOR FURTHER ACTION 
Because mounting uncertainty felt by so many 
people with diabetes the BDA is redoubling its 
efforts to answer important questions about 
hypoglycaemia and loss of warning symptoms 
outlined in this leaflet. 
The BDA Executive Council has pledged 
£ 100,000 to be made available to fund a Loss of 
Warnings (LOW) Task Force which will allow for: 
1) Further resources to be given to the BDA 
helpline 
2) Preparation of information sheets for all 
professionals involved in diabetes care - 
consultants, general practitioners and diabetes 
specialist nurses - containing information about 
the background to hypoglycaemia warning 
symptoms and proposed treatment schedules; 
3) The possibility of future research studies to be 
examined. 
A charity helping people with diabetes and supporting diabetes research 
BDA, 10 Queen Anne Street, London W1M OBD Telephone: 071-323 1531 
October 1991 
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